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ABSTRACT 
 
PYRROLO[2,3-d]PYRIMIDINE CLASSICAL ANTIFOLATES FOR TARGETED 
CANCER CHEMOTHERAPY- APPLICATIONS OF BIOISOSTERIC AND 
REGIOISOMERIC SUBSTITUTIONS FOR IMPROVED TUMOR-SELECTIVITY 
AND POTENCY 
 
By 
Manasa Punaha Ravindra 
December 2018 
 
Dissertation supervised by Dr. Aleem Gangjee 
 In 2018, it is estimated that 1,735,350 new cases of cancer and 609,640 deaths from 
the disease will be diagnosed in the United States alone. Conventional chemotherapy is by 
far the most successful category of clinical oncology, having cured (complete remission 
(CR), without return) or provided clinical benefit to millions of people. However, since its 
earliest discovery, the major causes of failure of conventional cancer chemotherapy have 
been dose-limiting toxicities and development of resistance. There is a desperate ongoing 
search for new cancer therapies as tumor-targeted agents (without harming normal cells or 
tissues) with low propensity for the development of resistance.  
Clinically used antifolates methotrexate (MTX; DHFR inhibitor), pemetrexed 
(PMX; TS and GARFTase inhibitor), pralatrexate (PTX; DHFR inhibitor), and raltitrexed 
(RTX; TS inhibitor), have two major disadvantages: (1) dose-limiting toxicities due to 
 v 
ubiquitous transport via the reduced folate carrier (RFC) and (2) drug-resistance; mutation 
and/or overexpression of RFC and target enzymes resulting in inadequate transport, 
reduced cellular retention, and decreased potency. However, two other folate transporters 
that are narrowly expressed in healthy tissue while overexpressed in many different types 
of cancer are the folate receptors (FRs) (epithelial ovarian cancer (EOC), NSCLC, renal, 
endometrial, colorectal, breast cancers, hematologic malignancies, etc.) and the proton-
coupled folate transporter (PCFT) (ovarian and NSCLC). Our aim is to design classical 
antifolates for selective uptake by FRs and PCFT over RFC and inhibition of multiple 
folate metabolizing enzymes in their monoglutamate forms. Successful identification of 
such small molecule single agents will potentially (a) have tumor-targeting action and (b) 
combat resistance development.   
 
This dissertation discusses the bioisosteric and regioisomeric optimization of 5-
and/or 6-substituted pyrrolo[2,3-d]pyrimidine antifolates for improved tumor-targeted 
activity. Molecular modeling with the help of known X-ray crystal structures of the 
transporters and the intracellular enzymes was used to rationalize the design of the analogs. 
NMR studies that were performed to provide structural evidence for the presence of a 
conformationally restricting intramolecular fluorine hydrogen bond have been described. 
 vi 
The dissertation also discusses the synthetic efforts for obtaining the pyrrolo[2,3-
d]pyrimidine analogs with regioisomeric substitutions, modified linkers and bioisoteric 
replacements (general structure I) for selective uptake, and inhibition of one or more 
enzymes in the de novo purine and/or pyrimidine biosynthetic pathway. The present work 
identified that, depending on the regioisomeric position, fluorine substitution on the side-
chain (het)aryl ring improves both potency as well as selectivity, most significantly towards 
PCFT-expressing cell lines. NMR-based structural evidence led to one of our hypotheses 
that entropic benefit due to conformational restriction caused by an intramolecular fluorine 
hydrogen bond may partly be responsible for improved biological activity. The current 
work led to the identification of a fluorinated pyrrolo[2,3-d]pyrimidine analog 184, the 
most potent inhibitor of PCFT-expressing Chinese hamster ovarian (CHO) cells (PCFT4 
IC50 = 1.5 (0.4) nM). Another important contribution of the current work is the discovery 
of multi-enzyme inhibitor 201, a C6-methylated version of the clinically used anticancer 
agent PMX, which showed selectivity over RFC (PMX PC43-10 IC50 = 26.2 nM; 201 
PC43-10 IC50 > 1000 nM). Such selectivity can potentially help overcome the dose-limiting 
toxicities of PMX. The fluorinated and methylated analogs described herein are 
testimonials for the profound effects that minor structural changes can have on 
polypharmacology. 
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I. BIOCHEMICAL REVIEW 
A. Folate receptor and/or proton-coupled folate receptor targeting antifolates with 
multiple enzyme inhibition as tumor-targeted antimetabolites 
A.1. Folates 
A.1.1. Introduction 
Folates is a generic term given to the group of vitamin B cofactors (Figure 1); folate 
metabolism is a universal process that falls into a broader set of transformations known as 
one-carbon (1C) metabolism.1 It allows for the activation and transfer of 1C units for 
metabolic processes including purine and thymidine synthesis, and homocysteine re-
methylation (Figure 2). Animals cannot synthesize folates and require dietary folate intake. 
Insufficient dietary folate leads to birth defects/death in developing fetuses and pathologic 
conditions such as anemia, cardiovascular diseases, cognitive decline, neurologic 
disorders, and cancer in adults.2-3  
Folates share a common core structure consisting of a pteridine ring 
(reduced/oxidized), a para-amino benzoic acid (pABA) linker, and a polyglutamate tail 
with variable chain length (Figures 1 and 2). Tetrahydrofolate (THF) with the reduced 
pteridine species, is the biologically active form. The 1C units are covalently bound to THF 
in three different carbon oxidation states to the 5-position nitrogen atom as 5-methyl-THF 
or 5-formyl-THF and/or the 10-position nitrogen atom as 5,10-methylene-THF or 10-
formyl-THF (Figure 1).1, 4 Typically, 5-methyl-THF is the natural dietary folate (Figure 
1).5 The synthetic dietary supplement for folates, folic acid (essential vitamin B9, 
 2 
developed in the 1940s for the treatment of anemia) is sequentially reduced to dihydrofolate 
(DHF) and then to THF for entry into the folate cycle.6  
 
Figure 1. The chemical structures of physiologically relevant folate derivatives with 
different carbon oxidation states.1 
Since folates are anionic at physiologic pH, mammals express folate specific 
transporters namely the reduced folate carriers (RFC), folate receptors (FRs) and proton-
coupled folate transporters (PCFT) for uptake across cell membranes (Figure 3). Within 
the cell, the 1C units of 5,10-methylene-THF, 5-methyl-THF, and 10-formyl-THF are 
interconverted between different oxidation states and compartmentalized for distinct 
biosynthetic functions. 5-formyl-THF serves as a 1C reserve (Figures 2 and 4). 
 
 3 
 
Figure 2. Biochemical transformations of folates. Folic acid is reduced to DHF and 
ultimately to THF. THF accepts 1C units and undergoes a series of oxidative/reductive 
transformations to 5-methyl-THF, 5,10-methylene-THF, 5-formyl-THF and 10-formyl-
THF.1 
 4 
 
Figure 3. RFC-, FR- and PCFT-mediated internalization of folates. 1) Concentrative uphill 
uptake of folate substrates by RFC is directly linked to organic phosphates gradients across 
the plasma membrane 2) PCFT-mediated transport of folates is electrogenic with net 
translocation of positive charges for each negatively charged folate (the coupling ratio is 
unknown as at acidic pH as the proton flux is uncoupled from folate transport) 3) The FRs 
are high affinity GPI-anchored folate binding proteins that mediate cellular folate uptake 
by endocytosis to form early endosomes, which undergo acidification to release folates.7 
A.1.2 Folate metabolism in development and proliferative adult tissues: 
Research over several decades has long-established the essential requirement for 
dietary folates during development.1 Nucleic acid biosynthesis in proliferating tissues is 
the best characterized essential function of folate metabolism. The anabolic process of 
folate metabolism also generates methionine, glycine, or serine (Figure 2). Recently, the 
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specific roles of individual folate-utilizing enzymes in supporting growth and 
development, folate pathways activated in fetal development, immune proliferation, and 
tissue homeostasis have also been uncovered.8-11 Particularly, the role and importance of 
mitochondrial folate metabolism is probably the most important discovery over the last 
decade. Mitochondrial folate metabolism intrinsically supplies 1C units in highly 
proliferative tissues such as the embryo, and deletion of these enzymes lead to neural tube 
defects and loss of viability (Figure 4).12-13 Defects in the function of the mitochondrial 
folate enzymes cannot be rescued metabolically.  
 
Figure 4. Compartmentalization of folate-mediated 1C metabolism.1 Folate metabolism 
supports 1C anabolic reactions through an interlinked set of mitochondrial and cytosolic 
reactions.1 All abbreviations are standard gene names. SHMT1/2, serine hydroxymethyl 
transferase, cytosolic (1)/mitochondrial (2); MTHFD1, methylenetetrahydrofolate 
dehydrogenase, cyclohydrolase, and formyltetrahydrofolate synthetase 1; MTFD2, 
methylenetetrahydrofolate dehydrogenase 2; MTHFD1L, monofunctional tetrahydrofolate 
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synthase, mitochondrial; TYMS, thymidylate synthetase; MTHFR, 
methylenetetrahydrofolate reductase; MTR, methionine synthase; DHFR, dihydrofolate 
reductase; GARFTase, glycinamide ribonucleotide formyl transferase; AICARFTase, 5-
aminoimidazole-4-carboxamide ribonucleotide formyl transferase. 
A.1.3. Folate metabolism in non-proliferative adult tissues 
Anabolic 1C reactions among non-proliferative adult tissues are predominantly 
localized to the liver and kidney for the synthesis of creatine and choline, the major sinks 
for SAM-bound 1C units.1 In rest of the non-proliferative tissues, folate metabolism 
maintains the homeostasis of nucleotides and amino acids (methionine, serine, and 
glycine), and generates ATP and NADPH from dietary choline, serine, and glycine 
(Figures 2 and 4).14  
A.1.4. Dietary folate intake and adult disease 
Insufficient dietary folate or reduced intestinal folate absorption results in folate 
deficiency. Increased homocysteine levels because of folate deficiency has been correlated 
with pathologic conditions such as cardiovascular diseases, cognitive decline, neurologic 
disorders, and cancer.3 Supplemental vitamin B intake in clinical trials have not shown any 
benefit in these conditions. Across various experimental and epidemiological studies, 
incidence of gastrointestinal cancers, particularly colorectal cancer, was observed to be 
inversely correlated with folate consumption.15 Population-based studies of breast and 
pancreatic cancers have also shown similar results.16-17 However, in a clinical study, 
supplemental folic acid while not suppressing the recurrence of colon polyps in patients 
with at least one adenoma, showed a trend toward both more polyps and carcinoma.18 As 
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such, while adequate long-term folate intake is essential for genome integrity, the growth 
of existing lesions may be fueled by added folates. 
A.1.5. Folate-based antimetabolite therapies for cancer 
Folate metabolism is important for cancer cell growth due to its essential role in 
nucleic acid synthesis and cellular proliferation (concurrent with increases in folate uptake 
and folate-metabolic enzymes). Inhibitors of folate transformations are widely used as 
antimetabolites for treating cancer.  
 
Figure 5. Structures of classical antifolates.  
The discovery of antifolate aminopterin, the 4-amino derivative of folic acid, in 
pediatric leukemia marked the beginning of modern science of chemotherapy (Figure 5).19 
Antifolates inhibit folate cofactors-using cellular enzymes to treat a variety of cancer types 
and have been in use for over >60 years.20-24  Though aminopterin caused remission of 
childhood leukemia, it showed substantial toxicity and led to the development of 
methotrexate (MTX), a N10-methylated version of aminopterin that inhibits dihydrofolate 
reductase, currently used widely in the treatment of many malignant conditions including 
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acute lymphoblastic leukemia (ALL), osteosarcoma, lymphoma, and breast cancer.19, 22, 25 
Pemetrexed (PMX, Alimta, LY231514), a 5-substituted pyrrolo[2,3-d]pyrimidine analog 
is another antifolate used as a first-line treatment for non-small cell lung cancer (NSCLC) 
which was FDA-approved in 2004 for the treatment of malignant pleural mesothelioma.26-
27 PMX primarily inhibits thymidylate synthase. Other clinically used antifolates include 
the most recently approved (2009) pralatrexate (PTX), a 10-deazaaminopterin analog of 
MTX which is a DHFR inhibitor used for the treatment of relapsed or refractory peripheral 
T-cell lymphoma. Raltitrexed (RTX), a thymidylate synthase inhibitor has been approved 
outside of the US, for treating advanced colorectal cancer.28-30 
 
A.2. Folate uptake 
Folate cofactors are hydrophilic anions at physiologic pH and diffuse poorly across 
cell membranes. Consequently, folate transport systems have evolved in mammalian cells 
to facilitate cellular uptake.  
In mammalian cells, folate transport is facilitated by genetically distinct systems.7, 
31-33 
A.2.1. Reduced folate carrier (RFC; Solute Carrier (SLC) 19A1)  
RFC, a ubiquitously expressed transport system, facilitates the majority of the folate 
uptake in mammalian healthy cells as well as malignant tissue.34  
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A.2.1.1. RFC: basic biology and physiology 
RFC is the best characterized folate transporter.34-39 RFC has high affinity (~50-
100-fold) for reduced folates (Ki ~1-5 μM) and a low affinity for folic acid (Ki ~150 μM) 
for transport from the blood into cells of peripheral tissues (Table 1).40 
Table 1. Comparison of the affinities of RFC for different folates at acidic or neutral pH.40 
Folate RFC Influx Kt or Ki 
(µM) 
pH = 5.5 pH = 7.4 
Folic acid 125 142 
(6S)5-formyl-THF  ~2 
(6R)5-formyl-THF  40 
(6S)5-methyl-THF  1-5 
 
RFC transport is temperature- and pH-dependent, characterized by a neutral 
optimum which decreases dramatically below pH 7 (Table 1).41 Concentrative uphill 
uptake of folate substrates by RFC is directly linked to organic phosphates gradient across 
the plasma membrane that are transported out via RFC (Figure 3).38, 42 Highly elevated 
human RFC (hRFC) transcripts have been detected in the placenta and liver, while 
significant levels in leukocytes, kidneys, lungs, bone marrow, intestines, and portions of 
the CNS and brain were also detected.43-44 RFC is essential for development; inactivating 
both its alleles is embryonic lethal and causes failure of the hematopoietic organs (bone 
marrow, the thymus, or the spleen).45 Although RFC is exposed to the cerebral spinal fluid 
(CSF), its role in folate transport in the central nervous system (CNS) is not clear.  
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Figure 6. Predicted and experimentally validated membrane topology of the human 
reduced-folate carrier (hRFC) is shown.46 Functionally important residues are highlighted 
in blue, and the N-glycosylation site is in green. EL, extracellular loop; IL, intracellular 
loop. 
RFC belongs to the major facilitator superfamily (MFS) of transporters and hRFC 
has a typical MFS protein structure with 591 amino acids arranged in 12 transmembrane 
domains (TMDs) (Figure 6).35, 47-48 The N- and C-termini and a large non-conserved loop 
domain between TMDs 6 and 7 face the cytosol.34-35, 46 Neither the termini, nor the 
intracellular loop domain participate in the binding and translocation of folate substrates.49-
51 In the extracellular loop domain connecting TMDs 1 and 2, hRFC is glycosylated at 
Asn58, mutation of which abolishes N-glycosylation with minimal effect on both 
membrane targeting and transport activity.52-53 The TMD6–7 loop domain provides 
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appropriate spacing between the TMD1–6 and TMD7–12 segments for optimal transport 
activity. Arg133, Ile134, Ala135, Tyr136, Ser138 of TMD4 and TMD5, Tyr281 in TMD7, 
Ser313 in TMD8, Arg373 in TMD10, and TMD11 form the membrane translocation 
pathway for the anionic folate substrates. Studies of nonfunctional hRFC and site-directed 
mutagenesis implicated functional or structural importance of some of these amino acids 
(Ser313, Arg133, Arg373).54-56 Other residues including Val29, Gly44, Glu45, Ser46, 
Ile48, Val106, Trp107, Ser127, and Ala132 were implicated as functionally important from 
studies in mouse and hRFCs.46 The γ-carboxylates of folate analogs form an ionic bond 
with Lys411 in TMD11 of hRFC, which is critical for binding and transport.57 It was 
suggested recently that, typical of MFS proteins, hRFC exists as a homo-oligomer with 
each hRFC monomer functioning independently via individual translocation pathways for 
folate substrates.58-59 Formation of oligomeric RFC may be necessary for intracellular 
trafficking and surface expression of the functional transporter. 
A.2.1.2. The role of RFC-mediated folate transport in tumors 
Not only is hRFC the predominant folate transporter in normal tissues, but hRFC 
transcripts measured by real-time polymerase chain reaction (qPCR), detected hRFC 
expression in almost all leukemia cell lines (Figure 7a) and all solid tumor cell lines (Figure 
7b).60  
All of the antifolates in clinic are transported primarily via RFC. In spite of their 
demonstrated clinical efficacy, none of these agents are selectively targeted to the diseased 
tissue, resulting in substantial dose-limiting toxicity toward normal tissues drawing no net 
therapeutic gain.34 The substantial toxicities encountered with these inhibitors are at least 
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partly due to their RFC-mediated transport with low micromolar Kt (Michaelis constant) 
into both tumors and normal tissues.34-35, 46, 61-64 
 
Figure 7. Transcripts for RFC in (A) leukemia and (B) solid tumor cell lines. Transcript 
levels were normalized to GAPDH transcripts.60 
Additionally, loss of RFC transport is an important contributing factor for antifolate 
resistance development. Loss of RFC-mediated antifolate transport results from decreased 
RFC expression, or synthesis of mutant RFC with impaired transport function.34, 65-66 
Clinical resistance to MTX in ALL and osteogenic sarcoma has been implicated due to 
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loss of RFC transport. While PMX is argued to have superior activity in solid tumors, 
toxicities are caused by inhibition of 1C metabolism in non-transformed cells, including 
those of the intestinal epithelium and bone marrow, resulting in gastric complications, 
anemia, and immune deficiency. While rescue therapy with 5-formyl-THF (folinic acid, 
marketed as leucovorin) (Figure 1) decreases toxicity, their therapeutic index remains 
modest.1, 22, 65  
A.2.2. The folate receptors (FRs) 
One other type of important folate uptake systems in mammalian cells and tissues 
include the glycosyl phosphatidylinositol (GPI)-tethered FRs α and β anchored at the 
plasma membrane, and FRγ (secreted due to the lack of GPI anchoring signal sequence).32, 
67-77  
A.2.2.1. FRs: basic biology and physiology 
The FRs are high affinity folate binding proteins that mediate cellular folate uptake 
by endocytosis.78 FRα is expressed in the choroid plexus, proximal renal tubules, retinal 
pigment epithelium, uterus, and placenta.67 In the proximal renal tubules, FRα is expressed 
at the apical brush-border membrane (not exposed to circulation, whereas RFC expressed 
at the basolateral membrane is exposed to circulation).32, 39, 67 During glomerulus filtration 
of urine, folates are reabsorbed and reenter the circulation primarily by FRα-mediated 
process at the apical membrane. Along with PCFT, folates are suggested to be actively 
transported via the FRα localized at the basal and apical membranes of the choroid plexus 
into the CSF.32, 79-80 In children with cerebral folate deficiency, loss of function mutations 
in FRα were described.81-82 FRβ is expressed in placenta and hematopoietic cells, as well 
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as inactivated macrophages.67, 83-84 Human FRβ (hFRβ) is a differentiation marker co-
expressed at relatively low levels with cluster of differentiation (CD) 14 in monocytes.85-
86 Low levels of human FRγ (hFRγ) is secreted by the lymphoid cells in the spleen, thymus, 
and bone marrow. The biological functions of hFRβ and hFRγ in normal tissue are 
unclear.74, 78, 84-90  
A.2.2.2. Structure of FRs 
 
Figure 8. Two views of the complex structure of FRα (green) bound to folic acid (grey).91 
The disulphide bonds are depicted as yellow sticks and N-acetyl glucosamine (NAG) is in 
orange. The N- and C- termini are labelled. 
 Folate receptors are cysteine-rich, highly homologous proteins (68-79% identical 
amino acid sequence) with 229 to 236 amino acids and two (β, γ) or three (α) N-
glycosylation sites.91 The cysteine rich crystal structure of human FRα (deglycosylated) 
in complex with folic acid was recently resolved at 2.8 Å resolution (Figures 8 and 9).91 
It consists of ∼205 residues that form a globular tertiary structure, comprising of four 
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long α-helices (α1, α2, α3, α6), two short α-helices (α4, α5), four short β-strands (β1–β4) 
and many loop regions (Figure 8). The tertiary structure is stabilized by eight disulphide 
bonds and has three N-glycosylation sites at N47, N139 and N179.70-71, 92 The long and 
open folate-binding pocket is formed by α1, α2 and α3 in the back; the amino-terminal 
loop, β1 and β2 in the bottom; the α1– α2 and α3– α4 loops in the left and top; and α4, 
α5, β4 and β3 in the right (Figure 8). 
 
Figure 9. Ligand interaction map of folic acid (magenta) with FR ligand-binding-pocket 
residues (black).91 Hydrogen bonds are shown as green dashed lines with bond distances 
(Å). Hydrophobic interactions are shown as curved red lines.  
The residues that form the folate-binding pocket in hFRα and hFRβ are conserved 
and only one residue in the binding pocket that makes a polar contact with the ligands 
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differs (Lys136α/Arg152β) (Figure 9). The folate-binding interactions are conserved 
among the subtypes. Folate cofactors are oriented with the basic pteroate moiety buried 
within the negatively charged pocket whereas the negatively charged glutamate moiety is 
solvent-exposed and sticks out of the positively charged pocket entrance. The pterin ring, 
stacked in between hydrophobic residues Tyr85 and Trp171, and Tyr175 is engaged in a 
series of hydrogen bonds with receptor residues (Figure 9). The N1 and N2 atoms form 
hydrogen bonds with the side-chain carboxyl of Asp81. This interaction is a key contributor 
to high-affinity ligand binding as replacement of Asp81 decreased affinity by more than 
one order of magnitude. The N3 and O4 atoms engage in hydrogen bonds with the hydroxyl 
group of Ser174, and the O4 atom additionally makes two hydrogen bonds with the Arg103 
and Arg106 guanidinium groups. The N5 atom forms a hydrogen bond with the side-chain 
of His135. The CH2 linker and the aminobenzoyl side-chain extend through the central 
region of the elongated ligand-binding pocket formed by the hydrophobic residues Tyr60, 
Trp102 and Trp134. The glutamate tail, also involved in extensive interactions, engages in 
six hydrogen bonds with the side-chains of Trp102, Lys136 and Trp140, and the backbone 
amide of His135, Gly137 and Trp138. These receptors transport folate via a cell division 
cycle 42 protein-dependent endocytic mechanism.75, 93-94 FRs transport function is 
proposed to occur via three discrete pH-dependent biological trafficking states (Figures 10 
and 11).95 
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Figure 10. Schematic model of three biological trafficking states of human folate receptors 
for ligand endocytosis.95 Apo-FR conformation at the cell surface, at neutral to slightly 
basic pH (state I). Structural transition occurs upon ligand binding leading to complex 
formation (state II). After endocytosis, the mildly acidic microenvironment of the recycling 
endosome promotes ligand release. A third distinct conformation (state III) is likely to form 
under acidic conditions after ligand release, before recycling to the cell surface. 
 
Figure 11. Cartoon models representing proposed states I-III (A–C respectively) of folate 
transport.95 (A) apo-hFRβ structure with conserved disulfides colored orange. (B) 
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hFRβ/FOL complex (interacting residues shown as sticks). (C) The apo-hFRα model with 
global conformational differences in the structure of apo-hFR at pH 5.5. (D) 
Conformational differences between the three trafficking states are illustrated (numbered 
with arrows in the order of movement). Regions varying in each individual model are a 
shade darker of the same color. 
The three conformational states of FR are the apo-receptor and folate bound 
receptor at the cell surface and the apo-receptor within the endosome (Figures 9 and 10). 
The apo-receptor in an open conformation at neutral pH, at the cell surface undergoes 
minor rearrangements in loop regions (1) connecting the β1 and β2 strands and (2) 
following the α1 helix. Changes in sidechain rotamer conformations (e.g., His151, Arg152, 
Ser190, not shown here) facilitate specific contacts with folate, thus forming the folate 
bound conformational state (Figures 9 and 10).  Subsequently, FRs are encapsulated into 
an endosome and endocytosed, wherein folate release occurs. This release is due to a 
conformational change in the hFR/folate complex within the acidic microenviroment of the 
endosome (pH range of 5.6–7.2 with an average value of 6.5).68, 78, 93, 96 The receptor 
undergoes several conformational changes wherein the movement of four surface loops 
(basic loop, switch helix, anchor loop, and inhibitory loop) ultimately occlude the folate 
binding site to prevent reassociation of the released folate (Figure 10). Several basic 
residues (Arg125/Arg119 (Frα/FRβ), His54/His48 (Frα/FRβ), His36, His37) facilitate 
these global structural rearrangements due to ionization at acidic pH. In addition, the 
changes in electrostatic surface potential of hFR/folate complex with varying pH may in 
part trigger ligand release. After endocytosis, the folates are released into the cytoplasm by 
PCFT. 97 
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A.2.2.3. The role of FR-associated folate transport in tumors 
FRα is the most widely overexpressed FR isoform in tumors such as, nonmucinous 
adenocarcinomas of the ovary (up to 90% of ovarian cancers), uterus, breast, cervix, 
kidney, and colon, as well as testicular choriocarcinoma, ependymal brain tumors, 
malignant pleural mesothelioma, and nonfunctioning pituitary adenocarcinoma and is 
exposed to the circulation significantly contributing to the folate uptake.33, 67, 90, 98-100 hFRβ 
is overexpressed in certain leukemias, (chronic myelogenous leukemia and acute 
myelogenous leukemia) and tumor-associated macrophages (TAMs).85, 101 TAMs may play 
an important role in tumor metastasis and angiogenesis by releasing proangiogenic factors, 
(e.g., vascular endothelial growth factor, matrix metalloproteinase).  
More recently, the emphasis in folate-mediated drug therapy has shifted towards 
the development of therapeutic molecules specifically transported via the FRs over RFC.67, 
102-103 The substantial levels of FR-overexpression in many tumors compared to most 
normal tissues, and their significant transport activity combined with the efficacy of 
clinically available classical antifolates as first line therapy for several types of cancers, 
call for the design of FR-selective tumor-targeted therapeutics. FR-selective cytotoxic 
agents are expected to exhibit reduced toxicity toward normal tissues than the clinically 
available antifolates.  
The overexpression of FRα and FRβ in several types of cancers as mentioned 
above, warrants the development of folate receptor selective tumor-targeting cytotoxic 
agents.83, 96, 102, 104-107 The FRs in healthy cells are presented on the apical surface of 
polarized epithelial cells, which renders them mostly inaccessible to the circulating 
antifolates following intravenous administration.32, 67, 90 This principle has been utilized for 
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the design of several cytotoxic folate conjugates that selectively target FR expressing 
tumors.24, 108 Furthermore, monoclonal anti-FR antibodies could promote clearance of FR-
positive cells by the immune system, folate-conjugated drugs/imaging agents can deliver 
cytotoxic cargo or imaging agents to FR-positive cells, and FR-targeted antifolates are 
expected to circumvent the cytotoxic side effects of current antifolates (due to ubiquitous 
uptake via RFC).23, 104, 109-112 Additionally, FRβ-positive TAMs constitute an additional 
potential therapeutic target in assorted cancers.84-85, 89 
A.2.2.4. Structural requirements for antifolate binding to FRs 
 The structural and mutational analyses of FRs provide rationale for the absolute 
requirement of the folate anchoring pterin group for binding to the receptor. Replacement 
of O4 with an amino group (MTX and aminopterin have reduced affinity for Frα) is not 
tolerated due to loss of the hydrogen bonds made with Arg103 and Arg106, along with 
steric/electronic clash of the amino group into the side-chain of Arg103.112-113 However, 
such a replacement is tolerated for uptake by RFC. PMX is a 5-substituted 2-amino-4-oxo-
pyrrolo[2,3-d]pyrimidine antifolate with a 2C linker connecting the bicyclic scaffold to the 
pABA sidechain (Figure 5). It is a potent KB human tumor subline (expresses hRFC, hFRs 
and hPCFT) inhibitor (IC50 = 68 (12) nM) and is a non-selective inhibitor of engineered 
CHO sublines; PC43–10 (expresses hRFC), RT16 (expresses hFRα) and D4 (expresses 
hFRβ). PMX is one- to two-fold more selective towards RFC-overexpressing CHO cells 
over those that overexpress FRs (Table 2).114 
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Table 2. Cell proliferation assays with 6-substituted pyrrolo[2,3-d]pyrimidine 
antifolates.114-118  
 
Antifolate CHO (IC50s) (nM) KB (IC50s) 
(nM) 
PC43-10 
(RFC) 
RT16 
(FRα) 
D4 
(FRβ) 
1 >1000 199 48 10.4 
2 304 (89) 4.1 (1.6) 5.6 (1.2) 1.7 (0.4) 
3 >1000 6.3 (1.6) 10 (2.0) 1.0 (0.7) 
4 >1000 1.3 (0.1) 0.51 (0.09) 0.37 (0.08) 
5 106 (17) 0.31(0.15) 0.16 (0.02) 0.26 (0.03) 
6 >1000 1.82 (0.28) 0.57 (0.09) 0.55 (0.1) 
7 197 (49) 0.33 (0.15) 0.34 (0.03) 0.17 (0.05) 
8 189 (51) 0.61 (0.11) 0.1 (0.01) 0.09 (0.02) 
9 >1000 2.5 (0.5) 0.43 (0.14) 0.17 (0.02) 
10 >1000 2.6 (0.59) 0.515 0.27 (0.07) 
PMX 26.2 (5.5) 42 (9) 60 (8) 68 (12) 
MTX 12 (1.1) 114 (31) 106 (11) 6.0 (0.6) 
RTX 6.3 (1.3) 15 (5) 22 (10) 5.9 (2.2) 
PTX 0.69 (0.07) 168 (50) ND 0.47 (0.20) 
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While the 6-regioisomer of PMX was inert toward tumor cells in culture, the 
conformationally extended and more flexible 3C (2) or 4C (3) linked analogs showed 
improved inhibition of proliferation of KB human tumor subline with IC50s of 1.7 and 1 
nM respectively.114, 119-120 Studies with the engineered PC43–10, RT16 and D4 CHO 
sublines convincingly showed that compounds 2 and 3 were highly selective inhibitors of 
proliferation of FR-expressing cells at nanomolar (nM) concentrations (Table 2).114 Both 
compounds 2 and 3 were ~6 to 11-fold more active toward hFR-expressing RT16 and D4 
cells and >100-fold selective for FRs over RFC, than PMX. These compounds are also 
more potent and selective than other clinically used folates, MTX, PTX, or RTX which 
showed no selectivity for hFRs over hRFC (Table 2). Furthermore, thienyl-for-
phenyl/pyridyl-for-phenyl sidechain replacements afforded some of the most potent FR-
selective antifolate compounds 4-10.104, 107, 115-116, 121 Pyrrolo[2,3-d]pyrimidine thienoyl 
regioisomers, 5 and 10 with 3C and 4C linkers are few of the most potent and selective 
inhibitors respectively (Table 2). Compound 5, 7 and 8 with 3C linked regioisomers are 
the most potent RT16, D4 and KB cell inhibitors but with submicromolar activity against 
PC43-10, whereas the 4C linked regioisomeric compounds 6, 9 and 10 are relatively less 
potent RT16, D4 and KB cell inhibitors but with >1µM IC50s against PC43-10. Activity 
generally declined dramatically as the linker lengths were increased beyond 4C.  
A.2.3. Proton-coupled folate transporter (PCFT, SLC46A1) 
 PCFT, identified in 2006 is a facilitative high affinity transporter of dietary folates 
in the duodenum.122 
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A.2.3.1. PCFT: basic biology and physiology 
PCFT is distantly related to RFC (~ 14% amino acid identity), belongs to the major 
facilitator superfamily (MFS) of secondary transporters, but with distinct substrate 
specificities, mechanism, pH optimum, and patterns of expression in tissues and tumors.46, 
122-124  
Table 3. Comparison of the affinities of PCFT for different folates at acidic or neutral pH. 
Folates  PCFT 
Influx Kt or Ki (µM)
pH = 5.5 pH = 7.4 
Folic acid 1.3 56.2 
(6S)5-formyl-THF 0.13  
(6R)5-formyl-THF 0.87  
(6S)5-methyl-THF 0.53  
 
Whereas RFC is optimally active at neutral, physiologic pH (pH 7.2–7.4), PCFT is 
a folate-proton symporter with an acidic maximal activity at pH 4.5–5.5, with appreciable 
activity up to pH 6.8 and dramatic loss with further increase (above pH 7).40, 123, 125-127 
PCFT is highly expressed in the apical brush border membranes in the proximal part of 
small intestine (jejunum and duodenum) where despite the presence of RFC, the acidic pH 
optimum of the upper gastro intestine (GI) (pH 5.8–6.0) permits PCFT-, but not RFC-
mediated membrane transport.32, 39, 112, 122, 126, 128-129 From the enterocytes, folates are 
transported across the surface of basolateral membrane [most likely by multidrug 
resistance-associated protein (MRP) 3] into the bloodstream for delivery to the liver by the 
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hepatic portal vein. From the liver, folates (primarily as 5-methyl THF) are released into 
the blood. PCFT also shows significant folate uptake in the CNS.97, 130 Unlike the 
ubiquitously expressed RFC, PCFT expression is elevated in only certain tissues (e.g., the 
kidney, the sinusoidal membrane of the liver, the basolateral membrane of the choroid 
plexus, retinal pigment epithelium, the placenta and spleen) and its broader physiologic 
role for folate uptake in these tissues is still uncertain and seems unlikely due to the 
characteristic non-acidic conditions (except transport across the choroid plexus due to a 
localized low pH at the basolateral membrane of ependymal cells).7, 32, 39, 97, 122, 126, 130-131 
The Kt (Michaelis constant) values of folate transport by PCFT changes with pH for 
individual substrates (Table 3).60, 104, 119, 132-133 While folic acid is poorly transported by 
RFC, it is a reasonably good PCFT substrate.127 Loss or mutations in human PCFT 
(hPCFT) as can be recapitulated in PCFT knockout mice, result in hereditary folate 
malabsorption syndrome, a rare autosomal recessive disorder characterized by the onset of 
macrocytic folate deficiency, anemia, and failure to thrive within the first few months of 
life.40, 80, 122, 134-141 Loss of hPCFT function also leads to gait disorders, peripheral 
neuropathies and seizures, and impaired folate uptake across the choroid plexus into the 
CNS.  
A.2.3.2. Structure of PCFT and biology of transport 
 PCFT is composed of 459 amino acids (Figure 12) and the predicted molecular 
mass is 49.8 kDa. It has 12 TMDs with cytosolic N and C termini.142-143 The extracellular 
loop domain connecting TMDs 1 and 2 has two N-glycosylation sites (Asn58 and Asn68). 
Single mutation of either Asn58 or Asn68 does not affect the expression and function, 
while Asn58/Asn68 double mutation reduces transport activity by 40%. Carboxyl-terminal 
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amino acids (up to position 449) are not involved in either targeting or transport activity. 
Also, the disulfide bond between Cys66 (first extracellular loop) and Cys298 (fourth 
extracellular loop) connecting TMDs 7 and 8 is not essential for transport activity. 
 
Figure 12. Predicted membrane topology of the hPCFT. Functionally important residues 
are highlighted in blue and the β-turn formed by residues 109–114 is in orange.46 Cys229 
is highlighted in yellow. Asn58 and Asn68, the two N-glycosylation sites are highlighted 
in green. EL, extracellular loop; IL, intracellular loop.143 
Functionally important hPCFT residues include Glu185 (TMD5, proton coupling), 
His281 (TMD7, PCFT protonation for enhanced substrate binding), Arg376 (TMD10, 
proton and substrate binding), a conserved stretch of amino acids linking TMDs 2 and 3 
(DXXGRR; positions109–114) including a β-turn, Asp109, Arg113, His247 [decreased 
rates of transport (Vmax), and increased affinities (Kt)], Leu161 (TMD4, substrate 
affinities), Glu232 (TMD6, rate of carrier translocation), Ile304 (TMD8, substrate 
affinities), and Pro425 (flanks TMD12, substrate affinities), Gly189 and Gly192, 
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(TMD5).40, 134, 137, 139, 142, 144-148 Residues Phe157, Gly158, and Leu161 in TMD4 and Ile188 
in TMD5 are predicted to lie within or nearby the folate binding site in hPCFT.148-149 Like 
the other MFS proteins, hPCFT is proposed to exist as a functionally significant 
homooligomer with TMD6 providing a structural interface between individual hPCFT 
monomer.148, 150-152 PCFT-mediated transport of folates is electrogenic with net 
translocation of positive charges for each negatively charged folate (Figure 3).122, 137, 142  
A.2.3.3. The role of facilitative folate transport by PCFT in tumors 
Within the tumor microenvironment, the extracellular pH (pHe) can be as low as ~ 
6.7–7.1, and intracellular pH (pHi) is ≥ 7.4 (a hallmark of cancer) while pHe is ~ 7.3 and 
pHi is ~ 7.2 in a normal differentiated cell.153-157 Since PCFT transports folates and related 
molecules under low pH conditions and is significantly active at pH 6.5–6.8, it is a major 
folate-proton symporter in the acidic microenvironment of many solid tumors.7, 60 In the 
acidic pH of tumors, the elevated electrochemical proton gradient favors high levels of 
membrane transport of cytotoxic PCFT. There is growing evidence supporting an 
association between PCFT levels and function with the malignant phenotype. Substantial 
PCFT expression in 52 of 53 human solid tumors (n = 53) was detected in a comprehensive 
analysis of folate transporter expression (Figure 13).60 Elevated PCFT transcript levels and 
transport activity at pH 5.5 are observed in hepatoma cells, epithelial ovarian cancer, 
malignant pleural mesothelioma, non-small cell lung cancer and pancreatic cancer cells.60, 
119, 158-160 PCFT levels are low-to-undetectable in leukemias (including ALL and acute 
myeloid leukemia).60, 161  
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Figure 13. Transcripts for PCFT in solid tumor cell lines. Transcript levels were 
normalized to GAPDH transcripts.60 
Even if PCFT is present in the normal tissue milieu, neutral pH and reduced 
electrochemical proton gradient favors membrane transport by RFC, limited PCFT-
mediated uptake of cytotoxic antifolates, and limited cytotoxicity toward normal tissues.  
Depending upon the substrates specificities for PCFT and/or RFC, PCFT/ RFC expression 
levels, their localization in the tumor/tissue which determines their access to circulating 
drug, and the pH of the tumor/tissue microenvironment relative to the pH for optimal 
transport by PCFT or RFC, net uptake of classical antifolate drugs by tumor and tissue 
confers antitumor efficacy and toxicity respectively. Antifolates such as MTX, PMX, 
RTX and PTX which are RFC substrates are also transported by PCFT, albeit to different 
extents.7, 22, 40, 46, 96, 112, 122-123, 127, 132, 135, 162-165 In mesothelioma patients treated with PMX, 
patients with low PCFT transcripts had significantly lower rates of disease control and 
shorter overall survival, strongly implying that PCFT is an important determinant of PMX 
clinical efficacy in malignant mesothelioma.160  
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The clinical successes of PMX, along with evidence that hPCFT can potentially 
offer tumor-targeted antifolate delivery, has steered drug discovery efforts to develop novel 
PCFT–selective cytotoxic antifolates over RFC. More recently, the emphasis in folate-
mediated drug therapy has shifted towards the development of therapeutic molecules 
specifically transported via PCFT over RFC.7, 60, 104, 107, 119, 121, 158-159, 166-167 The (1) 
substantial levels of FRs and PCFT-expression in many tumors compared to most normal 
tissues, and (2) significant transport activity of PCFT at tumor microenvironment specific 
acidic pH, combined with (3) the efficacy of clinically available classical antifolates as first 
line therapy for several types of cancers, call for the design of selective tumor-targeted 
therapeutics with high level substrate activity and selectivity for PCFT over RFC. PCFT-
selective cytotoxic agents are expected to exhibit reduced toxicity toward normal tissues 
than the clinically available antifolates.  
 
While PMX, a 5-substituted 2-amino-4-oxo-pyrrolo[2,3-d]pyrimidine antifolate 
with a 2C linker is a PCFT substrate, (Figure 5) the 6-sustituted regioisomer of PMX was 
inert toward tumor cells in culture (Table 4). Upon extension of the linker to 3C and 4C in 
compounds 2 and 3 respectively, activity was regained with much higher potency when 
compared to PMX. Compound 2 was ~40-fold more active and compound 3 was ~70-fold 
more potent than PMX (IC50s of 1.7, 1 and 68 (12) nM respectively) toward KB cells 
(Table 4). 
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Table 4. Cell proliferation assays with 6-substituted pyrrolo[2,3-d]pyrimidine 
antifolates.114-117   
 
Antifolate CHO (IC50s) (nM) KB (IC50s) (nM) 
PC43-10 
(RFC) 
R2/PCFT4 
(PCFT) 
1 >1000 >1000 10.4 
2 304 (89) 23.0 (3.3) 1.7 (0.4) 
3 >1000 213 (28) 1.0 (0.7) 
4 >1000 30.4 (10.7) 0.37 (0.08) 
5 106 (17) 3.3 (0.5) 0.26 (0.03) 
6 >1000 43.4 (4.1) 0.55 (0.1) 
7 197 (49) 5.4 (1.3) 0.17 (0.05) 
8 189 (51) 6.51 (1.3) 0.09 (0.02) 
9 >1000 41.5 (3.1) 0.17 (0.02) 
10 >1000 63.82 (16.23) 0.27 (0.07) 
PMX 26.2 (5.5) 8.3 (2.7) 68 (12) 
MTX 12 (1.1) 121 (17) 6.0 (0.6) 
RTX 6.3 (1.3) 99.5 (11.4) 5.9 (2.2) 
PTX 0.69 (0.07) 57 (12) 0.47 (0.20) 
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Studies with the engineered PC43–10 and PCFT expressing R2/hPCFT4 CHO 
sublines convincingly showed that these compounds were selective inhibitors of 
proliferation of hPCFT over RFC expressing cells unlike PMX.114 Compound 2 was ~9-
fold more active than compound 3 (IC50s of 23 (3.3) and 213 (28) nM respectively) toward 
hPCFT-expressingR2/hPCFT4 cells. A similar trend of improved potency as well as 
selectivity were observed when compared with the other clinically used antifolates MTX, 
PTX, or RTX (Table 4). Similar to improvement in FR mediated potency and selectivity, 
thienyl-for-phenyl/pyridyl-for-phenyl sidechain replacements afforded some of the most 
potent PCFT-selective antifolate compounds 4-10 (Table 4). Pyrrolo[2,3-d]pyrimidine 
thienoyl regioisomers with 3C linkers, 5 (2',5'-substituted thiophene), 7 (2',4'-substituted 
thiophene) and 8 (3',5'-substituted thiophene), showed the best PCFT-targeted activity with 
IC50s of 3.3 (0.5) and 5.4 (1.3), and 6.51 (1.3) nM respectively against R2/hPCFT4 cells. 
Activity generally declined dramatically for analogs with linker lengths longer than 4C.  
 
A.3. Folate compartmentalization 
A.3.1. Polyglutamylation encoded compartmentalization 
Folates, once inside a cell, are distributed between mitochondria, cytoplasm and 
nucleus. 168-169 Up to 40% of the intracellular folate is concentrated in the mitochondria, 
(transported in the mono-glutamylated form by a folate specific mitochondrial transporter 
SLC25A2).170-171 Furthermore, the intracellular folates are polyglutamylated (2–8 
glutamate moieties) by the addition of glutamate residues via a γ-peptide linkage catalyzed 
by folate polyglutamate synthetase (FPGS) (Figure 14).172-175 Polyglutamylation reduces 
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folate affinity for the transporters/efflux pumps and are thereby retained within. It also 
enhances the affinity of folates towards the target enzymes, and is essential for cell 
proliferation.172, 176-178  
Figure 14. Polyglutamylation reaction catalyzed by folylpolyglutamate synthetase. 
Representative example shown is diglutamylation of 5,10-methylene-THF.179 
Antifolate inhibitors such as MTX or PMX that are transported into tumors sustain 
potent antitumor activity upon polyglutamylation. Polyglutamyl antifoltes typically bind 
to their cellular targets with much higher affinities than their non-polyglutamyl drug 
forms.22, 63, 165, 180-181 For example, PMX inhibits thymidylate synthase ~100-fold more 
effectively following its polyglutamylation.182 Upregulated FPGS function in tumors likely 
contributes to the differences in the extent of antifolate polyglutamylation between normal 
tissues and tumors, drug selectivity and antitumor efficacy. Reduced FPGS activity is a 
known mechanism of resistance developed by tumor cells towards antifolates.66 However, 
antifolates with sufficiently potent folate-metabolizing enzyme inhibition independent of 
polyglutamylation could be efficient against antifolate resistant tumors with changes in 
FPGS function and expression.65, 183  
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A.4. Folate Metabolism 
A.4.1. Products of 10-formyl-THF  
 
Figure 15. The two folate-dependent 1C unit transfers in the purine biosynthetic process. 
De novo synthesis of purines in proliferating mammalian cells demands for the 
largest proportion of the folate 1C units in the form of 10-formyl-THF. The folate-
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dependent enzymes, glycinamide ribonucleotide formyl transferase and 5-aminoimidazole-
4-carboxamide ribonucleotide formyl transferase (GARFTase and AICARFTase) that 
catalyze the 1C unit transfer are a part of a putative multi-enzyme complex termed the 
purinosome that are co-localized in the cytoplasm outside of mitochondria.184-185 In the 11-
reaction purine biosynthetic process, two 10-formyl-THF units are incorporated into the 
purine backbone (Figure 15). As such, on an average, for every newly synthesized DNA 
or RNA base, one 10-formyl-THF is required.  
In the mitochondria, 10-formyl-THF formylates the initiator methionine transfer 
RNAs (tRNAs) for translation of mitochondrially encoded proteins.186 10-formyl-THF is 
reversibly hydrolyzed in an ATP-generating reaction to free formate by mitochondrial 
methylenetetrahydrofolate dehydrogenase 1 like (MTHFD1L) to enable transfer of 1C 
units between compartments.187 Additionally, the elimination of the 1C unit of 10-formyl-
THF via oxidation to CO2 by mitochondrial 10-formyltetrahydrofolate dehydrogenase 
(FDH) is coupled to NADPH-generation. As per recent findings, folate-mediated NADPH 
production may be vital for mitochondrial redox homeostasis.188-189  
A.4.2 Products of 5,10-methylene-THF:  
Catalyzed by Thymidylate synthase (TS), 5,10-methylene-THF methylates 
deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) in the 
cytoplasm (Figure 16). In this process, two electrons are abstracted from 5,10-methylene-
THF producing DHF as the product. DHF is reduced back to THF by the NADPH-
dependent activity of dihydrofolate reductase (DHFR). For every 4 newly synthesized 
DNA or RNA base, an average of one 5,10-methylene-THF is needed for DNA synthesis.  
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Figure 16. The dTMP cycle. 
5,10-methylene-THF-dependent hydroxymethylation of glycine to serine is 
synthesized in a reversible reaction by serine hydroxymethyltransferase (SHMT) (Figure 
16). SHMT-mediated metabolism of serine is compartmentalized between the 
mitochondria and cytoplasm, depending upon the supply and demand of 1C units (Figure 
4).190 
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A.4.3 Product of 5-methyl-THF:  
 
Figure 17. Methionine salvage. 
5-Methyl-THF is the 1C unit transferring cofactor of methionine synthase (MTR) 
used for remethylation of homocysteine to methionine (Figure 17).191-194 Methionine is the 
substrate for the synthesis of physiologically important reactive methyl carrier S-
adenosylmethionine (SAM) by SAM synthetase. SAM, the second most common 
enzymatic cofactor after ATP, plays a key role in epigenetics (histone methylation); 
biosynthetic processes including phosphatidylcholine (likely the largest 1C sink in adult 
mammals), creatine, and polyamine synthesis; and sulfur metabolism.  
 
A.5. Folate metabolizing enzymes 
A.5.1. Dihydrofolate reductase (DHFR) 
DHFR catalyzes the NADPH-dependent reduction of folic acid to DHF and THF. 
THF is an essential cofactor for the biosynthesis of purines, thymidylate, and several amino 
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acids, and biological methylation reactions.195 Altered enzymatic activity of DHFR due to 
DHFR gene polymorphisms alters the THF pool for 1C metabolism which may contribute 
towards diseases dependent on folate status, such as cancer and spina bifida. 
A.5.1.1. Structure of DHFR 
DHFR is a small monomeric enzyme with 159-250 amino acids. It has an α/β 
structure with the core made up of eight-stranded β-sheet (seven parallel and one 
antiparallel strands). It also has four α-helices. The active site for substrate and cofactor 
(nicotinamide portion of NADPH) binding is located in a hydrophobic pocket indicating 
an important role of van der Waals interactions in ligand binding. The polar residues and 
the backbone carbonyls in the hydrophobic pocket however, do complement the polar 
pteridine and glutamate portions of the folate substrate (Figure 18).196 
 
Figure 18. hDHFR in complex with folic acid (green) (PDB 1DRF) visualized using 
Maestro 11.2.196-197  
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As the reduced folates DHF and THF are susceptible to oxidative degradation, folic 
acid bound crystallographic structure of DHFR was resolved to gather structural 
information on protein-substrate interactions and substrate reduction by NADPH (Figure 
18).198 The 2-amino group of the pteridine moiety hydrogen bonds specifically with the 
carbonyl side-chain of Glu30. It also forms a network of hydrogen bond via a conserved 
water molecule with the side-chain oxygen of Thr136 and the backbone carbonyl of 
Phe134. The lactam O4 is hydrogen bonded to side-chain carboxylate of Glu30 and the 
indole nitrogen of Trp24 via the conserved water molecule. The pABA moiety is positioned 
in a hydrophobic subsite, and van der Waals contacts exist between the benzoyl ring and 
the sidechains of Phe31 and Phe34. The amide carbonyl oxygen forms a hydrogen bond 
with the sidechain amide nitrogen of Asn64. The α-carboxyl of the L-glutamate interacts 
strongly via a salt bridge with the side-chain guanidinium of the Arg70. In contrast, the γ-
carboxylate does not interact with any residue and is exposed to the bulk-solvent interface. 
This suggests that the folate polyglutamates polymerized via the γ-carboxylate could 
readily extend into the surrounding solvent for improved binding to hDHFR.199-200 
A.5.1.2. Catalytic mechanism 
One side of the pteridine ring faces the binding site of the nicotinamide moiety of 
the coenzyme from where a hydride ion is transferred during catalysis.201 Neither N5 nor 
N8 interact with the enzyme or to any of the water molecules. In the first step of folate 
reduction, a proton must be transferred from solution to N8, and to N5 after dihydrofolate 
reduction (after hydride transfer). Although no intermediates have been experimentally 
observed or characterized, multiple evidence point towards the first step of reduction to 
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7,8-DHF.196, 202-203 The proposed catalytic mechanism of 7,8-DHF reduction to THF by 
DHFR is shown in Figure 19.  
 
 
Figure 19. The catalytic mechanism of human DHFR. 
The dissociation of THF is the rate-determining stage of the catalytic cycle for all 
forms of DHFR, and occurs only after NADP+ is replaced by NADPH due to negative 
cooperative effect upon the formation of the ternary complex. X-ray diffraction studies 
confirmed that the final step of reduction afforded (6S)-THF.204 
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A.5.1.3. Role of DHFR in cancer 
THF shuttles carbon atoms for the action of folate-dependent enzymes and is thus 
essential for DNA synthesis and methylation. After a carbon unit is transferred, the folate 
is sequentially recycled by DHFR. Depleting THF levels by inhibiting DHFR, slows DNA 
synthesis and cell proliferation. Mutations and abnormal protein expression of DHFR has 
been related to specific cancers such as ALL, breast cancer, uterine sarcoma, cervical 
cancer etc.205-206 
A.5.2. Thymidylate synthase (TS) 
TS uses 5,10-methylene-THF  as  the  1C  methyl  donor for the catalytic reductive 
methylation  of  dUMP  to  dTMP, an essential precursor for DNA synthesis (Figure 16).207  
A.5.2.1. Structure of TS 
TS is a homodimeric enzyme (30-35kDa each) and contains about 316 amino acids. 
The overall fold of the enzyme is defined by 8 α-helices, 10 strands of β sheet, and several 
segments of coil that connect the secondary structural elements. Each subunit has a deep 
active site cavity that contains residues donated from both the subunits providing a 
structural basis for obligate dimerization of TS.208  
Sayre et al. reported a 2.89 Å  X-ray crystal structure of the ternary complex of hTS 
:dUMP:PMX.209 dUMP which binds first, forms part of the binding site for folates which 
bind to the active site on top of the nucleotide (Figure 20). The pterin ring of the folates 
adopt a folded conformation when bound to TS and is placed roughly perpendicular to the 
pABA side-chain. The largest contact of the pterin scaffold is made with the bound 
pyrimidine of dUMP in which the ring systems of the two ligands are stacked against each 
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other by nonpolar interactions with Trp109. The backbone carbonyl of Ala313 and the side-
chain carbonyl of Asp112 accept hydrogen bonds from the 2-NH2 group and the pyrrole 7-
NH respectively. The aromatic ring of the pABA sidechain is placed in a hydrophobic 
pocket lined with the sidechains of Phe225, Leu221 and IIe108.  The α-carboxyl of the 
glutamate forms an ionic interaction with Lys77. The binary crystal structures of TS with 
folate analogs confirm that folates can bind to the enzyme in the absence of the substrate.210-
215 
 
Figure 20. hTS in complex with dUMP and PMX (grey) (PDB 1JU6) visualized using 
Maestro 11.2.197, 208  
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A.5.2.2. Catalytic mechanism 
Figure 21 shows the salient features of the chemical mechanism of TS. A reversible 
ternary complex of TS is formed after sequential binding of the substrate dUMP followed 
by cofactor 5,10-methylene-THF.207 A Michael-type adduct formed by the nucleophilic 
attack of the sulfhydryl of Cys195 of human TS (hTS) on the C6-position of the uracil ring 
in dUMP activates the C5-position.  
Protonation of the N10-position opens the tricyclic ring of the cofactor forming the 
N5-imminium ion in the bicyclic form. The N5-imminium of the unstable, covalent ternary 
complex is then trapped by the C5 Michael-type adduct to form the intermediate, which is 
followed by abstraction of C5-proton by a yet to be identified base in the active site. Its 
conjugate base is resonance delocalized through the pyrimidine ring of the substrate, 
eventually leading to the elimination of the covalently bound folate and formation of the 
intermediate with an exocyclic methylene. Due its high carbonium ion character, the C7 
methylene readily accepts a hydride from C6 of the noncovalently bound folate. The final 
β-elimination of the enzyme from C6 of the pyrimidine occurs without any assistance.207 
A.5.2.3. Implications of Surface Charge Pattern on Polyglutamylation 
The folate-binding region of TS active site exhibits the largest area of positively 
charged surface as observed from the molecular electrostatic potential map. This is the 
region where the polyglutamate tail of the folate cofactor binds.216 The polyglutamyl 
moiety does not form fixed interactions with the protein except for the first glutamate 
residue. The additional glutamate chains are progressively more disordered and are 
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expected to bind to Lys50, Lys51, His-53, Arg55 Lys58 and Lys311 residues in the regions 
of positive electrostatic potential.217-219 
Figure 21. The catalytic mechanism of human TS. 
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A.5.2.4. Role of TS in cancer 
TS protein and mRNA levels are elevated in many human cancers such as 
colorectal, breast, cervical, bladder, kidney, and non-small cell lung cancers, which 
correlates with poor patient prognosis.220-224 2'-deoxythymidine-5'-triphosphate (dTTP) 
depletion due to inhibition of TS leads to dUTP misincorporation in to DNA, DNA 
fragmentation and growth prevention of actively dividing cells and finally apoptosis, 
referred to as “thymineless death”.225-226  
A.5.3. The purinosome 
The enzymes of the de novo purine biosynthetic pathway compartmentalize in the 
cytoplasm under conditions of purine depletion to form a functional complex termed the 
purinosome.184, 205 Purines are essential molecules that are components of a myriad of vital 
biomolecules such as DNA (cellular processes such as genetic transfer), RNA (translation 
and transcription), ATP and GTP (energy storage and transfer), cyclic AMP and GMP 
(signaling), and NADH, NADPH and coenzyme A (cofactors).227 Cells procure purine 
nucleotides either from de novo biosynthesis of inosine monophosphate (IMP) or by 
salvage from hypoxanthine, adenine or guanine. Increased de novo purine biosynthesis is 
linked to malignant transformation as purines are preferentially salvaged in a healthy 
cell.228-231 
The de novo biosynthesis of purines is a highly conserved pathway that forms 
inosine monophosphate (IMP) from 5-phosphoribosyl-α-1-pyrophosphate (PRPP) and 
glutamine. Ten enzymatic activities required to carry out this conversion in humans are 
catalyzed by six enzymes.232-233 A trifunctional enzyme (TGART) composed of 
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glycinamide ribonucleotide synthetase (GARS), GARFTase and aminoimidazole 
ribonucleotide synthetase (AIRS), and a bifunctional enzyme (ATIC) which is composed 
of AICARFTase and inosinemonophosphate cyclohydrolase (IMPCH) utilize folate 
cofactors for 1C transfer (a formyl group from 10-formyl-THF is transferred to the 
intermediate (Figure 15). X-ray crystal structures have been solved for TGART as well as 
ATIC.234-238 
The interplay of the purinosome with other metabolic pathways and its impact is 
only just beginning to be understood. The growth of cancer cells is dependent upon 
increased glucose uptake and lactic acid fermentation via a metabolic reprogramming 
phenomenon called the Warburg effect.156, 239 This process is tightly regulated by cellular 
purine levels. Pyruvate kinase, involved in glycolysis, plays a vital role in the growth and 
metabolic reprogramming of cancer cells and is allosterically stimulated by the purine 
biosynthetic pathway intermediate, succinyl-5-aminoimidazole-4-carboxamide-1-ribose-
5'-phosphate (SAICAR).240 This allosteric stimulation may then generate energy and 
metabolic flux in response to nutritional and energetic demands of rapidly multiplying 
cells. AICAR, a de novo purine biosynthetic intermediate and substrate of AICARFTase 
is an AMP analog and a known activator of AMP kinase (AMPK). AMPK is a regulatory 
switch for several intracellular processes such as glucose uptake, glycolysis, insulin 
signaling, lipogenesis, and cell cycle control among others.241-243  
A.5.3.1. GARFTase 
In higher eukaryotes, the enzyme GARFTase comprising the C-terminal domain of 
a trifunctional enzyme TGART catalyzes formylation of glycinamide ribonucleotide 
(GAR) to N-formyl glycinamide ribonucleotide (FGAR) (the first of two formyl transfer 
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reactions) in the de novo biosynthetic pathway of purines.236, 244-247 This is accompanied 
by the conversion of the cosubstrate, 10-formyl-THF, to THF.244, 248  
 
Figure 22. hGARFTase in complex with compound 11 (grey) (PDB 5J9F) visualized using 
Maestro 11.2.167, 197 Partial structure of GAR is shown in orange. 
 
Figure 23. Compound 11 co-crystallized as a complex with hGARFTase (PDB 5J9F).167 
A.5.3.1.1. Structure of GARFTase 
The apo protein, binary and ternary structures of human GARFTase (hGARFTase) 
with antifolates have been reported.167, 236, 249-251 Figure 22 shows the interactions made by 
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a co-crystallized GARFTase inhibitor, compound 11 in the folate binding pocket.167 The 
scaffold is stabilized in the binding site by multiple interactions, hydrogen bonds between 
(1) the N1 nitrogen and the backbone NH of Leu899, (2) 2-NH2 and the backbone carbonyl 
of Leu899 and Glu948, and (3) the 4-oxo and the backbone NH of Asp951 (Figure 22). 
Additionally, the 4-oxo form a water-mediated hydrogen bonding network via a conserved 
water molecule with Ala947, Gly953, and Asp949. The pyrrolo[2,3-d]pyrimidine bicyclic 
scaffold is also placed appropriately for van der Waals interactions with Val950. The N10 
hydrogen forms a hydrogen bond with the sidechain carboxyl of Asp951. The amide NH 
of the L-glutamate form a hydrogen bond with the carbonyl of Met896. The L-glutamates 
are oriented with the α-carboxylates forming a salt bridge with the side-chain of Arg871 
and a hydrogen bond interaction with the backbone amide NH of Ile898 and with the side-
chain of Arg897. The γ-carboxylate forms salt bridges with the side-chains of Lys844 and 
Arg897. 
A.5.3.1.2. Catalytic Mechanism 
Kinetic studies of hGARFTase suggest a random sequential binding and a direct 
nucleophilic attack of the GAR amino group on the formyl carbon of 10-formyl-THF for 
formyl group transfer.252 The formyl group in the bound 10-formyl-THF is suggested to 
twist out of the delocalized planar structure and relieve the resonance stabilization thereby 
increasing its electrophilicity.253  Further, a random-collision mechanism between the pre-
activated cosubstrate and the flexible nucleophilic end of GAR at extremely high local 
concentrations has been suggested for catalysis. A tetrahedral intermediate has been 
proposed that collapses to product via proton transfer relay between GAR (NH2) and 
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His915 (electrostatic interaction to GAR (NH2) through Asn913 and ultimately Asp951 
and His915) (Figure 24). 
 
Figure 24. Proposed mechanism for formyl transfer by human GARFTase.  
A.5.3.1.3. Implications of Surface Charge Pattern on Polyglutamylation.  
Polyglutamylation enhances affinity of folates by orders of magnitude towards 
hGARFTase.254-255 Surface potential of the ternary complex of the hGARFTase depicts that 
the electrostatic potential at its surface extending away from the γ-carboxylate of the 
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monoglutamate to the folate binding loop is either neutral or positively charged. Therefore, 
it would be complementary to the charge pattern of a polyglutamate (neutral and negatively 
charged regions) and may explain the improved binding affinity.  
A.5.3.1.4. Role of GARFTase in cancer 
GARFTase which catalyzes the first of the two folate-dependent 1C transfer 
reactions plays a pivotal role in the de novo purine biosynthetic pathway overexpressed in 
most tumor cells. A majority of cancer tissues such as hepatocellular carcinoma, renal 
cancer, head and neck cancer, liver cancer, pancreatic cancer, testicular- and urothelial 
cancer display moderate to strong GARFTase cytoplasmic expression. High mRNA 
expression correlates with shorter survival times with mostly unfavorable prognosis.256-257  
A.5.3.2. AICARFTase 
AICARFTase catalyzes the formylation of 5-aminoimidazole-4-carboxamide-
ribonucleotide (AICAR) to produce formyl-AICAR (fAICAR) accompanied by the 
conversion of the cosubstrate, 10-formyl-THF, to THF (Figure 15). AICARFTase has no 
significant homology with GARFTase. Homodimerization of ATIC is a requisite for 
transformylase activity of AICARFTase as the active sites form at the interface of the 
interacting proteins, with each monomer contributing residues to the folate and AICAR 
binding pockets.  
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A.5.3.2.1. Structure of AICARFTase 
 
Figure 25. Crystal structure of human AICARFTase in complex with folate-based inhibitor 
BW1540U88UD (green) (PDB 1P4R), visualized using Maestro 11.2.197, 258 AICAR is 
shown in yellow.  
 
Figure 26. Compound BW1540U88UD co-crystallized as a complex with hAICARFTase 
(PDB 1P4R).258 
AICARFTase is the functional, C-terminal domain (residues 200–593) of a 
bifunctional homodimer enzyme ATIC.258 Two sulfamido-linked 5,8-dideazafolate folate-
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based inhibitors that are specific for human ATIC were co-crystallized with human ATIC 
in the presence of the substrate AICAR. The AICARFTase active site is located at the 
dimer interface in a long, narrow cleft where AICAR and folate interact primarily with the 
opposing subunits (Figure 25).259 The 5,8-position of the dideazafolate ring of co-
crystallized BW1540U88UD (Figure 26) (homologous to the pterin ring in 10-formyl-
THF) is fixed within a hydrophobic environment Pro543,  Phe544,  above  and  side  chain  
of  Phe315  below. Hydrogen bond interactions are formed between the 2-amino group and 
side chain carbonyls of Asn489 and Asp546, N3 and side-chain carbonyl of Asp546, and 
4-oxo and side-chain carbonyl of Asn547. The AICAR imidazole and the phenyl moiety 
of pABA form π-stacking interactions with each other as well as with the side-chains of 
Phe541 and Phe315. The sulfonyl oxygen and NH (N10-formyl group mimic) form 
hydrogen bonds with the side-chain of Lys266.  The glutamate tail is oriented such that a 
hydrogen bond is made by the α-glutamate with the backbone amide of Ala566 and a water-
mediated hydrogen bond is made with the backbone of Pro543.  
Extensive electropositive surface near the active site likely accounts for binding to 
the negatively charged polyglutamate tail, for increased affinity to ATIC.260-261 
A.5.3.2.2. Catalytic mechanism 
The AICARFTase ternary complex formation is ordered and sequential and the 
folate cofactor binds first to the active site.262 The formyl group is transferred directly to 
AICAR without any enzyme-bound formylated intermediate (Figure 27).238, 259, 263 His267 
is the proposed catalytic base that deprotonates the AICAR amino group, thus increasing 
the nucleophilicity for concomitant nucleophilic attack on the formyl group of 10-formyl-
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THF.  The oxyanion transition state is stabilized in the oxyanion hole and protons are 
shuttled to the N10 of THF by Lys266.264-265  
 
Figure 27. Proposed mechanism for formyl transfer by human AICARFTase. 
A.5.3.2.3. Role of AICARFTase in cancer 
AICARFTase, which catalyzes the second folate-dependent 1C transfer reactions 
plays a pivotal role in the de novo purine biosynthetic pathway overexpressed in most 
tumor cells. A majority of cancer tissues such as colorectal, testicular, breast, stomach and 
pancreatic cancers, and melanomas, display strong AICARFTase cytoplasmic expression. 
High mRNA expression correlates with shorter survival times with mostly unfavorable 
prognosis.266  
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The de novo biosynthetic pathways of purine and pyrimidine nucleotides produce 
ATP, GTP, UTP, and CTP, precursors for DNA, precursors for RNA, and activated 
metabolites such as UDP-glucose and CDP-choline.267 More than 20% of all approved 
oncology drugs are purine or pyrimidine antimetabolites.268 TS is the primary target of 
clinically used antifolate anticancer agents PMX and RTX, while DHFR is the canonical 
target of the antifolate anticancer agents MTX and PTX and a secondary target of PMX 
(Figure 5).22, 165, 180, 269-271  
Currently, there are no clinically used inhibitors of the folate-dependent enzymes 
of the purinosome. Inhibitors of the enzymes of these pathways may be effective as drugs 
for treatment of cancer. Depletion of purines by targeting de novo purine nucleotide 
biosynthesis with folate analogs can limit nucleotide levels for DNA synthesis and repair, 
while also influencing the ATP and GTP cellular energetics stores. The folate-dependent 
enzymes GARFTase and/or AICARFTase are primary targets of “second generation” 
antifolates (Figure 28). Inhibition of glycinamide ribonucleotide GARFTase and/or 
AICARFTase, is a potential chemotherapeutic intervention that can provide both potency 
and selectivity due to two main reasons: 1) rapidly dividing tumors produce purines via de 
novo synthesis, whereas normal cells salvage them, and 2) common cellular folate transport 
systems can be used for dual targeting of both the folate-dependent enzymes.228-230, 272 
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Figure 28. Second generation GARFTase inhibitors.63, 273-274 
The discovery of a C6 R isomer of potent antipurine antifolate 5,10-
dideazatetrahydrofolate (DDATHF, lometrexol, LMX) in the mid-1980s  as the inhibitor 
of GARFTase validated GARFTase as a viable anticancer target (Figure 5).273 It entered 
clinical trials and demonstrated antitumor activity against a wide range of solid tumors. 
GARFTase in de novo purine nucleotide biosynthesis is a secondary target of PMX.165, 180, 
270-271 LY309887 and AG2034 (Figure 28) are the 2nd generation inhibitors which 
exclusively target de novo purine nucleotide biosynthesis at GARFTase and showed 
promising in vitro and in vivo antitumor activities in assorted preclinical tumor models 
associated with depletion of purine nucleotide pools.63, 273-275 Unfortunately, in phase I 
clinical trials, these inhibitors showed dose-limiting myelosuppression and mucositis 
toxicities due to RFC uptake thus hampering further clinical development.63-64, 276-277  
Gangjee and coworkers reported ternary crystallographic structures of the 
formyltransferase domain of hGARFTase complexed with the β-GAR substrate and eight 
structurally diverse 6-substituted pyrrolo- and thieno[2,3-d]pyrimidine antifolates 
(monoglutamates) that are relatively potent (compared to the clinically available 
antifolates) tumor-targeted inhibitors (Figure 29).251 Collectively, the results provide a 
rational basis for understanding the in vitro activity profiles of FR- and PCFT-targeted 
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antifolates that inhibit GARFTase. Differences in the positioning and number of contacts 
formed by the L-glutamyl tail, and the hydrogen bonding capability of the bicyclic ring 
correlate with the inhibitor potencies. The ideal positioning of the glutamyl tail is 
influenced by the inherent length and flexibility of the linkers, and the regioisomeric 
substitution on the side-chain (het)aryl ring. A 4C linker connected to a planar aromatic 
sidechain maximizes the number of contacts of L-glutamate tails atoms with the 
GARFTase binding pocket. A hydrogen bond interaction with Arg897 carboxyl by the 
pyrrolo[2,3-d]pyrimidine antifolates correlates with the loss of activity upon bioisosteric 
replacement of the pyrrole ring with a non-hydrogen bonding thiophene in the thieno[2,3-
d]pyrimidine antifolates. These structural determinants involved in GARFTase inhibition 
aid in the design of future generations of novel targeted antifolates that inhibit GARFTase. 
 
Figure 29. 6-substituted pyrrolo- and thieno[2,3-d]pyrimidine antifolates.251 
Along with inhibition of the de novo purine biosynthesis, AICARFTase inhibition 
also demonstrates inhibition of cell proliferation and cell cycle progression in human 
carcinomas by indirectly activating the AMP activated protein kinase (AMPK), 
Modulation of AICAR levels represents a novel means to AMPK signaling and cell cycle 
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control.270-271 The inhibition of AICARFTse activity along with RFC uptake displays non-
specific activity and undesirable side effects.267 The 6(S)-diastereomer of LMX and the 
tetraglutamyl derivative of dmAMT are potent AICARFtase inhibitors (Figures 5 and 
31).274 Little published information is available about another classical antifolate, AG2009 
(Figure 30), which is an AICARFTase specific inhibitor.278 Notably, AICARFTase, is a 
secondary target of PMX.165, 180, 270-271 Inhibition of AICARFTase in PMX-treated tumor 
cells causes accumulation of its substrate ZMP, ZMP-mediated activation of 5′ adenosine 
monophosphate-activated protein kinase (AMPK), AMPK-mediated phosphorylation of 
RapTOR and TSC2 and p53 independent mTOR inhibition.279  
 
Figure 30. AICARFTase inhibiting Antifolates.274, 278 
 
Figure 31. 5-substituted pyrrolo[2,3-d]pyrimidine linker extension analogs of PMX.120 
Gangjee and coworkers have reported relatively more potent tumor-targeted 5-
substituted pyrrolo[2,3-d]pyrimidine 3C-5C linker extension analogs of PMX which 
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displayed dual GARFTase and AICARFTase activity (Figure 31 and Table 5).117, 120 Unlike 
PMX, which is a pyrimidine biosynthesis inhibitor, they primarily inhibit the purine 
biosynthetic pathway as dual inhibitors. These novel, dual inhibitors will not only have 
reduced propensity for resistance development (another caveat of cancer chemotherapy) 
but will also circumvent the current TS resistance developed against PMX.  
Table 5. IC50 Values (nM) for 5-substituted pyrrolo[2,3-d]pyrimidine antifolates and 
classical antifolates.120 For KB cells, data are shown for the protective effects of nucleoside 
additions, including adenosine (Ade), thymidine (Thd), or AICA. 
Antifolate CHO (IC50s) (nM) KB 
(IC50s) 
(nM) 
KB 
(+Thd/Ade/AICA)PC43-10 
(RFC) 
RT16 
(FRα) 
PCFT4 
(PCFT) 
12 68.8 (21.2) 72.0 (27.1) 329 (61) 49.5 (13.2) Ade 
13 56.6 (5.8) 8.6 (2.1) 840 (90) 12.7 (5.4) Ade 
14 196.4 (55) 33.5(2.5) >1000 17.3(8.9) Ade/AICA 
PMX 26.2 (5.5) 42 (9) 8.3 (2.7) 68 (12) Thd/Ade 
MTX 12 (1.1) 114 (31) 121 (17) 6.0 (0.6) Thd/Ade 
RTX 6.3 (1.3) 15 (5) 99.5 (11.4) 5.9 (2.2) Thd 
PTX 0.69 (0.07) 168 (50) 57 (12) 0.47 (0.20) Ade/Thd 
 
Currently, there are no tumor targeted cytotoxic agents in clinical use; all the 
chemotherapeutic agents display dose-limiting toxicity. Clinically used antifolates not only 
have dose-limiting toxicities but also suffer from drug-resistance. As such, to circumvent 
these drawbacks, novel antifolates that block purine biosynthesis by targeting either or both 
the folate-utilizing enzymes selectively by virtue of their specificities for FRs and /or PCFT 
are needed. Inhibition of purine biosynthesis not only provides a novel mechanism of 
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action but also circumvents resistance developed by the currently clinically relevant 
antifolate enzyme targets; TS as well as DHFR. Moreover, targeting more than one purine 
metabolizing enzyme reduces the probability of resistance towards the additional target, 
thus preserving the cytotoxic activity of the inhibitors. 
The novel mechanisms of action, and improved potency and selectivity of the 5-and 6-
substituted pyrrolo[2,3-d]pyrimidine antifolates over the currently marketed counterparts 
call for the optimization of these analogs as a viable approach for the development of novel 
cancer chemotherapeutics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
II. CHEMICAL REVIEW 
 
The synthetic methodologies related to the present work is reviewed and includes the 
approaches to the following general structures: 
B.1. Synthesis of pyrrolo[2,3-d]pyrimidines 
B.2. Synthesis of alkyl benzoates by Sonogashira coupling 
B.3. Synthesis of alkyl benzoates by domino Heck reactions 
B.1. Synthesis of pyrrolo[2,3-d]pyrimidines 
The pyrrolo[2,3-d]pyrimidine scaffold finds application in medicinal chemistry 
design as a deazapurine analog. As such, its syntheses has been extensively reported using 
various strategies that can be classified into the following: 
1. Synthesis from pyrimidine precursors 
2. Synthesis from furan precursors 
3. Synthesis from pyrrole precursors  
B.1.1. From pyrimidine precursors 
Scheme 1. Synthesis of pyrrolo[2,3-d]pyrimidines 18-19. 
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Noell and Robins280 originally reported the synthesis of pyrrolo[2,3-d]pyrimidines 
18 and 19 (Scheme 1) via condensation of chloroacetaldehyde 16 with 2-amino-6-
alkylamino-4-oxopyrimidines 15 and 6-amino-1,3-dimethyluracil 17 respectively.  
Scheme 2. Synthesis of 2-methylthio-4-oxo-pyrrolo[2,3-d]pyrimidine 21. 
 
Noell and Robins280  also reported the synthesis of 2-methylthio-4-oxo-pyrrolo[2,3-
d]pyrimidine 21 (Scheme 2) in the same report, from 2-methylthio-6-amino-4-pyrimidone 
20 and chloroacetaldehyde 16.  
Scheme 3. Synthesis of 2-amino-4-oxo-pyrrolo[2,3-d]pyrimidines 27. 
 
Gibson et al.281 reported a synthetic approach for the preparation of 2-amino-4-oxo-
pyrrolo[2,3-d]pyrimidines 27 (Scheme 3) from condensation of an oxime 24 with 2,6-
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diamino-4-pyrimidone 22 in mildly basic conditions (sodium carbonate, sodium acetate, or 
triethylamine) to the intermediate adduct 25. Thermal cyclization/cyclization under acid-
catalyzed transoximation of 25 with substituted aldehydes 26 afforded the pyrrolo[2,3-
d]pyrimidine scaffolds substituted 27 at the C5 and C6 positions. 
Scheme 4. Synthesis of furo[2,3-d]pyrimidines 30 and pyrrolo[2,3-d]pyrimidines 31. 
 
 
Fumio et al.282 reported that the condensation of 6-amino-1,3-dimethyluracil 28 
(Scheme 4) with phenacyl bromides 29 in DMF afforded 1,3-dimethyl-6-
phenylpyrrolo[2,3-d]pyrimidines 31. However, running the reaction in acetic acid also 
afforded the 1,3-dimethyl-5-phenylfuro[2,3-d]pyrimidine-2,4-(1H,3H)-diones 31 as a side 
product. 
 
Davoll and coworkers283 reported an acid mediated cyclization of acetals or ketal 
derivatives of pyriminde 5-acetaldehyde or acetone 34 (Scheme 35) to various pyrrolo[2,3-
d]pyrimidines 35. The intermediate 34 were obtained from the cyclization of the substituted 
nitrile 32 with guanidine, urea and thiourea 33. 
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Scheme 5. Synthesis of pyrrolo[2,3-d]pyrimidines 35. 
 
Scheme 6. Synthesis of 2-amino-4-methyl-pyrrolo[2,3-d]pyrimidine 46. 
 
 
 
Gangjee and coworkers284 reported a novel ring closure method for the synthesis of 
2-amino-4-methyl-pyrrolo[2,3-d]pyrimidine 46 (Scheme 6). Condensation of 2-
acetylbutyrolactone 36 with guanidine 37 afforded the substituted pyrimidine 38. 
Chlorination with POCl3 to the dichloro derivative 40 and subsequent condensation with 
benzylamine 41 afforded the 7-benzyl-4-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-
2-amine 42. Oxidative aromatization of the dihydropyrrole ring in 42 with Mno2, followed 
by debenzylation with metallic sodium in ammonia provided the 2-amino-4-methyl-
pyrrolo[2,3-d]pyrimidine 46. 
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Scheme 7. Synthesis of 2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-6-
yl)acetic acid 48. 
 
 
Gangjee and coworkers285 also reported the synthesis of 2-(2-amino-4-oxo-4,7-dihydro-
1H-pyrrolo[2,3-d]pyrimidin-6-yl)acetic acid 48 (Scheme 7). Condensation of 2,6-
diaminopyrimidin-4(1H)-one 22 with ethyl 4-chloro-3-oxobutanone 47 in the presence of 
sodium acetate (Scheme 7) afforded the pyrrolo[2,3-d]pyrimidine 48. 
 
Scheme 8. Synthesis of 2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidine-5-
carbonitrile 50. 
 
 
In another report, Gangjee and coworkers286 also reported the synthesis of 2-amino-4-oxo-
4,7-1H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 50 (Scheme 8) from the condensation of 
pyrimidine 22 with 2-chloro-3-oxopropanenitrile 49 under basic conditions. 
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Scheme 9. Synthesis of 2,4-diamino-5-arylalkyl substituted pyrrolo[2,3-d]pyrimidines 
54-55. 
 
Miwa and coworkers287 reported the synthesis of a series of 2,4-diamino-5-arylalkyl 
substituted classical pyrrolo[2,3-d]pyrimidine antifolates in 1991. Condensation of 
guanidine 37 (Scheme 9) and the malonodinitrile derivative 52 afforded the bicyclic ring 
53. The lactam in 53 was reduced in the presence of borane to provide the pyrrolo[2,3-
d]pyrimidine intermediate 55 along with its 5,6-dihydro analog 54. 
Scheme 10. Synthesis of 5-substituted pyrrolo[2,3-d]pyrimidine 58. 
 
 64 
A procedure for the synthesis of PMX was reported by Miwa and coworkers287 utilizing 
the spontaneous cyclization of 6-amino-5-pyrimidylacetaldehyde (Scheme 10). The enol 
ether 55 was reacted with ethyl bromocyanoacetate in methanol under UV irradiation for 
photo-initiated free radical addition to regioselectively afford the acetal functionalized 
ethyl cyanoacetate 56. Guanidine 37 and cyanoacetate 56 were condensed at reflux to form 
the acetal protected 6-amino-5-pyrimidylacetaldehyde 57. The dimethyl acetal and t-butyl 
moieties were deprotected under acid catalyzed conditions to afford 4-[2-(2-amino-4-oxo-
pyrrolo[2,3-d]pyrimidin-5-yl)-ethyl]-benzoic acid 58. Acid 58 was peptide coupled to L-
glutamate ester and subsequently saponified to get to the target compound PMX. 
Scheme 11. Synthesis of 6-amino-5-pyrimidylacetaldehydes 62. 
 
Taylor and coworkers288 reported a concise method for the synthesis of PMX which 
involved the spontaneous cyclization of 6-amino-5-pyrimidylacetaldehydes 62 (Scheme 
11). The acid 58 was synthesized via the intermediate 62 by a one-pot five-step Nef reaction 
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of compound 61. Michael addition reaction between the C5 of pyrimidine 22 and the 
Michael acceptor 60 produced the compound 61. The synthesis of the Michael acceptor 
involved palladium-catalyzed cross-coupling of methyl 4-iodobenzoate 59 with an allyl 
alcohol, aldol condensation with nitromethane followed by dehydration using 
methanesulfonyl chloride in basic conditions. PMX was synthesized from the acid 58 in 
additional two steps that involved peptide coupling with diethyl L-glutamate ester and 
saponification. 
Scheme 12. Synthesis of PMX from α-bromo aldehyde 67. 
 
Another method for the synthesis of PMX was reported by Barnett and coworkers289 which 
involved the cyclization of 2-bromo-4-arylbutanal 66 (Scheme 12) with 2,4-diamino-6-
oxo-pyrimidine 22. The cyclization regioselectively afforded the 5-substituted pyrrolo[2,3-
d]pyrimidine 67. The key α-bromo aldehyde intermediate was synthesized via Sonogashira 
coupling of methyl 4-bromobenzoate 63 with 3-butyn-1-ol 64, reduction of the alkyne 
coupled product and oxidation of the alcohol to aldehyde 65 and subsequent α-bromination 
to 66. 
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Scheme 13. Synthesis of 7-substituted pyrrolo[2,3-d]pyrimidines 75. 
 
Legraverend and coworkers290 reported the synthesis of N7-substituted pyrrolo[2,3-
d]pyrimidine 75 (Scheme 13) from 2-amino-4,6-dichloro-5-(2,2-diethoxyethyl)pyrimidine 
72. Conversion of 5-allyl-2-amino-4,6-dihydroxypyrimidine 68 to the 4,6-dichloro 
derivative 69 was carried out in the presence of POCl3, PCl5. Compound 69 was then 
subjected to ozonolysis of the allyl group to afford the intermediate 2-(2-amino-4,6-
dichloropyrimidin-5-yl)acetaldehyde 71. The aldehyde was then converted to the 
diethylacetal 72 and subsequently cyclized under acidic conditions to 4-chloro-7R-
pyrrolo[2,3-d]pyrimidin-2-amine 74. The 4-chloro group was then hydrolyzed in the 
presence of 1 N HCl to afford the final compound 75. 
Scheme 14. Synthesis of pyrrolo[2,3-d]pyrimidine 79. 
 
Sakamoto and coworkers 291 reported the synthesis of pyrrolo[2,3-d]pyrimidines 79 
(Scheme 14) from acid catalyzed cyclization of protected 5-acetaldehyde pyrimidines 78. 
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Palladium catalyzed coupling of appropriate 2,4-disubstituted-5-bromo-6-acetamido 
pyrimidine 76 with (Z)-tributyl(2-ethoxyvinyl)stannane 77 afforded intermediate 78. 
Scheme 15. Synthesis of 4-methyl pyrrolo[2,3-d]pyrimidines 82. 
 
Another method for the synthesis of 4-methyl pyrrolo[2,3-d]pyrimidine 82 
(Scheme 15) was reported by Kondo et al.292 via a palladium(0) catalyzed cross-coupling 
of terminal alkynes 81 with N-(5-iodo-2-isopropyl-6-methylpyrimidin-4-
yl)methanesulfonamides 80.  
Scheme 16. Synthesis of 2,4-dimethyl pyrrolo[2,3-d]pyrimidines 89. 
 
Kondo et al.292 in the same report discussed the synthesis of 2,4-dimethyl 
pyrrolo[2,3-d]pyrimidine 89 (Scheme 16) via thermal or photoinduced cyclization of the 
C5 olefinic functionality of 4-azidopyrimidines 88. The olefinic moiety was introduced by 
a palladium catalyzed cross-coupling between the 5-iodopyrimidine 83 and appropriate 
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alkenes 84/85, and the azide functionality was introduced via nucleophilic displacement of 
the 4-chloro in the pyrimidine 86 by sodium azide 87. 
Scheme 17. Synthesis of pyrrolo[2,3-d]pyrimidines 91 via Fischer indole cyclization. 
 
 
Several reports employed the Fischer indole cyclization for the synthesis of 
pyrrolo[2,3-d]pyrimidines 91 (Scheme 17) from 4-pyrimidinylhydrazones 90.293-297 
However, the applicability of the method is limited by high reaction temperatures and the 
steric constraints for [3,3] sigmatropic rearrangement involved in the mechanism. 
 
Secrist and Liu298 provided a detailed structural study of the cyclization products 
afforded upon reacting 2,6-diamino-4-pyrimidone 22 (Scheme 18) with various types of α-
halo aldehydes and ketones 92. They reported that the cyclization with α-halo ketones 
could occur via two different mechanisms to produce either the furo[2,3-d]pyrimidine 93 
and pyrrolo[2,3-d]pyrimidine 94. Electron density at the C5 of the pyrimidine nucleus is 
critical for it to displace the leaving group at the α-carbon atom of the α-halo ketones to 
give specifically the pyrrolo[2,3-d]pyrimidines 94. 
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Scheme 18. Synthesis of pyrrolo[2,3-d]pyrimidines 94 and furo[2,3-d]pyrimidines 93. 
 
 
B.1.2. From furan precursors 
Scheme 19. Synthesis of 2,5,6-trisubstituted-4-amino-pyrrolo[2,3-d]pyrimidines 98. 
 
Taylor et al.299 reported a general method to obtain the 2,5,6-trisubstituted-4-
amino-pyrrolo[2,3-d]pyrimidine scaffold 98 (Scheme 19) via appropriately substituted 2-
amino-3-cyanofurans 97 as the intermediate. Condensation of appropriate α-
hydroxyketones 95 with malononitrile 96 afforded the substituted furan 97 which was then 
cyclized with guanidine 37 to afford the corresponding 2,5,6-trisubstituted-4-amino-
pyrrolo[2,3-d]pyrimidine rings 98 via a ring transformation/annulation sequence. 
B.1.3. From pyrrole precursors 
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Scheme 20. Synthesis of 4-amino-5-cyanopyrrolo[2,3-d]pyrimidine 107. 
 
Taylor et al.300-301 reported the synthesis of 4-amino-5-cyano-pyrrolo[2,3-
d]pyrimidine 107 (Scheme 20) from tetracyanoethylene 99 via the pyrrole intermediate 
102. Reaction with trimethylorthoformate followed by ammonia or condensation with 
formamidine acetate resulted in the cyclization of 2-mercapto-3,4-dicyano-5-aminopyrrole 
102 to the pyrrolo[2,3-d]pyrimidine 106. The mercapto group was removed by Raney Ni 
to afford 107. 
Scheme 21. Synthesis of 4-amino-5-substituted pyrrolo[2,3-d]pyrimidine 112. 
                                         
Taylor and coworkers301 also reported the synthesis of 4-amino-5-substituted 
pyrrolo[2,3-d]pyrimidine 112 (Scheme 21) from 2-amino-3-cyano-5-substituted pyrroles 
109. Appropriate α-aminoketones 108 were condensed with malonodinitrile 96 to afford 
the pyrroles 109 which were then treated with triethylorthoformate followed by ammonia 
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103 to the pyrrole 111. Cyclization under basic conditions afforded the pyrrolo[2,3-
d]pyrimidine 112. 
Scheme 22. Synthesis of 5,6-disubstituted pyrrolo[2,3-d]pyrimidine 115. 
 
Tolman and coworkers302 reported the cyclization of 2-amino-5-bromo-3,4-
dicyanopyrrole 114 (Scheme 22) in the presence of formamidine acetate 105 to 
pyrrolo[2,3-d]pyrimidine 115. The synthesis of the pyrrole intermediate was reported by 
Swayze and coworkers303 in an efficient one-step intramolecular self-condensation reaction 
from tetracyanoethylene 99 under controlled addition of HBr 113 in acetic acid.  
Scheme 23. Synthesis of 2,5,6-trimethyl pyrrolo[2,3-d]pyrimidine 120. 
 
Eger and coworkers304-305 reported the cyclization of 3-cyano-4,5-dimethyl-1-(1-
phenylethyl)-1H-pyrrol-2-amine 118 (Scheme 23) for the synthesis of 2,5,6-trimethyl 
pyrrolo[2,3-d]pyrimidine 120. The cyclocondensation of 3-hydroxy-2-butanone 116, 1-
phenyl-ethylamine 117 and malonodinitrile 96 afforded the pyrrole intermediate 118. 
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Scheme 24. Synthesis of 2,5-dimethyl-N7-substituted pyrrolo[2,3-d]pyrimidine 128. 
 
Chen and coworkers306 reported a multistep synthesis of pyrrolo[2,3-d]pyrimidine 
128 (Scheme 24). Condensation of acetone 121 and malonodinitrile 96 afforded 122 which 
was brominated using NBS 123 to afford 2-(1-bromopropan-2-ylidene)malononitrile 124. 
Compound 124 was cyclized with aryl amine 125 to afford the pyrrole 126 which was then 
cyclized to the pyrrolo[2,3-d]pyrimidine derivative 128 under acidic conditions. 
Scheme 25. Synthesis of 2,5-dimethyl pyrrole[2,3-d]pyrimidine 133. 
 
Girgis and coworkers307 reported the synthesis of 2,5-dimethyl pyrrole[2,3-
d]pyrimidine 133 (Scheme 25) from N-(3-cyano-4-methyl-1H-pyrrol-2-yl)acetamide 132 
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by heating under acidic conditions. The pyrrole 132 was obtained by cyclocondensation of 
129 or 130 with malonodintrile 96 under basic conditions to afford 131 followed by 
acetylation with acetic anhydride.308-309 
Scheme 26. Synthesis of N7-substituted analogs of PMX. 
 
Taylor and coworkers310 reported a novel synthetic route of N7-substituted analogs 
of PMX (Scheme 26). A diastereomeric mixture of the 3-carbomethoxy-2-pyrrolidinone 
139 was afforded via manganic triacetate catalyzed radical cyclization of methyl (E)-3-
(but-2-en-1-yl(1-(3,4-dimethoxyphenyl)ethyl)amino)-3-oxopropanoate 138.311 The 
intermediate 138 was afforded by alkylation of racemic 1-(3,4-dimethoxyphenyl)ethan-1-
amine 134 with crotyl bromide 135 followed by acylation with methyl malonyl chloride 
137 in the presence of catalytic DMAP. P2S5 was used to convert the pyrrolidinone 139 to 
the thiolactam 140 which was then cyclocondensed with guanidine 37 to successfully 
afford the N7-protected 5,6-dihydro-5-allyl-pyrrolo[2,3-d]pyrimidine 141. The 
pyrrolo[2,3-d]pyrimidine 141 was subsequently utilized to afford PMX analogs. 
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Scheme 27. Synthesis of PMX via guanidine cyclization. 
 
Barnett and coworkers312 reported a guanidine cyclization of a preformed 3-
carbethoxy-2-thiopyrrolidine 144 (Scheme 27) to 2-amino-4-oxo-5,6-dihydropyrrolo[2,3-
d]pyrimidine 145. The intermediate 143 was synthesized in several steps beginning with 
tert-butyl 4-(4-oxobutyl)benzoate 142. The bicyclic dihydropyrrole compound 145 was 
oxidized to the pyrrolo[2,3-d]pyrimidine intermediate 67 which was subsequently 
elaborated to PMX in three additional steps. 
Scheme 28. Synthesis of 2-methyl-4-amino-pyrrolo[2,3-d]pyrimidine 148. 
 
Dave et al.313 reported a general procedure for the synthesis of condensed 
pyrimidines. Acetonitrile 147 (Scheme 28) and substituted pyrrole 146 were condensed 
under HCl (g) conditions to afford 2-methyl-4-amino-pyrrolo[2,3-d]pyrimidine 148. 
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Scheme 29. Synthesis of 5-phenyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 151. 
 
Bookser et al.314 reported the condensation between substituted pyrrole 149 
(Scheme 29) and triethylorthoformate 150 under acidic conditions for the synthesis of 
pyrrolo[2,3-d]pyrimidine 151.  
 
B.2. Synthesis of alkyl benzoates by Sonogashira coupling 
Scheme 30. A general transformation of Sonogashira coupling.315-316 
 
Sonogshira et al.317 reported a novel method for the synthesis of symmetrically 
substituted alkynes via a coupling reaction between aryl iodides/vinyl bromides 152 
(Scheme 30) and acetylene gas 153 in the presence of catalytic Pd(PPh3)Cl2 and CuI. This 
copper-palladium catalyzed cross coupling of terminal alkynes with aryl and vinyl halides 
(or triflate) to give enynes is termed the Sonogashira coupling. Typically, for the reaction 
to occur, a Pd(0) catalyst, a halide salt of copper(I), and a base to neutralize the hydrogen 
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halide side product are necessary. The reactivity of the aryl/vinyl halides is 
I~OTf>Br>Cl.315-316  
Scheme 31. General mechanism of Sonogashira cross-coupling. 
 
Scheme 32. Synthesis of N-(7-benzyl-4-methyl-5-(phenylethynyl)-7H-pyrrolo[2,3-
d]pyrimidin-2-yl)-N-pivaloylpivalamide 161. 
 
Gangjee et al.318 reported the synthesis of N-(7-benzyl-4-methyl-5-
(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-N-pivaloylpivalamide 161 (Scheme 
32) from a tetrakis(triphenylphosphine) palladium(0) and CuI catalyzed Sonogashira cross-
coupling.  
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Scheme 33. Synthesis of classical 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine 
164 by Sonogashira coupling. 
 
Wang et al.133 reported the synthesis of a classical 2-amino-4-oxo-6-substituted-
pyrrolo[2,3-d]pyrimidines 164 (Scheme 33) via a tetrakis(triphenylphosphine) 
palladium(0) and CuI catalyzed Sonogashira cross-coupling between terminal alkynes 162 
and thiophenyl bromides 163.  
 
B.3. Synthesis of alkyl benzoates by domino Heck reactions 
Scheme 34. General transformation of Heck coupling. 
 
 
The Heck/Mizoroki-Heck reaction is a palladium catalyzed cross-coupling of an 
aryl/vinyl halides (or triflate) 152 (Scheme 34) with an alkene 165 in the presence of a base 
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to form a substituted alkene 166.319-320 A general Heck coupling transformation is shown 
in Scheme 34. 
Scheme 35. Heck coupling to synthesize aldehyde 169 and 170. 
 
 
Melpolder et al.321 and Chalk et al.322 reported the synthesis of aldehydes 169 and 
170 (Scheme 35) from phenyl iodide 167 and allyl alcohol 168 in one step reaction in the 
presence of catalytic palladium acetate.   
Scheme 36. A proposed mechanism of Heck coupling to synthesize aldehyde 169. 
 
A possible mechanism for Heck coupling synthesis of aldehydes is shown in Scheme 36.  
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Scheme 37. Improved Heck coupling for aldehyde synthesis 
 
Larock et al.323 reported an improved method for Heck coupling for the synthesis 
of the aldehydes 169 and 170 (Scheme 37). The reported reaction method involves a 
palladium acetate catalyzed coupling between phenyl iodide 167 and allyl alcohol 168. 
Additionally, tetrabutyl ammonium chloride as a phase transfer catalyst and lithium acetate 
as the base were used to improve the yield and lower the temperature requirement of the 
reaction. The mild reaction conditions helped in the synthesis of several aldehydes as 
versatile intermediates.324-326  
Scheme 38. Heck coupling with thiophenyl bromide 178. 
 
Another method for improved heck coupling was reported by Tamaru et al.327 and 
Yoshida et al.328 which involved the cross-coupling of a thiophenyl bromide 177 (Scheme 
38) and allylic alcohol 168. The coupling occurred in the presence of palladium acetate, 
sodium iodide, and sodium bicarbonate as base. The successful reaction demonstrated the 
application of Heck coupling in heteroaromatic systems such as 178. 
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III. STATEMENT OF THE PROBLEM 
The present section deals with the rationale behind the design of antifolate antimetabolites 
for tumor targeted chemotherapy via selective uptake and inhibition of 1C metabolism. 
C.1. GARFTase inhibitors with selectivity for FRs and/or PCFT over RFC 
1. 6-Substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-fluorophenyl classical 
antifolates 
2. 6-Substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-fluoropyridyl classical 
antifolates 
3. 6-Substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-fluorothienyl classical 
antifolates 
4. 6-Substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-difluorophenyl classical 
antifolates 
5. 6-Substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-2'-substitutedphenyl 
classical antifolates 
6. 6-Substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-pyrimidyl classical 
antifolates 
C.2. Multiple enzyme inhibitors (GARFTase and AICARFTase) with selectivity for 
FRs and/or PCFT over RFC 
1. 5-Substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-butylphenyl classical 
antifolates 
2. 5-Substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-4'- 
propyloxy/propylthio/propylamino/butylaminophenyl classical antifolates 
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3. 5-Substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-butyl-2'-fluorophenyl 
classical antifolates 
C.3. Multiple enzyme inhibitors (TS, GARFTase, AICARFTase) with selectivity for 
FRs and/or PCFT over RFC 
1. 5-Substituted, 2-amino-4-oxo-6-methyl pyrrolo[2,3-d]pyrimidine classical 
antifolates 
RFC is ubiquitously expressed in both healthy as well as tumor cells. Clinically used 
antifolate agents, such as MTX, PMX, PTX and RTX, display dose-limiting toxicities due 
to predominant uptake by RFC.34, 115  
FRs and PCFT are narrowly expressed in healthy tissue and overexpressed in many 
different types of cancer. FRs expressed in normal tissue are inaccessible to blood 
circulation and contribute mainly to the reabsorption of folates (FRα expression in 
proximal tubules of kidney) or are nonfunctional (FRβ in thymus).32, 39, 67 Several tumors 
(e.g., epithelial ovarian cancer (EOC), NSCLC, renal, endometrial, colorectal, breast 
cancers) often overexpress FRα exposed to the blood circulation for transport of folate 
cofactors.33, 67, 90, 98-100 FRβ is overexpressed in hematologic malignancies such as acute 
myeloid leukemia.85 In addition, FRβ is also overexpressed in tumor-associated 
macrophages (TAMs) and may play an important role in tumor metastasis and angiogenesis 
by releasing proangiogenic factors, (e.g., vascular endothelial growth factor, matrix 
metalloproteinase).101 PCFT is expressed in the upper gastrointestinal tract where it is the 
predominant transporter of dietary folates at acidic pH (pH 5.8–6.0).32, 39, 122, 126, 128-129 
While PCFT is expressed in a number of other normal tissues (e.g., liver, kidney), it is 
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inactive due to loss of transport function at physiological pH (pH 7.4). It functions 
optimally at pH < 7, reaching its maximum activity at pH 4.5 – 5.5, thus limiting folate 
transport via PCFT in healthy tissue. PCFT is the predominant transporter in solid tumors 
(e.g., ovarian, NSCLC), where the pH of the microenvironment is <7.7, 60, 161  
Accordingly, selective uptake of antifolate antimetabolites via FRs and/or PCFT 
over RFC, is an attractive approach for the development of tumor targeted chemotherapy. 
Additionally, inhibition of FRβ overexpressing TAMs by FRβ-targeted agents constitutes 
an additional potential therapeutic target against heterogeneous cancers.101 The principle 
of FR-targeting has been utilized for the design of cytotoxic folic acid-vindesine conjugate 
(vintafolide) that is internalized by FRs for intracellular release of the cytotoxic agent.24, 
108 Though these therapies are considered to have enormous potential, we envision 
limitations in this therapy with respect to a mechanism of action that requires cleavage of 
the cytotoxic agent (premature cleavage will result in undesirable side effects) and the use 
of folic acid as the targeting agent.108 Our aim is to design small molecule classical 
antifolates as single agents with tumor-targeting (as well as) cytotoxic potential. 
PMX is a 5-substituted 2-amino-4-oxo-pyrrolo[2,3-d]pyrimidine antifolate with a 
2C linker connecting the bicyclic scaffold to the pABA sidechain (Figures 5 and 32). It is 
a potent KB human tumor subline (expresses hRFC, hFRs and hPCFT) inhibitor (IC50 = 68 
(12) nM) and is a non-selective inhibitor of engineered PC43–10 (expresses hRFC), RT16 
(expresses hFRα), D4 (expresses hFRβ) and R2/hPCFT4 (expresses hPCFT) CHO sublines 
indicating its non-selective uptake (PMX is one- to two-fold more selective towards RFC 
expressing CHO sublines over FRs (Table 1).114-115 PMX undergoes rapid 
polyglutamylation and primarily binds to and inhibits TS (Ki = 1.3 ± 0.3 nM) after entering 
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normal cells through RFC and tumor cells through RFC and PCFT.165 PMX and its 
polyglutamate metabolites also inhibit DHFR (Ki = 72 ± 0.4 nM), GARFTase (Ki = 65 ± 
16 nM) and AICARFTase (Ki = 265 nM). Though it is considered a “multitargeted 
antifolate”, its principal target is TS (50 to 200 times stronger inhibition than the other 
targets).165, 270 It is currently used for the treatment of non-squamous NSCLC and 
malignant pleural mesothelioma in combination with cisplatin, among other types of 
cancers.329 However, the significant uptake of PMX via RFC renders it with severe dose-
limiting toxicities (e.g., hematological toxicities, hepatotoxicity, and gastrointestinal 
toxicity).330  
PMX not only has dose-limiting toxicities but its chemotherapeutic action is 
hindered due to the development of drug-resistance against its transport, cellular retention 
and enzyme inhibition.66 As such, novel antifolates that circumvent these drawbacks are 
needed. One such strategy is to selectively block purine biosynthesis by targeting either or 
both the folate-utilizing enzymes (GARFTase and/or AICARFTase) by virtue of their 
tumor specificities via FRs and /or PCFT. The optimization of the 5- and 6-substituted 
pyrrolo[2,3-d]pyrimidine antifolates for novel mechanisms of action, and improved 
potency and selectivity over the currently marketed agents is a viable approach for the 
development of novel non-toxic cancer chemotherapeutics.  
C.1. GARFTase inhibitors with selectivity for FRs and/or PCFT over RFC 
C.1.1 Design of 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-fluorophenyl 
classical antifolates 
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Figure 32. PMX, lead compounds 1-3, and target compounds 179-181. 
Gangjee and coworkers114, 118 designed and synthesized the 6-regioisomers of 
PMX. While compound 1, the 2C linked 6-regioisomer, of PMX was inert toward tumor 
cells in culture, compounds 2 and 3, the 3C and 4C linked analogs respectively, provided 
size extension and greater conformational flexibility, that resulted in improved inhibition 
of proliferation of KB human tumor subline (expresses human RFC (hRFC), FRs (hFR), 
and PCFT (hPCFT)) with IC50s of 1.7 (0.4) and 1.0 (0.7) nM respectively (>35-fold more 
potent than PMX). Studies with engineered PC43–10, RT16, D4 and R2/hPCFT4 CHO 
sublines convincingly showed that compounds 2 and 3 were highly selective inhibitors of 
proliferation of FR- and PCFT-expressing cells at nanomolar (nM) concentrations (Tables 
2 and 4). Both compounds 2 and 3 were ~6- to 11-fold more active toward hFR-expressing 
RT16 and D4 cells and ~100- to 300-fold selective for FRs over RFC, than PMX. These 
compounds are also more potent and selective than any other clinically used antifolates, 
MTX, PTX, or RTX which show no selectivity for hFRs over hRFC (Tables 2 and 4). 
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Though the analogs 2 and 3 were more selective due to reduced RFC uptake, they were 
moderately potent towards the hPCFT-expressing CHO cells when compared to PMX 
(Table 4). The 6-substituted pyrrolo[2,3-d]pyrimidine benzoyl L-glutamate antifolates 2 
and 3 (Figure 32) inhibit de novo purine nucleotide biosynthesis at GARFTase; a novel 
mechanism of action devoid of TS inhibition like PMX. 
Pendergast et al.331-333 observed that a 2'-fluoro substitution of a 
benzo[f]quinazoline antifolate increased RFC uptake and antitumor activity which was 
attributed to the conformational restriction of the side-chain L-glutamate via a fluorine-
hydrogen bond (Figure 33).  
 
Figure 33. Conformational restriction of the side-chain L-glutamate in benzo[f]quinazoline 
antifolate 1031U89 via an intramolecular fluorine-hydrogen bond. 
Introduction of fluorine atoms as a bioisosteric replacement of the hydrogen atom 
in bioactive molecules is a well-established strategy for modifying the biological properties 
of drugs, as exemplified by the growing percentage of FDA-approved fluorinated drugs 
(from 20% in 2010 to about 30% currently).334-335 Though fluorine is only ~20% larger 
than hydrogen (van der Waals radii), the C−F bond is longer and larger compared to a C−H 
bond, has a larger dipole moment in the opposite direction of a C−H, is modestly more 
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lipophilic and can form strong electrostatic interactions including fluorine-hydrogen bonds 
(Table 6).336-345 These properties provide fluorine with considerable versatility, however 
that is also very much dependent upon the biochemical context in which the fluorine 
substituted analog is to function.  
Table 6. Key Properties and applications of the C−F Bond Compared to the C−H bond. 
EN = electronegativity.341 
Properties C-H C-F Applications 
Bond length (Å) 1.09 1.35 Hydrophobic 
interactions, 
lipophilicity, 
conformational 
effects 
Total size (Å3) 2.29 2.82 
EN of the element 2.2 3.98 Molecular 
recognition 
(hydrogen bonding, 
dipole interactions), 
conformational 
effects. 
Dipole moment (µ) -0.4 1.4 
 
Owing to extensive development of RFC resistance mechanisms and heterogeneity 
of tumor subtypes (varying levels of folate transporters), potent as well as selective 
inhibitors of both FR and PCFT overexpressing tumor cells are expected to have wider 
applications.34, 65-66 The previous efforts of Gangjee and coworkers have been focused on 
the design and synthesis of antifolates that are superior to the currently marketed antifolates 
by virtue of (i) selective tumor-targeting as a result of reduced RFC uptake (ii) selective 
tumor-targeting and improved antitumor potency as a result of increased FRs/PCFT uptake, 
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and (ii) improved antitumor potency due to GARFTase inhibition (novel mechanism of 
action). 
 
Figure 34. Pictorial representation of molecular recognition interactions of fluorine. (A) 
Fluorine hydrogen bond and (B) dipole-dipole interaction of a C-F bond with carbonyl 
C=O. 
In order to test the improvement in tumor-targeted activity (selective uptake and 
GARFTase inhibition) upon fluorination of the previously reported 6-substituted 
pyrrolo[2,3-d]pyrimidine benzoyl L-glutamate antifolates 2 and 3, compounds 179, 180, 
and 181 with a fluorine on either the 2' [ortho (o-) to the L-glutamate] (179 and 181) or 3' 
[meta (m-) to the L-glutamate] position (180) were designed (Figure 32). The proposed 
analogs will evaluate (i) the influence of modified steric/electronic effects at the 2'- and 3'-
position (Table 6) and (ii) the presence of an intra-molecular fluorine-hydrogen bond and 
the significance of the resulting conformational restriction (Figures 33 and 34). 
Two dimensional heteronuclear 15N–1H double quantum-single quantum 
correlation experiment (relative signs and magnitudes of through space couplings), 19F and 
1H-NMR spectroscopic techniques together with density functional theoretical (DFT) 
calculations, and single crystal X-ray diffraction studies provided direct evidence for the 
existence of intra-molecular N-Hꞏ ꞏ ꞏF-C(sp2) hydrogen bond in 2-fluorobenzamide 
organofluorine derivatives, in the liquid state (Figure 35).346-348 Since the fluorinated 
analogs 179 and 181 (Figure 32) have a 2'-fluoroarylamide sidechain, it is of interest to 
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establish the presence of an intra-molecular N-H ꞏ ꞏ ꞏF-C(sp2) hydrogen bond in the 
fluorinated analogs. Such an interaction is expected to be energetically important for target 
binding as it will restrict the number of conformations of the aromatic side-chain and the 
amide group, thus potentially providing entropic benefit upon binding.349-350  
 
Figure 35. Chemical structures of benzanilides in which weak N-H ꞏ ꞏ ꞏF molecular 
interactions were observed.346-348 
 
 
Figure 36. Intramolecular fluorine−hydrogen bond (bond energy = −0.5 kcalꞏmol−1) 
detected in energy-minimized free ligand 179 using MOE 2016.08.351  
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To evaluate the presence of an intramolecular interaction between the fluorine atom 
and the amide NH (N-H ꞏ ꞏ ꞏF), energy minimization of the ligand 179 (Figure 36) was 
performed in its unbound solution state. The energy minima structure shows rotation about 
the C1'-C(O) bond and orients the fluorine and the amide NH in a syn conformation, 
facilitating a weak intramolecular fluorine-hydrogen bond (bond energy = -0.5 kcal.mol-1).  
Molecular modeling studies of the fluorinated analogs 179 and 180 were carried 
out using X-ray crystal structures of human FRα (5IZQ), FRβ (4KN2) and GARFTase 
(5J9F) to explore the binding interactions compared to the lead analog 3 to validate their 
drug targets (Figures 37-39). The compounds display similar interactions as the native 
crystal structure ligands (not shown here for clarity) and 3, by maintaining key interactions 
involving the bicyclic scaffolds and the benzoyl L-glutamate tail.  
 
Figure 37. Molecular modeling studies with human FRα (PDB 5IZQ).167 Superimposition 
of the docked pose of 179 (yellow, -53 kJ/mol), 180 (light pink, -56 kJ/mol) with the 
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docked pose of 3 (teal, -55 kJ/mol). Docking studies were performed using LeadIT 2.1.6 
and visualized using Maestro 11.2.197, 352  
The docked poses of 179 and 180 in FRα (Figure 37) show the 2-NH2 group 
interacting in a hydrogen bond with Asp103 (81) (for FRα, full-length gene product 
numbers are designated along with numbering of the mature protein in parentheses). The 
3-NH of 179 and 180 form a hydrogen bond each with the side-chain hydroxyl of Ser196 
(174) and the 4-oxo moieties make a hydrogen bond each with the side-chain nitrogen of 
Arg125 (103). Though hydrogen bond interaction with the side-chain of Arg128 (106) is 
not maintained as in 3 (teal), the 4-oxo of 179 and 180 are at a distance of 3.5 to 3.7 Å 
respectively, that can induce a hydrogen bond in situ (2.8 Å in 3, distances not shown for 
clarity). The pyrrolo[2,3-d]pyrimidine scaffolds are stacked amid the hydrophobic 
aromatic side-chains of Tyr82 (60), Tyr107 (85) and Trp193 (171) (for π-π, van der Waals 
and hydrophobic interactions). The L-glutamate moieties of 179 and 180 occupy a similar 
binding space as the corresponding L-glutamate of the native ligand. The amide NH forms 
a hydrogen bond with the backbone carbonyl of His157 (135). The α-carboxylates form a 
network of hydrogen bonds involving the backbone NH of Gly159 (137) and Trp160 (138), 
and the side-chain NH of Trp162 (140), while the γ-carboxylic acids form salt bridge 
interactions with the side-chain protonated amine of Lys158 (136) and hydrogen bonds 
with the side-chain NH of Gln122 (100) and Trp124 (102). The four carbon linkers and the 
fluorinated phenyl side-chains are positioned in a hydrophobic region formed by Tyr82 
(60), Trp124 (102), and His157 (135). 
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The docked poses of 179 and 180 in FRβ are shown (Figure 38). The 2-NH2 of the 
ligands interact in a hydrogen bond with the side-chain carboxyl of Asp99 (97) (again for 
FRβ, the full-length gene product numbers are designated with numbering of the mature 
protein in parentheses), and the 4-oxo moieties form two hydrogen bonds, one each with 
the side-chain nitrogens of Arg121 (119) and His153 (151). The pyrrolo[2,3-d]pyrimidine 
scaffolds are stacked amid the hydrophobic aromatic side-chains of Tyr103 (101) and 
Tyr189 (187) (for π-π, van der Waals and hydrophobic interactions) similar to the bicyclic 
ring of the crystallized ligand. The L-glutamate moieties occupy a similar binding space as 
the corresponding L-glutamate of the native ligand. The amide NH form a hydrogen bond 
with the backbone carbonyl of His153 (151). The α-carboxylate of 179 forms a salt bridge 
with the side-chain of Arg154 (152) and hydrogen bonds with the backbone NH of Gly155 
(153) and a conserved water molecule. The α-carboxylate of 180 forms hydrogen bonds 
with the backbone NH of Gly155 (153) and side-chain of Trp158 (156). The γ-carboxylic 
acid of 179 forms a salt bridge with the side-chain of Arg138 (136) and hydrogen bonds 
with the backbone NH of Ser119 (117) and the backbone NH of Gln118 (116), while the 
γ-carboxylic acid of 180 forms a salt bridge with the side-chain of Arg138 (136) and 
hydrogen bonds with the backbone NH of Ser119 (117), side chain NH of Gln118 (116) 
and side-chain NH of Trp120 (118). The four carbon linkers and the fluorinated phenyl 
rings are positioned in a hydrophobic region formed by Tyr78 (76), Trp120 (118), and 
Trp158 (156). 
The docked poses of fluorinated compounds 179-180 in the GARFTase active site 
show that the pyrrolo[2,3-d]pyrimidine scaffolds bind in the same region as that occupied 
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by the bicyclic scaffold of the native ligand in the GARFTase crystal structure (PDB 5J9F, 
native ligand not shown for clarity) (Figure 39). 
 
Figure 38. Molecular modeling studies with human FRβ (PDB 4KN2).95 Superimposition 
of the docked pose of 179 (yellow, -62.5 kJ/mol), 180 (pink, -57.3 kJ/mol) with the docked 
pose of 3 (teal, -56.9 kJ/mol). Docking studies were performed using LeadIT 2.1.6 and 
visualized using Maestro 11.2.197, 352  
The scaffold is stabilized in the binding site by multiple interactions, hydrogen 
bonds between (1) the N1 nitrogens and the backbone NH of Leu899, (2) 2-NH2 and the 
backbone carbonyl of Leu899 and (3) the 4-oxo and the backbone NH of Asp951. 
Additionally, the 4-oxo form a water-mediated hydrogen bonding network via a conserved 
water molecule with Ala947, Ala952, and Asp949. The N7-nitrogens form a hydrogen 
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bond with the backbone carbonyl of Arg897. The pyrrolo[2,3-d]pyrimidine bicyclic 
scaffolds are also positioned appropriately for van der Waals interactions with Val950. The 
amide NH of the L-glutamate form a hydrogen bond with the carbonyl of Met896. The L-
glutamates are oriented with the α-carboxylates forming a salt bridge with the side-chain 
of Arg897 and a hydrogen bond interaction with the backbone amide NH of Ile898 and/or 
with the side-chain of Arg871. The γ-carboxylate forms salt bridge interactions with the 
side-chains of Lys844 and Arg897. 
 
 
 
Figure 39. Molecular modeling studies with human GARFTase (PDB 5J9F).167 
Superimposition of the docked pose of 179 (yellow, -51.7 kJ/mol), 180 (blue, -53.3 kJ/mol) 
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with the docked pose of 3 (brown, -55.4 kJ/mol). Docking studies were performed using 
LeadIT 2.1.6 and visualized using Maestro 11.2.197, 352 Shown in orange is the substrate 
GAR. 
 
Comparing the docked poses of the parent desfluoro analog 3 and the fluorinated 
analogs 179 and 180 in FRα, FRβ, and in GARFTase (Figures 37-39), the slight increase 
in size at the 2'- (179) or 3'-position (180) due to C(sp2)F (1.32 Å) replacement of a C(sp2)H 
(1 Å) bond, preserved the required orientation and interactions of the scaffold and side-
chain groups. However, no interactions were observed by either of the fluorine atoms with 
the amino acids in the binding sites. A noteworthy observation is that, in a majority of the 
poses generated for each of the protein targets (Figures 37-39 are the best docked poses of 
the 10 generated poses within each protein, w.r.t docked scores, root mean square deviation 
(RMSD) and conserved interactions) with the 2'-fluorinated (o- to the L-glutamate) analog 
179, the fluorine atom and the amide NH are positioned in a syn conformation (-0.1° to -
30° dihedral angles). As such, an intramolecular N-H ꞏ ꞏ ꞏF interaction in the low energy 
state of the unbound ligand as predicted by the energy minima of 179 (Figure 36), could 
stabilize the bound conformation and provide an entropic benefit upon binding. However, 
this N-H ꞏ ꞏ ꞏF hydrogen bond observed in the unbound state is required to break upon 
binding, as the amide NH is involved in a much stronger and conserved hydrogen bond 
with the backbone carbonyl of the target proteins (Figures 37-39). 
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Table 7. Cell proliferation assays with 6-substituted pyrrolo[2,3-d]pyrimidine 
antifolates.114 
 
Antifolate 
CHO (IC50s) (nM) KB 
(IC50s) 
(nM) RFC 
PC43-10 
FRα 
RT16 
FRβ 
D4 
PCFT 
R2/PCFT4
3 >1000 6.3 (1.6) 10.0 (2) 213 (28) 1.9 (0.7) 
179 >1000 0.58 
(0.12) 
1.6 (0.44) 23 (2) 0.59 
180 >1000 1.4 0.93 207 1.67 
 
 
In the cell proliferation assays, the 3ʹ-fluorinated compound 180 showed ~5- to 10-
fold improved inhibition of the FR-expressing CHO cells (RT16 and D4) but retained 
similar activity as the parent desfluoro 3 in PCFT-expressing CHO cells (PCFT4) and KB 
cells. The 2ʹ-fluoro substitution in 179 improved activity/selectivity across all cell lines 
with the largest impact (11- and 9-fold, respectively) on the FRα- and PCFT-expressing 
CHO cell lines (Table 7).114 These results indicate that fluorine substitution influences the 
activity depending on its regioisomeric position. As dual PCFT- and FR-targeting provides 
the greatest utility of our targeted analogs, these results prompted further systematic studies 
of the impact of o-fluoro substitutions on the growth inhibitory activities of our previously 
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reported 6-substituted pyrrolo[2,3-d]pyrimidine compounds toward FR- and PCFT-
expressing cells (Tables 2, 4 and 5). 
 
C.1.2 Design of 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-fluoropyridyl 
classical antifolates 
 
Substituting a CH (sp2) group with an N (sp2) atom can lead to improvements in 
functional activities as N-substitution redistributes the electron density in the aromatic ring, 
and introduces a dipole moment, hydrogen bond capability and polarity into the molecule 
(Figure 40 and Table 8).353  
 
 
Figure 40. Changes in molecular properties upon substitution of a CH (sp2) group with an 
N (sp2) atom.353 
Each of the modified properties (Figure 40 and Table 8) could influence the 
biological activity.353 A pyridyl-for-phenyl replacement of the 6-substituted pyrrolo[2,3-
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d]pyrimidine benzoyl L-glutamate antifolate 3 afforded tumor-targeted GARFTase 
inhibitor 4 with improved activity (Tables 2 and 4).115 The phenyl side-chain was replaced 
with 3',6'; 2',5'; and 2',6' pyridyls, and proliferation inhibition of CHO, KB and NCI-
IGROV1 EOC cells were analyzed. The 2',5'-substituted compound 4 was ∼20-fold more 
active against FRβ-expressing CHO cells and ~4- to 5-fold more active against FRα- and 
PCFT-expressing CHO cells than the lead 3. Compound 4 was ~3-fold more potent than 3 
in in situ GARFTase assays (GARFTase IC50 value of 3 and 4 were 5.6 nM and 1.8 nM 
respectively). Antitumor efficacy of 4 in vivo with subcutaneous IGROV1 tumor 
xenografts in severe combined immunodeficiency (SCID) mice showed potent efficacy, as 
reflected in tumor growth delay (T-C to reach 1000 mg in days was 45 days for compound 
4 and 0 days for PMX).115 
 
Table 8. Changes in molecular and physicochemical properties upon substitution of a CH 
(sp2) group with an N (sp2) atom.341 
Properties A B 
Polar surface area (tPSA) - 12.9 Å2 
Lipophilicity (CLogP) 2.142 0.645 
Basicity (pKa) - 5.2 
C/N electronegativity (χ) 2.55 3.04 
Dipole moment (µ) - 2.2 D 
CH/N van der Waals 
radius (rw) 
1.77 Å 1.55 Å 
A-A/A-B π-stacking 
energy (∆E) 
-2.71 kcal/mol -3.23 kcal/mol 
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Figure 41. Lead compounds 2-4, and target compounds 182-183. 
From previous SAR studies it is evident that the 3C linker analogs of 6-substituted 
pyrrolo[2,3-d]pyrimidines are more potent while the 4C linkers are more selective 
inhibitors of CHO cells expressing human FRα (RT16), FRβ (D4) and PCFT (R2/PCFT4) 
(over CHO cells expressing human RFC (PC43-10)) (Tables 2 and 4). Fluorine substitution 
o- to the L-glutamate dramatically increased the tumor-targeted antiproliferative activity of 
the phenyl series, mediated through selective transport (especially PCFT). Consequently, 
it is of interest to investigate the contribution of the 3'-[ortho (o-) to the L-glutamate] 
fluorine substitution in the pyridyl series for a single agent with improved tumor potency 
as well as selectivity. The SAR study from 3'-fluorinated compounds 182 and 183 with 3C 
and 4C linkers respectively will determine the steric and electronic influence of o-
fluorination on tumor-targeted activity (especially PCFT over RFC transport) in the 2',5'-
substituted pyridyl analogs (Figure 41).  
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Figure 42. Molecular modeling studies with human FRα (PDB 5IZQ).167 Superimposition 
of the docked pose of 182 (violet, -56 kJ/mol) with the docked pose of 3 (teal, -55 kJ/mol) 
and 4 (yellow, -51 kJ/mol). Docking studies were performed using LeadIT 2.1.6 and 
visualized using Maestro 11.2.197, 352  
Molecular modeling studies of lead compounds 3,  and  4 along with 3'-fluorinated 
compounds 182 did not detect any additional interactions of the 2′,5′-pyridyl ring compared 
to the parent phenyl analog 3 (Figures 42 and 43). The improvement in potency of 4 (e.g., 
GARFTase IC50 value of 3 and 4 were 5.6 nM and 1.8 nM respectively) perhaps is a result 
of improved energies due to additional hydrophobic/van der Waals/CH-π/π-π/hydrogen 
bond interactions of the differentially polarized pyridyl ring (compared to the phenyl ring 
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in 3) with the side-chains of the aromatic amino acids (Trp124 (102) and Trp162 (140) in 
FRα/Trp120 (118), Trp158 (156) in FRβ) in the FRs (Figures 38, and 42-43). 
Compounds 182 and 183 (Figure 41) were tested against CHO cells expressing 
human FRα (RT16), FRβ (D4), RFC (PC43-10), and PCFT (R2/PCFT4), KB, and HeLa 
cells and, IGROV1 and A2780 epithelial ovarian cancer cells, for drug potency and 
transport selectivity.  
 
Figure 43. Molecular modeling studies with human GARFTase (PDB 5J9F).167 
Superimposition of the docked pose of 182 (violet, -57 kJ/mol) with the docked pose of 3 
(teal, -55.4 kJ/mol) and 4 (yellow, -53 kJ/mol). Docking studies were performed using 
LeadIT 2.1.6 and visualized using Maestro 11.2.197, 352 Shown in orange is the substrate 
GAR. 
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C.1.3 Design of 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-fluorothienyl 
classical antifolates 
 
Figure 44. Lead compounds 2, 3, 7 and 9 and target compounds 184-185. 
A thienyl-for-phenyl replacement (based on the previous GARFTase inhibitors 
LY309887 and AG2034, Figure 28) of the 6-substituted pyrrolo[2,3-d]pyrimidine benzoyl 
L-glutamate antifolates not only restored PCFT potency, but also afforded the most potent 
PCFT-selective antifolates known (Tables 2 and 4).60, 104, 107, 116, 119, 121, 158-159, 166, 354 Among 
the various thienyl ring regioisomeric substitutions tested (2',5'-, 2',4'-, and 3',5')-, the 2',4'-
substituted antifolates 7 and 9 with 3C and 4C linkers respectively, showed substantial 
PCFT-targeted activity towards R2/hPCFT4 CHO cells, with IC50s of 5.4 (1.3) and 41.5 
(3.1) nM, respectively (Table 4).  While 7 is one of the most potent hPCFT4 cell inhibitors, 
it has significant non-selective activity against hRFC-expressing PC43-10 CHO cells 
(Tables 2 and 4). Though 8 is not as potent as its 3C linker analog, it is the most potent 
hPCFT4 cell inhibitor amongst the analogs that are inactive toward PC43-10 CHO cells 
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(IC50 = >1000 nM) (Table 4). Consequently, it is of interest to explore the thienyl series 
for a single agent with both potency and selectivity towards PCFT-expressing cells (the 
crystal structure of the membrane bound transporters, RFC and PCFT, have not been 
resolved yet).  Molecular modeling studies in FRs and GARFTase did not detect any 
additional interactions made by the thiophene ring. Compared to a phenyl ring, thiophene 
ring is differentially polarized and the bond angle between the substitutions on the ring 
vary (Table 9). As such, the improved potency of the thienyl series could be a result of: (a) 
improved energies of ligand-protein interactions in the transport protein and enzyme 
binding pockets due to better alignment of the scaffold and the L-glutamate side-chain 
and/or (b) additional hydrophobic/van der Waals/CH-π/π-π/ interactions with the side-
chains of the aromatic amino acids (e.g., Trp102, Trp140 in FRα/Trp 118, Trp156 in FRβ) 
in the FRs. 
Table 9. Changes in relative angles of substitution and dipole moments upon bioisosteric 
replacement of phenyl with thienyl ring. Dipole moments were calculated using QikProp, 
Maestro 11.2.197, 355  
Compd. No. Regioisomeric 
substitution 
Relative orientation 
of the substituents 
Dipole µ (D) 
 
3 1',4' Linear (180°) 5.7 
7/9 2',4' Non-linear 6.7 
 
Fluorine substitution o- to the L-glutamate dramatically increased tumor-targeted 
antiproliferative activity of the phenyl series, mediated through selective transport 
(particularly PCFT) (Table 7).114 It is therefore of interest to investigate the contribution of 
a 3' [ortho (o-) to the L-glutamate] fluorine substitution on tumor-targeted activity 
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(selective uptake and GARFTase inhibition) in the thienyl analogs 184-185. The limited 
SAR study from compounds 184-185 will determine the steric and/or electronic influence 
of o-fluorination on tumor-targeted activity (especially PCFT over RFC uptake) in the 2',4'-
substituted thienyl analogs.  
Compounds 184-185 were tested against CHO cells expressing human FRα 
(RT16), FRβ (D4), RFC (PC43-10), and PCFT (R2/PCFT4), KB, and HeLa cells and, 
IGROV1 and A2780 epithelial ovarian cancer cells, for drug potency and transport 
selectivity.  
C.1.4 Design of 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-difluorophenyl 
classical antifolates 
 
Figure 45. Lead compounds 179-180 and target compounds 186-188. 
The predictability associated with fluorine substitutions in bioactive molecules is not 
straight forward and often necessitates “fluorine scanning” approaches for the discovery of 
optimized fluorine-substituted drugs.341 From the biological activity of the fluorinated 
phenyl series it is apparent that fluorine substitutions either on the 2'- or 3'-position (o- or 
m-substiution to the L-glutamate respectively) of the aryl ring are tolerated in the binding 
sites of FRs and GARFTase (Table 7).114 
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Table 10. Changes in volume and dipole moment upon bioisosteric replacement of CH 
(sp2) with CF (sp2). Physicochemical properties were calculated using QikProp, Maestro 
11.2.197, 355  
 
Compd. 
No. 
R1 R2 R3 Volume 
(Å3) 
 
Dipole µ 
(D) 
 
Intra-
molecular 
N-H ꞏ ꞏ ꞏF 
bond 
3 H H H 380 5.7 - 
179 F H H 396 5.3 + 
180 H F H 396 4 - 
186 F H F 412 7.11 + 
187 F F H 412 5.7 + 
188 H F F 412 4.2 + 
 
Therefore, systematic structure-activity relationship (SAR) study of tumor-targeted 
antifolates was extended by strategic fluorine scanning on the side-chain phenyl ring. 
Compounds 186-188 include a 4C linker with the possible (o-/m-) combinations of 
difluorinated analogs (Figure 45). The proposed analogs will determine if more than one 
fluorine atom substitution is beneficial/detrimental to activity and if a specific difluoro 
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regioisomeric substitution is more tolerated over the others owing to modified (i) sterics 
and/or (ii) electronics (Table 10).  
Compounds 186 and 187 (Figure 45) were tested against CHO cells expressing 
human FRα (RT16), FRβ (D4), RFC (PC43-10), and PCFT (R2/PCFT4) as well as KB 
tumor cells in culture, for drug potency and transport selectivity.  
C.1.5 Design of 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-2'-
substitutedphenyl classical antifolates 
From the biological activity of the fluorinated phenyl series, the 2'-fluoro substitution 
dramatically increased antiproliferative activity mediated through FRα, FRβ and PCFT 
transport with the largest impact (11- and 9-fold, respectively) on the FRα- and PCFT-
expressing CHO cell lines (Table 7).114 These results indicate that not only does fluorine 
substitution influence the activity but its regioisomeric position on the phenyl ring dictates 
the improvement/loss of activity. 
 
 
Figure 46. Lead compounds 3 and 179 and target compounds 189-191. 
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Table 11. Changes in volume and dipole moment upon replacement of CH (sp2) with 
C(CH3) (sp2), C(CF3) (sp2), C(Cl) (sp2). Physicochemical properties were calculated using 
QikProp, Maestro 11.2.197, 355  
 
Compd. 
No. 
R1 Volume 
(Å3) 
 
Dipole µ (D) 
  
Intra-
molecular 
N-H ꞏ ꞏ ꞏF 
bond 
3 H 380 5.7 - 
179 F 396 5.3 + 
189 CH3 440 5.9 - 
190  Cl 424 5.6 - 
191 CF3 477 7.2 + 
 
As dual PCFT- and FR-targeting provides the greatest utility of our targeted 
analogs, these results prompted further systematic evaluation of the impact of ortho-
substitutions on the growth inhibitory activities of the 6-substituted pyrrolo[2,3-
d]pyrimidine compounds. To separate the influence of the steric property from the 
electronic (electron withdrawing effect, hydrogen bonding and dipole interactions) 
properties on tumor-targeted activity, compounds 189-191 were designed (Figure 46). 
Compounds 189 and 190 with bulkier 2'-CH3 and 2'-Cl substitutions respectively on the 
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phenyl side-chain occupy larger volumes than the unsubstituted phenyl but have similar 
dipole moment at the side-chain benzamide as the parent 3 (Table 11). In compound 191, 
a 2'-CF3 substituted analog occupies a larger volume and has a larger dipole as well, in the 
direction of the carbonyl of the amide (Table 11).   
 
Figure 47. Molecular modeling studies with human FRα (PDB 5IZQ).167 Docked pose of 
191 (pink, -54.2 kJ/mol). Docking studies were performed using LeadIT 2.1.6 and 
visualized using Maestro 11.2.197, 352  
The analog with the largest 2'-substitution (2'-CF3), compound 191, was modeled in FRα 
and GARFTase to identify the presence of steric clashes of the larger substitutions 
(compared to a H substitution) with the neighboring amino acids (Figure 47-48). 
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Figure 48. Molecular modeling studies with human GARFTase (PDB 5J9F).167 Docked 
pose of 191 (dark grey, -54.7 kJ/mol). Docking studies were performed using LeadIT 2.1.6 
and visualized using Maestro 11.2.197, 352 Shown in orange is the substrate GAR. 
All the interactions are maintained and the binding pockets of both the transporter 
FRs (only FRα is shown) and the enzyme GARFTase have sufficient space to 
accommodate the larger 2'-substitutions, however oriented anti to the sidechain amide NH. 
The CF3 group is placed favorably to from van der Waals interactions with the surrounding 
hydrophobic residues (Tyr82 (60) and Trp162 (140) in FRα, and Ile898 in GARFTase, 
Figure 48). The anti conformation can be stabilized in 191 due to the capability of the CF3 
group to form an intramolecular dipole-dipole interaction with the carbonyl of the amide 
(Figure 34).356  
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The modifications in these three compounds 189-191 will systematically evaluate 
the influence of size and electronics (individually and in combination) of the side-chain 
phenyl, on tumor-targeted activity.  
 
Compounds 189 and 191 (Figure 46) were tested against CHO cells expressing 
human FRα (RT16), FRβ (D4), RFC (PC43-10), and PCFT (R2/PCFT4) as well as KB 
tumor cells in culture, for drug potency and transport selectivity.  
 
C.1.6 Design of 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-pyrimidyl 
classical antifolates. 
Thienyl-for-phenyl and pyridyl-for-phenyl sidechain replacements afforded some of the 
most potent, and FR- and PCFT-selective antifolate compounds known (Tables 2 and 4).104, 
107, 115-116, 121 
 
 
Figure 49. Lead compounds 3 and target compounds 192. 
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Table 12. Changes in volume and dipole moment upon isosteric replacement of the phenyl 
ring with a pyrimidyl. Physicochemical properties were calculated using QikProp, Maestro 
11.2.197, 355  
 
Compd. 
No. 
A Volume 
(Å3) 
 
Dipole µ (D) 
  
3 CH 380 5.7 
192 N 351 7.02 
 
From the biological activity of the fluorinated phenyl analogs 179 and 180 (Table 
7), the 2'-fluoro substitution dramatically increased antiproliferative activity mediated 
through FRα, FRβ and PCFT transport with the largest impact (11- and 9-fold, 
respectively) on the FRα- and PCFT-expressing CHO cell lines (Table 7).114 These results 
indicate that stereoelectronic modification of the phenyl ring positively influences the 
potency and selectivity of the 6-substituted, pyrrolo[2,3-d]pyrimidine classical antifolates. 
As dual PCFT- and FR-targeting provides increased utility of our targeted analogs, these 
results prompted further systematic studies into the impact of isosteric sidechain 
replacements on the growth inhibitory activities of the 6-substituted pyrrolo[2,3-
d]pyrimidine compounds. To elucidate the influence of electronic (electron withdrawing 
 111 
effect, hydrogen bonding and dipole interactions) properties on tumor-targeted activity, 
compound 192 was designed as a pyrimidyl-for-phenyl replacement which has similar size 
but with a larger dipole in the direction of the amide carbonyl (Figure 49 and Table 12).  
Compound 192 (Figure 49) was tested against CHO cells expressing human FRα 
(RT16), FRβ (D4), RFC (PC43-10), and PCFT (R2/PCFT4) as well as KB tumor cells in 
culture, for drug potency and transport selectivity.  
C.2. Multiple enzyme inhibitors (GARFTase and AICARFTase) with selectivity for 
FRs and/or PCFT over RFC 
C.2.1. Design of 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-butylphenyl 
classical antifolates 
 
Figure 50. Lead compound 13 and target compound 193. 
 
Gangjee et al.120 previously reported 5-substituted pyrrolo[2,3-d]pyrimidine 
antifolate 13 with  4C linker and a phenyl L-glutamate sidechain as a chain extension 
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analog of the clinically used PMX for improved tumor cell potency as well as tumor-
selectivity (Figure 31 and Table 5). Compound 13 is a first-in-class examples of antifolates 
that act via dual inhibition of AICARFTase and GARFTase alone (Table 5). Compared to 
PMX, extension to 4C linker in compound 13 improved inhibition of proliferation of KB 
human tumor as well as FRα-expressing CHO cells (RT16). However, 13 had reduced 
activity toward PCFT-expressing CHO cells (PCFT4). Additionally, high activity toward 
RFC-expressing CHO cells renders it only moderately selective for FRα over RFC and 
selective for RFC over PCFT. Previous studies of related 6-substituted pyrrolo[2,3-
d]pyrimidines established that the conformation of the scaffold and side-chain, as a 
consequence of linker length and flexibility, plays an important role in determining tumor 
cell potency and selectivity. Thus, it was of interest to synthesize the regioisomeric, 1',3'-
substituted analog 193 of the most potent analog 13 to evaluate its influence on selectivity 
and potency (Figure 50). The 1',3'-substitution provides a non-linear conformational 
orientation of the substitutions on the phenyl ring and subsequently influences the 
orientation of the scaffold and the L-glutamate sidechain in the binding pockets (RFC, FRs, 
PCFT, GARFTase and AICARFTase).  
 
Molecular modeling studies of 193 compared to the parent analog 13 (Figures 51 
and 52) in the FR and GARFTase pockets showed that the binding poses are 
superimposable and 193 retained all the important interactions (all the key interactions 
have been explained in detail in Figures 37 and 39).  
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Figure 51. Molecular modeling studies with human FRα (PDB 5IZQ).167 Superimposition 
of the docked poses of 193 (blue, -55 kJ/mol and 13 (green, -56.8 kJ/mol). Docking studies 
were performed using LeadIT 2.1.6 and visualized using Maestro 11.2.197, 352  
In the AICARFTase active site, the pyrrolo[2,3-d]pyrimidine scaffolds of 
compound 193 and lead 13 are superimposable and are fixed within the hydrophobic 
environment of Pro543 and  Phe544  above,  and the side  chain  of Phe315  below (Figure 
53).259 Hydrogen bond interactions are formed between the 2-amino group and side chains 
of Asn489 and Asp546, N-3 and side chain of Asp546, and 4-oxo and side chain of Asn547. 
The phenyl moieties of the side-chain form π-stacking interactions with the side-chain of 
Phe315. The orientation of the L-glutamate tail of the docked compounds vary due to the 
para/meta variation in the phenyl substitution pattern. The α-glutamates of both docked 
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analogs interact via a salt bridge with the protonated Lys358. In 13, the γ-glutamate makes 
a hydrogen bond with the backbone NH of of Ala566 and a water mediated hydrogen bond 
with the backbone NH of Pro543 while the γ-glutamate of 193 makes a hydrogen bond 
only with the backbone NH of Ala566.  
 
Figure 52. Molecular modeling studies with human GARFTase (PDB 5J9F).167 
Superimposition of the docked poses of 193 (blue, -42.7 kJ/mol) and 13 (green, -48.6 
kJ/mol). Docking studies were performed using LeadIT 2.1.6 and visualized using Maestro 
11.2.197, 352 Partial structure of substrate GAR is shown in orange. 
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Figure 53. Molecular modeling studies with human AICARFTase (PDB 1P4R).258 Docked 
poses of 193 (blue, -42.3 kJ/mol) and 13 (green, -36.5 kJ/mol). Docking studies were 
performed using LeadIT 2.1.6 and visualized using Maestro 11.2.197, 352 
Compound 193 (Figure 50) were tested against CHO cells expressing human FRα 
(RT16), FRβ (D4), RFC (PC43-10), and PCFT (R2/PCFT4) as well as KB tumor cells in 
culture, for drug potency and transport selectivity. 
C.2.2. Design of 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-4'-
propyloxy/propylthio/propylamino/butylaminophenyl classical antifolates 
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Figure 54. Lead compounds 13 and 14 and target compounds 194-197. 
Gangjee et al.120 previously reported 5-substituted pyrrolo[2,3-d]pyrimidine 
antifolates 13 and 14 with 4C and 5C linkers respectively, and a phenyl L-glutamate 
sidechain (Table 5) as a series of chain extension analogs of clinically used PMX for 
improved tumor cell potency as well as tumor selectivity. Compounds 13 is a first-in-class 
examples of antifolates that act via dual inhibition of AICARFTase and GARFTase alone 
(Table 5). Extension to a 4C linker in compound 13 not only improved potency in KB 
human tumor compared to PMX, but also improved inhibition of proliferation of FRα-
expressing CHO cells (RT16). However, 13 had reduced activity toward PCFT-expressing 
CHO cells (PCFT4). Additionally, high activity toward RFC-expressing CHO cells (PC43-
10) renders it moderately selective for FRα over RFC and selective for RFC over PCFT. 
While compound 14 with 5C linker was moderately active, it showed the least uptake by 
RFC-expressing CHO cells (PC43-10 IC50 >1000 nM) (Table 5).  
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Table 13. Predicted bond angle variations of benzylic substitutions (X) in 194-197. Bond 
angles were measured using energy-minimized conformations of compounds with Maestro 
11.2.197  
 
Compd. 
No. 
X Angle (a) 
13 CH 112.2° 
194/197 NH 120.9° 
195 O 118.3° 
196 S 106.8° 
 
Previous studies of related 6-substituted pyrrolo[2,3-d]pyrimidines established that 
the distance between the scaffold and side-chain as a consequence of linker length and 
flexibility, plays an important role in determining tumor cell inhibitory potency and 
selectivity (Tables 2 and 4).104, 107, 115-116, 121 Thus, it was of interest to introduce 
heteroatoms (NH, O or S substitutions of the benzylic CH2) in the most potent carbon 
analog 13, to evaluate the influence of varied bond angles of the benzylic position on 
selectivity and potency (Table 13). The varied bond angles of the C−X−C bonds in ligands 
194-196 provide different conformational orientations of the scaffold and the L-glutamate 
sidechain and could impact transport selectivity, as well as dual GARFTase and 
AICARFTase inhibition (Figure 54).  
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Though analog 14 with a 5C-linker is less potent than compound 13, it has ~4-fold 
reduced activity toward CHO cells expressing RFC (Table 5). As a preliminary study, 
analog 197 with a 5-atom linker and a benzylic NH substitution was also designed to 
investigate the contribution of further conformational flexibility towards potency and 
selectivity in the 5C-linker series of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates 
(Figure 54).  
 
Figure 55. Molecular modeling studies with human FRα (PDB 5IZQ).167 Superimposition 
of the docked poses of 194 (pink, -57.8 kJ/mol), 195 (green, -58 kJ/mol), 196 (blue, -58 
kJ/mol), and 197 (violet, -58 kJ/mol). Docking studies were performed using LeadIT 2.1.6 
and visualized using Maestro 11.2.197, 352  
Molecular modeling studies of the heteroatom analogs 194-197 were carried out using X-
ray crystal structures of human FRα (5IZQ), GARFTase (5J9F) and AICARFTase (1P4R) 
to explore the binding interactions (Figures 55-57). The compounds display similar 
interactions as the native crystal structure ligands and the lead compounds 13 or 14 (not 
shown here for clarity), by maintaining key interactions involving the bicyclic scaffolds 
and the benzoyl L-glutamate tail.  
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Figure 56. Molecular modeling studies with human GARFTase (PDB 5J9F).167 
Superimposition of the docked poses of 194 (pink, -52.6 kJ/mol), 195 (green, -46.3 kJ/mol), 
196 (blue, -50 kJ/mol), and 197 (violet, -52.5 kJ/mol). Docking studies were performed 
using LeadIT 2.1.6 and visualized using Maestro 11.2.197, 352 Substrate GAR is shown in 
orange. 
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Figure 57. Molecular modeling studies with human AICARFTase (PDB 1P4R).258 
Superimposition of the docked poses of 194 (pink, -39.3 kJ/mol), 195 (green, -34.9 kJ/mol), 
196 (blue, -32 kJ/mol), and 197 (violet, -41.1 kJ/mol). Docking studies were performed 
using LeadIT 2.1.6 and visualized using Maestro 11.2.197, 352 Substrate AICAR is not shown 
for clarity. 
Zooming into the docked poses of 194-197 in FRα (Figure 55) shows that the 
benzylic heteroatom substitutions not only influence linker conformations due to varied 
bond angles but are also near (~4 to 6 Å away) the backbone amide formed by Trp134 and 
His135. Within the flexible environment of a protein, such distances may be shortened 
(ideal distance required for hydrogen bond formation is ~3 Å) to promote hydrogen bond 
interactions for improved binding energies.  
Similarly, the docked poses of compounds 196 and 197 in the GARFTase active 
site show that the region occupied by the benzylic heteroatomic substitutions are ~2 to 4 Å 
away from hydrogen donors (conserved water, side-chain protonated amine of GAR) and 
acceptor (side-chain carbonyl of Asp951) (Figure 56).  
In the AICARFTase active site, the docked pose of compounds 197 forms an 
additional hydrogen bond interaction formed between the benzylic NH and the side-chain 
carbonyl of the Phe315 (Figure 57). Additionally, the benzylic NH of 194 is ~3.23 Å away 
from the backbone carbonyl (hydrogen bond acceptor) of Phe315.  
The hydrogen bond interactions that are not recognized in the docking studies are 
plausible within the constantly moving, flexible environment of a protein in aqueous 
solution in vivo which can further stabilize binding for better transport and/or inhibition. 
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The novel analogs 195 and 196 were tested as growth inhibitors against CHO cells 
expressing human FRα (RT16), FRβ (D4), RFC (PC43-10), and PCFT (R2/PCFT4) as well 
as KB tumor cells in culture.  
C.2.3 Design of 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-butyl-2'-
fluorophenyl classical antifolates 
 
Figure 58. Lead compounds 13 and target compound 198. 
Extension of the 2C-linker in PMX to a 4C-linker in compound 13 not only 
improved potency against KB human tumor but also the inhibition of proliferation of FRα-
expressing CHO cells. However, 13 had reduced activity toward PCFT-expressing CHO 
cells. Additionally, high activity toward RFC- expressing CHO cells renders selective for 
RFC over PCFT. 2'-[ortho (o-) to the L-glutamate] fluorine substitution in 6-substituted 
pyrrolo[2,3-d]pyrimidines dramatically increased tumor-targeted antiproliferative activity 
of the phenyl series mediated through selective transport (especially PCFT) (Table 7).114 
Consequently, it is of interest to investigate the contribution of 2'-fluorine substitution in 
the phenyl series of 5-substituted pyrrolo[2,3-d]pyrimidines for improved PCFT-targeted 
potency as well as selectivity. Compound 198 (Figure 58) was designed and its impact on 
drug potency and transport selectivity was determined.  
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The novel analog 198 was tested as growth inhibitors against CHO cells expressing 
human FRα (RT16), FRβ (D4), RFC (PC43-10), and PCFT (R2/PCFT4) as well as KB 
tumor cells in culture.  
C.3. Multiple enzyme inhibitors (TS, GARFTase, AICARFTase) with selectivity for 
FRs and/or PCFT over RFC 
C.3.1. Design of 5-substituted, 2-amino-4-oxo-6-methyl pyrrolo[2,3-d]pyrimidine 
classical antifolates 
 
Figure 59. Lead compounds 2, 3, PMX, 12 and 13 and target compounds 200 and 201. 
Although the methyl group often considered as chemically inert, only participates 
in London dispersion interactions, it plays a very important role in the molecular 
recognition of endogenous and exogenous ligands by bioreceptors.357 The stereoelectronic 
effects of a methyl leads to selective binding and increased potency, among various other 
pharmacological effects.330, 358-359 As such, it is a useful tool used in medicinal chemistry 
design to modify aspects related to conformation, electronic factors, pharmacokinetics, 
among other factors.358-359   
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Table 14. IC50 Values (nM) and FR-and PCFT-expressing CHO cell selectivity ratios over 
RFC-expressing CHO cells for 12, 199, and PMX. For KB cells, data are shown for the 
protective effects of nucleoside additions, including adenosine (Ade), thymidine (Thd), or 
AICA. 
Compd. No. KB 
IC50 
(nM) 
Potency 
RFC/FRα 
Selectivity 
ratios 
(IC50) for 
FRα over 
RFC 
RFC/FRβ
Selectivity 
ratios 
(IC50)  for 
FRβ over 
RFC 
RFC/PCFT 
Selectivity 
ratios (IC50) 
for PCFT 
over RFC 
KB 
(+Thd/Ade
/AICA) 
PMX 9.94 
(3.11) 
0.62 0.44 3.15 Thd/Ade 
12 49.5 
(13.2) 
0.95 - 0.2 Ade 
199 49.9 >15 >385 >17 Ade/AICA/
Thd 
 
Studies of 5- and 6-substituted pyrrolo[2,3-d]pyrimidines established that while the 
6-substituted analogs are selective (>100 fold for FR and/or PCFT expressing CHO cells 
over those that express RFC) and potent GARFTase inhibitors, the related 5-substituted 
pyrrolo[2,3-d]pyrimidines are non-selective (<10 fold for FR and/or PCFT expressing 
CHO cells over those that express RFC) dual GARFTase and AICARFTase inhibitors 
(Tables 2, 4 and 5).104, 107, 116, 120-121 A superior inhibitor to the above two series of analogs 
would be a compound that is a FR- and PCFT-selective (over RFC), dual GARFTase and 
AICARFTase inhibitor. Thus, it was of interest to synthesize and evaluate 6-methylated, 
2-amino-4-oxo-pyrrolo[2,3-d]pyrimidines 200 and 201 as the hybrids of 5- and 6-
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substituted analogs, to evaluate for improved selectivity and dual enzyme inhibitory 
activity.  
Gangjee et al360 performed a preliminary study of a 5-substituted, 2-amino-4-oxo-
6-methyl pyrrolo[2,3-d]pyrimidine 199 with a 3C-linker and found that the hypothesis for 
selectivity due to a 6-methyl substitution was supported by the biological activity. 
Compound 200 is a multi-enzyme inhibitor of purine and pyrimidine biosynthesis (Table 
14); in vitro growth inhibition of IGROV1 tumor cells was completely protected only in 
the presence of both Ade (adenine) and Thd (thymidine) (Table 14). The potency of 
compound 199 towards KB cells (49.9 nM) was identical to its parent desmethyl analog 12 
(Table 14). Unlike 12 (equally selective for RFC- and FRα-expressing CHO cells, and ~5-
fold selective for RFC- over PCFT-expressing CHO cells), it is selective for FRα, FRβ and 
PCFT over RFC- expressing CHO cells (>15-, >385- and >17-fold respectively) primarily 
due to loss of uptake by RFC (Table 14). This study led to the discovery of a compound 
that was ~5-fold less potent against KB cell proliferation and ~5-(PCFT) to 900-(FRβ) fold 
more selective than PMX. 
The pharmacological influences of a methyl substitution for the observed loss of RFC 
binding is perhaps due to steric repulsion. The crystal structure of hRFC is not known and 
hence the arrangement of the amino acids that line the folate binding pocket and the binding 
interactions remain unidentified. However, based on the general trend of reduced RFC 
binding by the 6-substituted pyrrolo[2,3-d]pyrimidine series of analogs, a possible steric 
repulsion in the scaffold binding subsite caused by the alkyl group at 6-position is 
proposed. 
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To investigate the contribution of 6-methyl substitution in the phenyl series of 5- 
substituted pyrrolo[2,3-d]pyrimidine series for improved potency as well as selectivity, 
compounds 200 and 201 with 2C- (6-methyl analog of PMX) and 4C-linkers respectively 
were designed (Figure 59).  
Molecular modeling studies of the 6-methylated analogs 199-201 were carried out using 
X-ray crystal structures of human FRα (5IZQ), GARFTase (5J9F) and TS (1JU6) to 
explore the binding interactions and to validate their drug targets (Figures 60-63). The 
compounds display similar interactions as the native crystal structure ligands (not shown 
here for clarity)  
The docked poses of the 2C-, 3C- and 4C-linker analogs 200, 199 and 201 respectively, in 
FRα (Figure 60) display similar interactions as the native crystal structure ligands (not 
shown here for clarity) by maintaining key interactions involving the bicyclic scaffolds and 
the benzoyl L-glutamate tail. However, due to its shorter length, the 2C-linker analog 200 
does not fully occupy the extended pocket of FRα. In order to accommodate energetically 
favorable ionic interactions of the side-chain L-glutamate, the bicyclic scaffold is shifted 
to the right, away from the scaffold binding region. As a result, the hydrogen bond 
interactions of the 3-NH with the side-chain hydroxyl of Ser196 (174) and the 4-oxo moiety 
with the side-chain nitrogen of Arg125 (103) are lost, reducing the energy of binding. Apart 
from shifting the bicyclic ring away from the scaffold binding region, the 6-methyl 
substitution neither sterically clashes with the binding site of FRα, nor does it alter the 
conformation of the scaffold when compared to the desmethyl analog.  
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Figure 60. Molecular modeling studies with human FRα (PDB 5IZQ).167 Superimposition 
of the docked poses of 199 (yellow, -61.5 kJ/mol), 200 (blue, -49.2 kJ/mol) and 201 (pink, 
-55.8 kJ/mol). Docking studies were performed using LeadIT 2.1.6 and visualized using 
Maestro 11.2.197, 352  
 
The docked poses of the 6-methyl compounds 199-201 in the GARFTase active 
site show that they bind in the same region as native ligand in the GARFTase crystal 
structure (PDB 5J9F, native ligand not shown for clarity) (Figure 61). 
 
Unlike the extended pocket of the FRs, the binding pocket in GARFTase is curved 
and forces a conformation such that the linker projects the sidechain aryl almost at a 90° 
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angle. As such the binding pocket accommodates and maintains key interactions with 
classical folate analogs that have linkers ranging from 2-atoms to 5-atoms. For the 6-methyl 
analogs, the bent conformation forces the bulky 6-methyl group in 199-201 close to its 
sidechain aryl ring (~2 Å, not shown for clarity). This steric hindrance may destabilize the 
bound conformation, thus drastically reducing the binding energies. 
 
 
Figure 61. Molecular modeling studies with human GARFTase (PDB 5J9F).167 
Superimposition of the docked poses of 199 (yellow, -40.9 kJ/mol), 200 (blue, -35.5 
kJ/mol) and 201 (pink, -48.7 kJ/mol). Docking studies were performed using LeadIT 2.1.6 
and visualized using Maestro 11.2.197, 352 Substrate GAR is shown in orange. 
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Figure 62. Molecular modeling studies with human TS (PDB 1JU6).209 Superimposition 
of the docked poses of 200 (blue, -38.2 kJ/mol) and PMX (green, - 40.4 kJ/mol). Substrate 
UMP is shown in orange. Docking studies were performed using LeadIT 2.1.6 and 
visualized using Maestro 11.2.197, 352  
Protection studies show that Thd by itself does not protect KB cells from the 
cytotoxic action of compound 199 and Ade by itself is partially protective. However, a 
combination of Ade and Thd are fully protective, implying a weak/secondary inhibition of 
TS. Docking studies were performed to validate TS as one of the drug targets. The analogs 
199-201 bind in the same region as PMX (Figures 62 and 63) and the interactions are 
maintained with docked scores in the order of PMX (2C linker) > 200 (2C linker) > 201 
(3C linker) > 199 (4C linker).  
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Figure 63. Molecular modeling studies with human TS (PDB 1JU6).209 Superimposition 
of the docked poses of 199 (yellow, - 36.8 kJ/mol) and 201 (pink, -37.5 kJ/mol). Substrate 
UMP is shown in orange. Docking studies were performed using LeadIT 2.1.6 and 
visualized using Maestro 11.2.197, 352  
The bicyclic pyrrolo[2,3-d]pyrimidine ring of the analogs 199-201 make van der 
Waals contacts with the bound pyrimidine of dUMP in which the ring systems of the two 
ligands are stacked against each other by nonpolar interactions with Trp109 (Figures 62 
and 63). The backbone carbonyl of Ala312 accepts a hydrogen bond from the 2-amino 
group. The N7 of PMX forms a hydrogen bond with the side-chain carbonyl of Asn112 
(Figure 62). Its 6-methylated analog 200 twists out of plane and instead forms a water 
mediated hydrogen bond with the backbone carbonyl of Val313 while the N7 nitrogens of 
the 3C- and 4C-analogs are not involved in any interactions (Figure 62). The aromatic rings 
of the pABA sidechains in all the analogs are placed in a hydrophobic pocket lined with 
the sidechains of Phe225, Leu221 and IIe108 (Figures 62 and 63).  Similar to PMX, the 
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glutamate α-carboxyl of its 6-methyl analog 200 forms an ionic interaction with Lys77. 
Compound 200 additionally orients its γ-carboxylate for a favorable ionic interaction with 
Lys77. The 3C- and 4C-linker extended analogs 199 and 201, being longer than the pocket, 
extend their L-glutamate chain outside the pocket, and do not make any of the standard 
ionic interactions (Figure 63). Based on the docking studies, it is anticipated that 200, the 
6-methyl analog of PMX would inhibit TS more efficiently than 199. In addition, 200, an 
isosterically modified PMX, should potentially circumvent the PMX-associated dose-
limiting toxicities against healthy cells thus exemplifying the “magic-methyl effect” where 
a simple methylation results in improved selectivity (loss of RFC binding and uptake, Table 
14).330 
The novel analogs were tested as growth inhibitors against CHO cells expressing 
human FRα (RT16), FRβ (D4), RFC (PC43-10), and PCFT (R2/PCFT4) as well as KB 
tumor cells in culture.  
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IV. CHEMICAL DISCUSSION 
This section contains the synthetic schemes developed for the compounds in the following 
three projects: 
D.1. GARFTase inhibitors with selectivity for FRs and/or PCFT over RFC 
1. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-fluorophenyl classical 
antifolates 
2. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-fluoropyridyl classical 
antifolates 
3. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-fluorothienyl classical 
antifolates 
4. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-difluorophenyl classical 
antifolates 
5. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-2'-substitutedphenyl 
classical antifolates 
6. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-pyrimidyl classical 
antifolates 
D.2. Multiple enzyme inhibitors (GARFTase and AICARFTase) with selectivity for 
FRs and/or PCFT over RFC 
1. 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-butylphenyl classical 
antifolates 
2. 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-4'- 
propyloxy/propylthio/propylamino/butylaminophenyl classical antifolates 
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3. 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-butyl-2'-fluorophenyl 
classical antifolates 
D.3. Multiple enzyme inhibitors (TS, GARFTase, AICARFTase) with selectivity for 
FRs and/or PCFT over RFC 
1. 5-substituted, 2-amino-4-oxo-6-methyl pyrrolo[2,3-d]pyrimidine classical 
antifolates 
D.1.1 The synthesis of 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-
fluorophenyl classical antifolates (179-181). 
 The synthesis of target compounds was achieved via key intermediate diethyl (4-
(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)alk-1-yn-1-
yl)fluorobenzoyl)-L-glutamates, 212-213.  
Following a reported procedure, the commercially available terminal acetylene 
pent-4-ynoic acid 203 (Scheme 39) was converted to its acid chloride 204 which was 
reacted with in situ synthesized diazomethane to form the α-diazoketone 205.121 The 
unstable diazoketone 205 was immediately reacted with 48% aq. HBr to give the desired 
α-bromo-methylketone 206 by displacing N2 gas. Condensation of the α-bromo-
methylketone 206 with 2,4-diamino-6-hydroxypyrimidine 22 at room temperature for 72 h 
afforded the 6-substituted pyrrolo[2,3-d]pyrimidine with a terminal acetylene 162 in 37% 
yield and the 5-substituted 2,4-diamino-furo[2,3-d]pyrimidines 207 in 5% yield.298 The 
structures were confirmed via clear differences in the magnitude of chemical shift of the 
C5-CH and C6-CH protons and the number of exchangeable 2-NH2 protons in 1H NMRs 
of pyrrolo and furo[2,3-d]pyrimidines 162 and 207 respectively.  
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Scheme 39. Synthesis of 162. 
 
Reagents and conditions: (a) oxalyl chloride, CH2Cl2, reflux, 1 h; (b) diazomethane, Et2O, 
0 °C-rt, 1 h; (c) 48% HBr, 80 °C, 2 h; (d) DMF, rt, 72 h, 5-37% yields. 
Scheme 40. Synthesis of 210-211. 
 
Reagents and conditions: N-methylmorpholine (NMM), 2-chloro-4,6-dimethoxy-1,3,5-
triazine (CDMT), L-glutamate diethyl ester hydrochloride, DMF, rt, 12 h, 67-85% yields. 
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Scheme 41. Synthesis of 212-213. 
 
Reagents and conditions: (a) CuI, Pd(0)(PPh3)4, Et3N, DMF, rt, 12 to 72 h; (b) CuI, 
Pd(0)(PPh3)4, Et3N, DMF, 70 °C, µW, 12 h, 31-42% yields. 
Table 15. Reaction conditions for the synthesis of 212. 
Reaction conditions Progress of the reaction 
rt, 12 h to 72 h, benchtop No reaction 
rt, 12 h, µW No reaction 
50 °C, 12 h, µW New nonpolar TLC spot observed; 
starting material remaining 
70 °C, 12 h, µW New nonpolar TLC spot observed; 
starting material disappeared 
 
For the synthesis of the intermediates 2-amino-6-(but-3-yn-1-yl)-3,7-dihydro-4H-
pyrrolo[2,3-d]pyrimidin-4-one, 212-213 (Scheme 41), the reported procedure was 
 135 
followed for Sonogashira coupling of the alkyne 162 with the bromo-glutamate esters 210-
211.116 However, the room temperature reaction with 
tetrakis(triphenylphosphine)palladium(0) (0.16 eq) and copper(I) iodide (0.16 eq) as 
catalysts and triethylamine (10 eq) as base did not yield the coupled product even after 
extending the reaction from 12 h to 3 days. To improve the scope and repeatability of the 
reaction, the method was moved from benchtop to microwave (Table 15). As a test 
reaction, Sonogashira coupling of 162 with 210 was run over a range of temperatures 
starting from room temperature till 70 °C for 12 hours at which point the starting material 
162 was completely used up affording 212 in 31% yield. Repeating the reaction conditions 
with 211 gave 213 in 42% yield. Reduced yields despite complete disappearance of starting 
material is attributed to the compound lost during column chromatography because of its 
basic polarity (sticks to the slightly acidic silica). 
As per the reported procedure, hydrogenation of 212 and 213 (Scheme 42) at 55 psi 
gave the saturated analogs 214 and 215 respectively in 81% and 70% yields. Subsequent 
saponification of the glutamate esters in 214 and 215 afforded the target compounds 179 
and 180, respectively in 69% and 93% yields respectively.  
Compounds 210-211 (Scheme 40) were synthesized in 67-85% yields by peptide 
coupling of the commercially available bromo-carboxylic acids 208-209 and L-glutamate 
diethyl ester hydrochloride in the presence of N-methylmorpholine (NMM) and 2-chloro-
4,6-dimethoxy-1,3,5-triazine (CDMT) as the coupling agents.  
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Following a similar procedure (Schemes 39-42) for the synthesis of target 
compound 181, would require the generation of the intermediate 219 (Scheme 43). 
However, the reaction did not proceed from the conversion of acid chloride 217 to the α-
diazoketone 218. The reduced pKa (~15) (calculated using Chemicalize)361 of the CH2-
proton of the acid chloride 217 along with resonance stabilization of the electron pair 
(Scheme 44) could provide an explanation for the failed conversion. 
  
Scheme 42 Synthesis of target compounds 179-180 
 
Reagents and conditions: (a) 10% Pd/C, H2, 55 psi, EtOH, MeOH, 12 h, 70-92%; (b) (i) 1 
N NaOH, rt, 1 h; (ii) 0-4 °C, 1 N HCl , 69-80% yields. 
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Scheme 43 Synthesis of intermediate 219 
 
Reagents and conditions: (a) oxalyl chloride, CH2Cl2, reflux, 1 h; (b) diazomethane, Et2O, 
KOH, EtOH, 0 °C-rt, 1 h. 
 
We speculate that an allene 221 (Scheme 44) is generated from the acid chloride at reflux 
conditions which is in conjugation with the carbonyl group. This reduces the electron 
deficiency of the acid chloride thus interfering with the displacement of the chloride ion by 
diazomethane. This strategy was abandoned and an alternate procedure was used. 
Scheme 44 Possible mechanism of allene formation instead of α-diazoketone 
 
Reagents and conditions: diazomethane, Et2O, 0 °C-rt, 1 h. 
 
The synthesis of target compound 181 (Scheme 45) was initiated by following a 
reported procedure of a palladium(II)-catalyzed Sonogashira coupling of but-3-yn-1-ol 222 
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with methyl 4-bromo-2-fluorobenzoate, 223, to afford the butynyl alcohol 224  in 65% 
yield.121 The reported procedure was slightly altered and periodic acid/PCC oxidation of 
the butynyl alcohol was (repeatedly) attempted, but the conversion of 224 to acid 225 was 
unsuccessful. Upon monitoring the reaction progress on TLC (12 h), the starting material 
remained and no new fluorescent spot was observed. We hypothesize that the complex 
formed by the alcohol with the powerful oxidizing agent, chlorochromatoperiodate (CCP) 
236 (Scheme 46), is a reversible process in which the equilibrium is shifted towards left.362 
This could be because of an energetically costing unstable oxidized product, the alpha-
alknyl aldehyde 238. Our hypothesis is supported by literature evidence in which an 
alternate TEMPO oxidation of butyn-1-ol to its aldehyde failed to work.363 
 
Hence, as per reported procedure, the alkyne was first reduced by catalytic hydrogenation 
to the saturated alcohol 226 (Scheme 45) in 96% yield and subsequently oxidized using 
periodic acid/PCC to the carboxylic acid 227  in 97% yield.121 The acid was converted to 
the acid chloride 228, immediately reacted with in situ synthesized diazomethane followed 
by 48% aq. HBr to give the α-bromomethylketone 230. The bis-electrophile was condensed 
with 2,4-diamino-6-hydroxypyrimidine 22 at room temperature for 3 days to afford the 
crude 6-substituted pyrrolo[2,3-d]pyrimidine 231 in 28% yield over 4 steps, which was 
hydrolyzed to yield the acid 232  in 47% yield. The free acid was subsequently peptide 
coupled with L-glutamate diethyl ester hydrochloride in the presence of NMM and CDMT 
as the coupling agents to afford the diesters 233 in 50% yield. Final saponification of the 
diesters gave the desired final compound 181 in 88% yield. 
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Scheme 45. Synthesis of target compound 181. 
 
 
Reagents and conditions: (a) PdCl2, Ph3P, TEA, CuI, ACN, µW, 100 °C, 30 min, 65%; (b)  
10% Pd/C, H2, 55 psi, EtOH, MeOH, 96%; (c) H5IO6, PCC, ACN, 0 °C - rt, 3 h, 97%; (d) 
(i) oxalyl chloride, CH2Cl2, reflux, 1 h; (e) diazomethane, (Et)2O, 0 °C - rt, 1 h; (f) 48% 
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HBr, (Et)2O, 50 °C, 2 h; (g) DMF, rt, 3 days, 28% over 4 steps; (h) (i) 1N, NaOH, rt, 12 h, 
(ii) 1N HCl, 47%; (i) NMM, CDMT, diethyl-L-glutamate, DMF, rt, 12 h, 50%; (j) (i) 1N, 
NaOH, rt, 1 h; (ii) 1N HCl, 88%. 
Scheme 46 Possible mechanism for unsuccessful oxidation of butynol 224 to acid 225 
 
D.1.2. The synthesis of 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-
fluoropyridyl classical antifolates (182-183). 
Scheme 47. Synthesis of target compounds 182. 
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Reagents and conditions: (a) PdCl2, Ph3P, TEA, CuI, ACN, µW, 100 °C, 30 min, 62%; (b)  
10% Pd/C, H2, 55 psi, EtOH, MeOH, 96%; (c) H5IO6, PCC, ACN, 0 °C - rt, 12 h, 80%; (d) 
(i) oxalyl chloride, CH2Cl2, reflux, 1 h; (e) diazomethane, (Et)2O, 0 °C - rt, 1 h; (f) 48% 
HBr, (Et)2O, 50 °C, 2 h; (g) DMF, rt, 3 days, 30% yield over 4 steps; (h) (i) 1N, NaOH, rt, 
12 h, (ii) 1N HCl, 80%; (i) NMM, CDMT, diethyl-L-glutamate, DMF, rt, 12 h, 54%; (j) (i) 
1N, NaOH, rt, 1 h; (ii) 1N HCl, 70%. 
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The synthesis of target compound 182 (Scheme 47) was initiated by following a reported 
procedure of a palladium(II)-catalyzed Sonogashira coupling of but-3-yn-1-ol, 222 with 
methyl 5-bromo-3-fluoropicolinate, 239 to afford the butynyl alcohol 240 in 62% yield.121 
The alkyne 240 was first reduced by palladium catalyzed hydrogenation to the saturated 
alcohol 241 in 96% yield and subsequently oxidized using periodic acid/PCC to the 
carboxylic acid 242 in 80% yield. The acid was converted to the acid chloride 243, 
immediately reacted with in situ synthesized diazomethane followed by 48% aq. HBr to 
give the α-bromomethylketone 245. During the extraction of 245, it was observed that the 
intermediate was mostly concentrated in the acidic aqueous layer due to protonation of the 
pyridine sidechain (pKa ~1). The aqueous layer was cooled to 0 °C and neutralized with 
10% aq. sodium carbonate (Na2CO3) to extract the α-bromomethylketone 245. The bis-
electrophile was condensed with 2,4-diamino-6-hydroxypyrimidine 22 at room 
temperature for 3 days to afford the 6-substituted pyrrolo[2,3-d]pyrimidine 246 in 30% 
yield over 4 steps, which was hydrolyzed to yield the acid 247  in 80% yield. The free acid 
was subsequently peptide coupled with L-glutamate diethyl ester hydrochloride in the 
presence of NMM and CDMT as the coupling agents to afford the diesters 248 in 54% 
yield. Final saponification of the diesters gave the desired final compound 182 in 70% 
yield. 
Scheme 48. Synthesis of 250. 
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Reagents and conditions: NMM, CDMT, L-glutamate diethyl ester hydrochloride, DMF, 
rt, 12 h, 73% yield. 
Scheme 49. Synthesis of target compounds 183. 
 
 
Reagents and conditions: (a) CuI, Pd(0)(PPh3)4, Et3N, DMF, 70 °C, µW, 12 h, 45% yield; 
(b) 10% Pd/C, H2, 55 psi, EtOH, MeOH, 12 h, 78%; (c) (i) 1 N NaOH, rt, 1 h; (ii) 0-4 °C, 
1 N HCl , 86% yield. 
The synthesis of target compound 183 (Scheme 49) started from the reported intermediate 
162 (Scheme 39).116 Sonogashira coupling of 162 with diethyl (5-bromo-3-
fluoropicolinoyl)-L-glutamate 250 utilizing the optimized microwave reaction (Table 15), 
afforded 251 in 45% yield. Subsequent palladium catalyzed hydrogenation to 252 in 78% 
yield and saponification afforded the target compound 183 in 86% yield. Compound 250 
(Scheme 48) was synthesized by peptide coupling of the commercially available 5-bromo-
3-fluoropicolinic acid 249 with L-glutamate diethyl ester hydrochloride in 73% yield. 
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D.1.3 The synthesis of 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-
fluorothienyl classical antifolates (184-185). 
Scheme 50. Synthesis of 184. 
 
 
Reagents and conditions: (a) PdCl2, Ph3P, TEA, CuI, ACN, µW, 100 °C, 30 min, 64%; (b)  
10% Pd/C, H2, 55 psi, EtOH, MeOH, 98%; (c) H5IO6, PCC, ACN, 0 °C - rt, 12 h, 79%; (d) 
(i) oxalyl chloride, CH2Cl2, reflux, 1 h; (e) diazomethane, (Et)2O, 0 °C - rt, 1 h; (f) 48% 
HBr, (Et)2O, 50 °C, 2 h; (g) (i) 22, DMF, rt, 3 days; (ii) 1N, NaOH, rt, 12 h, (iii) 1N HCl, 
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7% yield over 5 steps; (h) NMM, CDMT, diethyl-L-glutamate, DMF, rt, 12 h, 28%; (i) (i) 
1N, NaOH, rt, 1 h; (ii) 1N HCl, 55%. 
The synthesis of target compound 184 (Scheme 50) was initiated by following a reported 
procedure of a palladium(II)-catalyzed Sonogashira coupling of but-3-yn-1-ol, 222 with 
methyl 4-bromo-3-fluorothiophene-2-carboxylate 253, to afford the butynyl alcohol 254 in 
64% yield.121 The alkyne of 254 was first reduced by palladium catalyzed hydrogenation 
to the saturated alcohol 255 in 98% yield and subsequently oxidized using periodic 
acid/PCC to the carboxylic acid 256 in 79% yield. The acid was converted to the acid 
chloride 257, immediately reacted with in situ synthesized diazomethane followed by 48% 
aq. HBr to give the α-bromomethylketone 259. The bis-electrophile was condensed with 
2,4-diamino-6-hydroxypyrimidine 22 at room temperature for 3 days and ester hydrolyzed 
to yield the pteroic acid 260 in 7% yield over 5 steps. The free acid was subsequently 
peptide coupled with L-glutamate diethyl ester hydrochloride in the presence of NMM and 
CDMT as the coupling agents to afford the diesters 261 in 28% yield. Final saponification 
of the diesters gave the desired final compound 184 in 55% yield. 
 
Scheme 51. Synthesis of 263. 
 
Reagents and conditions: NMM, CDMT, L-glutamate diethyl ester hydrochloride, DMF, 
rt, 12 h, 63% yield. 
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Scheme 52. Synthesis of 185. 
 
 
Reagents and conditions: (a) CuI, Pd(0)(PPh3)4, Et3N, DMF, 70 °C, µW, 12 h, 59% yield; 
(a) 10% Pd/C, H2, 55 psi, EtOH, MeOH, 12 h, 75% yield; (b) (i) 1 N NaOH, rt, 1 h; (ii) 0-
4 °C, 1 N HCl , 96% yield. 
The synthesis of target compound 185 (Scheme 52) started from the reported intermediate 
162 (Scheme 39).116 Sonogashira coupling utilizing the optimized microwave reaction of 
162 with diethyl (4-bromo-3-fluorothiophene-2-carbonyl)-L-glutamate 263 afforded 264 
in 59% yield. Subsequent palladium catalyzed hydrogenation to 265 in 75% yield and 
saponification of 265 afforded the target compound 185 in 96% yield. Compound 263 
(Scheme 51) was synthesized by peptide coupling of the commercially available 4-bromo-
3-fluorothiophene-2-carboxylic acid 262 with L-glutamate diethyl ester hydrochloride in 
63% yield. 
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NMR Evidence for the Presence of Intramolecular N–HꞏꞏꞏF–C(sp2) Hydrogen Bond 
in Solution State of the Fluorinated Analogs 
 
 
Figure 64. Structure of non-fluorinated compound 266. 
 
In the 1H NMR spectra (in DMSO-d6) of the benzoyl-L-glutamate and thiophene-
2-carbonyl-L-glutamate of the desfluoro analogs 266 (Figure 64) and 9 (Table 2), the amide 
NH protons split into a doublet due to coupling with the α-CH proton (Figures 65A: 3J(H-H) 
= 7.98 Hz and 65B 3J(H-H) = 10.51 Hz).116 The corresponding protons in the 2-
fluorobenzoyl-L-glutamate and 3-fluorothiophene-2-carbonyl-L-glutamate (o- to L-
glutamate) of fluorinated analogs 179/ and 184 respectively, are split into doublet of a 
doublet, indicating the presence of spin-spin coupling between fluorine and the amide NH 
(Figures 65C: J(F-H) = 2.08 Hz, 3J(H-H) = 7.83 Hz and 65D: J(F-H) = 2.91 Hz, 3J(H-H) = 7.88 
Hz). 
In target compound 179 (representative example), the amide NH doublet of a 
doublet collapsed to a doublet either when decoupled from the α-CH proton (Figure 66, 
J(H,F) = 1.54 Hz), or in 1H{19F} 
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Figure 65. NH signals of 266, 9, 179 and 185 in 1H NMR. (A) 400 MHz 1H NMR, doublet 
peak of L-glutamate CONH (arrow pointed) of 266. (B) 400 MHz 1H NMR, doublet peak 
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of L-glutamate CONH (arrow pointed) of 9. (C) 400 MHz 1H NMR, doublet of a doublet 
peak of L-glutamate CONH (arrow pointed) of 179. (D) 400 MHz 1H NMR, doublet of a 
doublet peak of L-glutamate CONH (arrow pointed) of 185. NMR studies were carried out 
in DMSO-d6. 
NMR (Figure 66, 3J(H-H) =  7.11 Hz) indicating nuclear spin coupling of the NH 
proton with the fluorine atom as well as the α-CH proton. Such coupling between a fluorine 
atom and the amide proton of the side-chain L-glutamate was generalized in previous 
reports as a N-H ꞏ ꞏ ꞏF-C(sp2) hydrogen bond.332-333 
 
Figure 66. Representative example compound 179 and its NH signal by 1H NMR. (A) 
400 MHz 1H NMR α-CH decoupled signal of NH proton (1hJ(F-H) = 1.54 Hz). (C) 500 
MHz 1H NMR, 1H{19F} NMR signal of NH proton (3J(H-H) = 7.11 Hz). NMR studies were 
carried out in DMSO-d6 and the excessive broadening of the NH signal is due to 14N 
quadrapolar relaxation. 
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Figure 67. The two directions in which nuclear spin coupling between fluorine and the 
amide NH can transmitted is shown. Shown in green is the through space N–HꞏꞏꞏF–C(sp2) 
hydrogen bond and shown in blue is nuclear spin information transmitted through covalent 
bonds. 
 
  Though the collapse of the doublet of doublets in in 1H{19F} NMR spectra confirm 
coupling between 19F and 1H, it is still ambiguous whether nuclear spin information is 
transmitted through covalent bonds or through space (hydrogen bond) (Figure 67). When 
equal concentrations of the corresponding compounds 266 and 179, dissolved in DMSO-
d6 were D2O exchanged, the amide NH proton of the fluorinated analog 179 took longer 
time periods (>1 h) to exchange completely compared to the non-fluorinated analog 266 
(<5 mins) (Figure 68). This observation supports, in part, the notion of a significant 
involvement of the NH proton of the fluorinated analog 179 in a fluorine-hydrogen bond.364  
The detection of “through-space” couplings between the nuclei directly involved in 
hydrogen-bonding can establish the presence of a -NH ꞏ ꞏ ꞏF-C(sp2) hydrogen bond.348 
However, the 1H-19F HOESY (heteronuclear NOESY) NMR of 179 (representative 
example) did not detect any through-space coupling between the fluorine and the NH 
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proton. This observation is ambiguous as the absence of an observable interaction in the 
2D HOESY NMR does not necessarily rule out the presence of a weak hydrogen bond.365  
 
 
Figure 68. D2O exchange studies of representative example 179. The integration of NH 
signal over 60 minutes upon exchange of 0.8 mg of compound 179 in 0.7 mL DMSO-d6 
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with 0.01 mL D2O. (A) Integration of NH signal before exchange with D2O (B) Integration 
of NH signal 5 minutes after exchange with D2O. (C) Integration of NH signal 15 minutes 
after exchange with D2O. (D) Integration of NH signal 30 minutes after exchange with 
D2O. (E) Integration of NH signal 60 minutes after exchange with D2O. 
Temperature-induced perturbations of 1hJ(F-H) are of particular interest as increased 
temperature disrupts intramolecular hydrogen bonds and consequently diminishes the 
intensity of the observable 1hJ(F-H) coupling.346 Compound 179 was subjected to 
temperature perturbations over the range of 292-352 K in DMSO-d6 and ΔJ(F-H) were 
monitored (Table 16). The J(F-H) varied from 1.54 (292 k) to 3.12 (352 k) Hz, which is 
uncommon for spin-spin couplings across covalent bonds. This clear variation of J(F-H)  with 
temperature is a strong indicator of through space scalar 1hJ(F-H) coupling (the observable 
spin-spin coupling constants of the other protons in the 1H NMR did not change 
significantly). The numerical values of 1hJ(F-H) at varied temperatures are reported (Table 
16). However, contrary to an expected loss, increased 1hJ(F-H) interaction at higher 
temperatures was observed. It remains to be determined if the -NH ꞏ ꞏ ꞏF-C(sp2) hydrogen 
bond in 179 is stabilized at higher temperatures owing to a conformational shift to a more 
linear -NH ꞏ ꞏ ꞏF bond angle and geometric proximity. 
  Exceptionally, in the fluorinated pyridyl analogs 182 and 183, the amide NH 
protons are observed as doublets similar to the corresponding proton in the desfluoro 
analog 4 (not shown, refer to Experimental, compounds 182 and 183).115 Though the 
reasons for the absence of fluorine hydrogen coupling (J(F-H)) in 182 and 183 are yet to be 
determined, it however provides supplementary evidence that the coupling between the 
 154 
fluorine and amide NH, where observed, occurs through space and not across covalent 
bonds. 
Table 16 The variation of J(F-H) in 179 with temperature 
 
Temperature 
(K) 
1hJ(F-H) (Hz)   
292 1.54 
312 2.38 
332 2.70 
352 3.12 
 
The presence of an intramolecular -NH ꞏ ꞏ ꞏF-C(sp2) hydrogen bond in the solution state of 
of the free ligands 179, 181, 184 and 185 indicates that the fluorine and amide NH are in a 
relative syn orientation in its energy minimized conformations similar to their docked 
(bound) conformations (in the target proteins FRα/β and GARFTase). 
 
D.1.4. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-difluorophenyl classical 
antifolates (186-189). 
The synthesis of target compounds 186-188 (Scheme 54) started from the synthesis of 
reported intermediate 162 (Scheme 39).116 
 155 
Scheme 53. Synthesis of 270-272. 
 
Reagents and conditions: NMM, CDMT, L-glutamate diethyl ester hydrochloride, DMF, 
rt, 12 h, 56-88% yields. 
Scheme 54. Synthesis of target compounds 186-188. 
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Reagents and conditions: (a) CuI, Pd(0)(PPh3)4, Et3N, DMF, 70 °C, µW, 12 h, 40-45% 
yields; (a) 10% Pd/C, H2, 55 psi, EtOH, MeOH, 12 h, 58-72% yields; (b) (i) 1 N NaOH, rt, 
1 h; (ii) 0-4 °C, 1 N HCl , 78-89% yields. 
Sonogashira coupling of 162 with diethyl-L-glutamates 270-272 afforded 273-275 
respectively, in 40-45% yields. Subsequent palladium catalyzed hydrogenation to 276-278 
in 58-72% yields and saponification afforded the target compounds 186-188 in 78-89% 
yields. Compounds 270-272 (Scheme 53) were synthesized by peptide coupling of the 
commercially available acids 267-269 with L-glutamate diethyl ester hydrochloride in 56-
88% yields. 
D.1.5. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-2'-substitutedphenyl 
classical antifolates (189-191). 
Scheme 55. Synthesis of intermediates 282-284. 
 
Reagents and conditions: NMM, CDMT, L-glutamate diethyl ester hydrochloride, DMF, 
rt, 12 h, 72-89% yields. 
The synthesis of target compounds 189-191 (Scheme 57) started from the reported 
intermediate 162 (Scheme 39).116 Sonogashira coupling of 162 with diethyl-L-glutamates 
282 and 284 afforded the alkynes 285 and 287 respectively, in 44 and 26% yields 
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respectively (Scheme 56). Sonogoashira coupling of glutamate 283 (2'-chloro substituent; 
R = Cl) selectively afforded the desired bromo-coupled product 286 in 30% yield 
(Scheme 56). Subsequent palladium catalyzed hydrogenation of 285 and 287 (Scheme 
57) afforded the reduced glutamate esters 288 and 291 in quantitative and 79% yields 
respectively. Saponification of 288 and 291 afforded the target compounds 189 and 191 
in 58% and 79% yields respectively. 
Scheme 56. Synthesis of intermediates 285-287. 
 
Reagents and conditions: CuI, Pd(0)(PPh3)4, Et3N, DMF, 70 °C, µW, 12 h, 26-44% yields. 
Scheme 57. Synthesis of target compound 189-191. 
Reagents and conditions: (a) 10% Pd/C, H2, 55 psi, EtOH, MeOH, 1-12 h 74%-quant. 
yields; (b) (i) 1 N NaOH, rt, 1 h; (ii) 0-4 °C, 1 N HCl, 58-79% yields. 
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When the alkyne 286 with 2'-chloro substituent (R = Cl) was reduced by palladium 
catalyzed hydrogenation at 55 psi H2, dehalogenation ensued to give a mixtire of 
compounds 289 and 290 (Scheme 57) in 74% yield. Reduction of 286 was attempted 
several times with reduced time duration each time (1 h to 12 h). Irrespective of the number 
of hours, dehalogenation was non-selective and occurred simultaneously with alkyne 
reduction to give a mixture of chlorinated and non-chlorinated intermediates. The presence 
of a mixture of compounds was confirmed by 1H NMR as well as CHN analysis of the 
mixture of diacid compounds 190 and 3. 1H NMR of 190 and 3 showed clear doublets 
(indicating dehalogenation) within the multiplets near the aromatic region that integrated 
to more than 4 protons (should have ideally integrated to 3 protons). Dehalogenation was 
additionally confirmed by >4% decrease in the required chlorine percentage of 190, from 
the CHN analysis of the hydrolyzed mixture 190 and 3. Since the synthesis of the target 
compound 190 using the reported procedure involves unavoidable hydrogenation of the 
alkyne, attempts to make 190 were terminated. It remains to be tested if decreasing the 
pressure variable would selectively reduce the alkyne. Compounds 282-284 (Scheme 55) 
were synthesized by peptide coupling of the commercially available acids 279-281 with L-
glutamate diethyl ester hydrochloride in 72-89% yields. 
D.1.6. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-pyrimidyl classical 
antifolates (192). 
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Scheme 58. Synthesis of intermediate 293. 
 
Reagents and conditions: N-methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-
glutamate diethyl ester hydrochloride, DMF, rt, 12 h. 
Scheme 59. Alternate method for the synthesis of intermediate 293. 
 
Reagents and conditions: (a) (i) Pyridine, rt, 96 h; (ii) 2N HCl, sat. Na2CO3, 12.4% yield; 
(b) (i) SOCl2, EtOH, 75 °C, 12 h, 59% yield. 
Scheme 60. Alternate CDMT peptide coupling conditions for the synthesis of 
intermediate 293. 
 
Reagents and conditions: (a) NMM, CDMT, L-glutamate diethyl ester hydrochloride, 
DMF, rt, 12 h, 83% yield. 
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The synthesis of target compounds 192 (Scheme 61) started from the reported intermediate 
162 (Scheme 39).116 Sonogashira coupling of 162 with diethyl-L-glutamate 293 afforded 
297 in 40% yield. 
Table 17.  Reaction conditions for the synthesis of 293. 
Reagents and 
conditions 
Sequence of addition Product (301) 
CDMT, NMM,  
DMF, rt, 12 h 
Amine added after carboxylic 
acid activation 
 
CDMT, NMM All together 83% 
 
Palladium catalyzed hydrogenation of 6-substituted pyrrolo[2,3-d]pyrimdines  with a 
pyrimidyl side chain, at 55 psi of H2, reduces the pyrimidine side-chain along with the 
alkyne  (data not shown). Pyrimidine ring and alkyne reductions occur simultaneously at 
55 psi of H2 but decreasing the H2 pressure from 55 psi to 15 psi (~1 atm) selectively 
reduces the alkyne but not the side-chain pyrimidine ring. As such, palladium catalyzed 
hydrogenation of 297 at 15 psi of H2 gave the alkyne reduced product 298 in 75% yield.  
Subsequent saponification of 298 afforded the target compound 192 in 68% yield. The L-
glutamate ester of alkyne 297 was also hydrolyzed to afford the final compound 202 to test 
the influence of modified flexibility on biological acitivty, due to the presence of a 
conformationally restricting alkyne group in the linker. The synthesis of L-glutamate ester 
intermediate 293 (Scheme 58) was initially attempted using the reported procedure of 
peptide coupling of the commercially available acid 292 with L-glutamate diethyl ester 
hydrochloride in the presence of N-methylmorpholine (NMM) and 2-chloro-4,6-
dimethoxy-1,3,5-triazine (CDMT) as the coupling agents. The reaction proceeds with 
 161 
initial activation of the acid (for 2 hours) followed by addition of the amine. However, this 
procedure failed to produce the peptide coupled product and the starting material was 
recovered. Alternatively, the reaction was carried out using N,N'-dicyclohexylcarbodiimide 
in pyridine as the peptide coupling agents (Scheme 59).366 However, peptide coupled 
monoacid product 293 (Scheme 59) was formed in 12.4% yield due to hydrolysis of the α-
carboxylate ester during the acid/base workup with 2N HCl followed by sat. NaHCO3. 
Difficulty in separating the polar N,N'-dicylohexylurea side product 296 and re-
esterification using SOCl2 in ethanol to afford 293 in 59% yield, collectively reduced the 
overall yield of 293 to 7.3%.  
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Scheme 61. Synthesis of target compound 192.  
 
Reagents and conditions: (a) CuI, Pd(0)(PPh3)4, Et3N, DMF, 70 °C, µW, 12 h, 40% yield. 
(b) 10% Pd/C, H2, 15 psi, 7 h, 75% yield; (c) (i) 1 N NaOH, rt, 1 h; (ii) 0-4 °C, 1 N HCl , 
56-68% yield. 
Peptide coupling with NMM and CDMT was revisited in order to rationalize the 
failure of a predominantly successful reaction that worked with several (het)aryl carboxylic 
acids. Following an alternate reported method for peptide coupling using CDMT and 
NMM, when the reacting groups, activating agent (CDMT) and base (NMM) were added 
all at once (instead of sequential addition), compound 293 (Scheme 60) formed in 83% 
yield.367 The synthesis of 293 was achieved under similar conditions (Scheme 58) with the 
only variation of sequence of addition. This indicates that the successful reaction 
necessitates immediate nucleophilic attack by the amine of the L-glutamate on the activated 
carboxylic acid.  
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D.2.1. 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-butylphenyl classical 
antifolates (193) 
Scheme 62. Synthesis of target compound 193.   
 
 
 
Reagents and conditions: (a) Pd(OAc)2, LiCl, LiOAc, Bu4NCl, DMF, 80 °C, 3 h, 76%; (b) 
5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane, 1N HCl in (Et)2O, (Et)2O, rt, 48 h; (c) 
CH3COONa, MeOH, H2O, 45 °C, 4 h, 5 % yield over 2 steps; (d) (i) 1 N NaOH, rt, 1 h; (ii) 
0-4 °C, 1 N HCl, 81 % yield. 
Compound 193 (Scheme 62) was obtained using a reported procedure in which 
condensation of the α-bromo aldehyde 303 with 2,6-diamino-4-oxo-pyrimidine 22 is the 
key step.120 As reported by Larock et al.,323 Heck coupling reaction of commercially 
available hex-5-en-1-ol 299 with diethyl (3-bromobenzoyl)-L-glutamate 300, afforded the 
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unsaturated, coupled alcohol that rearranged to the vinyl alcohol and tautomerised to afford 
the aldehyde 301 in 76% yield. Subsequent α-bromonation of 301 with 5,5-dibromo-2,2-
dimethyl-4,6-dioxo-1,3-dioxane (DBMA) 302 at room temperature afforded 
corresponding α-bromo aldehyde 303 which was immediately condensed with 2,6-
diamino-4-oxo-pyrimidine 22 in the presence of sodium acetate to afford the 5-substituted 
pyrrolo[2,3-d]pyrimidine 304 in 5% yield over 2 steps. Final saponification of the diesters 
with 1 N NaOH and neutralization to pH 4, provided target compound 193 in 81%yield. 
Compound 300 (Scheme 62) was obtained from the repository of intermediates synthesized 
by Dr. Yiqiang Wang.  
D.2.2. 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-4'- 
propyloxy/propylthio/propylamino/butylaminophenyl classical antifolates (194-197). 
Syntheses of 194-197 were envisioned to occur via Sonogashira coupling of intermediate 
iodide 305 and alkynes 306-308 (Figure 69). N-(5-iodo-4-oxo-4,7-dihydro-3H-
pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide 305 can be synthesized following a reported 
procedure and the intermediates 306-308 could be synthesized via nucleophilic 
substitutions of propargyl bromides with nucleophilic heteroatom substituted benzoate 
ester.368-371 
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Figure 69. Proposed retrosynthesis of target compounds 194-197. 
This convergent procedure not only will improve the overall yield in lesser number of steps, 
but can also be applied for the synthesis of homologous compounds. 
Scheme 63. Synthesis of intermediate 305.  
 
Reagents and conditions: (a) Chloroacetaldehyde, CH3COONa, MeOH, H2O, 45 °C, 4 h, 
quant.; (b) pivaloyl chloride, pyridine, 90 °C, 30 min, 43%; (c) 
bis(trimethylsilyl)acetamide, DMF, 40 °C, 2 h; (d) NIS, DMF, rt, 12 h, 65%. 
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Synthesis of the key intermediate 305 (Scheme 63) began with the condensation of 2,4-
diamino-6-hydroxypyrimidine 22 with chloroacetaldehyde in the presence of sodium 
acetate yielding the cyclized product 2-amino-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-
one 309 in quantitative yield.368 The pyrrolo[2,3-d]pyrimidine 309 was treated with 
trimethylacetyl chloride to yield the N(2)-monoacylated compound 310 in 43% yield. The 
procedure reported by Barnett et al. 371 was adopted for the regiospecific C5 iodination of 
310. The 4-oxo and N-7 groups were silylated using bis(trimethylsilyl)acetamide to a 
silylated intermediate 311, followed immediately by C5 iodination using N-
iodosuccinimide (NIS). The unstable silyl protecting groups were deprotected under 
aqueous work-up conditions to yield the intermediate 305 in 65% yield.  
The key Sonogashira coupling partners 306 and 307 (alkynyl esters) (Scheme 64) were 
synthesized by reacting propargyl bromide 312 with ethyl 4-aminobenzoate 313 and 
methyl 4-hydroxybenzoate 314 in the presence of potassium carbonate in 95% and 21% 
yields respectively.369 An alkyne glutamate coupling partner 316 (Scheme 65) was also 
synthesized by hydrolyzing the methyl 4-hydroxybenzoate 307 to the acid 315 in 83% 
yield. The free acid was subsequently peptide coupled with L-glutamate diethyl ester 
hydrochloride in the presence of N-methylmorpholine (NMM) and 2-chloro-4,6-
dimethoxy-1,3,5-triazine (CDMT) as the coupling agents to afford the alkyne glutamate 
ester 316  in 85% yield. 
However, the Sonogashira coupling reactions of 305 (Scheme 66, Table 18) with the 
alkynyl esters 306 and 307 to afford 317 and 318 were unsuccessful under various coupling 
conditions. Predominantly, no new product spots were observed on TLC and the starting 
material was recovered as the dehalogenated intermediate 310. It was evident that 
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independent of temperature and the oxidation state of the palladium catalyst, the 
competitive reaction of Sonogashira coupling of N-(5-iodo-4-oxo-4,7-dihydro-3H-
pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide 305 was C5 deiodination. In one case, 
Sonogashira coupling of 305 (Scheme 67) with the alkynyl glutamate 316 besides 
deiodination, resulted in acetylenic Glaser coupling of 316 to the homodimer 319 in 9% 
yield, a common side product observed in Cu (I) cocatalyzed Sonogashira reaction 
conditions.372 Deiodination depletes the key coupling partner 305 and therefore this method 
was abandoned and an alternate procedure was considered. 
Scheme 64. Synthesis of intermediates 306 and 307. 
 
Reagents and conditions: (a) K2CO3, EtOH, reflux, 18 h, 21%; (b) K2CO3, acetone, reflux, 
3 h, 95% (b) 
Scheme 65. Synthesis of intermediate 316. 
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Reagents and conditions: (a) 1 N NaOH, MeOH, reflux, 2.5 h. (ii) 1 N HCl, 83 % yield. 
(b) N-methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, L-glutamate diethyl ester 
hydrochloride, DMF, rt, 12 h, 85% yield. 
Scheme 66. Synthesis of intermediates 317 and 318. 
 
Reagents and conditions: Pd catalyst, CuI, TEA, Solvent, temp, 12 h. 
Table 18. Reaction conditions for the synthesis of 317 and 318. 
Catalyst Solvent Temp. (°C) 
Pd[(C6H5)3P]4 DMF 21, 50, 80 
Pd[(C6H5)3P]4 TEA 21, 50, 80 
Pd(OAc)2 ACN 21, 50, 80 
PdCl2(PPh3)2 DMF 21, 50, 80 
Pd2(dba)3 DMF 21, 50, 80 
 
Compound 194-197 (Scheme 72) was obtained using a reported procedure in which 
condensation of the α-bromo aldehydes 339-342 with 2,6-diamino-4-oxo-pyrimidine 22 is 
the key step.120  
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Scheme 67. Synthesis of intermediate 319. 
 
Reagents and conditions: (a) CuI, Pd(0)(PPh3)4, Et3N, DMF, rt, 12 h, 25% yield. 
Scheme 68. Synthesis of intermediates 320-323. 
 
Reagents and conditions: (a) Ac2O, CH2Cl2, rt, 12 h, 90%; (b) (CF3CO)2O, rt, 2 h, quant; 
(c) Piv2O, 80 °C, 8 h, 56%; (d) Boc2O, 1,4-dioxane, 80 °C, 24 h, 90%. 
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Scheme 69. Synthesis of intermediates 325-330, 332 and 334.  
 
Reagents and conditions: (a) base, solvent, temp, time (Table 19); (b) K2CO3, acetone, 80 
°C, 24 h, 62%; (c) Cs2CO3, TBAI, DMF, 0-rt, 4 h, 80%. 
Nucleophilic substitution reactions of heteroatom substituted aromatic esters 314, 323 and 
331 (Scheme 69) with commercially available bromo alkanols 324 and 333 under basic 
conditions, afforded the hydroxyalkyl benzoates 329, 330, 332 and 334. Several basic 
conditions were attempted for the nucleophilic displacement of 324 (Scheme 69, Table 19) 
by ethyl 4-aminobenzoate 313 and its N-protected derivatives 320-323. 
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Table 19. Reaction conditions for the synthesis of 325-329 and 334. 
Compd. 
No. 
Reagents and conditions 
Base Solvent Temp. Yield 
325 NaH DMF rt - 50 °C - 
325 TEA DMF 80 °C 20% 
325 Cs2CO3 DMF 0 °C- 70 °C - 
325 2,6-lutidine DMF 0 °C- 70 °C - 
326 NaH DMF rt - 50 °C - 
327 Cs2CO3/TBAI DMF 0 °C- 70 °C - 
328 Cs2CO3/TBAI DMF 0 °C- 70 °C - 
329 Cs2CO3/TBAI DMF 0 °C- 70 °C 74% 
334 Cs2CO3/TBAI DMF 0 °C- 70 °C 51% 
 
Initial efforts for the synthesis of intermediate 325 from ethyl 4-aminobenzoate 313 in the 
presence of NaH (rt-50°C), Cs2CO3 (0°C-70°C) and 2,6-lutidine (0°C-70°C), in DMF failed 
to work. When triethylamine (TEA) was used as base, the reaction proceeded to give 325 
in 20% yield. It was anticipated that increasing the acidity of the 4-NH2 proton of ethyl 4-
aminobenzoate could promote the reaction by facilitating its ease of extraction by a mild 
base. The N-acetyl protecting group decreased the pKa of the NH proton but the reaction 
was unsuccessful in the presence of NaH (Tables 19 and 20).373 
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Table 20. Partial charges and pKa of compounds 313 and 326-329 were calculated using 
Maestro 11.2 and Chemicalize respectively.208, 361  
Compd. No. R 
 
Partial charge of N 
(electron unit) 
pKa  
313 H -0.9 ~30 
326 CH3CO -0.38 13.6 
327 CF3CO -0.38 10.4 
328 Piv -0.38 13.5 
329 Boc -0.52 12.6 
 
Though the early attempt for N-alkylation using Cs2CO3 failed, but based upon 
numerus reports of efficient N-alkylation using cesium bases, another set of reactions with 
the N-protected ethyl 4-aminobenzoates 320-323 were examined with Cs2CO3 as the base 
accompanied by TBAI (phase transfer agent).374-376 Cesium reagents are generally far 
superior to their alkali metal counterparts with respect to reaction time, yield, 
chemoselectivity and are highly compatible with a wide range of functional groups. The 
improved reactivity under mild conditions is defined as the "cesium effect" that stems from 
better solubility and the generation of highly reactive "naked anions" (due to weak 
coordination of the cesium cation). TBAI not only acts as a phase transfer catalyst but may 
also facilitate an internal Finkelstein-type reaction for the in situ generation of 5-
iodopentanol from bromide 324, hence producing high product yields. Among 320-323, 
the N-boc protected ethyl-4-aminobenzoate 323 was favorably alkylated to ethyl 4-((tert-
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butoxycarbonyl)(5-hydroxypentyl)amino)benzoate 329 in 74% yield. We hypothesize that, 
along with the presence of naked anions (cesium effect) and phase transfer agent (TBAI), 
a balance between reduced pKa and availability of lone pair of electrons was struck in the 
N-boc protected derivative 329 due to reduced resonance stabilization of the lone pair of 
electrons (compared 326-328) for the efficient nucleophilic displacement of 5-
bromopentanol (Table 20). The synthesis of ethyl 4-((5-hydroxypentyl)oxy)benzoate 330 
(Scheme 69) was accomplished via a straightforward displacement of 5-bromopentanol 
324 by ethyl 4-hydroxybenzoate 314 in the presence of potassium carbonate.369 When 
similar reagents and conditions were used for the synthesis of 332 from the nucleophilic 
displacement of 324 by ethyl 4-mercaptobenzoate 331, the reaction failed to proceed. 
Consequently, the procedure reported by Salvatore et al.,377 was adopted wherein Cs2CO3 
as base and tetrabutylammonium iodide (TBAI) as a phase transfer agent, in DMF was 
successfully utilized to facilitate the synthesis of 332 in 80% yield (Scheme 69). The 
successful reaction conditions used for the synthesis of 329 (Scheme 69) were repeated for 
the synthesis of ethyl 4-((tert-butoxycarbonyl)(5-hydroxyhexyl)amino)benzoate 334 via 
nucleophilic displacement of 6-bromohexanol 333 by 323. 
Intermediates 320-323 (Scheme 68) were synthesized by following reported 
procedures. N-acetyl, N-piv and N-boc protections in 320, 322 and 323 were carried out in 
the presence of Ac2O, Piv2O and Boc2O in 90%, 56% and 90% yields respectively.373, 378 
The N-trifluoroacetyl protecting group in 321 (Scheme 68) was introduced in quantitative 
yield by reacting ethyl 4-aminobenzoate 313 with excess trifluoroacetic acid as per 
reported procedure.167  
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The terminal alcohols 329, 330, 332 and 334 (Scheme 70) were subjected to 
oxidation using Dess-Martin periodinane to afford the aldehydes 335-338 in 60-84% 
yields.379 α-bromination of the N-boc-protected aldehydes 335 and 338 with bromine (Br2) 
in 1,4-dioxane at room temperature failed. The unsuccessful α-bromination is attributed to 
depletion of bromine due to a potential electrophilic substitution of the aniline ring. 
Therefore, an alternate bromination procedure described earlier for the synthesis of target 
compound 193 was utilized. Freshly bought 5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-
dioxane (DBMA) 302 successfully yielded the α-bromo aldehydes 339 and 342 from 335 
and 338 respectively. The aldehydes of ether and thioether linker analogs 336 and 337 were 
α-brominated with bromine (Br2) in 1,4-dioxane at room temperature to the corresponding 
α-bromo aldehydes 340 and 341.380  
The corresponding α-bromo aldehydes 339-342  (Scheme 71) were immediately 
condensed with 2,6-diamino-4-oxo-pyrimidine 22 in the presence of sodium acetate for 4 
hours followed by base catalyzed hydrolysis to afford the 5-substituted pyrrolo[2,3-
d]pyrimidine pteroic acids with heteroatom linkers 343-346 in 16-27% yields over 3 steps. 
Intermediates 343 and 346 were subjected to hydrolysis under acidic conditions to yield 
the N-boc deprotected pteroic acids 347 and 348 in 93% and 97% yields respectively. The 
acids 347, 344, 345 and 348 were subsequently peptide coupled with L-glutamate diethyl 
ester hydrochloride in the presence of N-methylmorpholine (NMM) and 2-chloro-4,6-
dimethoxy-1,3,5-triazine (CDMT) as the coupling agents to afford the diesters 349, 350, 
351 and 352 respectively in 37-76% yields (Scheme 72). Final saponification of the diesters 
gave the desired final compounds 194-197 in 45-90% yields. 
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Scheme 70. Synthesis of intermediates 339-342. 
  
Reagents and conditions: (a) Dess-Martin periodinane, CH2Cl2, 0 °C-rt, 0.5-4 h, 60-84%; 
(b) 5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 302, 1N HCl in (Et)2O, (Et)2O, rt, 48 
h; (c) Br2, 1,4-dioxane, CH2Cl2, 5 h. 
Scheme 71. Synthesis of intermediates 344, 345, 347 and 348. 
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Reagents and conditions: (a) (i) CH3COONa, MeOH, H2O, 45 °C, 4 h; (ii) (i) 1 N NaOH, 
rt, 12 h, 16-27% yields over 3 steps; (b) (i) 3N HCl, 1,4-dioxane, rt, 16 h; (ii) 1 N NaOH, 
rt, -10 °C; (iii) 0-4 °C, 1 N HCl , 93-97% yields. 
 
Scheme 72. Synthesis of target compounds 194-197. 
 
Reagents and conditions: (a) NMM, CDMT, diethyl-L-glutamate, DMF, rt, 12 h, 37-76% 
yields; (b) (i) 1N, NaOH, rt, 1 h; (ii) 0-4 °C, 1 N HCl, 45-90% yields. 
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D.2.3. Synthesis of 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-butyl-2'-
fluorophenyl classical antifolates 198. 
Scheme 73. Synthesis of target compound 198.  
 
Reagents and conditions: (a) Pd(OAc)2, LiCl, LiOAc, Bu4NCl, DMF, 90 °C, 2.5 h, 59%; 
(b) 5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 302, 1N HCl in (Et)2O, (Et)2O, rt, 48 
h; (c) CH3COONa, MeOH, H2O, 45 °C, 4 h, 20 % yield over 2 steps; (d) (i) 1 N NaOH, rt, 
12 h; (ii) 1 N HCl , 61% yield; (e) NMM, CDMT, diethyl-L-glutamate, DMF, rt, 12 h, 
81%; (f) (i) 1N, NaOH, rt, 1 h; (ii) 0-4 °C, 1 N HCl, 80%. 
Compound 198 (Scheme 73) was obtained using a reported procedure in which 
condensation of the α-bromo aldehyde 355 with 2,6-diamino-4-oxo-pyrimidine 22 is the 
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key step.120 As reported by Larock et al.,323 Heck coupling reaction of commercially 
available hex-5-en-1-ol 299 and methyl 4-bromo-2-fluorobenzoate 353 afforded the 
unsaturated, coupled alcohol that rearranged to the vinyl alcohol and tautomerized to afford 
the aldehyde 354 in 59% yield. It was observed that the Heck coupling of the fluorinated 
benzoate 353 does not proceed at temperatures below 90 °C, unlike the non-fluorinated 
analogs such as 300 (Scheme 62) which undergo Heck coupling at temperatures >70 °C. 
Subsequent α-bromination of 354 with 5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 
(DBMA) 302 at room temperature afforded corresponding α-bromo aldehyde 355 which 
was immediately condensed with 2,6-diamino-4-oxo-pyrimidine 22 in the presence of 
sodium acetate to afford the 5-substituted pyrrolo[2,3-d]pyrimidine 356 in 20% yield over 
2 steps. The terminal ester of 356 was subjected to base catalyzed hydrolysis to afford the 
pteroic acid 357 in 61% yield. The acid 357 was subsequently peptide coupled with L-
glutamate diethyl ester hydrochloride in the presence of NMM and CDMT as the coupling 
agents to afford the diester 358 in 81% yield. Final saponification of the diesters with 1 N 
NaOH and neutralization to pH 4, provided target compound 198 in 80% yield. 
D.3. Multiple enzyme inhibitors (TS, GARFTase, AICARFTase) with selectivity for FRs 
and/or PCFT over RFC 
D.3.1. 5-substituted, 2-amino-4-oxo-6-methyl pyrrolo[2,3-d]pyrimidine classical 
antifolates (200-201) 
A key step in the synthesis of the 5-substituted, 2-amino-4-oxo-6-methyl pyrrolo[2,3-
d]pyrimidine classical antifolates involved thermal indolization of the hydrazone 364 
(Scheme 75) using a reported method.381 Palladium-catalyzed Heck coupling of 
commercially available starting materials methyl 4-bromobenzoate 361 (Scheme 75) and 
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4-penten-2-ol 362 gave the coupled, unsaturated secondary alcohol that rearranged to the 
vinyl alcohol and tautomerized to afford the ketone 363 in 72% yield.323 Condensation of 
the ketone 363 with the hydrazine 360 under reflux conditions in 2-methoxyethanol 
afforded the key intermediate hydrazonopyrimidine 364 in 89% yield.381 The Fischer 
indole cyclization of hydrazone 364 was accomplished regioselectively to the 5-
substituted, 2-amino-4-oxo-6-methyl pyrrolo[2,3-d]pyrimidine 365 in 77% yield by 
thermolysis in diphenyl ether at reflux conditions. 1H NMR did not show any evidence for 
the presence of the other possible regioisomer 368 (Figure 70) (a key determinant is the 
presence of C6-C(CH3) peak at δ 1.8 ppm). The aromatic ester of 365 was subjected to 
base catalyzed hydrolysis to afford the pteroic acid 366 in 63% yield. The acid 366 was 
subsequently peptide coupled with L-glutamate diethyl ester hydrochloride in the presence 
of N-methylmorpholine (NMM) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) as the 
coupling agents to afford the diester 367  in 42% yield. Final saponification of the diesters 
with 1 N NaOH and neutralization to pH 4, provided the 2C linker target compound 200 in 
75% yield. Nucleophilic aromatic substitution of the commercially available 2-amino-6-
chloropyrimidin-4(3H)-one 359 (Scheme 74) with hydrazine hydrate afforded the 
intermediate hydrazine 360 in 72% yield.381 
Scheme 74. Synthesis of intermediate 360. 
 
Reagents and conditions: Hydrazine hydrate, H2O, reflux, 3 h, 72%. 
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Scheme 75. Synthesis of target compound 200. 
  
 
 
Reagents and conditions: (a) Bu4NH4Cl, Pd(OAc)2, LiCl, LiOAc, DMF, 80 °C, 3 h, 72%, 
(b) 360, methoxyethanol, 145 °C, 14 h, 89%; (c)  Ph2O, 270 °C, 6 h, 77%; (d) 1N, NaOH, 
rt, 12 h, 63%; (e) Diethyl-L-glutamate, NMM, CDMT, DMF, rt, 12 h, 42%; (f) (i) 1N, 
NaOH, rt, 1 h; (ii) 0-4 °C, 1 N HCl, 75%. 
 
Figure 70. The other possible Fischer indole cyclization product 368.  
When a similar procedure was pursued for the synthesis of 5-substituted, 2-amino-
4-oxo-6-methyl pyrrolo[2,3-d]pyrimidine classical antifolate 201 with a 4C linker, the 
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thermal indolization of the hydrazone 371 was repeatedly unsuccessful (Scheme 76). 
Palladium-catalyzed Heck coupling of commercially available starting material methyl 4-
bromobenzoate 361 with 6-hexen-2-ol 369 gave the coupled, unsaturated secondary 
alcohols that rearranged to the vinyl alcohol and tautomerized to afford the ketone 370 in 
64% yield.323 Condensation of the ketone 370 with the hydrazine 360 under reflux 
conditions in 2-methoxyethanol afforded the key intermediate hydrazonopyrimidine 371 
in 87% yield. The Fischer indole cyclization of hydrazone 371 to the 5-substituted, 2-
amino-4-oxo-6-methyl pyrrolo[2,3-d]pyrimidine 372 was unsuccessful due to degradation 
of the reaction mixture as confirmed by 1H NMR. It is speculated that the reduced melting 
point of the longer, 7C alkyl chain linked intermediate 371 (mp 152 °C) when compared 
with the 5C linker counterpart 364 (mp 240 °C) causes degradation of the intermediate 371 
under thermolytic conditions of the cylcilization reaction (270 °C) to 372. 
Scheme 76. Synthesis of intermediate 372 
 
 
Reagents and conditions: (a) Bu4NH4Cl, Pd(OAc)2, LiCl, LiOAc, DMF, 80 °C, 3 h, 64%; 
(b) 372, methoxyethanol, 145 °C, 14 h, 87%; (c)  Ph2O, 270 °C, 6 h. 
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Figure 71. Proposed retrosynthesis of target compound 201. 
Alternate procedure for the synthesis of the 5-substituted, 2-amino-4-oxo-6-methyl 
pyrrolo[2,3-d]pyrimidine classical antifolates with a 4C linker was envisioned to be 
accomplished via a Sonogashira coupling of intermediate iodide 373 and alkyne 374 
(Figure 71). N-(5-iodo-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-
yl)pivalamide 373 can be synthesized by following a reported procedure382 and the 
intermediate 374 could be synthesized via a reported Barbier reaction383 of propargyl 
bromides with 4-formylbenzoate. This convergent procedure not only will improve the 
overall yield in lesser number of steps, but can also be applied for the synthesis of 
homologous compounds. 
The key intermediate, secondary homopropargyl alcohol 376 (Scheme 77) was 
synthesized as per a reported Barbier type synthesis.383 Aromatic aldehyde 375 and 
propargyl bromide 312 in the presence of activated zinc and saturated aqueous NH4Cl 
afforded the secondary homopropargyl alcohol 376 in 70% yield. Having obtained 376, 
deoxygenation of the benzyl alcohol using triethylsilane (TES) was carried out. However, 
instead of the deoxygenated product methyl 4-(but-3-yn-1-yl)benzoate 374, the 
trifluoroacetyl protected intermediate 377 (Scheme 77) was obtained in 48% yield. The 
 183 
deoxygenation step was temporarily abandoned and the homopropargyl alcohol 376 was 
taken forward to test the feasibility of Sonogashira coupling of the alkynes 376 with 
intermediate halide 373. 
Scheme 77. Synthesis of intermediates 374, 376 and 377. 
 
Reagents and conditions: (a) Zn, sat. aq, NH4Cl,  THF, 0 °C - rt, 24 h, 70%; (b) TFA, TES, 
CH2Cl2, 0 °C - rt, 7 days, 48%. 
Scheme 78.  Synthesis of intermediates 373 and 380. 
 
Reagents and conditions: (a) chloroacetone, CH3COONa, DMF, reflux, 3.5 h, 69%; (b) 
(Piv)2O, 120 °C, 12 h,  93%; (c) halogenating reagent, CH2Cl2, 40 °C, 30 min, 93%. 
 184 
Table 21. Halogenating agents used for the synthesis of intermediates 373 and 380 
(Scheme 78). 
Halogenating 
reagent 
Product 
NIS 373 
NBS 380 
 
Synthesis of the key halogenated intermediates 373 and 380 (Scheme 78) began with the 
condensation of 2,4-diamino-6-hydroxypyrimidine 22 with bromoacetone in the presence 
of sodium acetate yielding the cyclized product 2-amino-6-methyl-3,7-dihydro-4H-
pyrrolo[2,3-d]pyrimidin-4-one 378 in 51% yield.382 Compound 378 was treated with 
trimethylacetic anhydride to yield the N(2)-monoacylated compound 379 in 93% yield. 
Aromatic iodination or bromination using NIS or NBS afforded the C5 halogenated 
intermediates 373 or 380 respectively in 93% yields (Table 21). Halogenation at the 
benzylic position was not observed.384  
Scheme 79. Synthesis of intermediate 381.  
 
Reagents and conditions: Pd[P(Ph)3]4, CuI, TEA, Solvent, temp, time. 
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Table 22. Reagents and conditions for the synthesis of intermediate 381. Whereever 
iodinated and brominated intermediates yielded different results under similar coupling 
conditions, the products are correspondingly color coded with the starting material halide. 
Solvent X Reagents and conditions Product % Yield 
of 
compd. 
381 
CuI 
(eq) 
Pd(0)
(eq) 
TEA 
(eq) 
Temp. Time 
 
DMF I/Br 0.2 0.5 10 rt 72 h 379/NA - 
DMF I/Br 0.2 0.5 10 55 °C 12 h 379 - 
DMF I/Br 0.2 0.5 10 90 °C 12 h 379 - 
DMF I/Br 0.2 0.5 10 150 °C 3 min 379 - 
3:1 
THF:DMF 
I/Br 0.4 0.1 1 rt 72 h 381 and 
379 /NA 
30% 
3:1 
THF:DMF 
I/Br 0.4 0.1 1 90 °C 12 h 381 and 
379 / 387 
10% 
3:1  
THF: DMF 
I/Br 0.4 0.1 1 150 °C 3 min 379 - 
THF I 0.4 0.1 1 rt 72 h 381 and 
379 
70% 
 
Scheme 80. Synthesis of intermediate 382.  
 
Reagents and conditions: 1N, NaOH, rt, 12 h. 
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Sonogashira coupling reactions of halides 373 and 380 (Scheme 79, Table 22) with 
the alkyne 376 were carried out under various coupling conditions. Upon varying the 
reacting halide (iodo or bromo), solvents, and equivalents of catalysts and base, it was 
observed that the solvent in which the reaction was carried out was the most vital variable. 
The Sonogashira coupling method optimized for the synthesis of 212-213 (Scheme 41) 
produced no new product spots on TLC in the presence of iodo 373 and alkyne 376. 
Majority of the starting material was deiodinated to the intermediate 379 (Table 22). 
Similar results were observed at lower temperatures (55 °C and rt) or higher temperature 
(150 °C), analogous to the results obtained in the Sonogashira coupling of the iodo 305 
with alkynes 306 and 307 (Scheme 66). Though a palladium complex is formed with the 
6-methyl pyrrolo[2,3-d]pyrimidine scaffold (confirmed from 1H NMR studies), however 
the consecutive reaction step appears to be the temperature independent C5 deiodination. 
Repeating the reactions with the brominated analog 380 either proceeded without any 
depletion of starting material (rt) or resulted in dehalogenation at higher temperatures. In 
another set of reactions, a reported procedure of Sonogashira coupling where the catalysts 
Pd[(PPh)3]4 , CuI and base TEA were used in modified equivalents in THF:DMF solvent 
ratio of 3:1 at room temperature in 4 hours (4 h) was followed.385 The coupling of the 
alkyne 376 with the iodo 373 at room temperature did not proceed to form any new spot 
over a period of 4 h and was therefore continued for additional period of time. After 8 h a 
new polar spot was observed on the TLC. The reaction did not go to completion and the 
intensity of the new spot did not increase beyond 72 h at which point, the reaction spots 
were separated on a column chromatograph to afford the required Sonogashira coupled 
product 381 (confirmed by 1H NMR) in 30% yield. However, the product was difficult to 
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purify (due to formation of multiple unidentified side products with similar Rf) and 
warranted further optimization of the reaction procedure. Replacing 373 with bromo 380 
at rt and/or increasing the reaction temperature was detrimental to the palladium complex 
formation and/or resulted in dehalogenation. Since replacing DMF with 3:1 ratio of THF 
and DMF afforded the required intermediate 381, the next logical step was to examine the 
scope of the reaction in pure THF. This was feasible due to the improved solubility of N(2)-
monoacylated 373. The reaction in THF not only improved the yield to 70% (crude), but 
the separation of the reaction mixture was easier. However, base catalyzed hydrolysis of 
381 to 382 (Scheme 80) at room temperature failed to work and instead resulted in 
degradation of the starting material. Our hypothesis is that the under basic conditions, the 
CH2 protons (diastereotopic) next to the alkyne may have been deprotonated to produce a 
carbanion that is resonance stabilized by the neighboring pi orbitals. In the future attempts 
for the synthesis of 201, it will be worthwhile to reduce the triple bond in 373 before 
carrying it forward for base-catalyzed hydrolysis.   
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V. EXPERIMENTAL 
All evaporations were carried out in vacuum with a rotary evaporator. Analytical samples 
were dried in vacuo in a CHEM-DRY drying apparatus over P2O5 at 50 °C. Melting points 
were determined either using a MEL-TEMP II melting point apparatus with FLUKE 51 
K/J electronic thermometer or using an MPA100 OptiMelt automated melting point system 
and are uncorrected. Nuclear magnetic resonance spectra for proton (1H NMR) were 
recorded on the Bruker Avance II 400 (400 MHz) or Bruker Avance II 500 (500 MHz) 
NMR systems with TopSpin processing software. 19F NMR were recorded using a Bruker 
WH-400 (400 MHz) spectrometer or a Bruker AV-III 700 MHz spectrometer using a 
BBFO-Plus probe. The 1H homonuclear decoupling experiments were carried out 
individually at each elevated temperature (data acquisition each time was delayed until the 
temperature was stabilized). The 2D HOESY NMR was carried out using a standard 1H/19F 
HOESY experiment with 19F detection. 1H and 19F spectra were referenced to TMS and 
trifluoroacetic acid, respectively, as the internal standards to express the chemical shift 
values (δ) in ppm (parts per million): s, singlet; d, doublet; dd, doublet of doublet; t, triplet; 
q, quartet; m, multiplet; br, broad singlet; td, triplet of doublet; dt, doublet of triplet; quin, 
quintet. 1H NMR of alkyl CH2s of target compounds merged with DMSO and water peaks 
have been omitted from the experimental whenever not visible in 1H NMR. 1H NMR of 
alkyl CH2s of intermediate compounds within DMSO and water peaks and D2O 
exchangeable peaks that were exchanged due to excess moisture have also been omitted 
from the experimental whenever not visible in 1H NMR. Thin-layer chromatography (TLC) 
was performed on Whatman® PE SIL G/UV254 flexible silica gel plates and the spots 
were visualized under 254 and 365 nm ultraviolet illumination. Proportions of solvents 
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used for TLC are by volume. All analytical samples were homogeneous on TLC in at least 
two different solvent systems. Column chromatography was performed on the silica gel 
(70 to 230 meshes, Fisher Scientific) column. Flash chromatography was carried out on 
the CombiFlash® Rf systems, model COMBIFLASH RF. Pre-packed RediSep® Rf 
normal-phase flash columns (230 to 400 meshes) of various sizes were used. The amount 
(weight) of silica gel/celite for column chromatography was in the range of 5-10 times the 
amount (weight) of the crude reaction mixture being separated. Elemental analyses were 
performed by Atlantic Microlab, Inc., Norcross, GA. Element compositions are within ± 
0.4% of the calculated values. Fractional moles of water or organic solvents frequently 
found in some analytical samples could not be prevented despite 24 to 48 hours of drying 
in vacuo and were confirmed where possible by their presence in the 1H NMR spectra. 
High Performance Liquid Chromatography (HPLC) was performed on Waters® 600E 
Multisolvent Delivery System, components: Waters® 600 Controller (model code: 600), 
600E Pump (model code: 60F), Waters® 2487 Dual λ Absorbance Detector. Mobile phase 
was an aqueous blend of water with a miscible, polar organic solvent acetonitrile. 
 
General Procedure for the Synthesis of Compounds 162 and 207.  
To the solution of commercially available 4-pentynoic acid 203 (1 eq) in anhydrous CH2Cl2 
was added oxalyl chloride (6 eq) and stirred at reflux for 1 h to form the acid chloride 204. 
After cooling to room temperature, the solvent was evaporated under reduced pressure and 
the residue was dissolved in Et2O without further characterization. The solution was added 
in a dropwise manner to an ice-cooled (ice-bath) diazomethane solution (generated in situ 
from diazald (5 eq) by using Aldrich Mini Diazald apparatus). The resulting mixture was 
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allowed to stand for 30 min after which it was stirred for 1 h to give the unstable α-
diazoketone 205. Subsequently, 48% HBr in water (20 eq) was added to this solution, and 
stirred at reflux temperature for 1.5 h. The solution was then brought down to room 
temperature and the organic layer was separated. The aqueous layer was extracted twice 
with Et2O and combined with the organic layer. The Et2O extract was washed twice with 
10% Na2CO3 solution, dried over Na2SO4, filtered and solvent was evaporated under 
reduced pressure to afford α-bromoketone 206 a light-yellow/orange syrup. Without 
further characterization, the residue was dissolved in anhydrous DMF to which 2,6-
diamino-3H-pyrimidin-4-one 22 (1 eq), was added. The resulting mixture was stirred at 
room temperature for 72 h under N2, until a new spot was observed under TLC 
(CHCl3/MeOH) after which the solvent was evaporated to afford a sticky crude solid. A 
silica plug was prepared by adding silica gel and methanol followed by evaporation of the 
solvent in vacuo, which was then loaded on to a silica gel column and eluted with CHCl3 
followed by gradual increase in polarity to 10% MeOH in CHCl3. The desired fractions 
(TLC) were pooled and evaporated to afford the alkyne intermediates. 
2-Amino-6-(but-3-yn-1-yl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (162) 
Following the general procedure described for the synthesis of 162 and 207, cyclization of 
203 (1.96 g, 20 mmol) at room temperature for 72 h afforded the intermediate 162 (1.5 g, 
7.42 mmol, 37% yield after 4 steps) as a pink colored powder. TLC Rf = 0.45 (CHCl3/ 
MeOH 5:1); mp 269 ºC dec. 1H NMR (DMSO-d6, 400 MHz): δ 2.44-2.48 (dt, J = 2.53, 
7.51, 7.47 Hz, 2H, CH2), 2.66-2.7 (t, J = 7.45, 7.45 Hz, 2 H, CH2), 2.8-2.81 (t, J = 2.59, 
2.59 Hz, 1 H, CH), 5.98-5.99 (d, J = 2.20 Hz, 1 H, C5-CH), 6.21 (s, br, 2 H, 2-NH2, exch), 
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10.37 (s, 1 H, 3-NH, exch), 10.95 (s, 1 H, 7-NH, exch). The 1H NMR matches the 1H NMR 
of the reported compound.107  
5-(but-3-yn-1-yl)furo[2,3-d]pyrimidine-2,4-diamine (207) 
Following the general procedure described for the synthesis of 162 and 207, cyclization of 
203 (1.96 g, 20 mmol) at room temperature for 72 h afforded the intermediate 207 as a side 
product (200 mg, 1 mmol, 5% yield after 4 steps) as a buff colored powder. TLC Rf = 0.56 
(CHCl3/ MeOH 5:1); mp 189.2 ºC dec. 1H NMR (DMSO-d6, 400 MHz): δ 2.34-2.38 (dt, J 
= 2.63, 7.32, 6.97 Hz, 2 H, CH2), 2.7-2.74 (t, J = 7.30, 7.30 Hz,  2 H, CH2), 2.82-2.83 (t, J 
= 2.66, 2.66 Hz, 1 H, CH), 4.95 (s, 2 H, 2-NH2, exch), 5.4 (s, 1 H, C6-CH), 7.7 (s, br, 2 H, 
4-NH2, exch). The intermediate 207 was not characterized further. 
General Procedure for the Synthesis of Compounds 210–211.  
A mixture of bromo-fluoro-arylcarboxylic acids (208-209) (1 eq), N-methylmorpholine 
(1.2 eq), 2-chloro-4,6-dimethoxy-1,3,5-triazine (1.2 eq) in anhydrous DMF in a round 
bottomed flask, was stirred for 1.5 h, at room temperature. Subsequently, N-
methylmorpholine (1.2 eq) and L-glutamic acid diethylester hydrochloride (1.5 eq) was 
added to the mixture and stirred at room temperature for 5 h until disappearance of the 
starting material and a new major non-polar spot was observed on TLC (hexane/EtOAc). 
After evaporation of the solvent in vacuo, MeOH was added followed by silica gel and the 
solvent was evaporated by further drying. The resulting plug was loaded on to a silica gel 
column and eluted with hexanes followed by gradual increase of EtOAc to 50% EtOAc in 
hexanes. Fractions with the desired Rf (TLC) were pooled and evaporated to afford 
glutamate esters 210-211 as colorless syrups.  
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Diethyl (4-bromo-2-fluorobenzoyl)-L-glutamate (210).  
Compound 210 was prepared using the general method described for the preparation of 
210-211, from 4-bromo-2-fluorobenzoic acid, 208 (2 g, 9 mmol), to give 210 (2.45 g, 67%) 
as a colorless syrup. TLC Rf = 0.45 (hexane/EtOAc, 1:1); 1H NMR (500 MHz, CDCl3): δ 
1.24-1.27 (t, J = 7.15, 7.15 Hz, 3 H, γ-COOCH2CH3), 1.32-1.35 (t, J = 7.14, 7.14 Hz, 3 H, 
α-COOCH2CH3), 2.12-2.53 (m, 4 H, β-CH2, γ-CH2), 4.11-.4.16 (dq, J = 0.60, 7.12, 7.07, 
7.07 Hz, 2 H, γ-COOCH2CH3), 4.24-4.3 (dq, J = 1.70, 7.14, 7.12, 7.12 Hz, 2 H, α-
COOCH2CH3), 4.83-4.87 (ddt, J = 2.02, 5.11, 7.33, 7.33 Hz, 1 H, α-CH), 7.33-7.39 (m, 2 
H, Ar, CONH, exch), 7.43-7.45 (dd, J = 1.71, 8.44 Hz, 1 H, Ar), 7.95-7.99 (t, J = 8.38 Hz, 
1 H, Ar). The intermediate 210 was used for the next reaction without further 
characterization. 
Diethyl (4-bromo-3-fluorobenzoyl)-L-glutamate (211).  
Compound 211 was prepared using the general method described for the preparation of 
210-211, from 4-bromo-3-fluorobenzoic acid, 209 (500 mg, 2.3 mmol), to give 211 (780 
mg, 85%) as a colorless syrup. TLC Rf = 0.45 (hexane/EtOAc 1:1); 1H NMR (400 MHz, 
CDCl3): δ 1.24-1.28 (dd, J = 0.78, 7.09 Hz, 3 H, γ-COOCH2CH3), 1.32-1.35 (dd, J = 0.76, 
7.12 Hz, 3 H, α-COOCH2CH3), 2.14-2.58 (m, 4 H, β-CH2, γ-CH2), 4.10-4.19 (dq, J = 2.95, 
7.11, 7.04, 7.04 Hz, 2 H, γ-COOCH2CH3), 4.23-4.3 (q, J = 6.37, 6.37, 6.50 Hz, 2 H, α-
COOCH2CH3), 4.73-4.78 (dt, J = 4.97, 7.51, 7.63 Hz, 1 H, α-CH), 7.25-7.27 (d, J = 7.31 
Hz, 1 H, Ar), 7.49-7.51 (dd, J = 1.77, 8.27 Hz, 1 H, Ar), 7.63-7.69 (m, 2 H, Ar, CONH, 
exch). The intermediate 211 was used for the next reaction without further characterization. 
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General Procedure for the Synthesis of Compounds 212-213.  
To a round-bottomed flask equipped with a magnetic stirrer and purged with N2, was added 
a mixture of tetrakis(triphenylphosphine)palladium(0) (0.16 eq), triethylamine (10 eq), 
210-211 (1.5 eq) and anhydrous DMF. To the stirred mixture, under N2, was added 
copper(I) iodide (0.16 eq) and 162 (1 eq) and the reaction mixture was stirred at 70 °C for 
12 h in a microwave. TLC showed the disappearance of the starting material and one a new 
non-polar spot (CHCl3/MeOH). After evaporation of solvent under reduced pressure, 
MeOH was added followed by silica gel and the solvent was evaporated. The resulting plug 
was loaded on to a silica gel column and eluted with CHCl3 followed by 10% MeOH in 
CHCl3. Fractions with desired Rf (TLC) were pooled and evaporated to afford the alkynes 
212-213. 
Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-
1-yl)-2-fluorobenzoyl)-L-glutamate (212).  
Compound 212 was prepared using the general method described for the preparation of 
212-213, from 162 (100 mg, 0.5 mmol) and diethyl (4-bromo-2-fluorobenzoyl)-L-
glutamate, 210 (300 mg, 0.74 mmol) to give 212 (80 mg, 31%) as a golden-brown sticky 
solid. TLC Rf  = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6):  1.15-1.20 (m, 
6 H, COOCH2CH3), 1.87-2.14 (m, 2 H, β-CH2), 2.4-2.45 (m, 2 H, γ-CH2), 4.02-4.13 (m, 4 
H, COOCH2CH3), 4.38-4.49 (m, 1 H, α-CH), 6.02-6.05 (m, 3 H, C5-CH, 2-NH2, exch), 
7.26-7.32 (m, 1 H, Ar), 7.51-7.81 (m, 2 H, Ar), 8.75-8.77 (dd, J = 2.08, 7.83 Hz, 1 H, 
CONH, exch), 10.22 (s, 1 H, 3-NH, exch), 10.92 (s, 1 H, 7-NH, exch). The intermediate 
212 was used for the next reaction without further characterization. 
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Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-
1-yl)-3-fluorobenzoyl)-L-glutamate (213).  
Compound 213 was prepared using the general method described for the preparation of 
212-213, from 162 (100 mg, 0.5 mmol) and diethyl (4-bromo-3-fluorobenzoyl)-L-
glutamate, 211 (300 mg, 0.74 mmol) to give 213 (110 mg, 42%) as a brown sticky solid. 
TLC Rf  = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.12-1.18 (m, 6 H, 
COOCH2CH3), 1.95-2.13 (m, 2 H, β-CH2), 2.40-2.44 (m, 2 H, γ-CH2), 2.65-2.67 (m, 2H, 
CH2),  4.01-4.12 (m, 4H, COOCH2CH3), 4.38-4.43 (m, 1 H, α-CH), 5.88 (s, 1 H, C5-CH), 
6.0 (s, 2 H, 2-NH2, exch), 7.37-7.41 (m, 1 H, Ar), 7.59-7.64 (m, 2 H, Ar), 8.77-8.80 (d, J 
= 8.26 Hz, 1 H, CONH, exch), 10.23 (s, 1 H, 3-NH, exch), 10.83 (s, 1 H, 7-NH, exch). The 
intermediate 213 was used for the next reaction without further characterization. 
General procedure for the synthesis of compounds 214-215. 
To a Parr flask with 10% palladium on activated carbon (0.5 wt eq) soaked in ethanol was 
added a methanolic solution of 212-213. Hydrogenation was carried out at 55 psi of H2 for 
12 h. TLC showed the disappearance of the starting material and one a new slightly non-
polar spot (CHCl3/MeOH). The reaction mixture was filtered through celite, washed with 
MeOH and concentrated under reduced pressure to give the reduced alkanes 214-215 as 
sticky solids. 
Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
fluorobenzoyl)-L-glutamate (214).  
Compound 214 was prepared using the general method described for the preparation of 
214-215, from 212 (80 mg, 0.13 mmol) to give 214 (65 mg, 81%) as a light yellow sticky 
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solid. TLC Rf  = 0.52 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.16-1.22 
(m, 6 H, COOCH2CH3), 1.57-1.61 (m, 4 H, CH2CH2), 1.92-2.13 (m, 2 H, β-CH2), 2.44-
2.48 (m, 2 H, γ-CH2), 2.63-2.68 (m, 2 H, Ar-CH2), 4.03-4.08 (dd, J = 6.98, 14.09 Hz, 2 H,  
COOCH2CH3), 4.1-4.15 (m, 2 H, COOCH2CH3), 4.41-4.43 (m, 1 H, α-CH), 5.84-5.85 (d, 
J = 2.05 Hz, 1 H, C5-CH), 5.96 (s, 2 H, 2-NH2, exch), 7.11-7.16 (m, 2 H, Ar), 7.48-7.52 
(t, J = 7.80, 7.80 Hz, 1 H, Ar), 8.57-8.58 (dd, J = 0.82, 5.91 Hz, 1 H, CONH, exch), 10.12 
(s, 1 H, 3-NH, exch), 10.80 (s, 1 H, 7-NH, exch). The intermediate 214 was used for the 
next reaction without further characterization. 
Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3-
fluorobenzoyl)-L-glutamate (215).  
Compound 215 was prepared using the general method described for the preparation of 
214-215, from 213 (100 mg, 0.19 mmol) to give 215 (70 mg, 70%) as a light yellow sticky 
solid. TLC Rf  = 0.52 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.12-1.18 
(m, 6 H, COOCH2CH3), 1.54-1.61 (m, 4 H, CH2CH2), 1.95-2.12 (m, 2 H, β-CH2), 2.4-2.44 
(m, 2 H, γ-CH2), 2.66-2.68 (m, 2 H, Ar-CH2), 4.0-4.12 (m, 4 H,  COOCH2CH3), 4.38-4.42 
(m, 1 H, α-CH), 5.88 (s, 1 H, C5-CH), 6.1 (s, 2 H, 2-NH2, exch), 7.38-7.43 (m, 1 H, Ar), 
7.59-7.64 (m, 2 H, Ar), 8.77-8.81 (m, 1 H, CONH, exch), 10.23 (s, 1 H, 3-NH, exch), 10.83 
(s, 1 H, 7-NH, exch). The intermediate 215 was used for the next reaction without further 
characterization. 
General procedure for the synthesis of compounds 179-180. 
To the reduced alkanes 214-215 was added 1 N NaOH and the mixture was stirred at room 
temperature for 1 h. TLC showed the disappearance of the starting material and one major 
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spot at the origin (CHCl3/ MeOH 5:1). The solution was cooled in an ice bath and the pH 
was adjusted to 3-4 with dropwise addition of 1 N HCl. The resulting suspension was 
cooled to 4-5 °C in the refrigerator overnight and filtered. The residue was thoroughly 
washed with cold water and dried in vacuum using P2O5 to afford the target compounds 
179-180. 
(4-(4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
fluorobenzoyl)-L-glutamic acid (179).  
Compound 179 was prepared using the general method described for the preparation of 
179-180, from 214 (65 mg, 0.12 mmol) to give 179 (40 mg, 69%) as a light yellow powder. 
mp 137.4 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.57-1.58 (m, 4 H, CH2CH2), 1.85-
2.11 (m, 2 H, β-CH2), 2.33-2.37 (m, 2 H, γ-CH2), 2.63-2.66 (t, J = 6.40, 6.40 Hz, 2 H, Ar-
CH2), 4.36-4.41 (m, 1 H, α-CH), 5.85-5.86 (d, J = 2.10 Hz, 1 H, C5-CH), 6.02 (s, 2 H, 2-
NH2, exch), 7.10-7.15 (m, 2 H, Ar), 7.50-7.54 (t, J = 7.86, 7.86 Hz, 1 H, Ar), 8.41-8.43 
(dd, J = 2.08, 7.83 Hz, 1 H, CONH, exch), 10.18 (s, 1 H, 3-NH, exch), 10.83 (s, 1 H, 7-
NH, exch). Anal. Calcd for C22H24FN5O6 ꞏ 0.82 H2O: C, 54.12; H, 5.29; N, 14.34; F, 3.89. 
Found: C, 54.19; H, 5.13; N, 14.05; F, 3.76.  
 (4-(4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3-
fluorobenzoyl)-L-glutamic acid (180).  
Compound 180 was prepared using the general method described for the preparation of 
179-180, from 215 (60 mg, 0.13 mmol) to give 180 (50 mg, 93%) as a light yellow powder. 
1H NMR (400 MHz, DMSO-d6): δ 1.5-1.60 (m, 4 H, CH2CH2), 1.89-2.12 (m, 2 H, α-CH2), 
2.32-2.35 (m, 2H, β-CH2), 2.65-2.68 (m, 2 H, Ar-CH2), 4.35-4.43 (m, 1 H, α-CH), 5.8 (s, 
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1 H, C5-CH), 5.99 (s, 2 H, 2-NH2, exch), 7.37-7.41 (m, 1 H, Ar), 7.6-7.65 (m, 2 H, Ar), 
8.61-8.63 (d, J = 8.2 Hz, 1 H, CONH, exch), 10.2 (s, 1 H, 3-NH, exch), 10.80 (s, 1 H, 7-
NH, exch). Anal. Calcd for C22H24FN5O6 ꞏ 1.15 H2O: C, 53.46; H, 5.36; N, 14.17; F, 3.84. 
Found: C, 53.54; H, 5.11; N, 13.83; F, 3.64. mp 163.1 °C dec.  
Methyl 2-fluoro-4-(4-hydroxybut-1-yn-1-yl)benzoate (224).  
To a solution of 3-butynol 222 (508 g, 8.25 mmol) and methyl 4-bromo-2-fluorobenzoate 
223 (2 g, 8.6 mmol, 1.04 eq) in anhydrous acetonitrile (10 mL) was added palladium 
chloride (59 mg, 0.33 mmol, 0.04 eq), triphenylphosphine (86.6 mg, 0.33 mmol, 0.04 eq), 
copper iodide (251.4 mg, 1.32 mmol, 0.16 eq), and triethylamine (11.5 mL, 86mmol, 10 
eq). The reaction mixture was heated to 100 °C and run for 0.5 h under microwave heating 
until the starting material disappeared a new polar spot was observed on TLC 
(hexane/EtOAc). A silica plug was prepared by adding silica gel and methanol followed 
by evaporation of the solvent in vacuo, which was then loaded on to a silica gel column 
and eluted with hexane followed by 50% EtOAc in hexane. The fractions with the desired 
Rf were pooled and evaporated to afford 224 (1.2 g, 65%) of 19a as a colorless syrup. TLC 
Rf = 0.2 (hexane/EtOAc, 1:1). 1H NMR (400 MHz, CDCl3): δ 1.8 (s, br, OH, exch), 2.73-
2.76 (t, J = 6.02, 6.02 Hz, 2 H, CH2), 3.85−3.88 (t, J = 6.09, 6.09 Hz, 2 H, CH2), 3.95 (s, 
3 H, COOCH3), 7.18-7.29 (m, 2 H, Ar), 7.87-7.91 (t, J = 7.77, 7.77 Hz, 1 H, Ar). The 
intermediate 224 was used for the next reaction without further characterization. 
Methyl 2-fluoro-4-(4-hydroxybutyl)benzoate (226).  
To 10% palladium on activated carbon (600 mg, 0.5 wt eq) in a Parr flask, ethanol (10 mL) 
was added to quench. Methanolic solution of alcohols 224 (1.2 g, 5.4 mmol) was added 
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and hydrogenation was carried out at 55 psi of H2 for 12 h until the disappearance of 
starting material and formation of a slightly non-polar spot in TLC. The reaction mixture 
was filtered through celite, washed with MeOH, passed through a short silica gel column 
(3 cm × 5 cm) and concentrated under reduced pressure to give 226 (1.17 g, 96%) as a 
colorless syrup. TLC Rf = 0.22 (hexane/EtOAc, 1:1); 1H NMR (400 MHz, CDCl3): δ 1.5-
1.79 (m, 5 H, CH2CH2, OH, exch), 2.67-2.71 (t, J = 7.60, 7.60 Hz, 2 H, CH2), 3.65-3.69 
(t, J = 6.37, 6.37 Hz, 2 H, CH2), 3.92 (s, 3 H, COOCH3), 6.95-6.99 (d, J = 1.32 Hz, 1 H, 
Ar), 7.01-7.04 (dd, J = 1.50, 8.02 Hz, 1 H, Ar), 7.83-7.87 (t, J = 7.84, 7.84 Hz, 1 H, Ar). 
The intermediate 226 was used for the next reaction without further characterization. 
4-(3-Fluoro-4-(methoxycarbonyl)phenyl)butanoic acid benzoate (227). 
To acetonitrile (35mL), periodic acid (3.12g, 13.7 mmol, 2.65 eq), was added and stirred 
for 15 min. To this solution at 0 °C (in an ice–water bath), compound 226 (1.17 g, 5.17 
mmol, 1 eq) was added followed by the addition of PCC (33.44 mg, 0.16 mmol, 0.03 eq). 
The mixture was then stirred for 6 h until no starting material was detected on TLC a new 
non-polar spot was observed (hexane/EtOAc). The solvent was evaporated in vacuo to a 
residue which was dissolved in EtOAc, washed successively with brine–water, satd. aq. 
NaHSO3 solution, and brine, dried over anhydrous Na2SO4, and concentrated to give 227 
(1.2 g, 97%) as a colorless syrup. TLC Rf = 0.58 (hexane/EtOAc 1:1); 1H NMR (400 MHz, 
CDCl3): δ 1.97-2.04 (m, 2 H, CH2), 2.39-2.43 (t, J = 7.31, 7.31 Hz, 2 H, CH2), 2.72-2.76 
(m, 2 H, CH2), 3.94 (s, 3 H, COOCH3), 6.98-7.01 (d, J = 1.23 Hz, 1 H, Ar), 7.04-7.07 (dd, 
J = 1.37, 8.01 Hz, 1 H, Ar), 7.87-7.91 (t, J = 7.82, 7.82 Hz, 1 H, Ar). The intermediate 227 
was used for the next reaction without further characterization. 
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Methyl 4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-2-
fluorobenzoate (231).  
To the solution of acid 227 (500 mg, 2.08 mmol, 1 eq) in anhydrous CH2Cl2 (10 mL) was 
added oxalyl chloride (1.1 mL, 12.5 mmol, 6 eq) and stirred at reflux for 1 h to the acid 
chloride 228. After cooling to room temperature, the solvent was evaporated under reduced 
pressure and without further characterization, the residue was dissolved in Et2O (10 mL). 
This was added in a dropwise manner to an ice-cooled (ice-bath) diazomethane solution 
(generated in situ from diazald (5 eq) by using Aldrich Mini Diazald apparatus). The 
resulting mixture was allowed to stand for 30 min after which it was stirred for 1 h to afford 
the unstable α-diazoketone 229. Subsequently, 48% HBr in water (5 mL, 20 eq) was added 
to this solution, and stirred at reflux temperature for 1.5 h. The solution was then brought 
down to room temperature and the organic layer was separated. The aqueous layer was 
extracted twice with Et2O (10 mL) and combined with the organic layer. The Et2O extract 
was washed twice with 10% Na2CO3 (10 mL) solution and dried over Na2SO4. Solvent was 
evaporated under reduced pressure to afford the α-bromoketone 230 as an orange syrup. 
Without further characterization, the residue was dissolved in anhydrous DMF (5 mL) to 
which 2,6-diamino-3H-pyrimidin-4-one 22 (275 mg, 2.18 mmol, 1.05 eq), was added. The 
resulting mixture was stirred at room temperature for 72 h under N2 until no starting 
material was detected on TLC a new non-polar spot was observed (CHCl3/MeOH). The 
solvent was evaporated to afford a sticky crude solid. MeOH was added to it followed by 
silica gel and the solvent was evaporated. The resulting plug was loaded on to a silica gel 
column and eluted with 10% MeOH in CHCl3. Fractions with desired Rf were pooled and 
evaporated to afford the crude pteroic ester 231 (200 mg, 28%) as a pink sticky solid. NMR 
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of the crude 231 clearly had the required peaks of the bicyclic pyrrolo[2.3-d]pyrimidine 
scaffold and the side chain phenyl confirming successful cyclization to 231. TLC Rf  = 0.45 
(CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.77-1.94 (m, 2 H, CH2), 2.45-
2.48 (m, 2 H, Ar-CH2), 2.62-2.74 (m, 2 H, Ar-CH2), 3.9 (s, 3 H, COOCH3), 5.72 (s, 1 H, 
C5-CH),  6.33 (s, 2 H, 2-NH2, exch),  7.14-7.15, (m, 2 H, Ar), 7.77-8.17, (m, 1 H, Ar), 
10.77 (s, 1 H, 3-NH, exch), 11.54  (s, 1 H, 7-NH, exch). The intermediate 231 was used 
for the next reaction without further characterization. 
4-(3-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-2-
fluorobenzoic acid (232). 
Saturated methanolic solutions of the crude ester 231 (200 mg, 0.58 mmol) was dissolved 
in 1 N NaOH (3 mL) and stirred under N2 for 12 h. Upon consumption of the starting 
materials and one major polar spot on TLC was obtained, the pH was adjusted to 3–4 with 
dropwise addition of 1 N HCl to form a precipitate. The resulting suspensions were cooled 
in the refrigerator overnight and filtered, washed with cold water and dried under reduced 
pressure using P2O5 to afford the crude acid 232 (90 mg, 47%) as a yellow powder. TLC 
Rf  = 0.4 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6):  1.79-1.92 (m, 2 H, CH2), 
2.63-2.69 (m, 2 H, CH2), 5.94 (s, 1 H, C5-CH), 7.16-7.21 (m, 2 H, Ar), 7.79-7.84 (m, 1 H, 
Ar), 10.3 (s, 1 H, 3-NH, exch), 10.97 (s, 1 H, 7-NH, exch). The intermediate 232 was used 
for the next reaction without further characterization. 
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Diethyl (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-
2-fluorobenzoyl)-L-glutamate (233).  
A mixture of the crude acid 232 (90 mg, 0.3 mmol, 1 eq), N-methylmorpholine (33.07 mg, 
0.33 mmol, 1.2 eq) and 2-chloro-4,6-dimethoxy-1,3,5 triazine (57.40 mg, 0.33 mmol, 1.2 
eq) in anhydrous DMF (5 mL) was stirred at room temperature for 2 h. N-
methylmorpholine (33.07 mg, 0.33 mmol, 1.2 eq) and L-glutamate diethyl ester 
hydrochloride (83.06 mg, 0.4 mmol, 1.5 eq) were then added to the mixture and stirred for 
an additional 4 h at room temperature until disappearance of starting material and formation 
of a new non-polar major spot (CHCl3/MeOH). The residue obtained after evaporation of 
the solvent under reduced pressure was dissolved in MeOH followed by addition of silica 
gel. The solution was evaporated to from a silica plug and chromatographed on a silica gel 
column and eluted with CHCl3 followed by gradual increase of polarity to 5% MeOH in 
CHCl3. Fractions that showed the desired Rf were pooled and the solvent was evaporated 
to dryness under reduced pressure to afford the intermediate glutamate esters 233 (70 mg, 
50%) as an orange sticky solid. TLC Rf = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, 
DMSO-d6):  1.15-1.20 (m, 8H, COOCH2CH3, CH2), 1.91-2.13 (m, 2 H, β-CH2), 2.40-2.44 
(m, 2 H, γ-CH2), 3.54-3.56 (t, J = 4.28, 4.28 Hz, 2 H, CH2), 4.02-4.12 (m, 4 H, 
COOCH2CH3), 4.38-4.43 (m, 1 H, α-CH), 5.69 (s, 1 H, C5-CH), 6.3 (s, 2 H, 2-NH2, exch), 
7.13-7.17 (m, 2 H, Ar), 7.46-7.50 (t, J = 7.75, 7.75 Hz, 1 H, Ar), 8.59-8.61 (d, J = 6.97 Hz, 
1 H, CONH, exch), 10.75 (s, 1H, 7-NH, exch). The intermediate 233 was used for the next 
reaction without further characterization. 
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(4-(3-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-2-
fluorobenzoyl)-L-glutamic acid (181).  
Compound 181 was prepared using the general method described for the preparation of 
179-180 (70 mg, 0.15 mmol) to give 55 mg (88%) of 9 as a light yellow powder. mp 139.4 
°C dec. 1H NMR (500 MHz, DMSO-d6): δ 1.87-2.11 (m, 4 H, CH2, β-CH2), 2.33-2.37 (dt, 
J = 2.92, 7.89, 8.12 Hz, 2 H, γ-CH2), 2.64-2.67 (t, J = 7.53, 7.53 Hz, 2 H, Ar-CH2), 4.37-
4.41 (m, 1 H, α-CH), 5.89-5.90 (d, J = 2.11 Hz, 1 H, C5-CH), 6.01 (s, 2 H, 2-NH2, exch), 
7.13-7.17 (m, 2 H, Ar), 7.53-7.56 (t, J = 7.80, 7.80 Hz, 1 H, Ar), 8.44-8.46 (dd, J = 2.12, 
7.64 Hz, 1 H, CONH, exch), 10.17 (s, 1 H, 3-NH, exch), 10.86 (s, 1 H, 7-NH, exch). Anal. 
Calcd for C21H22FN5O6 ꞏ 1.11 H2O: C, 52.60; H, 5.09; N, 14.60; F, 3.96. Found: C, 52.58; 
H, 5.02; N, 14.68; F, 3.88.  
Ethyl 3-fluoro-5-(4-hydroxybut-1-yn-1-yl)picolinate (240).  
To a solution of 3-butynol 222 (243 mg, 3.47 mmol, 1 eq) and ethyl 5-bromo-3-
fluoropicolinate 239 (895 mg, 3.61 mmol, 1.04 eq) in anhydrous acetonitrile (10 mL) was 
added palladium chloride (24.6 mg, 0.14 mmol, 0.04 eq), triphenylphosphine (36.4 mg, 
0.14 mmol, 0.04 eq), copper iodide (106 mg, 0.55 mmol, 0.16 eq), and triethylamine (5 
mL, 35 mmol, 10 eq). The reaction mixture was heated to 100 °C and run for 30 min under 
microwave heating until the starting material disappeared and a new polar spot was 
observed under TLC (hexane/EtOAc). A silica plug was prepared by adding silica gel and 
methanol followed by evaporation of the solvent in vacuo, which was then loaded on to a 
silica gel column and eluted with hexane followed by 50% EtOAc in hexane. The desired 
fractions (TLC) were pooled and evaporated to afford 240 (511 mg, 62%) as a yellow 
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syrup. TLC Rf = 0.25 (hexane/EtOAc, 3:1); 1H NMR (400 MHz, CDCl3): δ 1.3-1.34 (t, J 
= 7.14, 7.14 Hz, 3 H, COOCH2CH3), 2.63-2.66 (t, J = 6.30, 6.30 Hz, 2 H, CH2), 3.6-3.63 
(m, 2 H, CH2), 4.34-438 (q, J = 7.15, 7.15, 7.14 Hz, 2 H, COOCH2CH3), 4.98 (s, br, 1 H, 
OH), 7.98-8.01 (dd, J = 1.48, 10.59 Hz, 1 H, Ar) 8.55 (s, 1 H, Ar). The intermediate 240 
was used for the next reaction without further characterization. 
Ethyl 3-fluoro-5-(4-hydroxybutyl)picolinate (241).  
To 10% palladium on activated carbon (250 mg, 0.5 wt eq) in a Parr flask, ethanol (5 mL) 
was added to quench. Methanolic solution of alcohols 240 (511 mg, 2.15 mmol) was added 
and hydrogenation was carried out at 55 psi of H2 for 6 h until the disappearance of starting 
material and formation of a slightly non-polar spot in TLC. The reaction mixture was 
filtered through celite, washed with MeOH, passed through a short silica gel column (3 cm 
× 5 cm) and concentrated under reduced pressure to give 241 (500 mg, 96%) as a yellow 
syrup. TLC Rf = 0.27 (hexane/EtOAc, 3:1); 1H NMR (400 MHz, DMSO-d6): δ 1.3-1.34 (t, 
J = 7.11, 7.11 Hz, 3 H, COOCH2CH3), 1.38-1.47 (td, J = 6.45, 6.45, 13.24 Hz, 2 H, CH2), 
1.6-1.68 (td, J = 7.64, 7.64, 15.37 Hz, 2 H, CH2), 2.7-2.73 (m, 2 H, Ar-CH2), 3.39-3.43 (m, 
2 H, OH-CH2), 4.3-4.37 (q, J = 7.09, 7.09, 7.11 Hz, 2 H, COOCH2CH3), 4.4-4.43 (t, J = 
5.19, 5.19 Hz, 1 H, OH, exch), 7.77-7.8 (dd, J = 1.28, 11.70 Hz, 1 H, Ar), 8.41-8.44 (s, 1 
H, Ar). The intermediate 240 was used for the next reaction without further 
characterization. 
4-(6-(ethoxycarbonyl)-5-fluoropyridin-3-yl)butanoic acid (242).  
To acetonitrile (6 mL), periodic acid (1.25 g, 5.5 mmol, 2.65 eq) was added and stirred for 
15 min. To this solution at 0 °C (in an ice–water bath), compound 241 (500 mg, 2.07 mmol, 
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1 eq) was added followed by the addition of PCC (11.2 mg, 0.06 mmol, 0.03 eq). The 
mixture was then stirred for 6 h until no starting material and a non-polar spot was detected 
on TLC (hexane/EtOAc). The solvent was evaporated in vacuo to a residue which was 
dissolved in EtOAc, washed successively with brine–water, satd. Aq. NaHSO3 solution, 
and brine, dried over anhydrous Na2SO4, and concentrated to give 242 (425 mg, 80%) as a 
yellow syrup. TLC Rf = 0.6 (hexane/EtOAc 1:1); 1H NMR (400 MHz, CDCl3): δ 1.31-1.33 
(t, J = 7.09, 7.09 Hz, 3 H, COOCH2CH3), 1.83-1.89 (m, 2 H, CH2), 2.24-2.27 (t, J = 7.37, 
7.37 Hz, 2 H, CH2), 2.71-2.75 (t, J=7.68, 7.68 Hz, 2 H, CH2), 4.33-4.38 (q, J=7.07, 7.07, 
7.08 Hz, 2 H, COOCH2CH3), 7.78-7.8 (dd, J=1.14, 11.61 Hz, 1 H, Ar), 8.41 (s, 1 H, Ar), 
12.09 (s, br, 1 H, COOH, exch). The intermediate 240 was used for the next reaction 
without further characterization. 
Ethyl 5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3-
fluoropicolinate (246).  
To the solution of acid 242 (426 mg, 1.67 mmol, 1 eq) in anhydrous CH2Cl2 (5 mL) was 
added oxalyl chloride (1.43 mL, 16.7 mmol, 10 eq) and stirred at reflux for 1 h to the acid 
chloride 243. After cooling to room temperature, the solvent was evaporated under reduced 
pressure and without further characterization, the residue was dissolved in Et2O. This was 
added in a dropwise manner to an ice-cooled (ice-bath) diazomethane solution (generated 
in situ from diazald (5 eq) by using Aldrich Mini Diazald apparatus). The resulting mixture 
was allowed to stand for 30 min after which it was stirred for 1 h to afford the unstable α-
diazoketone 244. Subsequently, 48% HBr (5 mL, 20 eq) in water was added to this solution, 
and stirred at reflux temperature for 1.5 h. The solution was then brought down to room 
temperature and the organic layer was separated. The aqueous layer was extracted twice 
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with Et2O (10 mL) and combined with the organic layer. Furthermore, the pH of the aqeous 
layer was carefully neutralized using 10% Na2CO3 and extracted with Et2O (2X10 mL). 
The organic layers were combined and were washed twice with 10% Na2CO3 (10 mL) 
solution and dried over Na2SO4. Solvent was evaporated under reduced pressure to afford 
the α-bromoketone 245 as an orange syrup. Without further characterization, the residue 
was dissolved in anhydrous DMF (5 mL) to which 2,6-diamino-3H-pyrimidin-4-one 22 
(211 mg, 1.67 mmol, 1 eq), was added. The resulting mixture was stirred at room 
temperature for 72 h under N2 until a new non-polar spot was observed under TLC 
(CHCl3/MeOH), after which the solvent was evaporated to afford a sticky crude solid. 
MeOH was added to it followed by silica gel and the solvent was evaporated. The resulting 
plug was loaded on to a silica gel column and eluted with 10% MeOH in CHCl3. Fractions 
with desired Rf were pooled and evaporated to afford the crude pteroic ester 246 (180 mg, 
30%) as a orange-brown sticky solid. TLC Rf = 0.4 (CHCl3/MeOH 5:1); 1H NMR (400 
MHz, DMSO-d6): δ 1.3-1.34 (t, J = 7.10, 7.10 Hz, 3 H, COOCH2CH3), 1.91-1.99 (td, J = 
7.53, 7.53, 14.92 Hz, 2 H, CH2), 2.72-2.76 (m, 2 H, Ar-CH2), 4.32.4.38 (q, J = 7.10, 7.10, 
7.08 Hz, 2 H, COOCH2CH3), 5.99-6.01 (d, J = 1.70 Hz, 1 H, C5-CH), 6.59 (s, br, 2 H, 2-
NH2, exch), 7.79-7.82 (d, J = 11.73 Hz, 1 H, Ar), 8.41 (s, 1 H, Ar), 10.67 (s, br, 1 H, 3-
NH, exch), 11.1 (s, br, 1 H, 7-NH, exch). The intermediate 246 was used for the next 
reaction without further characterization. 
5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3-
fluoropicolinic acid (247).  
Saturated methanolic solutions of the crude ester 246 (150 mg, 0.42 mmol) was dissolved 
in 1 N NaOH (3 mL) was added and stirred under N2 for 12 h. Upon consumption of the 
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starting materials and one major polar spot (CHCl3/MeOH) on a TLC was obtained, the 
pH adjusted to 3–4 with dropwise addition of 1 N HCl to form a precipitate. The resulting 
suspensions were cooled in the refrigerator overnight and filtered, washed with cold water 
and dried under reduced pressure using P2O5 to afford the crude acid 247 (110 mg, 80%) 
as a yellow powder. TLC Rf  = 0.3 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6):  
1.93-1.98 (m, 2 H, CH2), 2.70-2.74 (m, 2 H, Ar-CH2), 5.91-5.913 (d, J=1.21 Hz, 1 H, C5-
CH), 6.08 (s, 2 H, 2-NH2, exch), 7.75-7.78 (d, J=11.61 Hz, 1 H, Ar), 8.39 (s, 1 H, Ar), 
10.23 (s, 1 H, 3-NH, exch), 10.84 (s, 1 H, 7-NH, exch). The intermediate 247 was used for 
the next reaction without further characterization. 
Diethyl (5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-
3-fluoropicolinoyl)-L-glutamate (248).  
A mixture of the crude acid 247 (95 mg, 0.29 mmol, 1 eq), N-methylmorpholine (0.04 mL, 
0.34 mmol, 1.2 eq) and 2-chloro-4,6-dimethoxy-1,3,5 triazine (60.40 mg, 0.34 mmol, 1.2 
eq) in anhydrous DMF (5 mL) was stirred at room temperature for 2 h. N-
methylmorpholine (0.04 mL, 0.34 mmol, 1.2 eq) and L-glutamate diethyl ester 
hydrochloride (87.4 mg, 0.43 mmol, 1.5 eq) were then added to the mixture and stirred for 
an additional 4 h at room temperature until disappearance of starting material and formation 
of a new non-polar major spot on TLC (CHCl3/MeOH). The residue obtained after 
evaporation of the solvent under reduced pressure was dissolved in MeOH followed by 
addition of silica gel. The solution was evaporated to from a silica plug and 
chromatographed on a silica gel column with CHCl3 as the eluent and gradual increase in 
polarity to 5% MeOH in CHCl3 as the eluent. Fractions that showed the desired Rf were 
pooled and the solvent was evaporated to dryness under reduced pressure to afford the 
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intermediate glutamate esters 248 (80 mg, 54%) as an orange sticky solid. TLC Rf  =  0.5 
(CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6):  1.14-1.24 (m, 6 H, COOCH2CH3), 
1.93-2.18 (m, 4 H, CH2, β-CH2), 2.38-2.42 (m, 2 H, γ-CH2), 2.72-2.75 (m, 2 H, Ar-CH2), 
4.01-4.06 (dd, J=7.00, 14.10 Hz, 2 H, COOCH2CH3), 4.1-4.16 (m, 2 H, COOCH2CH3), 
4.45-4.52 (m, 1 H, α-CH), 5.91-5.92 (d, J=1.47 Hz, 1 H, C5-CH), 5.98 (s, 2 H, 2-NH2, 
exch), 7.75-7.78 (dd, J = 0.76, 12.20 Hz, 1 H, Ar), 8.38 (s, 1 H, Ar), 8.89-8.91 (d, J = 7.92 
Hz, 2 H, CONH, exch), 10.15 (s, 1 H, 3-NH, exch), 10.83 (s, 1 H, 7-NH, exch). The 
intermediate 248 was used for the next reaction without further characterization. 
(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3-
fluoropicolinoyl)-L-glutamic acid (182).   
Compound 182 was prepared using the general method described for the preparation of 
179-180 (80 mg, 0.15 mmol) to give 182 (50 mg, 70%) as a light yellow powder. mp 161.9 
°C. 1H NMR (400 MHz , DMSO-d6): δ 1.91-2.17 (m, 4 H, CH2,  α-CH2), 2.3-2.33 (t, 
J=7.33, 7.33 Hz, 2 H, β-CH2), 2.71-2.75 (t, J=7.33, 7.33 Hz, 2 H, Ar-CH2), 4.44-4.49 (m, 
1 H, α-CH), 5.92 (s, 1 H, C5-CH), 5.97 (s, 2 H, 2-NH2, exch), 7.75-7.78 (d, J=11.88 Hz, 1 
H, Ar), 8.37 (s, 1 H, Ar), 8.76-8.78 (d, J=8.20 Hz, 1 H, CONH, exch), 10.13 (s, 1 H, 3-
NH, exch), 10.83 (s, 1 H, 7-NH, exch). Anal. Calcd for C20H21FN6O6 ꞏ 1.08 H2O: C, 50.05; 
H, 4.86; N, 17.5; F, 3.95. Found: C, 50.15; H, 5.17; N, 17.37; F, 3.81.   
Diethyl (5-bromo-3-fluoropicolinoyl)-L-glutamate (250).  
Compound 250 was prepared using the general method described for the preparation of 
210-211, from 5-bromo-3-fluoropicolinic acid 249 (2 g, 9 mmol), to give 250 (2.7 g, 73%) 
of as a yellow syrup. TLC Rf = 0.45 (hexane/EtOAc, 1:1). 1H NMR (400 MHz, CDCl3): δ 
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1.26-1.29 (t, J = 7.14, 7.14 Hz, 3 H, γ-COOCH2CH3) 1.31-1.35 (t, J = 7.13, 7.13 Hz, 3 H, 
α-COOCH2CH3), 2.08-2.57 (m, 4 H, β -CH2 and γ-CH2), 4.13-4.18 (q, J = 7.15, 7.15, 7.14 
Hz, 2 H, COOCH2CH3) 4.24-4.29 (q, J = 7.14, 7.14, 7.13 Hz, 2 H, COOCH2CH3), 4.80-
4.86 (dt, J = 4.95, 7.70, 7.63 Hz, 1 H, α-CH), 6.78-6.80 (d, J = 7.52 Hz, 1 H, CONH, exch), 
7.18-7.2 (m, 2 H, Ar). The intermediate 250 was used for the next reaction without further 
characterization. 
Diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-
1-yl)-3-fluoropicolinoyl)-L-glutamate (251).  
Compound 251 was prepared using the general method described for the preparation of 
212-213, from 162 (100 mg, 0.5 mmol) and diethyl (5-bromo-3-fluoropicolinoyl)-L-
glutamate, 250 (300 mg, 0.74 mmol) to give 251 (116.6 mg, 45%) as a brown sticky solid; 
TLC Rf  = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6):  1.14-1.21 (m, 6 H, 
COOCH2CH3), 1.95-2.18 (m, 2 H, β-CH2), 2.38-2.42 (t, J = 8.07, 8.07 Hz,  2 H, γ-CH2), 
4.01-4.06 (q, J = 7.11, 7.11, 7.10 Hz, 2 H, γ-COOCH2CH3),  4.09-4.16 (dq, J = 1.80, 7.02, 
6.93, 6.93 Hz, 2 H, α-COOCH2CH3), 4.44-4.49 (m, 1 H, α-CH), 6.01-6.04 (m, 3 H, C5-
CH, 2-NH2, exch), 7.92-7.96 (dd, J = 1.53, 11.24 Hz, 1 H, Ar), 8.47 (s, 1 H, Ar), 8.98-9.00 
(d, J = 7.89 Hz, 1 H, CONH, exch), 10.18 (s, 1 H, 3-NH, exch), 10.91-10.92 (d, J = 1.71 
Hz, 1H, 7-NH, exch). The intermediate 251 was used for the next reaction without further 
characterization. 
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Diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3-
fluoropicolinoyl)-L-glutamate (252).  
Compound 252 was prepared using the general method described for the preparation of 
214-215, from 251 (116 mg, 0.13 mmol) to give 252 (91 mg, 78%) as a light yellow sticky 
solid. TLC Rf  = 0.51 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.11-1.25 
(m, 6 H, COOCH2CH3), 1.53-1.65 (m, 4 H, CH2CH2), 1.99-2.17 (m, 2 H, β-CH2), 2.38-
2.42 (m, 2 H, γ-CH2), 2.65-2.75 (m, 2 H, Ar-CH2), 3.96-4.16 (m, 4 H,  COOCH2CH3), 
4.40-4.54 (m, 1 H, α-CH), 5.84-5.88 (m, 1 H, C5-CH), 6.08 (s, 2 H, 2-NH2, exch), 7.71-
7.8 (d, J=10.98 Hz, 1 H, Ar), 8.38 (s, 1 H, Ar), 8.84-8.98 (m, 1 H, CONH, exch), 10.79 (s, 
1 H, 7-NH, exch). The intermediate 252 was used for the next reaction without further 
characterization. 
(5-(4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3-
fluoropicolinoyl)-L-glutamic acid (183).  
Compound 183 was prepared using the general method described for the preparation of 
179-180, from 252 (91 mg, 0.17 mmol) to give 183 (70 mg, 86%) as a brown powder. 1H 
NMR (400 MHz, DMSO-d6): δ 1.56-1.69 (m, 4 H, CH2CH2), 1.96-2.34 (m, 4 H, β-CH2, γ-
CH2), 2.70-2.73 (m, 2 H, Ar-CH2), 4.31-4.37 (m, 1 H, α-CH), 5.87-5.88 (d, J = 2.12 Hz, 1 
H, C5-CH), 5.98 (s, 2 H, 2-NH2, exch), 7.71-7.75 (dd, J=1.37, 11.85 Hz, 1 H, Ar), 8.37 (s, 
1 H), 8.68-8.70 (d, J = 7.81 Hz, 1 H, CONH, exch), 10.15 (s, 1 H, 3-NH, exch), 10.81 (s, 
1 H, 7-NH, exch). Anal. Calcd for C21H23FN6O6 ꞏ 2.02 H2O ꞏ 0.21 NaCl: C, 48.21; H, 5.21; 
N, 16.06; F, 3.63, Cl, 1.40. Found:  C, 48.12; H, 5.21; N, 16.37; F, 3.50, Cl, 1.14. mp 200.6 
°C dec. 
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Methyl 3-fluoro-4-(4-hydroxybut-1-yn-1-yl)thiophene-2-carboxylate (254).  
To a solution of 3-butynol 222 (0.5 g, 7.13 mmol) and ethyl 4-bromo-3-fluorothiophene-
2-carboxylate 253 (1.9 g, 7.42 mmol) in anhydrous acetonitrile (10 mL) was added 
palladium chloride (51 mg, 0.28 mmol, 0.04 eq), triphenylphosphine (75 mg, 0.28 mmol, 
0.04 eq), copper iodide (218 mg, 1.14 mmol, 0.16 eq), and triethylamine (10 mL, 71.3 
mmol, 10 eq). The reaction mixture was heated to 100 °C and run for 30 min under 
microwave heating until the starting material disappeared and a new polar spot was 
detected on TLC (hexane/EtOAc). A silica plug was prepared by adding silica gel and 
methanol followed by evaporation of the solvent in vacuo. The plug was then loaded on to 
a silica gel column and eluted with hexane followed by gradual increase to 50% EtOAc in 
hexane. The fractions with desired Rf were pooled and evaporated to afford 254 (1.1 g, 
64%) as a yellow syrup. TLC Rf = 0.25 (hexane/EtOAc, 1:1); 1H NMR (400 MHz, CDCl3): 
δ 2.70-2.73 (t, J = 6.23, 6.23 Hz, 2 H, CH2), 3.83−3.86 (t, J = 6.23, 6.23 Hz, 2 H, CH2), 
3.81 (s, 3 H, COOCH3), 7.46-7.47 (d, J = 4.15 Hz, 1 H, Ar). The intermediate 254 was 
used for the next reaction without further characterization. 
Methyl 3-fluoro-4-(4-hydroxybutyl)thiophene-2-carboxylate (255).  
To 10% palladium on activated carbon (500 mg, 0.5 wt eq) in a Parr flask, ethanol (10 mL) 
was added to quench. Methanolic solution of alcohol 254 (1.4 g, 5.78 mmol) was added 
and hydrogenation was carried out at 55 psi of H2 for 12 h until the disappearance of 
starting material and formation of a slightly non-polar spot on TLC (hexane/EtOAc). The 
reaction mixture was filtered through celite, washed with MeOH, passed through a short 
silica gel column (3 cm × 5 cm) and concentrated under reduced pressure to give 255 (1.1 
g, 98%) as a yellow syrup. TLC Rf = 0.25 (hexane/EtOAc 1:1); 1H NMR (400 MHz, 
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DMSO-d6): δ 1.39-1.46 (td, J = 6.47, 6.47, 13.30 Hz, 2 H, CH2), 1.54-1.62 (td, J = 7.63, 
7.63, 15.45 Hz, 2 H, CH2), 3.8 (s, 3 H, COOCH3), 3.38-3.42 (dd, J = 6.32, 11.63 Hz, 2 H, 
CH2), 4.4-4.43 (t, J=5.15, 5.15 Hz, 1 H, OH, exch), 7.65-7.67 (d, J = 4.80 Hz, 1 H, Ar). 
The intermediate 255 was used for the next reaction without further characterization. 
4-(4-Fluoro-5-(methoxycarbonyl)thiophen-3-yl)butanoic acid (256).  
To acetonitrile (20 mL), periodic acid (3 g, 13.3 mmol, 2.65 eq), was added and stirred for 
15 min. To this solution at 0 °C (in an ice–water bath), compound 255 (1.4 g, 6 mmol, 1 
eq) was added followed by the addition of PCC (26 mg, 0.12 mmol, 0.02 eq). The mixture 
was then stirred for 6 h until no starting material was detected and a new non-polar spot 
was detected on TLC (hexane/EtOAc). The solvent was evaporated in vacuo to a residue 
which was dissolved in EtOAc, washed successively with brine–water, satd. Aq. NaHSO3 
solution, and brine, dried over anhydrous Na2SO4, and concentrated to give 256 (1.2 g, 
79%) as a yellow syrup. TLC Rf = 0.65 (hexane/EtOAc 1:1). 1H NMR (400 MHz, CDCl3): 
δ 1.94-2.01 (td, J = 7.34, 7.34, 14.47 Hz, 2 H, CH2), 2.41-2.45 (t, J = 7.29, 7.29 Hz, 2 H), 
2.62-2.66 (t, 2 H, CH2), 3.91 (s, 3 H, COOCH3), 7.11-7.17 (d, J = 4.29 Hz, 1 H). The 
intermediate 256 was used for the next reaction without further characterization. 
4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3-
fluorothiophene-2-carboxylate (260).  
To the solution of acid 256 (1.18 g, 4.79 mmol, 1 eq) in anhydrous CH2Cl2 (10 mL) was 
added oxalyl chloride (2.5 mL, 28.75 mmol, 6 eq) and stirred at reflux for 1 h to the acid 
chloride 257. After cooling to room temperature, the solvent was evaporated under reduced 
pressure and without further characterization the residue was dissolved in Et2O. This was 
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added in a dropwise manner to an ice-cooled (ice-bath) diazomethane solution (generated 
in situ from diazald (5 eq) by using Aldrich Mini Diazald apparatus). The resulting mixture 
was allowed to stand for 30 min after which it was stirred for 1 h to afford the unstable α-
diazoketone 258. Subsequently, 48% HBr (10 mL, 20 eq) in water was added to this 
solution, and stirred at reflux temperature for 1.5 h. The solution was then brought down 
to room temperature and the organic layer was separated. The aqueous layer was extracted 
twice with Et2O and combined with the organic layer. The Et2O extract was washed twice 
with 10% Na2CO3 solution and dried over Na2SO4. Solvent was evaporated under reduced 
pressure to afford the α-bromoketone 259 as an orange syrup. Without further 
characterization, the residue was dissolved in anhydrous DMF (5 mL) to which 2,6-
diamino-3H-pyrimidin-4-one 22 (604 mg, 4.79 mmol, 1 eq), was added. The resulting 
mixture was stirred at room temperature for 72 h under N2, until a new non-polar spot was 
observed under TLC (CHCl3/MeOH) The solvent was evaporated to afford a sticky crude 
solid to which MeOH was added followed by silica gel and subsequently evaporated. The 
resulting plug was loaded on to a silica gel column and eluted with 10% MeOH in CHCl3. 
The collected fractions were pooled and evaporated to afford a pink sticky solid (TLC Rf  
= 0.4; CHCl3/MeOH 5:1) which was without further characterization, dissolved in minimal 
amount of methanol and 1 N NaOH (3 mL) and stirred for 12 h. Upon completion of base-
catalyzed hydrolysis and consumption of the starting materials and appearance of one 
major polar spot on a TLC was obtained (CHCl3/MeOH), the pH adjusted to 3–4 with 
dropwise addition of 1 N HCl to form a precipitate. The resulting suspensions were cooled 
in the refrigerator overnight and filtered, washed with cold water and dried under reduced 
pressure using P2O5 to afford the crude acid 260 (100 mg, 7%) as a buff colored powder. 
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TLC Rf  = 0.3 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6):  1.81-1.89 (td, J = 
7.50, 7.50, 15.20 Hz, 2 H, CH2), 2.46-2.5 (m, 2 H, Ar-CH2), 5.89-5.90 (d, J = 2.10 Hz, 1 
H, C5-CH), 6.08 (s, 1 H, 2-NH2, exch), 7.40-7.41 (m, 1 H, Ar), 10.26 (s, 1 H, 3-NH, exch), 
10.85 (s, 1 H,  7-NH, exch). The intermediate 260 was taken forward without further 
characterization. 
Diethyl (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-
3-fluorothiophene-2-carbonyl)-L-glutamate (261).  
A mixture of the crude acid 260 (70 mg, 0.2 mmol, 1 eq), N-methylmorpholine (0.02 mL, 
0.25 mmol, 1.2 eq) and 2-chloro-4,6-dimethoxy-1,3,5 triazine (44 mg, 0.25 mmol, 1.2 eq) 
in anhydrous DMF (5 mL) was stirred at room temperature for 2 h. N-methylmorpholine 
(0.02 mL, 0.25 mmol, 1.2 eq) and L-glutamate diethyl ester hydrochloride (63 mg, 0.3 
mmol, 1.5 eq) were then added to the mixture and stirred for an additional 4 h at room 
temperature until disappearance of starting material and formation of a new non-polar 
major spot (CHCl3/MeOH). The residue obtained after evaporation of the solvent under 
reduced pressure was dissolved in MeOH followed by addition of silica gel. The solution 
was evaporated to from a silica plug and chromatographed on a silica gel column and eluted 
initially with CHCl3 followed by gradual increase to 10% MeOH in CHCl3. Fractions with 
the desired Rf were pooled and the solvent was evaporated to dryness under reduced 
pressure to afford the intermediate glutamate esters 261 (30 mg, 28%) as an orange sticky 
solid. TLC Rf  = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6):  1.11-1.21 (m, 
6H, COOCH2CH3), 1.86-1.91 (m, 2 H, CH2) 1.96-2.17 (m, 2 H, β-CH2), 2.38-2.42 (t, J = 
7.65 Hz, 2H, γ-CH2), 4.01-4.14 (m, 4H, COOCH2CH3), 4.38-4.44 (m, 1H, α-CH), 5.91-
5.92 (d, J = 2.07 Hz, 1 H, C5-CH), 5.99 (s, 1 H, 2-NH2, exch), 7.55-7.56 (d, J = 4.65 Hz, 
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1 H, Ar), 8.15-8.17 (dd, J = 2.98, 7.38 Hz, 1 H, CONH, exch), 10.16 (s, 1 H, 3-NH, exch), 
10.86 (s, 1 H, 7-NH, exch). The intermediate 261 was used for the next reaction without 
further characterization.  
(4-(3-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3-
fluorothiophene-2-carbonyl)-L-glutamic acid (184).  
Compound 184 was prepared using the general method described for the preparation of 
179-180 from 261 (30 mg, 0.15 mmol) to give 184 (20 mg, 75%) as a yellow powder. mp 
207.8 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.84-2.14 ( m, 4 H, CH2, β-CH2), 2.30-
2.34 (t, J = 7.37, 7.37 Hz, 2 H, γ-CH2), 2.52-2.55 (m, 2 H, Ar-CH2), 4.35-4.41 (m, 1 H, α-
CH), 5.91-5.92 (d, J = 1.69 Hz, 1 H, C5-CH), 5.99 (s, 2 H, 2-NH2, exch), 7.55-7.56 (d, J 
= 4.53 Hz, 1 H, Ar), 7.98-8.01 (dd, J = 3.47, 7.42 Hz, 1 H, CONH, exch), 10.15 (s, 1 H, 
3-NH, exch), 10.86 (s, 1 H, 7-NH, exch). Anal. Calcd for C19H20FN5O6S ꞏ 1.15 H2O: C, 
46.93; H, 4.62; N, 14.40; F, 3.90; S, 6.59. Found: C, 46.99; H, 4.68; N, 14.33; F, 3.85; S, 
6.41.   
Diethyl (4-bromo-3-fluorothiophene-2-carbonyl)-L-glutamate (263).  
Compound 263 was prepared using the general method described for the preparation of 
210-211, from 4-bromo-3-fluorothiophene-2-carboxylic acid, 262 (1.75 g, 7.8 mmol) to 
afford 263 (2 g, 63%) as a colorless syrup. TLC Rf = 0.44 (hexane/EtOAc, 1:1); 1H NMR 
(400 MHz, DMSO-d6): δ 1.15-1.21 (m,  6H, COOCH2CH3), 1.95-2.16 (m, 2 H, β-CH2), 
2.38-2.42 (m, 2 H, γ-CH2), 4.02-4.14 (m, 4 H, COOCH2CH3), 4.34-4.43 (m, 1 H, α-CH), 
7.45 (s, 1 H, Ar), 8.26-8.29 (dd, J = 2.22, 7.49 Hz, 1 H, CONH, exch). The intermediate 
263 was used for the next reaction without further characterization. 
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Diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-
1-yl)-2-fluorothiophene-3-carbonyl)-L-glutamate (264).  
Compound 264 was prepared using the general method described for the preparation of 
212-213, from 162 (60 mg, 0.3 mmol) and 263 (180 mg, 0.44 mmol) to give 264 (92 mg, 
59%) as a brown sticky solid; TLC Rf = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, 
DMSO-d6):  1.15-1.24 (m, 6 H, COOCH2CH3), 1.96-2.15 (m, 2 H, β-CH2), 2.39-2.42 (t, 
J = 8.0 Hz, 2 H, γ-CH2), 2.72-2.77 (m, 2 H, Ar-CH2), 4.01-4.14 (m, 4 H, COOCH2CH3), 
4.37-4.43 (m, 1 H, α-CH), 6-6.02 (m, 3 H, C5-CH, 2-NH2, exch), 7.94-7.95 (d, J = 4.13 
Hz, 1 H, Ar), 8.35-8.36 (dd, J = 0.66, 7.87 Hz, 1 H, CONH, exch), 10.17 (s, 1 H, 3-NH, 
exch), 10.88 (s, 1H, 7-NH, exch). The intermediate 264 was used for the next reaction 
without further characterization. 
Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3-
fluorothiophene-2-carbonyl)-L-glutamate (265).  
Compound 265 was prepared using the general method described for the preparation of 
214-215, from 264 (92 mg, 0.17 mmol) to give 265 (70 mg, 75%) as a brown sticky solid; 
TLC Rf  = 0.55 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6):  1.13-1.24 (m, 6 H, 
COOCH2CH3), 1.54-1.65 (m, 4 H, CH2CH2), 1.96-2.17 (m, 2 H, β-CH2), 2.37-2.43 (t, J = 
7.36, J = 7.36 Hz, 2 H, γ-CH2), 3.15-3.17 (m, 2 H, Ar-CH2), 4-4.16 (m, 4 H, COOCH2CH3) 
4.38-4.46 (m, 1 H, α-CH), 5.87-5.9 (m, 1 H, C5-CH), 5.97 (s, 1H, 2-NH2, exch), 7.5-7.55 
(m, 1 H, Ar), 8.13-8.24 (m, 1 H, CONH, exch), 10.16 (s, 1 H, 3-NH, exch), 10.84 (s, 1 H, 
7-NH, exch). The intermediate 265 was used for the next reaction without further 
characterization. 
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(5-(4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
fluorothiophene-3-carbonyl)-L-glutamic acid (185).  
Compound 185 was prepared using the general method described for the preparation of 
179-180, from 265 (70 mg, 0.13 mmol) to give 185 (60 mg, 96%) as a yellow powder. mp 
162 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.59-1.6 (m, 4 H, CH2CH2), 1.91-2.16 (m, 
2 H, β-CH2), 2.30-2.34 (t, J = 7.36, J = 7.36 Hz, 2 H, γ-CH2), 4.35-4.44 (m, 1 H, α-CH), 
5.86-5.87 (d, J = 1.80 Hz, 1 H, C5-CH), 5.97 (s, 1H, 2-NH2, exch), 7.51-7.52 (d, J = 4.85 
Hz, 1 H, Ar), 7.97-8.0 (dd, J = 2.91, 7.88 Hz, 1 H, CONH, exch), 10.14 (s, 1 H, 3-NH, 
exch), 10.83 (s, 1 H, 7-NH, exch). Anal. Calcd for C20H22FN5O6S ꞏ 1.26 H2O: C, 47.83; H, 
4.92; N, 13.94; F, 3.78; S, 6.38. Found: C, 47.85; H, 4.83; N, 13.85; F, 3.59; S, 6.46.  
Diethyl (4-bromo-2,6-difluorobenzoyl)-L-glutamate (270).  
Compound 270 was prepared using the general method described for the preparation of 
210-211, from 4-bromo-2,6-difluoro benzoic acid 267 (128 mg, 0.13 mmol), to give 270 
(200 mg, 88%) as a colorless syrup. TLC Rf = 0.5 (hexane/EtOAc 1:1); 1H NMR (400 
MHz, DMSO-d6): δ 1.16-1.23 (m, 6 H, COOCH2CH3) 1.82-2.12 (m, 2 H, β-CH2), 2.4-2.45 
(m, 2 H, γ-CH2), 4.04-4.07 (q, J=7.11, 7.11, 7.10 Hz, 2 H, γ-COOCH2CH3), 4.1-4.16 (dq, 
J=2.36, 7.11, 7.10, 7.10 Hz, 2 H, α-COOCH2CH3), 4.44-4.48 (ddd, J=5.14, 7.72, 9.49 Hz, 
1 H, α-CH), 7.60-7.62 (d, J=6.95 Hz, 2 H, Ar), 9.2-9.21 (d, J=7.62 Hz, 1 H, CONH, exch). 
The intermediate 270 was used for the next reaction without further characterization. 
Diethyl (4-bromo-2,5-difluorobenzoyl)-L-glutamate (271).  
Compound 271 was prepared using the general method described for the preparation of 
210-211 from 4-bromo-2,5-difluoro benzoic acid 268 (1 g, 4.22 mmol) to give 271 (1 g, 
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56%) as a colorless syrup. TLC Rf = 0.5 (hexane/EtOAc 1:1). 1H NMR (400 MHz, CDCl3): 
δ 1.24-1.35 (m, 6 H, COOCH2CH3), 2.13-2.55 (m, 4 H, β-CH2, γ-CH2), 4.11-4.3 (m, 4 H, 
COOCH2CH3), 4.83-4.88 (m, 1 H, α-CH), 7.43 (s, 2 H, Ar), 7.83-7.87 (m, 1 H, CONH, 
exch). The intermediate 271 was used for the next reaction without further characterization. 
Diethyl (4-bromo-2,3-difluorobenzoyl)-L-glutamate (272). 
Compound 272 was prepared using the general method described for the preparation of 
210-211 from from 4-bromo-2,3-difluoro benzoic acid 269 (1 g, 4.22 mmol) to give 272 
(1.2 g, 67%) as a colorless syrup. TLC Rf = 0.45 (hexane/EtOAc 1:1). 1H NMR (400 MHz, 
CDCl3): δ 1.25-1.28 (t, J = 6.85, 6.85 Hz, 3 H, γ-COOCH2CH3), 1.32-1.36 (t, J=7.15, 7.15 
Hz, 3 H, α-COOCH2CH3), 2.12-2.55 (m, 4 H, β-CH2, γ-CH2) 4.12-4.17 (q, J=7.07, 7.07, 
7.07 Hz, 2 H, γ-COOCH2CH3), 4.24-4.3 (q, J=7.00 Hz, 2 H, α-COOCH2CH3), 4.81-4.86 
(m, 1 H, α-CH) 7.32-7.35 (m, CONH, exch) 7.44-7.48 (m, 1 H, Ar), 7.71-7.75 (m, 1 H, 
Ar). The intermediate 272 was used for the next reaction without further characterization. 
Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-
1-yl)-2,6-difluorobenzoyl)-L-glutamate (273).  
Compound 273 was prepared using the general method described for the preparation of 
212-213, from 162 (131 mg, 0.65 mmol) and 270 (412 mg, 0.98 mmol) to give 273 (142 
mg, 40%) as a brown sticky solid. TLC Rf  = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, 
DMSO-d6): δ 1.15-1.23 (m, 6 H, COOCH2CH3), 1.85-1.22 (m, 2 H, β-CH2), 2.32-2.47 (m, 
2 H, γ-CH2), 4.04-4.14 (m, 4 H, COOCH2CH3), 4.45-4.51 (m, 1 H, α-CH), 6.49 (m, 1 H, 
C5-CH), 7.01-7.06 (m, 2 H, Ar), 9.07-9.18-9.23 (d, J=7.11 Hz, 1 H, CONH, exch). The 
intermediate 273 was used for the next reaction without further characterization. 
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Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-
1-yl)-2,5-difluorobenzoyl)-L-glutamate (274).  
Compound 274 was prepared using the general method described for the preparation of 
212-213, from 162 (140 mg, 0.7 mmol) and diethyl (4-bromo-2,5-difluorobenzoyl)-L-
glutamate 271 (443 mg, 1.05 mmol) to give 274 (165 mg, 43%) as a brown sticky solid. 
TLC Rf  = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.14-1.23 (m, 6 H, 
COOCH2CH3), 1.83-2.16 (m, 2 H, β-CH2), 2.4-2.44 (t, J=7.81, 7.81 Hz, 2 H, γ-CH2), 3.61-
3.65 (m, 2 H, Ar-CH2), 4.03-4.19 (m, 4 H, COOCH2CH3), 4.4-4.44 (m, 1 H, α-CH), 6.01-
6.02 (m, 3 H, C5-CH, 2-NH2, exch), 7.44-7.5 (m, 2 H, Ar), 8.83-8.85 (d, J=7.55 Hz, 1 H, 
CONH, exch), 10.17 (s, 1 H, 3-NH, exch), 10.91-10.92 (d, J=1.79 Hz, 1 H, 7-NH, exch). 
The intermediate 274 was used for the next reaction without further characterization. 
Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-
1-yl)-2,3-difluorobenzoyl)-L-glutamate (275).  
Compound 275 was prepared using the general method described for the preparation of 
212-213, from 162 (140 mg, 0.7 mmol) and diethyl (4-bromo-2,3-difluorobenzoyl)-L-
glutamate 272 (443 mg, 1.05 mmol) to give 275 (170 mg, 45%) as a brown sticky solid. 
TLC Rf  = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.16-1.22 (m, 6 H, 
COOCH2CH3), 1.9-2.12 (m, 2 H, β-CH2), 2.42-2.46 (t, J=7.69, 7.69 Hz, 2 H, γ-CH2), 4.03-
4.15 (m, 4 H, COOCH2CH3), 4.38-4.44 (m, 1 H, α-CH), 6.02 (m, 3 H, C5-CH, 2-NH2, 
exch) 7.34-7.35 (d, J = 5.02 Hz, 1 H, Ar), 7.72-7.74 (m, 2 H, Ar), 8.91-8.93 (d, J = 6.98 
Hz, 1 H, CONH, exch) 10.17 (s, 1 H, 3-NH, exch) 10.89-10.895 (d, J=1.51 Hz, 1 H, 7-
NH, exch). The intermediate 275 was used for the next reaction without further 
characterization. 
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Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-
2,6-difluorobenzoyl)-L-glutamate (276).  
Compound 276 was prepared using the general method described for the preparation of 
214-215, from 273 (142 mg, 0.26 mmol) to give 276 (100 mg, 70%) as an orange sticky 
solid. TLC Rf  = 0.51 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.15-1.21 (m, 
6 H, COOCH2CH3), 1.56-1.6 (m, 4 H, CH2CH2), 1.81-2.1 (m, 2 H, β-CH2), 2.40-2.43 (m, 
2 H, γ-CH2), 2.61-2.65 (m, 2 H, CH2), 4.02-4.17 (m, 4 H, COOCH2CH3), 4.37-4.46 (m, 1 
H, α-CH), 5.92-5.925 (d, J=1.76 Hz, 1 H, C5-CH), 7.01-7.06 (m, 2 H, Ar), 9.07-9.09 (d, J 
= 7.66 Hz, 1 H, CONH, exch) 11.03 (s, 1 H, 7-NH, exch). The intermediate 276 was used 
for the next reaction without further characterization. 
Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-
2,5-difluorobenzoyl)-L-glutamate (277).  
Compound 277 was prepared using the general method described for the preparation of 
214-215, from 274 (165 mg, 0.3 mmol) to give 277 (120 mg, 72%) as an orange sticky 
solid. TLC Rf  = 0.51 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.16-1.22 (m, 
6 H, COOCH2CH3), 1.55-1.62 (m, 4 H, CH2CH2), 1.89-2.14 (m, 2 H, β-CH2), 2.41-2.46 (t, 
J=7.51, 2 H, γ-CH2), 2.65-2.68 (m, 2 H, Ar-CH2), 4.03-4.15 (m, 4 H, COOCH2CH3), 4.39-
4.44 (m, 1 H, α-CH), 5.84-5.85 (d, J=2.05 Hz, 1 H, C5-CH), 6.01 (s, 2 H, 2-NH2, exch) 
7.29-7.37 (m, 2 H, Ar), 8.69-8.70 (dd, J=1.05, 7.50 Hz, 1 H, CONH, exch) 10.22 (s, 1 H, 
3-NH, exch) 10.8 (d, J=1.26 Hz, 1 H, 7-NH, exch). The intermediate 277 was used for the 
next reaction without further characterization. 
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Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-
2,3-difluorobenzoyl)-L-glutamate (278).  
Compound 278 was prepared using the general method described for the preparation of 
214-215, from 275 (170 mg, 0.3 mmol) to give 278 (100 mg, 58%) as an orange sticky 
solid. TLC Rf  = 0.51 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.1-1.22 (m, 
6 H, COOCH2CH3), 1.55-1.61 (m, 4 H, CH2CH2), 1.89-2.13 (m, 2 H, β-CH2), 2.39-2.45 
(m, 2 H, γ-CH2), 2.67-2.72 (m, 2 H, CH2), 4.03-4.15 (m, 4 H, COOCH2CH3), 4.37-4.47 
(m, 1 H, α-CH), 5.87-5.88 (d, J=2.05 Hz, 1 H, C5-CH) 6.01 (s, 2 H, 2-NH2, exch), 7.16-
7.21 (m, 1 H, Ar), 7.27-7.32 (m, 1 H, Ar), 8.8-8.83 (m, 1 H, CONH, exch) 10.22 (s, 1 H, 
3-NH, exch) 10.82-10.83 (m, 1 H, 7-NH, exch). The intermediate 278 was used for the 
next reaction without further characterization. 
(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2,6-
difluorobenzoyl)-L-glutamate (186).  
Compound 186 was prepared using the general method described for the preparation of 
179-180, from 276 (100 mg, 0.18 mmol) to give 186 (70 mg, 78%) as a yellow powder. 
mp159.6 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.54-1.62 (m, 4 H, CH2CH2) 1.76-2.1 
(m, 2 H, β-CH2), 2.32-2.36 (m, 2 H, γ-CH2), 2.63-2.65 (m, 2 H, Ar-CH2), 4.36-4.43 (m, 1 
H, α-CH), 5.86 (s, 1 H, C5-CH), 5.97 (s, 2 H, 2-NH2, exch) 7.02-7.04 (d, J=8.54 Hz, 2 H, 
Ar), 8.92-8.95 (d, J=7.99 Hz, 1 H, CONH, exch) 10.14 (s, 1 H, 3-NH, exch), 10.82 (s, 1 
H, 7-NH, exch). Anal. Calcd for C22H23F2N5O6 ꞏ 1.85 H2O: C, 50.34; H, 5.12; N, 13.34; F, 
7.23. Found: C, 50.33; H, 4.83; N, 13.21; F, 7.31.  
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(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2,5-
difluorobenzoyl)-L-glutamate (187).  
Compound 187 was prepared using the general method described for the preparation of 
179-180, from 277 (120 mg, 0.22 mmol) to give 187 (95 mg, 88%) of as an orange powder. 
mp 169.12 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.56-1.61 (m, 4 H, CH2CH2) 1.83-
2.12 (m, 2 H, β-CH2), 2.33-2.37 (t, J=7.61, 7.61 Hz, 2 H, γ-CH2), 2.66-2.68 (t, J=5.53, 5.53 
Hz, 2 H, Ar-CH2), 4.35-4.44 (m, 1 H, α-CH), 5.84-5.85 (d, J=2.13 Hz, 1 H, C5-CH), 5.97 
(s, 2 H, 2-NH2, exch) 7.29-7.37 (m, 2 H, Ar), 8.53-8.56 (dd, J=2.32, 7.67 Hz, 1 H, CONH, 
exch) 10.13 (s, 1 H, 3-NH, exch) 10.81-10.82 (d, J=1.77 Hz, 1 H, 7-NH, exch). Anal. Calcd 
for C22H23N5F2O6 ꞏ 1.11 H2O: C, 51.65; H, 4.97; N, 13.69; F, 7.42. Found: C, 51.77; H, 
4.98; N, 13.38; F, 7.19.  
(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2,3-
difluorobenzoyl)-L-glutamate (188).  
Compound 188 was prepared using the general method described for the preparation of 
179-180, from 278 (100 mg, 0.18 mmol) to give 188 (80 mg, 89%) as a buff powder. mp: 
150.5 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.53-1.64 (m, 4 H, CH2CH2), 1.9-2.12 
(m, 2 H, β-CH2), 2.32-2.38 (t, J=7.25, 7.25 Hz, 2 H, γ-CH2), 2.67-2.73 (t, J=6.41, 6.41 Hz, 
2 H, Ar-CH2), 4.32-4.44 (m, 1 H, α-CH), 5.8-5.88 (s, 1 H, C5-CH) 5.92-6.0 (s, 2 H, 2-NH2, 
exch) 7.13-7.23 (t, J=7.61, 7.61 Hz, 1 H, Ar), 7.26-7.35 (t, J=6.99, 6.99 Hz, 2 H, Ar), 8.56-
8.7 (s, br, 1 H, CONH, exch) 10.18 (s, br, 1 H, 3-NH, exch) 10.83 (s, br, 1 H, 7-NH, exch). 
HPLC analysis: retention time, 8.5 min; peak area, 95.12%; eluent A, H2O; eluent B, ACN; 
gradient elution (95% H2O to 100% ACN) over 10 mins with flow rate of 0.5 mL/min and 
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detection at 254 nm; column temperature, rt. LRMS calculated for C22H23F2N5O6 = 491.16, 
found [M+H]+ 492.1 and [M-H]- 490.2. 
Diethyl (4-bromo-2-methylbenzoyl)-L-glutamate (282).  
Compound 282 was prepared using the general method described for the preparation of 
210-211, from 4-bromo-2-methylbenzoic acid 279 (1.5 g, 7 mmol), to give 282 (2 g, 72%) 
as a colorless syrup. TLC Rf = 0.5 (hexane/EtOAc, 1:1); 1H NMR (400 MHz, DMSO-d6): 
δ 1.25-1.29 (t, J = 7.14, 7.14 Hz, 3 H, γ-COOCH2CH3), 1.32-1.35 (t, J = 7.14, 7.14 Hz, 3 
H, α-COOCH2CH3), 2.07-2.37 (m, 2 H, β-CH2),  2.42-2.57 (m, 5 H, γ-CH2, Ar-CH3), 4.12-
4.17 (q, J=7.10, 7.10, 7.14 Hz, 2 H, γ-COOCH2CH3), 4.24-4.29 (q, J=7.09, 7.09, 7.10 Hz, 
2 H, α-COOCH2CH3), 4.76-4.81(dt, J=5.00, 7.96, 7.94 Hz, 1 H, α-CH), 6.56-6.58 (d, 
J=7.63 Hz, 1 H, CONH, exch), 7.28-7.42 (m, 3 H, Ar). The intermediate 282 was used for 
the next reaction without further characterization. 
Diethyl (5-bromo-2-chlorobenzoyl)-L-glutamate (283).  
Compound 283 was prepared using the general method described for the preparation of 
210-211, from 4-bromo-2-chlorobenzoic acid 280 (1 g, 4.25 mmol), to give 283 (1.4 g, 
78%) as a colorless syrup. TLC Rf = 0.5 (hexane/EtOAc, 1:1); 1H NMR (400 MHz, DMSO-
d6): δ 1.17-1.23 (m, 6 H, COOCH2CH3), 1.85-2.13 (m, 2 H, β-CH2), 2.44-2.48 (m, 2 H, γ-
CH2), 4.03-4.09 (m, 2 H, γ-COOCH2CH3), 4.1-4.19 (m, 2 H, α-COOCH2CH3), 4.4-4.45 
(m, 1 H, α-CH), 7.37-7.39 (d, J=8.18 Hz, 1 H, Ar), 7.65-7.67 (dd, J=1.43, 8.14 Hz, 1 H, 
Ar), 7.83-7.834 (d, J=1.51 Hz, 1 H, Ar), 8.93-8.95 (d, J=7.53 Hz, 1 H, CONH, exch). The 
intermediate 283 was used for the next reaction without further characterization. 
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Diethyl (4-bromo-2-(trifluoromethyl)benzoyl)-L-glutamate (284).  
Compound 284 was prepared using the general method described for the preparation of 
210-211 from 4-bromo-2-(trifluoromethyl)benzoic acid 281 (1 g, 3.72 mmol) to give 284 
(1.50 g, 89%) as a colorless syrup. TLC Rf = 0.25 (H:E, 3:1). 1H NMR (400 MHz, DMSO-
d6):  1.16-1.23 (6 H, COOCH2CH3), 1.84-2.13 (m, 2 H, β-CH2), 2.41-2.45 (t, J=7.81, 7.81 
Hz, 2 H, γ-CH2) 4.04-4.09 (q, J=7.09, 7.09, 7.11 Hz, 2 H, COOCH2CH3), 4.1-4.16 (dq, 
J=1.70, 7.08, 7.03, 7.03 Hz,  2 H, COOCH2CH3), 4.39-4.45 (ddd, J=5.12, 7.70, 9.62 Hz, 
1 H, α-CH), 7.47-7.5 (d, J=8.80 Hz,  1 H, Ar), 8-8.02 (m, 2 H, Ar), 9-9.02 (d, J=7.70 Hz, 
1 H, CONH, exch). The intermediate 284 was used for the next reaction without further 
characterization. 
Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-
1-yl)-2-methylbenzoyl)-L-glutamate (285).  
Compound 285 was prepared using the general method described for the preparation of 
212-213, from 162 (100 mg, 0.5 mmol) and diethyl (4-bromo-2-methylbenzoyl)-L-
glutamate, 282 (300 mg, 0.74 mmol) to give 285 (70 mg, 44%) as a golden-brown sticky 
solid. TLC Rf  = 0.56 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6):  1.17-1.23 (6 
H, COOCH2CH3), 1.84-2.11 (m, 2 H, β-CH2), 2.3 (s, 3 H, Ar-CH3) 2.42-2.46 (m, 2 H, γ-
CH2), 4.03-4.16 (m, 4 H, COOCH2CH3), 4.36-4.45 (m, 1 H, α-CH), 6.02-6.022 (m, 3 H, 
C5-CH, 2-NH2), 7.24-7.35 (m, 3 H, Ar), 8.69-8.7 (d, J = 7.19 Hz, 1 H, CONH, exch), 10.18 
(s, 1 H, 3-NH, exch), 10.9 (s, 1 H, 7-NH, exch). The intermediate 285 was used for the 
next reaction without further characterization. 
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Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-
1-yl)-2-chlorobenzoyl)-L-glutamate (286).  
Compound 286 was prepared using the general method described for the preparation of 
212-213, from 162 (70 mg, 0.35 mmol) and diethyl (4-bromo-2-chlorobenzoyl)-L-
glutamate, 283 (218 mg, 0.52 mmol) to give 286 (55 mg, 30%) as a brown sticky solid. 
TLC Rf  = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6):  1.17-1.24 (6 H, 
COOCH2CH3), 1.86-2.15 (m, 2 H, β-CH2), 2.3 (m, 2 H, γ-CH2) 4.04-4.2 (m, 4 H, 
COOCH2CH3), 4.4-4.46 (m, 1 H, α-CH), 6.02 (s, 1 H, C5-CH), 7.38-7.4 (m, 2 H, Ar), 7.5 
(s, 1 H, Ar), 8.9-8.92 (d, J=7.48 Hz, 1 H, CONH, exch), 10.18 (s, 1 H, 3-NH, exch), 10.9 
(s, 1 H, 7-NH, exch). The intermediate 286 was used for the next reaction without further 
characterization. 
Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-
1-yl)-2-(trifluoromethyl)benzoyl)-L-glutamate (287).  
Compound 287 was prepared using the general method described for the preparation of 
212-213, from 162 (200 mg, 0.99 mmol) and diethyl (4-bromo-2-trifluoromethyl)-L-
glutamate, 284 (674 mg, 1.48 mmol) to give 287 (150 mg, 26%) as a brown sticky solid. 
TLC Rf  = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6):  1.16-1.23 (6 H, 
COOCH2CH3), 1.82-2.12 (m, 2 H, β-CH2), 2.4-2.44 (t, J=7.81, 7.81 Hz, 2 H, γ-CH2) 4.04-
4.19 (m, 4 H, COOCH2CH3), 4.39-4.44 (m, 1 H, α-CH), 6.02 (s, 3 H, C5-CH, 2-NH2, exch), 
7.48-7.5 (d, J=7.66 Hz, 2 H, Ar), 7.72-7.95 (m, 2 H, Ar), 8.9-9.0 (d, J=7.55 Hz, 1 H, 
CONH, exch), 10.2 (s, 1 H, 3-NH, exch), 10.92-10.923 (d, J=1.79 Hz, 7-NH, exch). The 
intermediate 287 was used for the next reaction without further characterization. 
 225 
Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
methylbenzoyl)-L-glutamate (288). 
 Compound 288 was prepared using the general method described for the preparation of 
214-215, from 285 (70 mg, 0.22 mmol) to give 288 (70 mg, quant) as a light yellow sticky 
solid. TLC Rf  = 0.56 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.15-1.23 
(m, 6 H, COOCH2CH3), 1.42-1.5 (m, 2 H, CH2), 1.62-1.7 (m, 2 H, CH2), 1.87-2.13 (m, 2 
H, β-CH2), 2.34 (s, 3 H, Ar-CH3), 2.43-2.47 (m, 2 H, γ-CH2), 4.02-4.17 (m, 4 H, 
COOCH2CH3), 4.37-4.44 (m, 1 H, α-CH), 6.95 (m, 1 H, C5-CH), 7.17-7.36 (m, 3 H, Ar), 
8.64-8.65 (d, J=7.43 Hz, 1 H, CONH, exch). The intermediate 288 was used for the next 
reaction without further characterization. 
Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
benzoyl)-L-glutamate mixtures (289) and (290).  
Using the general method described for the preparation of 214-215, hydrogenation of 286 
(40 mg, 0.07 mmol) gave a mixture of 289 and 290 (30 mg, 74%) as a yellow sticky solid. 
TLC Rf  = 0.52 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.15-1.23 (6 H, 
COOCH2CH3), 1.54-1.65 (m, 4 H, CH2CH2), 1.94-2.16 (m, 2 H, β-CH2), 2.42-2.46 (m, 2 
H, γ-CH2), 2.63-2.66 (m, 2 H, Ar-CH2), 4.02-4.11 (m, 4 H, COOCH2CH3), 4.37-4.47 (m, 
1 H, α-CH), 5.85 (s, 1 H, C5-CH), 6.09 (s, 2 H, 2-NH2, exch), 7.23-7.35 (m, 3 H, Ar), 7.78-
7.8 (m, Ar), 8.65-8.69 (m, CONH, exch), 10.37 (s, 1 H, 3-NH, exch), 10.8 (s, 1 H, 7-NH, 
exch). The intermediate mixture of 289 and 290 were used for the next reaction without 
further characterization. 
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Diethyl (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
(trifluoromethyl)benzoyl)-L-glutamate (291).  
Compound 291 was prepared using the general method described for the preparation of 
214-215, from 287 (120 mg, 0.21 mmol) to give 291 (95 mg, 79%) as a yellow sticky solid. 
TLC Rf  = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.16-1.23 (6 H, 
COOCH2CH3), 1.53-1.65 (m, 4 H, CH2CH2), 1.86-2.12 (m, 2 H, β-CH2), 2.41-2.45 (t, 
J=8.19, 8.19 Hz, 2 H, γ-CH2) 2.71-2.73 (s, 2H, Ar-CH2), 4.04-4.15 (m, 4 H, COOCH2CH3), 
4.37-4.43 (m, 1 H, α-CH), 5.84 (s, 1 H, C5-CH), 6.1 (s, 2 H, 2-NH2, exch), 7.42-7.44 (d, J 
= 7.61 Hz, 1 H, Ar), 7.57-7.61 (m, 2 H, Ar), 8.88-9.0 (d, J = 7.16 Hz, 1 H, CONH, exch), 
10.3 (s, 1 H, 3-NH, exch), 10.82 (s, 1 H, 7-NH, exch). The intermediate 291 was used for 
the next reaction without further characterization. 
(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
methylbenzoyl)-L-glutamic acid (189).  
Compound 189 was prepared using the general method described for the preparation of 
179-180, from 288 (50 mg, 0.09 mmol) to give 189 (26 mg, 58%) as a light yellow powder. 
mp 170.2 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.52-1.61 (m, 4 H, CH2CH2), 1.8-2.1 
(m, 2 H, β-CH2), 2.32 (s, 3 H, Ar-CH3), 2.36-2.38 (m, 2 H, γ-CH2),  2.57-2.61 (s, 2 H, Ar-
CH2), 4.3-4.37 (m, 1 H, α-CH), 5.85 (m, 1 H, C5-CH), 5.98 (s, 2 H, 2-NH2, exch), 7.05-
7.06 (d, J = 4.42 Hz, 2 H, Ar), 7.25-7.27 (d, J = 8.16 Hz, 1 H, Ar), 8.41-8.43 (d, J = 7.45 
Hz, 1 H, CONH, exch), 10.16 (s, 1 H, 3-NH, exch), 10.82 (s, 1 H, 7-NH, exch). Anal. Calcd 
for C23H27N5O6 ꞏ 0.78 H2O:  C, 57.11; H, 5.95; N, 14.48. Found: C, 57.18; H, 5.89; N, 
14.2.  
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(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
benzoyl)-L-glutamate mixture (3) and (190).  
Using the general method described for the preparation of 179-180, hydrolysis of 
compound mixture of 289 and 290 (40 mg, 0.07 mmol) gave a mixture of 3 and 190 (25 
mg, 70%) as a light yellow powder. 1H NMR (400 MHz, DMSO-d6): δ 1.54-1.66 (m, 6 H, 
CH2CH2), 1.89-2.14 (m, 3 H, β-CH2), 2.34-2.37 (t, J=6.92, 6.92 Hz, 3 H, γ-CH2) 2.65 (s, 
3 H, Ar-CH3), 4.36-4.41 (m, 2 H, α-CH), 5.85 (s, 1 H, C5-CH), 5.98 (s, 2 H, 2-NH2, exch), 
7.22-7.35 (m, 3 H, Ar), 7.79-7.8 (m, 2 H, Ar), 8.53-8.55 (d, J=6.7 Hz, 1 H, CONH, exch), 
8.65-8.67 (d, J = 7.33 Hz, 1 H, CONH, exch), 10.14 (s, 1 H, 3-NH, exch), 10.81 (s, 1 H, 
7-NH, exch). Anal. Calcd for C22H24ClN5O6: C, 53.94; H, 4.94; N, 14.30; Cl, 7.24; Found. 
C, 54.64; H, 5.59; N, 14.34; Cl, 2.74; The elemental analysis had a >4% deviation in Cl 
percentage, indicating dechlorination during hydrogenation of 286. The mixture was not 
characterized further. 
(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
(trifluoromethyl)benzoyl)-L-glutamate (191).  
Compound 191 was prepared using the general method described for the preparation of 
179-180, from 291 (70 mg, 0.12 mmol) to give 191 (50 mg, 79%) as a yellow powder. TLC 
Rf  = 0.3 (CHCl3/MeOH 5:1); mp 185 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.56-1.66 
(m, 4 H, CH2CH2), 1.8-2.11 (m, 2 H, β-CH2), 2.31-2.39 (s, 2 H, γ-CH2), 2.7-2.77 (m, 2 H, 
Ar-CH2) 4.33-4.43 (m, 1 H, α-CH), 5.84 (m, 1 H, C5-CH) 5.99 (s, 1 H, 2-NH2, exch) 7.42-
7.44 (d, J=7.98 Hz, 1 H, Ar), 7.57-7.61 (m, 2 H, Ar) 8.74-8.76 (d, J = 8.2 Hz, 1 H, CONH, 
exch) 10.15 (s, 1 H, 3-NH, exch) 10.82 (s, 1 H, 7-NH, exch). HPLC analysis: retention 
time, 2 min; peak area, 98.49%; eluent A, H2O; eluent B, ACN; gradient elution (100% 
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H2O to 10% H2O) over 10 mins with flow rate of 0.5 mL/min and detection at 254 nm; 
column temperature, rt. LRMS calculated for C23H24F3N5O6 = 523.17, found [M+H]+ 
524.20. 
Diethyl (5-bromopyrimidine-2-carbonyl)-L-glutamate (293). 
 Compound 293 was prepared using the general method described for the preparation of 
210-211. However, the amine and second equivalent of NMM were also added at once 
with the acid 292 (1.05 g, 4.77 mmol) and the reaction proceeded to completion in 1 h to 
give 293 (1.67 g, 83%) as a yellow syrup. TLC Rf = 0.15 (hexane/EtOAc 3:1); 1H NMR 
(400 MHz, DMSO-d6): δ 1.14-1.21 (m, 6 H, COOCH2CH3), 1.99-2.2 (m, 2 H, β-CH2) 2.38-
2.41 (t, J = 7.14, 7.14 Hz, 2 H, γ-CH2), 4.01-4.06 (q, J = 7.11, 7.11, 7.10 Hz, 2 H, 
COOCH2CH3), 4.06-4.16 (dq, J = 2.14, 7.07, 7.01, 7.01 Hz, 1 H, COOCH2CH3), 4.51 (m, 
1 H, α-CH), 9.17-9.21 (m, 3 H, Ar, CONH, exch). The intermediate 293 was used for the 
next reaction without further characterization. 
 (S)-2-(5-bromopyrimidine-2-carboxamido)-5-ethoxy-5-oxopentanoic acid (295). To a 
solution of 5-bromopyrimidine-2-carboxylic acid 292 (1 g, 4.93 mmol, 1 eq) and diethyl 
L-glutamate hydrochloride (1 g, 4.93 mmol, 1 eq) in pyridine (10 mL) was added 
dicyclohexylcarbodiimide 294 (1.02 g, 4.93 mmol, 1 eq) and the mixture was stirred at 
room temperature for 96 h until the formation of a new non-polar spot on TLC Rf  = 0.1 
(hexane/EtOAc 3:1). The reaction mixture was filtered to decant the dicyclohexylurea side 
product 296 and the filtrate was evaporated. The residue of the filtrate was washed with 2 
N HCl followed by sat. NaHCO3 to afford 295 (220 mg, 12.4%) as a yellow syrup. 1H 
NMR (400 MHz, CDCl3): δ 1.23-1.27 (t, J=7.14, 7.14 Hz, 3 H, γ-COOCH2CH3), 2.14-
2.54 (m, 4 H, α-CH2, β-CH2), 4.1-4.16 (dq, J=3.38, 7.13, 7.12, 7.12 Hz, 2 H, , γ-
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COOCH2CH3 ), 4.89-4.94 (dt, J=4.82, 8.05, 7.94 Hz, 1 H, α-CH), 8.45-8.47 (d, J=8.34 
Hz, 2 H, CONH, exch), 8.96 (s, 2 H, Ar). The intermediate 295 was not characterized 
further. 
Diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-
1-yl)pyrimidine-2-carbonyl)-L-glutamate (297). 
Compound 297 was prepared using the general method described for the preparation of 
211-212, from 162 (200 mg, 0.99 mmol) and diethyl (5-bromopyrimidine-2-carbonyl)-L-
glutamate 293 (576 mg, 1.48 mmol) to give 297 (200 mg, 40%) as an orange sticky solid. 
TLC Rf  = 0.4 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.14-1.21 (m, 6 H, 
COOCH2CH3), 2.03-2.2 (m, 2 H, β-CH2), 2.37-2.41 (t, J=7.60, 7.60 Hz, 2 H, γ-CH2), 4-
4.06 (q, J=7.11, 7.11, 7.13 Hz, 2 H, COOCH2CH3), 4.08-4.16 (dq, J=2.15, 7.11, 7.05, 7.05 
Hz, 2 H, COOCH2CH3), 4.47-4.54 (m, 1 H, α-CH) 6.04 (m, 3 H, C5-CH, 2-NH2, exch) 
8.98 (s, 2 H, Ar) 9.16-9.18 (d, J=7.90 Hz, 1 H, CONH, exch), 10.18 (s, 1H, 3-NH, exch) 
10.93-10.94 (d, J=1.65 Hz, 1 H, 7-NH, exch). The intermediate 297 was used for the next 
reaction without further characterization. 
Diethyl (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)pyrimidine-2-carbonyl)-L-glutamate (298).  
To a Parr flask with 10% palladium on activated carbon (0.5 wt eq) soaked in ethanol was 
added a methanolic solution of 297 (160 mg, 0.3 mmol). Hydrogenation was carried out at 
15 psi of H2 for 12 h. TLC showed the disappearance of the starting material and one a new 
non-polar spot (CHCl3/ MeOH). The reaction mixture was filtered through celite, washed 
with MeOH and concentrated under reduced pressure to give the reduced alkane 298 (120 
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mg, 75%) as a brown sticky solid. TLC Rf  = 0.5 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, 
DMSO-d6): δ 1.14-1.21 (m, 6 H, COOCH2CH3), 1.57-1.68 (m, 4 H, CH2CH2), 2.03-2.2 
(m, 2 H, β-CH2), 2.37-2.41 (t, J=7.83, 7.83 Hz, 2 H, γ-CH2), 2.7-2.74 (t, J=7.16, 7.16 Hz, 
2 H, CH2), 4-4.06 (q, J=7.12, 7.12, 7.13 Hz, 2 H, COOCH2CH3), 4.09-4.15 (dq, J=2.19, 
7.12, 7.08, 7.08 Hz, 2 H, COOCH2CH3), 4.47-4.54 (m, 1 H, α-CH) 5.87 (s, 1 H, C5-CH), 
5.97 (m, 3 H, C5-CH, 2-NH2, exch) 8.85 (s, 2 H, Ar) 9.08-9.10 (d, J = 7.95 Hz, 1 H, CONH, 
exch), 10.13 (s, 1H, 3-NH, exch) 10.82-10.825 (d, J = 2.05 Hz, 1 H, 7-NH, exch). The 
intermediate 298 was used for the next reaction without further characterization. 
(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)pyrimidine-2-carbonyl)-L-glutamic acid (192).  
Compound 192 was prepared using the general method described for the preparation of 
179-180 from 298 (50 mg, 0.1 mmol) to give 192 (30 mg, 68%) as an orange powder. TLC 
Rf  = 0.3 (CHCl3/MeOH 5:1); mp 121.8 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.6-1.65 
(m, 4 H, CH2CH2), 1.99-2.19 (m, 2 H, β-CH2), 2.29-2.33 (t, J=7.20, 7.20 Hz, 2 H, γ-CH2), 
2.7-2.74 (t, J=6.91, 6.91 Hz, 2 H, Ar-CH2), 4.42-4.48 (m, 1 H, α-CH) 5.87-5.88 (d, J = 
2.18 Hz, 1 H, C5-CH), 5.97 (s, 2 H, 2-NH2, exch) 8.84 (s, 2 H, Ar) 8.93-8.95 (d, J = 7.94 
Hz, 1 H, CONH, exch), 10.14 (s, 1H, 3-NH, exch) 10.82-10.825 (d, J = 1.71 Hz, 1 H, 7-
NH, exch). Anal. Calcd for (C20H23N7O6 ꞏ 0.81 H2O) C, 50.87; H, 5.25; N, 20.76. Found 
C, 50.94; H, 5.26; N, 20.61.  
Diethyl (3-(6-oxohexyl)benzoyl)-L-glutamate (301).  
To a solution of diethyl (3-bromobenzoyl)-L-glutamate 300 (2.16 g, 5 mmol, 1 eq) in 
anhydrous DMF (20 mL) was added hex-2-en-1-ol 299 (1.31 g, 5 mmol, 1 eq), LiCl (210 
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mg, 5 mmol, 1 eq), LiOAc (850 mg, 12.5 mmol, 2.5 eq), Bu4NCl (1.4 g, 5 mmol, 1 eq), 
Pd(OAc)2 (60 mg, 0.3 mmol, 0.06 eq) and the mixture was stirred at 70 °C for 3 hours. TLC 
showed the disappearance of the starting material and formation of one major non-polar 
spot (hexane/EtOAc). To the reaction mixture cooled to room temperature was added 
EtOAc. The resulting solution was extracted with H2O and dried over Na2SO4. After 
evaporation of solvent, the residue was loaded on a silica gel column and eluted with 
hexane followed by gradual increase to 50% EtOAc and the desired fractions were pooled 
and evaporated to afford 301 (1.54 g, 76%), as colorless syrup. TLC Rf = 0.8 
(hexane/EtOAc, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 0.99-1.14 (m, 2 H, CH2), 1.20-
1.24 (t, J=7.13, 7.13 Hz, 2 H, COOCH2CH3), 1.26-1.3 (, J=7.13, 7.13 Hz, 2 H, 
COOCH2CH3), 1.69-1.71 (m, 4 H, CH2CH2), 2.09-2.35 (m, 2 H, β-CH2), 2.5-2.53 (t, 
J=7.25, 7.25 Hz, 2 H, γ-CH2), 2.68-2.72 (m, 2 H, Ar-CH2), 4.08-4.13 (q, J=7.12, 7.12, 
7.13 Hz, 2 H, COOCH2CH3), 4.18-4.24 (q, J=7.10, 7.10, 7.12 Hz, 2 H, COOCH2CH3), 
4.63-4.66 (dd, J=5.20, 9.43 Hz, 1 H, α-CH), 7.34-7.35 (m, 2 H, Ar), 7.64-7.67 (m, 1 H, 
Ar), 7.7 (s, 1 H, Ar), 7.91 (s, 2 H, CHO, CONH, exch). The intermediate 301 was used for 
the next reaction without further characterization. 
Diethyl (3-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzoyl)-L-glutamate (304).  
To a solution of aldehyde 301 (1.54 g, 3.8 mmol, 1 eq) in anhydrous Et2O was added 5,5-
dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 302 (572 mg, 1.9 mmol, 0.5 eq), 2 N HCl in 
Et2O solution (0.02 mL, 0.1 eq) and the mixture was stirred at room temperature for 24 
hours. TLC showed the disappearance of the starting material and formation of one major 
non-polar spot (hexane/EtOAc). The reaction solution was washed with 5% NaHCO3 
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solution and extracted with H2O and dried over Na2SO4. After evaporation of solvent, the 
residue 303 was used directly in the next step without further characterization. TLC Rf = 
0.9 (hexane/EtOAc 1:1) 
 To a solution of 2,6-diaminopyrimidin-4(3H)-one 22 (479 mg, 3.8 mmol, 1 eq) and 
sodium acetate (623 mg, 7.6 mmol, 2 eq) in water (5 mL) and methanol (5 mL) was added 
α-bromo aldehyde 303 (1.54 g, 3.8 mmol, 1 eq). The reaction mixture was stirred at 45 °C 
for 3 hours. TLC showed the disappearance of starting materials and the formation of one 
major spot (CHCl3/MeOH). After evaporation of solvent, CH3OH was added followed by 
silica gel and solvent was evaporated to afford a plug. The plug was loaded onto a silica 
gel column and eluted initially with CHCl3 followed by gradual increase of 10% MeOH in 
CHCl3. Fractions with the required Rf were pooled and evaporated to afford 304 (100 mg, 
5% over two steps) as a light pink sticky solid. TLC Rf = 0.3 (CHCl3/MeOH, 10:1);  1H 
NMR (400 MHz, DMSO-d6); δ 1.14-1.2 (m, 6 H, COOCH2CH3), 1.64 (s, 4 H, CH2CH2), 
1.96-2.14 (m, 2 H, β-CH2), 2.42-2.45 (t, J=7.16, 7.16 Hz, 2 H, γ-CH2), 2.58-2.6 (m, 2 H, 
Ar-CH2), 2.61-2.65 (s, 2 H, Ar-CH2), 4.02-4.06 (m, 2 H, COOCH2CH3), 4.08-4.12 (m, 2 
H, COOCH2CH3), 4.4-4.45 (td, J=5.94, 5.94, 7.94 Hz, 1 H, α-CH) 5.96 (s, 2 H, 2-NH2, 
exch) 6.32 (s, 1 H, C6-CH), 7.35-7.36 (m, 2 H, Ar) 7.66-7.69 (m, 2 H, Ar,), 8.67-8.68 (d, 
J=7.04 Hz, 1 H, CONH, exch), 10.09 (s, 1H, 3-NH, exch) 10.59 (s, 1 H, 7-NH, exch). The 
intermediate 304 was used for the next reaction without further characterization. 
(3-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)benzoyl)-
L-glutamic acid (193).  
To 304 (51 mg, 0.1 mmol), was added 1 N NaOH (2 mL) and the resulting mixture was 
stirred at rt for 1 h. TLC indicated the disappearance of starting material and the formation 
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of one major spot at the origin. The solution was cooled in an ice bath, and the pH was 
adjusted 3 to 4 using 1 N HCl. The resulting suspension was chilled in a dry ice/acetone 
bath and thawed to 4 °C overnight in a refrigerator. The precipitate was filtered, washed 
with cold water, and dried in a desiccator under reduced pressure using P2O5 to yield 193 
(37 mg, 81%) as a yellow powder. TLC Rf = 0.3 (CHCl3/MeOH, 10:1 in a drop of 
CH3COOH); mp 139.5 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.57-1.69 (m, 4 H, 
CH2CH2), 1.91-2.14 (m, 2 H, β-CH2), 2.34-2.37 (t, J=7.52, 7.52 Hz, 2 H, γ-CH2), 2.58-
2.64 (m, 4 H, CH2, CH2), 4.37-4.42 (td, J=5.94, 5.94, 7.94 Hz, 1 H, α-CH) 5.96 (s, 2 H, 2-
NH2, exch) 6.34 (s, 1 H, C6-CH), 7.35-7.37 (m, 2 H, Ar) 7.65-7.74 (m, 2 H, Ar,), 8.56-
8.58 (d, J = 7.72 Hz, 1 H, CONH, exch), 10.11 (s, 1H, 3-NH, exch) 10.6 (s, 1 H, 7-NH, 
exch). HPLC analysis: retention time, 19 min; peak area, 95.11%; eluent A, H2O; eluent 
B, ACN; gradient elution (100% H2O to 100% ACN) over 60 mins with flow rate of 0.5 
mL/min and detection at 254 nm; column temperature, rt. LRMS calculated for 
C22H25N5O6: 455.18, found [M+H]+ 456.1887.  
2-Amino-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (309).  
2,4-Diamino-6-hydroxypyrimidine 22 (2.1 g, 16.65 mmol, 1 eq), sodium acetate (2.73 g, 
33.3 mmol, 2 eq) and chloroacetaldehyde (1.05 mL, 16.65  mmol, 1 eq)  were dissolved in 
MeOH (25 mL) and water (25 mL) and the resulting yellow solution was stirred at 45 °C 
for 4 h until a new non-polar spot was observed on TLC (CHCl3/MeOH). The reaction 
mixture was then concentrated in vacuo and MeOH was added followed by silica gel. 
Evaporation of the solvent afforded a plug, which was loaded onto a silica gel column and 
eluted initially with CHCl3 followed by gradual increase of polarity to 10% MeOH in 
CHCl3. Fractions with the required Rf were pooled and evaporated to afford 309 (2.5 g, 
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quant.) as a light pink powder. TLC Rf = 0.5 (CHCl3/MeOH, 5:1); mp >300 °C.386 1H NMR 
(400 MHz, DMSO-d6): δ 6.04 (s, 2 H, 2-NH2, exch), 6.17-6.19 (dd, J=2.16, 3.27 Hz, 1 H, 
C5-CH), 6.6-6.62 (dd, J=2.30, 3.23 Hz, 1 H, C6-CH), 10.21 (s, 1 H, 3-NH, exch), 10.97 
(s, 1 H, 7-NH, exch). 1H NMR matches with the 1H NMR of reported compound.387  
N-(4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide (310).  
A solution of 309 (2.4 g, 16 mmol, 1 eq) in pyridine (30 mL) was treated with 
trimethylacetyl chloride (7 mL, 56 mmol, 3.5 eq) at 90 °C for 0.5 h. The solvent was 
evaporated and the residue was dissolved in MeOH and precipitated in 10% aqueous 
ammonia for 30 min to selectively cleave the N(7)- pivaloyl group. The precipitate was 
filtered, washed with cold MeOH, and dried on high vacuum to give 310 (1.6 g, 43% yield) 
as a pink powder. TLC Rf = 0.7 (CHCl3/MeOH 5:1); mp 297 °C.388 1H NMR (400 MHz, 
DMSO-d6): δ 1.2 (s, 9 H, (CH3)3), 6.4-6.42 (dd, J=2.05, 3.38 Hz, 1 H, C5-CH), 6.95-6.96 
(dd, J=2.4, 3.33 Hz, 1 H, C6-CH), 10.81 (s, 1 H, 2-NH, exch), 11.62 (s, 1 H, 3-NH, exch), 
11.85 (s, 1 H, 7-NH, exch). 1H NMR matches with the 1H NMR of reported compound.388  
N-(5-iodo-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide (305).  
To the solution of 310 (1.6 g, 6.83 mmol, 1 eq) in DMF (40 mL), 
bis(trimethylsilyl)acetamide (4.2 mL, 17.1 mmol, 2.5 eq) was added and the resulting 
solution was stirred at 40 °C for 1 h to give the intermediate 311. The reaction was cooled 
to room temperature after which, NIS (1.84 g, 8.2 mmol, 1.2 eq) was added to the reaction. 
The reaction vessel was protected from light and stirred overnight at room temperature. 
The mixture was then poured into water (100 mL) and stirred for another 2 h to form a 
precipitate, which was filtered to afford 305 (1.6 g, 65%) as a pink powder. TLC Rf = 0.47 
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(CHCl3/MeOH 10:1); mp 151.3 °C dec. 1H NMR (400 MHz, DMSO-d6) δ 1.24 (s, 9 H, 
(CH3)3), 7.15-7.16 (d, J=2.44 Hz, 1 H, C6-CH), 10.84 (s, 1 H, 2-NH, exch), 11.83 (s, 1 H, 
3-NH, exch), 11.93 (s, 1 H, 7-NH, exch). 1H NMR matches with the 1H NMR of reported 
compound.389  
Ethyl 4-(prop-2-yn-1-ylamino)benzoate (306).  
To ethyl 4-aminobenzoate 313 (1.52 g, 10 mmol, 1 eq) dissolved in EtOH (30 mL), K2CO3 
(1.4 g, 10.1 mmol, 1.01 eq) and propargyl bromide (80% wt in toluene) 312 (1.11 mL, 10 
mmol, 1 eq) were added, and the mixture was refluxed for 18 h until a new non-polar spot 
was observed on TLC (hexane/EtOAc). The solvent was removed in vacuo, MeOH was 
added followed by silica gel and evaporated to afford a plug. The plug was loaded onto a 
silica gel column and eluted initially with hexane followed by gradual increase of polarity 
to 100% EtOAc. Fractions with the required Rf were pooled and evaporated to afford 306 
(420 mg, 21%) as a yellow powder. TLC Rf = 0.7 (hexane/EtOAc, 1:1); mp 58.3 °C. 1H 
NMR (400 Mhz, DMSO-d6): 1H NMR (500 MHz, CDCl3): δ 1.26-1.3 (t, J=7.09, 7.09 Hz, 
3 H, COOCH2CH3), 3.13-3.15 (t, J=2.21, 2.21 Hz, 1 H, CH), 3.94-3.96 (d, J = 2.38 Hz, 2 
H, CH2), 4.19-4.25 (q, J=7.07, 7.07, 7.08 Hz, 2 H, COOCH2CH3),  6.66-6.68 (d, J=8.73 
Hz, 2 H, Ar), 6.86-6.89 (t, J=5.85, 5.85 Hz, 1 H, NH, exch), 7.72-7.74 (d, J=8.69 Hz, 2 H, 
Ar). The intermediate 306 was used for the next reaction without further characterization. 
Methyl 4-(2-propynyloxy)-benzoate (307).  
To methyl 4-hydroxybenzoate 314 (1.32 g, 8.7 mmol, 1 eq) dissolved in dry acetone (15 
mL), and K2CO3 (2.77 g, 2.77 mmol, 2.3 eq) was added, propargyl bromide (80% wt in 
toluene) 312 (1.54 mL, 17.4 mmol, 2 eq), and the mixture was refluxed for 3 h until a new 
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non-polar spot was observed on TLC (hexane/EtOAc). The mixture was then diluted with 
CH2Cl2 (50 mL), washed with H2O (25 mL) and brine (25 mL), dried over Na2SO4, and 
the solvent was removed in vacuo. To the residue, MeOH was added followed by silica gel 
and evaporated to afford a plug, which was loaded onto a silica gel column and eluted 
initially with hexane followed by gradual increase to 100% EtOAc. Fractions with the 
required Rf were pooled and evaporated to afford 307 (1.56 g, 95%) as a white powder. 
TLC Rf = 0.8 (hexane/EtOAc, 1:1); mp 58 °C.390 1H NMR (400 MHz, DMSO-d6): δ 3.64-
3.65 (t, J = 2.36, 2.36 Hz, 1 H, CH), 3.82 (s, 3 H, COOCH3), 4.90-4.91 (d, J = 2.38 Hz, 2 
H, CH2), 7.09-7.1 (d, J = 8.91 Hz, 2 H, Ar), 7.92-7.94 (d, J = 8.94 Hz, 2 H, Ar). 1H NMR 
matches with the 1H NMR of reported compound.390  
4-(prop-2-yn-1-yloxy)benzoic acid (315).  
To a solution of methyl 4-(2-propynyloxy)-benzoate 307 (225 mg, 1.18 mmol, 1 eq) 
dissolved in MeOH (1 mL) and THF (1 mL), was added 1 N NaOH (1 mL). The resultant 
mixture was refluxed for 2.5 h until disappearance of starting material and a new polar spot 
was observed on TLC (hexane/EtOAc). The organic solvents were removed in vacuo and 
the pH of the solution was adjusted to 2-3 using 1 N HCl to afford a white precipitate. The 
precipitate was filtered, washed with water and dried overnight in vacuo to afford 315 (173 
mg, 83%) as a white powder. TLC Rf = 0.7 (hexane/EtOAc, 1:1); 1H NMR (400 MHz, 
DMSO-d6): δ 3.63-3.64 (t, J = 2.29, 2.29 Hz, 1 H, CH), 4.89-4.90 (d, J = 2.32 Hz, 2 H, 
CH2), 7.06-7.08 (d, J = 8.84 Hz, 2 H, Ar), 7.9-7.92 (d, J=8.86 Hz, 2 H, Ar). 1H NMR 
matches with the 1H NMR of reported compound.391 The intermediate 315 was used for 
the next reaction without further characterization. 
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Diethyl (4-(prop-2-yn-1-yloxy)benzoyl)-L-glutamate (316).  
Compound 316 was prepared using the general method described for the preparation of 
210-211, from 4-(prop-2-yn-1-yloxy)benzoic acid 315 (175 mg, 1 mmol), to give 316 (308 
mg, 85%) as a colorless liquid. TLC Rf = 0.4 (hexane/EtOAc, 3:1); 1H NMR (400 MHz, 
DMSO-d6): δ 1.14-1.2 (m, 6 H, COOCH2CH3), 1.94-2.14(m, 2 H, β-CH2), 2.41-2.445 (t, 
J=7.53, 7.53 Hz, 2 H, γ-CH2), 3.59-3.6 (t, J = 2.28, 2.28 Hz, 1H, CH), 4.01-4.13 (m, 4 H, 
COOCH2CH3), 4.39-4.4 (dd, J=5.23, 9.63 Hz, 1 H, α-CH), 4.87-4.88 (d, J = 2.30 Hz, 2 H, 
CH2), 7.05-7.07 (d, J = 8.83 Hz, 2 H, Ar), 7.85-7.87 (d, J=8.77 Hz, 2 H, Ar). The 
intermediate 316 was used for the next reaction without further characterization. 
Tetraethyl 2,2'-((4,4'-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(benzoyl))bis(azanediyl))-
(2S,2'S)-diglutarate (319).  
A mixture of 316 (26 mg, 0.09 mmol, 1.3 eq), Pd(PPh3)4 (5.6 mg, 0.005 mmol, 7 mol %), 
and TEA (0.02 mL, 0.14 mmol, 2 equiv) in DMF (1 mL) was stirred at room temperature, 
away from light for 15 min to. N-(5-iodo-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-
2-yl)pivalamide 305 (26 mg, 0.07 mmol, 1 eq) and CuI (2 mg, 15 mol %) were added to 
this reaction mixture, which was then stirred at room temperature for 12 h. The solvent was 
removed in vacuo and MeOH followed by silica gel was added to the residue, and 
evaporated to afford a plug. The plug was loaded onto a silica gel column and eluted 
initially with CHCl3 followed by gradual increase to 1% CHCl3 in MeOH. Fractions with 
required Rf were pooled and evaporated to afford the Glaser coupling product 319 (13 mg, 
25%) as an orange sticky solid. TLC Rf = 0.8 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, 
DMSO-d6): δ 1.14-1.2 (m, 12 H, COOCH2CH3), 1.96-2.16 (m, 4 H, β-CH2), 2.41-2.46 (m, 
4 H, γ-CH2), 4.02-4.13 (m, 8 H, COOCH2CH3), 4.38-4.47 (m, 2 H, α-CH), 6.99-7.01 (d, J 
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= 8.82 Hz, 4 H, Ar), 7.84-7.86 (d, J=8.77 Hz, 4 H, Ar), 8.56-8.57 (d, J=7.73 Hz, 2 H, 
CONH, exch). LRMS calculated for C38H44N2O12 = 720.29, found [M+Na]+ 743.2792 . 
The intermediate 319 was not characterized further. 
Ethyl 4-acetamidobenzoate (320).  
To ethyl 4-aminobenzoate 313 (1 g, 6 mmol, 1 eq) in dry CH2Cl2 (20 mL) was added acetic 
anhydride (0.7 mL, 7.26 mmol, 1.2 eq) and the reaction was stirred at room temperature 
and monitored by TLC. Upon completion of the reaction after 12 h and appearance of a 
new non-polar spot on TLC (hexan/EtOAc), the reaction mixture was washed with sat. 
Na2CO3, dried over Na2SO4 and the solvent was removed under reduced pressure. The 
product 320 (1.13 g, 90%), was obtained as a white powder. TLC Rf = 0.4 (hexane/EtOAc 
1:1);  1H NMR (400 MHz, DMSO-d6): δ 1.29-1.32 (t, J=7.05, 7.05 Hz, 3 H, COOCH2CH3), 
2.08 (s, 3 H, CH3), 4.25-4.31 (q, J=7.10, 7.10, 7.09 Hz, 2 H, COOCH2CH3), 7.7-7.72 (d, J 
= 8.74 Hz, 2 H, Ar), 7.89-7.91 (d, J = 8.75 Hz, 2 H, Ar), 10.29 (s, 1 H, NH, exch). 1H NMR 
matches with the 1H NMR of reported compound.392 mp 101 °C.393 
Ethyl 4-(2,2,2-trifluoroacetamido)benzoate (321).  
A suspension of ethyl 4-aminobenzoate 313 (5 g, 30 mmol) in trifluoroacetic anhydride 
(50 mL) was stirred under anhydrous conditions at room temperature for 2 h, and was 
subsequently allowed to stand at room temperature overnight. Excess trifluoroacetic 
anhydride was removed under reduced pressure and the residue was dissolved in CH2Cl2 
(70 mL), washed with cold 2% HCl (50 mL), cold 5% NaHCO3 (50 mL), and cold water 
(2 × 100 mL). The organic layer was dried over Na2SO4, filtered, and the solvent was 
evaporated under reduced pressure to afford 321 (7.9 g, quant.) as a buff colored powder. 
 239 
TLC Rf = 0.6 (hexane/EtOAc 1:1); mp 128 °C dec.394 1H NMR (400 MHz, DMSO-d6) δ 
1.31-1.34 (t, J=6.98, 6.98 Hz, 3 H, COOCH2CH3), 4.29-4.33 (q, J=6.92, 2 H, 
COOCH2CH3), 7.83-7.85 (d, J=7.63 Hz, 2 H, Ar), 8-8.01 (d, J=7.64 Hz, 2 H, Ar). 1H NMR 
matches with the 1H NMR of reported compound.394 LRMS calculated for C13H9F6NO4 = 
261.06, found [M-H]- 260.0. 
Ethyl 4-pivalamidobenzoate (322).  
A solution of ethyl 4-aminobenzoate 313 (3 g, 18.2 mmol, 1 eq) in pivalic anhydride (50 
mL) was stirred at 80 °C for 8 h. The reaction was cooled to room temperature and then 
evaporated to dryness. MeOH followed by silica gel was added to the residue and 
evaporated to afford a plug which was loaded onto a silica gel column and eluted initially 
with hexane followed by gradual increase to 100% EtOAc. Fractions with the required Rf 
were pooled and evaporated to afford 322 (1.4 g, 56%) as a white powder. TLC Rf = 0.6 
(hexane/EtOAc 1:1); 1H NMR (400 MHz, DMSO-d6): δ 1.24 (s, 9 H, (CH3)3), 1.29-1.33 
(t, J = 7.09, 7.09 Hz, 3 H, COOCH2CH3), 4.25-4.31 (q, J=7.07, 7.07, 7.08 Hz, 2 H, 
COOCH2CH3), 7.81-7.83 (d, J = 8.77 Hz, 2 H, Ar), 7.89-7.91 (d, J = 8.80 Hz, 2 H, Ar), 
9.52 (s, br, 1 H, NH, exch). 1H NMR matches with the 1H NMR of reported compound.395 
The intermediate 322 was used for the next reaction without further characterization. 
Ethyl 4-((tert-butoxycarbonyl)amino)benzoate (323).  
To a solution of ethyl 4-aminobenzoate 313 (3 g, 18.2 mmol, 1 eq) in 1,4-dioxane (67 mL), 
di-tert-butyl dicarbonate (6.3 g, 29 mmol, 1.6 eq) was added and the mixture was stirred at 
80 °C for 24 h. The reaction was cooled to room temperature, solvent was removed in vacuo 
and MeOH followed by silica gel was added to the residue and evaporated to afford a plug. 
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The plug was loaded onto a silica gel column and eluted initially with hexane followed by 
gradual increase in polarity to 100% EtOAc. Fractions with the required Rf were pooled 
and evaporated to afford 323 (4.35 g, 90%) as a buff colored powder. TLC Rf = 0.5 
(hexane/EtOAc 3:1); mp 135.8 °C dec. 1H NMR (400 MHz, CDCl3): δ 1.39-1.42 (m, 3 H, 
COOCH2CH3), 1.55 (s, 9 H, (CH3)3), 4.35-4.4 (q, J = 6.41 Hz, 2 H, COOCH2CH3), 6.7 (s, 
br, 1 H, NH, exch), 7.44-7.46 (d, J = 8.09 Hz, 2 H, Ar), 7.99-8.01 (d, J = 7.27 Hz, 2 H, Ar). 
1H NMR matches with the 1H NMR of reported compound.396 The intermediate 323 was 
used for the next reaction without further characterization. 
Ethyl 4-((5-hydroxypentyl)amino)benzoate (325).  
To a solution of ethyl 4-aminobenzoate 313 (1 g, 6.05 mmol, 1 eq) in DMF (10 mL), TEA 
(1.69 g, 12.1 mmol, 2 eq) was added and the mixture was stirred at 80 °C for 18 h. The 
reaction was cooled to room temperature, solvent was removed in vacuo and MeOH 
followed by silica gel was added to the residue and evaporated to afford a plug. The plug 
was loaded onto a silica gel column and eluted initially with hexane followed by gradual 
increase in polarity to 100% EtOAc. Fractions with the required Rf were pooled and 
evaporated to afford 325 (300 mg, 20%) as a yellow syrup. TLC Rf = 0.3 (hexane/EtOAc 
1:1); 1H NMR (400 MHz, CDCl3): δ 1.25-1.29 (t, 3 H, J=7.10, 7.10 Hz, COOCH2CH3), 
1.38-1.45 (m, 2 H, CH2), 1.52-1.61 (m, 4 H, CH2CH2), 3.04-3.07 (t, J=6.92, 6.92 Hz, 2 H, 
NH-CH2), 3.41-3.45 (t, J=6.37, 6.37 Hz, 2 H, OH-CH2), 3.56 (s, br, 1 H, OH, exch), 4.17-
4.23 (q, J=7.08, 7.08, 7.09 Hz, 2 H, COOCH2CH3), 6.56-6.58 (d, J=8.82 Hz, 2 H, Ar), 
7.66-7.69 (d, J=8.79 Hz, 2 H, Ar). The intermediate 325 was was not characterized further. 
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Ethyl 4-((tert-butoxycarbonyl)(5-hydroxypentyl)amino)benzoate (329).  
To a suspension of Cs2CO3 (2.46 g, 7.54 mmol, 1 equiv), tetrabutylammonium iodide (2.79 
g, 7.54 mmol, 1 equiv) in anhydrous DMF (40 mL), was added ethyl 4-((tert-
butoxycarbonyl)amino)benzoate 323 (2 g, 7.54 mmol, 1 eq) and the mixture was stirred for 
1 h at room temperature. The reaction mixture was subsequently cooled to 0 °C and 5-
bromopentanol 324 (1 mL, 8.3 mmol, 1.1 equiv) was added dropwise and the resulting 
mixture was gradually heated to 70 °C and stirred for an additional 18 h. The resultant 
suspension was then poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). 
The organic layer was washed further with water (3 x 100 mL), brine (100 mL), and dried 
over Na2SO4 and the solvent was removed in vacuo. To the residue, MeOH was added 
followed by silica gel and the solvent was evaporated to afford a plug. The plug was loaded 
onto a silica gel column and eluted initially with hexane followed by gradual increase in 
polarity to 100% EtOAc. Fractions with the required Rf were pooled and evaporated to 
afford 329 (1.96 g, 74%) as a yellow syrup. TLC Rf = 0.15 (hexane/EtOAc, 3:1).  1H NMR 
(400 MHz, DMSO-d6): δ 1.23-1.6 (m, 18 H, CH2CH2CH2, COOCH2CH3, NHCO(CH3)3), 
3.32-3.4 (m, 2 H, Ar-CH2), 3.63-3.68 (m, 2 H, OH-CH2), 3.99-4.05 (m, 3 H, COOCH2CH3,  
OH, exch), 7.38-7.40 (d, J=8.42 Hz, 2 H, Ar), 7.90-7.93 (d, J=8.59 Hz, 2 H, Ar). The 
intermediate 329 was used for the next reaction without further characterization. 
Methyl 4-((5-hydroxypentyl)oxy)benzoate (330).  
To methyl 4-hydroxybenzoate 314 (2.75 g, 18.07 mmol, 1 eq) dissolved in dry acetone (40 
mL), and K2CO3 (5 g, 36.15 mmol, 2 eq) was added, 5-bromopentanol 324 (2.2 mL, 18.07 
mmol, 1 eq), and the mixture was stirred at 80 °C for 24 h. The solvent was removed in 
vacuo and to the residue, MeOH was added followed by silica gel and evaporated to afford 
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a plug. The plug was loaded onto a silica gel column and eluted initially with hexane 
followed by gradual increase in polarity to 100% EtOAc. Fractions with the required Rf 
were pooled and evaporated to afford 330 (2.65 g, 62%) as a white syrup. TLC Rf = 0.4 
(hexane/EtOAc, 1:1).  1H NMR (400 MHz, DMSO-d6): δ 1.4-1.52 (m, 4 H, CH2CH2), 1.7-
1.77 (m, 2 H, CH2), 3.39-3.43 (m, 2 H, OH-CH2), 3.81 (s, 3 H, COOCH3), 4.03-4.06 (t, 
J=6.49, 6.49 Hz, 2 H, ArO-CH2), 4.38-4.4 (t, J=5.14, 5.14 Hz, 1 H, OH, exch), 7.02-7.05 
(d, J=8.90 Hz, 2 H, Ar), 7.89-7.91 (d, J=8.88 Hz, 2 H, Ar). The intermediate 330 was used 
for the next reaction without further characterization. 
Methyl 4-((5-hydroxypentyl)thio)benzoate (332).  
To a suspension of Cs2CO3 (2.5 g, 7.7 mmol, 1 equiv), tetrabutylammonium iodide (2.83 
g, 7.7 mmol, 1 equiv) in anhydrous DMF (40 mL), was added ethyl 4-mercaptobenzoate 
331 (1.3 g, 7.7 mmol, 1 eq) and the mixture was stirred for 1 h at room temperature. The 
reaction mixture was subsequently cooled to 0 °C and 5-bromopentanol 324 (1.04 mL, 8.5 
mmol, 1.1 equiv) was added dropwise and the resulting mixture was gradually warmed to 
room temperature while being stirred for an additional 3 h. The resultant suspension was 
then poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The organic 
layer was washed further with water (3 x 100 mL), brine (100 mL), and dried over Na2SO4 
and the solvent was removed in vacuo. To the residue, MeOH was added followed by silica 
gel and the solvent was evaporated to afford a plug. The plug was loaded onto a silica gel 
column and eluted initially with hexane followed by gradual increase in polarity to 100% 
EtOAc. Fractions with the required Rf were pooled and evaporated to afford 332 (1.53 g, 
80%) as a white syrup. TLC Rf = 0.4 (hexane/EtOAc, 1:1).  1H NMR (500 MHz, DMSO-
d6): δ 1.42-1.45 (m, 4 H, CH2CH2), 1.59-1.65 (m, 2 H, CH2), 3.03-3.06 (m, 2 H, OH-CH2), 
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3.83 (s, 3 H, COOCH3), 4.42-4.44 (m, 1 H, OH, exch), 7.38-7.40 (d, J=8.53 Hz, 2 H, Ar), 
7.85-7.87 (d, J=8.52 Hz, 2 H, Ar).  The intermediate 332 was used for the next reaction 
without further characterization. 
Ethyl 4-((tert-butoxycarbonyl)(6-hydroxyhexyl)amino)benzoate (334).  
To a suspension of Cs2CO3 (614 mg, 1.88 mmol, 1 equiv), tetrabutylammonium iodide 
(695 mg, 1.88 mmol, 1 equiv) in anhydrous DMF (10 mL), was added ethyl 4-((tert-
butoxycarbonyl)amino)benzoate 323 (500 mg, 1.88 mmol, 1 eq) and the mixture was 
stirred for 1 h at room temperature. The reaction mixture was subsequently cooled to 0 °C 
and 6-bromohexanol 333 (0.27 mL, 2.07 mmol, 1.1 equiv) was added dropwise and the 
resulting mixture was gradually heated to 80 °C and stirred for an additional 18 h. The 
resultant suspension was then poured into water (100 mL) and extracted with EtOAc (3 x 
25 mL). The organic layer was washed further with water (3 x 25 mL), brine (25 mL), and 
dried over Na2SO4 and the solvent was removed in vacuo. To the residue, MeOH was added 
followed by silica gel and the solvent was evaporated to afford a plug. The plug was loaded 
onto a silica gel column and eluted initially with hexane followed by gradual increase in 
polarity to 100% EtOAc. Fractions with the required Rf were pooled and evaporated to 
afford 334 (350 mg, 51%) as a yellow syrup. TLC Rf = 0.15 (hexane/EtOAc, 3:1).  1H NMR 
(400 MHz, CDCl3): δ 1.32-1.45 (m, 16 H, CH2CH2, COOCH2CH3, NHCO(CH3)3), 1.52-
1.72 (m, 4 H, CH2, CH2) 3.62-3.71 (m, 4 H, OH-CH2, N-CH2), 4.1-4.16 (m, 1 H, OH, 
exch), 4.36-4.42 (q, J=7.13, 7.13, 7.12 Hz, 2 H, COOCH2CH3), 7.27-7.29 (d, J=8.72 Hz, 
2 H, Ar), 8.01-8.04 (d, J=8.79 Hz, 2 H, Ar). The intermediate 334 was used for the next 
reaction without further characterization. 
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General procedure for the synthesis of aldehydes 335-338. 
 Alcohols 329, 330, 332 and 334 (1 eq) in anhyd. CH2Cl2 were added to a stirred solution 
of Dess-Martin periodinane (1.2 eq) in CH2Cl2 at 0 °C and the mixture was allowed to 
warm to room temperature while being stirred for 0.5-4 h. TLC (hexane/EtOAc) showed 
formation of one new major non-polar spot. Excess oxidant was destroyed by vigorously 
stirring the reaction mixture for 5 min with 1 N NaOH (0.2 eq). The mixture was diluted 
with (Et)2O and washed with water and brine solution, and dried over Na2SO4. The solvent 
was evaporated, MeOH and celite were added to the residue, and evaporated to dryness. 
The resultant plug was loaded on a silica gel column and flash-chromatographed with 
hexanes followed by gradual increase of EtOAc to 50% EtOAc in hexanes. Fractions with 
the desired Rf (TLC) were pooled and evaporated to afford target compounds 335-338 as 
syrups. 
Ethyl 4-((tert-butoxycarbonyl)(5-oxopentyl)amino)benzoate (335).  
Compound 335 was prepared using the general method described for the preparation of 
335-338 in 0.5 h, from 329 (500 mg, 1.42 mmol) to give 335 (300 mg, 60%) as a colorless 
syrup. TLC Rf  = 0.31 (hexane/EtOAc, 3:1); 1H NMR (400 MHz, CDCl3): δ 1.39-1.43 (t, 
J=7.13, 7.13 Hz, 3 H, COOCH2CH3), 1.45 (s, 9 H, NHCO(CH3)3), 1.54-1.68 (m, 4 H, 
CH2), 2.45-2.49 (dt, J=1.45, 7.03, 7.11 Hz, 2 H, CHO-CH2), 3.69-3.73 (t, J=7.01, 7.01 Hz, 
2 H, N-CH2), 4.36-4.42 (q, J=7.13, 7.13, 7.13 Hz, 2 H, COOCH2CH3), 7.27-7.29 (d, 
J=8.62 Hz, 2 H, Ar), 8.02-8.04 (d, J=8.58 Hz, 2 H, Ar), 9.75-9.76 (t, J=1.51, 1.51 Hz, 1 
H, CHO). The intermediate 335 was used for the next reaction without further 
characterization. 
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Methyl 4-((5-oxopentyl)oxy)benzoate (336).  
Compound 336 was prepared using the general method described for the preparation of 
335-338 in 4 h, from 330 (1.46 g, 6.11 mmol) to give 336 (859 mg, 60%) as a colorless 
syrup. TLC Rf  = 0.7 (hexane/EtOAc, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 1.63-1.78 
(m, 4 H, CH2CH2), 3.81 (s, 3 H, COOCH3), 7.02-7.04 (d, J=8.84 Hz, 2 H, Ar), 7.89-7.91 
(d, J=8.88 Hz, 2 H, Ar), 9.69 (m, 1 H, CHO). The intermediate 336 was used for the next 
reaction without further characterization. 
Methyl 4-((5-oxopentyl)thio)benzoate (337).  
Compound 337 was prepared using the general method described for the preparation of 
335-338 in 4 h, from 332 (447 mg, 1.77 mmol) to give 337 (373 mg, 84%) as a colorless 
syrup. TLC Rf  = 0.7 (hexane/EtOAc, 1:1); 1H NMR (400 MHz, DMSO-d6): δ 1.58-1.7 (m, 
4 H, CH2CH2), 3.05-3.09 (t, J=6.82, 6.82 Hz, 2 H, Ar-CH2), 3.83 (s, 3 H, COCH3), 7.39-
7.41 (d, J=8.42 Hz, 2 H, Ar), 7.85-7.87 (d, J=8.46 Hz, 2 H, Ar), 9.66 (s, 1 H, CHO). The 
intermediate 337 was used for the next reaction without further characterization. 
Ethyl 4-((tert-butoxycarbonyl)(5-oxohexyl)amino)benzoate (338).  
Compound 338 was prepared using the general method described for the preparation of 
335-338, from 334 (1.35 g, 3.69 mmol) to give 338 (900 mg, 67%) as a colorless syrup. 
TLC Rf  = 0.3 (hexane/EtOAc, 3:1); 1H NMR (400 MHz, CDCl3): δ 1.31-1.37 (m, 2 H, 
CH2), 1.37-1.43 (t, J=7.13, 7.13 Hz, 3 H, COOCH2CH3), 1.45 (s, 9 H, NHCO(CH3)3), 1.54-
1.67 (m, 4 H, CH2), 2.4-2.45 (dt, J=1.66, 7.30, 7.33 Hz, 2 H, CH2), 3.67-3.71 (m, 2 H, 
CH2), 4.1-4.17 (dd, J=7.16, 14.28 Hz, 2 H, CH2), 4.36-4.43 (q, J=7.16, 7.16, 7.12 Hz, 2 H, 
COOCH2CH3), 7.26-7.28 (m, 2 H, Ar), 8.01-8.04 (d, J=8.48 Hz, 2 H, Ar), 9.75-9.76 (t, 
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J=1.65, 1.65 Hz, 1 H, CHO). The intermediate 338 was used for the next reaction without 
further characterization. 
General procedure for the synthesis of 343 and 346.  
To the solution of aldehydes 335 and 338 (1 eq) in anhydrous Et2O was added 5,5-dibromo-
2,2-dimethyl-4,6-dioxo-1,3-dioxane 302 (1.2 mmol), 2 N HCl in Et2O solution (0.1 eq) and 
the mixture was stirred at room temperature for 48 hours. TLC showed formation of one 
major non-polar spot (hexane/EtOAc 3:1). The reaction solution was washed with 5% 
NaHCO3 solution and extracted with H2O and dried over Na2SO4. Evaporation of the 
solvent yielded unstable α-bromo aldehyde residues 339 and 342 which were used directly 
for the next step without purification and further characterization. To a solution of 2,6-
diamino-4-oxopyrimidine 22 (1 eq) and sodium acetate (2 eq) in water were added α-bromo 
aldehydes (1 eq) and the reaction mixture was stirred at 45 °C for 4 hours. TLC showed 
one major non-polar spot (CHCl3/MeOH). After evaporation of the solvents, CH3OH was 
added followed by celite and methanol was evaporated to afford a plug. The plug was 
loaded onto a silica gel column and flash chromatographed with 10% MeOH in CHCl3. 
Desired fractions (TLC Rf  = 0.5 ; CHCl3/MeOH, 5:1) were pooled and evaporated to afford 
crude pink sticky solids which were dissolved in minimal amount of MeOH and 1 N NaOH.  
The mixture was stirred at room temperature for 12 h. Monitoring the reaction using 
TLC indicated consumption of the starting materials and generation of one major spot at 
the baseline (CHCl3/MeOH). The methanol in the reaction mixture was then evaporated 
under reduced pressure. The resulting basic solution was cooled in ice bath, and the pH 
was adjusted to 3–4 with dropwise addition of 1 N HCl. The resulting suspension was 
cooled at 4–5 °C in the refrigerator for 2 h, and filtered. The residues were washed with a 
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cold water and dried under reduced pressure using P2O5 to afford boc-protected, ester 
hydrolyzed acids 343 and 346. 
General procedure for the synthesis of 344 and 345.  
Bromine (0.9 eq) was added dropwise to 1,4-dioxane and stirred for 10 min. To this 
mixture, CH2Cl2 was added and the resultant solution was added dropwise to an ice-cooled 
solution of 336 and 337 in CH2Cl2. The reaction mixture was then stirred for 3.5 h after 
which aqueous solution of sat. Na2CO3 was added and stirred for an additional 0.5 h. The 
organic layer was then extracted with chloroform, washed with sat. Na2S2O3 followed by 
water, dried over Na2SO4 and concentrated in vacuo to give crude α-bromo aldehyde 
residues 340 and 341 as syrups. The intermediates 340 and 341 were used directly for the 
next step without purification and further characterization. To a solution of 2,6-diamino-4-
oxopyrimidine 22 (1 eq) and sodium acetate (2 eq) in water were added α-bromo aldehydes 
(1 eq) and the reaction mixture was stirred at 45 °C for 4 hours. TLC showed one major 
non-polar spot (CHCl3/MeOH). After evaporation of the solvents, MeOH was added 
followed by celite. Evaporation of the MeOH afforded a plug, which was loaded onto a 
silica gel column and flash chromatographed with 10% MeOH in CHCl3. Desired fractions 
(TLC Rf  = 0.5 ; CHCl3/MeOH, 5:1) were pooled and evaporated to afford crude pink sticky 
solids which were dissolved in minimal amount of MeOH and 1 N NaOH.  
The mixture was stirred at room temperature for 12 h. Monitoring the reaction using 
TLC indicated consumption of the starting materials and generation of one major spot at 
the baseline (CHCl3/MeOH). The methanol in the reaction mixture was then evaporated 
under reduced pressure. The resulting basic solution was cooled in ice bath, and the pH 
was adjusted to 3–4 with dropwise addition of 1 N HCl. The resulting suspension was 
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cooled at 4–5 °C in the refrigerator for 2 h, and filtered. The residues were washed with a 
cold water and dried under reduced pressure using P2O5 to afford acids 344 and 345. 
4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)(tert-
butoxycarbonyl)amino)benzoate (343).  
Compound 343 was prepared using the general method described for the preparation of 
343 and 346, from 335 (240 mg, 0.7 mmol) to give crude 343 (70 mg, 23% over three 
steps) as a light pink powder. TLC Rf  = 0.23 (CHCl3/MeOH, 5:1); 1H NMR (400 MHz, 
DMSO-d6): δ 1.37 (s, 9 H, NHCO(CH3)3), 1.76-1.84 (m, 2 H, CH2), 3.62-3.66 (m, 2 H, 
CH2), 6.34 (s, 1 H, C6-CH), 6.52 (s, br, 2 H, 2-NH2, exch) 7.36-7.38 (d, J=8.40 Hz, 2 H, 
Ar), 7.87-7.90 (d, J=8.48 Hz, 2 H, Ar), 10.56 (s, 1 H, 3-NH, exch), 10.86 (s, 1 H, 7-NH, 
exch). The intermediate 343 was used for the next reaction without further characterization. 
4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propoxy)benzoate 
(344). 
 Compound 344 was prepared using the general method described for the preparation of 
344 and 345, from 336 (859 mg, 3.4 mmol) to give crude 344 (300 mg, 27% over three 
steps) as a pink powder. TLC Rf  = 0.3 (CHCl3/MeOH, 5:1); 1H NMR (400 MHz, DMSO-
d6): δ 2.04-2.13 (m, 2 H, CH2), 2.69-2.73 (m, 2 H, Ar-CH2), 4.02-4.05 (t, J=6.40, 6.40 Hz, 
2 H, ArO-CH2), 6.25-6.42 (s, br, 3 H, C6-CH, 2-NH2, exch), 6.99-7.01 (d, J=8.83 Hz, 2 H, 
Ar), 7.86-7.88 (d, J=8.77 Hz, 2 H, Ar), 10.46 (s, 1 H, 3-NH, exch), 10.81 (s, 1 H, 7-NH, 
exch). The intermediate 344 was used for the next reaction without further characterization. 
 
 249 
4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)thio)benzoate (345).  
Compound 345 was prepared using the general method described for the preparation of 
344 and 345, from 337 (823 mg, 3.6 mmol) to give crude 345 (210 mg, 18% over three 
steps) as a pink powder. TLC Rf  = 0.3 (CHCl3/MeOH, 5:1); 1H NMR (500 MHz, DMSO-
d6): δ 1.692-1,695 (m, 2 H, CH2), 3.01-3.04 (t, J=6.81, 6.81 Hz, 2 H, CH2), 6.74 (s, br, 2 
H, 2-NH2, exch), 7.33-7.34 (d, J=7.15 Hz, 2 H, Ar), 7.82-7.84 (d, J=7.03 Hz, 2 H, Ar), 
10.42 (s, 1 H, 3-NH, exch), 10.58 (s, 1 H, 7-NH, exch). The intermediate 345 was used for 
the next reaction without further characterization. 
4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)(tert-
butoxycarbonyl)amino)benzoate (346).  
Compound 346 was prepared using the general method described for the preparation of 
343 and 346, from 338 (1.06 g, 2.40 mmol) to give crude 346 (85 mg, 16% over three 
steps) as a pink powder. TLC Rf  = 0.25 (CHCl3/MeOH, 5:1); 1H NMR (400 MHz, DMSO-
d6): δ 1.37 (s, 9 H, NHCO(CH3)3), 1.42-1.48 (m, 2 H, CH2), 1.53-1.61 (m, 2 H, CH2), 3.62-
3.66 (m, 2 H, CH2), 6.0 (s, 2 H, 2-NH2, exch), 6.29-6.3 (d, J = 1.73 Hz, 1 H, C6-CH), 7.34-
7.36 (d, J = 8.60 Hz, 2 H, Ar), 7.87-7.90 (d, J = 8.56 Hz, 2 H, Ar), 10.15 (s, 1 H, 3-NH, 
exch), 10.62 (s, 1 H, 7-NH, exch). The intermediate 346 was used for the next reaction 
without further characterization. 
General procedure for the synthesis of 347 and 348.  
Solutions of 343 and 346 (1 eq) in hydrochloric acid/dioxane (3 M in 1,4-dioxane, 16 eq.) 
were stirred at room temperature for 16 h, then the pH was adjusted to 3-4 with NaOH 
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solution at -10 deg °C. The resulting suspension was warmed to 4–5 °C, refrigerated for 2 
h, and filtered. The residues were washed with a cold water and dried under reduced 
pressure using P2O5 to afford crude acids 347 and 348. 
4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)amino)benzoic acid (347).  
Compound 347 was prepared using the general method described for the preparation of 
347 and 348, from 343 (70 mg, 0.16 mmol) to give crude 347 (50 mg, 93%) as a pink 
powder. TLC Rf  = 0.2 (CHCl3/MeOH, 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.83-1.90 
(m, 2 H, CH2), 2.63-2.67 (t, J=7.23, 7.23 Hz, 2 H, CH2), 3.03-3.06 (t, J=6.82, 6.82 Hz, 2 
H, CH2), 6.43-6.74 (m, 6 H, C6-CH, Ar, 2-NH2, exch, Ar-NH, exch), 7.63-7.66 (d, J=8.46 
Hz, 2 H, Ar), 10.67 (s, 1 H, 3-NH, exch), 10.93 (s, 1 H, 7-NH, exch). The intermediate 347 
was used for the next reaction without further characterization. 
4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)amino)benzoic acid (348).  
Compound 348 was prepared using the general method described for the preparation of 
347 and 348, from 346 (80 mg, 0.18 mmol) to give crude 348 (60 mg, 97%) as a pink 
powder. TLC Rf  = 0.2 (CHCl3/MeOH, 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.50-1.74 
(m, 4 H, CH2CH2), 3.06-3.08 (m, 2 H, CH2), 6.15-6.55 (m, 6 H, C6-CH, Ar, Ar-NH, exch, 
2-NH2, exch), 7.63-7.65 (m, 2 H, Ar), 10.28 (s, br, 1 H, 3-NH, exch), 10.72 (s, br, 1 H, 7-
NH, exch). The intermediate 348 was used for the next reaction without further 
characterization. 
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General procedure for the synthesis of 349-352.  
To the acids 347, 344, 345 and 348 (1 eq) in anhydrous DMF were added N-
methylmorpholine (1.2 eq) and 2-chloro-4,6-dimethoxy-1,3,5 triazine (1.2 eq). The 
resulting mixture was stirred at room temperature for 2 h. To this mixture were added N-
methylmorpholine (1.2 eq) and L-glutamate diethyl ester hydrochloride (1.5 eq). The 
reaction mixture was stirred for an additional 12 h at room temperature until disappearance 
of the starting material and formation of a new non-polar spot on TLC and then evaporated 
to dryness under reduced pressure. To the residue, was added minimum amount of MeOH 
followed by silica gel and evaporated to dryness. The resulting plug was loaded on to a 
silica gel column and eluted with CHCl3 followed by gradual increase in polarity to 5% 
MeOH in CHCl3. Fractions with required Rf were pooled and evaporated to afford 
glutamate esters 349-352.  
Diethyl (4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)amino)benzoyl)-L-glutamate (349).  
Compound 349 was prepared using the general method described for the preparation of 
349-352, from 347 (50 mg, 0.22 mmol) and L-glutamate diethyl ester hydrochloride (70 
mg, 0.34 mmol) to give 349 (40 mg, 76%) as a yellow sticky solid. TLC Rf  = 0.6 
(CHCl3/MeOH, 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.15-1.2 (m, 6 H, COOCH2CH3), 
1.83-2.12 (m, 4 H, β-CH2, CH2), 2.39-2.43 (t, 2 H, J=7.49, 7.49 Hz, γ-CH2), 2.63-2.67 (t, 
J=7.30, 7.30 Hz, 2 H, CH2), 3.03-3.06 (m, 2 H, CH2), 4.02-4.11 (m, 4 H, COOCH2CH3), 
4.34-4.4 (m, 1 H, α-CH), 6.00 (s, 2 H, 2-NH2, exch), 6.30-6.32 (t, J = 5.09, 5.09 Hz, 1 H, 
Ar-NH, exch), 6.38 (s, 1 H, C6-CH), 6.52-6.55 (d, J = 8.50 Hz, 2 H, Ar), 7.63-7.66 (d, J = 
8.48 Hz, 2 H, Ar), 8.22-8.24 (d, J = 7.25 Hz, 1 H, CONH, exch), 10.2 (s, 1 H, 3-NH, exch), 
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10.67 (s, 1 H, 7-NH, exch). The intermediate 349 was used for the next reaction without 
further characterization. 
Diethyl (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propoxy)benzoyl)-L-glutamate (350). 
Compound 350 was prepared using the general method described for the preparation of 
349-352, from 344 (287 g, 0.87 mmol) and L-glutamate diethyl ester hydrochloride (315.6 
g, 1.55 mmol) to give 350 (300 mg, 67%) as a pink sticky solid. TLC Rf  = 0.6 
(CHCl3/MeOH, 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.15-1.2 (m, 6 H, COOCH2CH3), 
1.83-2.14 (m, 4 H, β-CH2, CH2), 2.41-2.45 (m, 2 H, γ-CH2), 2.69-2.73 (m, 2 H, CH2), 4.02-
4.13 (m, 4 H, COOCH2CH3), 4.36-4.46 (m, 1 H, α-CH), 5.99 (s, 2 H, 2-NH2, exch), 6.37 
(s, 1 H, C6-CH), 6.98-7.0 (d, J = 8.82 Hz, 2 H, Ar), 7.83-7.85 (d, J = 8.79 Hz, 2 H, Ar), 
8.55-8.57 (d, J = 7.34 Hz, 1 H, CONH, exch), 10.17 (s, 1 H, 3-NH, exch), 10.66 (s, 1 H, 
7-NH, exch). The intermediate 350 was used for the next reaction without further 
characterization. 
Diethyl (4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)thio)benzoyl)-L-glutamate (351).  
Compound 351 was prepared using the general method described for the preparation of 
349-352, from 345 (220 mg, 0.64 mmol) and L-glutamate diethyl ester hydrochloride (195 
g, 0.96 mmol) to give 351 (120 mg, 37%) as a pink sticky solid. TLC Rf  = 0.6 
(CHCl3/MeOH, 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.15-1.22 (m, 6 H, COOCH2CH3), 
1.68 (m, 2 H, CH2), 1.8-2.04 (m, 2 H, β-CH2), 2.42-2.46 (t, J=7.50, 7.50 Hz, γ-CH2), 3.0-
3.04 (t, J = 7.18, 7.18 Hz,  2 H, CH2), 4.02-4.13 (m, 4 H, COOCH2CH3), 4.39-4.44 (m, 1 
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H, α-CH), 5.99 (s, 2 H, 2-NH2, exch), 6.72 (s, 1 H, C6-CH), 7.34-7.35 (d, J = 8.37 Hz, 2 
H, Ar), 7.78-7.80 (d, J = 8.35 Hz, 2 H, Ar), 8.68-8.70 (d, J = 7.36 Hz, 1 H, CONH, exch), 
10.17 (s, 1 H, 3-NH, exch), 10.57 (s, 1 H, 7-NH, exch). The intermediate 351 was used for 
the next reaction without further characterization. 
Diethyl (4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)amino)benzoyl)-L-glutamate (352).  
Compound 352 was prepared using the general method described for the preparation of 
349-352, from 348 (65 mg, 0.19 mmol) and L-glutamate diethyl ester hydrochloride (50 
mg, 0.23 mmol) to give 352 (50 mg, 50%) as a yellow sticky solid. TLC Rf  = 0.5 
(CHCl3/MeOH, 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.15-1.2 (m, 6 H, COOCH2CH3), 
1.52-1.72 (m, 4 H, CH2CH2), 1.93-2.12 (m, 2 H, β-CH2), 2.40-2.43 (t, 2 H, J=7.42, 7.42 
Hz, γ-CH2), 2.58-2.61 (m, 2 H, CH2), 3.04-3.09 (m, 2 H, CH2), 4.02-4.11 (m, 4 H, 
COOCH2CH3), 4.34-4.41 (m, 1 H, α-CH), 5.98 (s, 2 H, 2-NH2, exch), 6.21-6.24 (t, J=4.72, 
4.72 Hz, 1 H, Ar-NH, exch), 6.36 (s, 1 H, C6-CH), 6.53-6.56 (d, J = 8.48 Hz, 2 H, Ar), 
7.64-7.66 (t, J = 8.55 Hz, 2 H, Ar), 8.22-8.24 (d, J = 7.16 Hz, 1 H, CONH, exch), 10.14 
(s, br, 1 H, 3-NH, exch), 10.64 (d, J = 0.70 Hz, 1 H, 7-NH, exch). The intermediate 352 
was used for the next reaction without further characterization. 
General procedure for the synthesis of 194-197.  
To the glutamate esters 349-352 was added 1 N NaOH and the mixture was stirred at room 
temperature for 1 h. Monitoring the reaction using TLC indicated consumption of the 
starting material and generation of one major spot at the baseline (CHCl3/MeOH 5:1). The 
pH of the solution was then adjusted to 3–4 with 1 N HCl (dropwise addition). The resulting 
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suspension was refrigerated at 4–5 °C for 2 h and filtered. The residue was washed with a 
small amount of cold water and dried in vacuum using P2O5 to afford acids 194-197.  
(4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)amino)benzoyl)-L-glutamate (194).  
Compound 194 was prepared using the general method described for the preparation of 
194-197, from 349 (25 mg, 0.05 mmol) to give 194 (20 mg, 90%) as a yellow powder. mp 
149.4 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.84-2.09 (m, 4 H, β-CH2, CH2), 2.32-
2.35 (t, J=7.52, 7.52 Hz, 2 H, γ-CH2), 2.64-2.67 (t, J=7.04, 7.04 Hz, 2 H, CH2), 3.02-3.06 
(dd, J = 6.73, 12.61 Hz, 2 H, CH2), 4.32-4.36 (m, 1 H, α-CH), 5.99 (s, 2 H, 2-NH2, exch), 
6.26-6.28 (t, J = 5.37, 5.37 Hz, 1 H, Ar-NH, exch), 6.37-6.38 (d, J = 2.01 Hz, 1 H, C6-
CH), 6.52-6.54 (d, J = 8.81 Hz, 2 H, Ar), 7.64-7.65 (d, J = 8.78 Hz, 2 H, Ar), 8.1-8.12 (d, 
J = 7.74 Hz, 1 H, CONH, exch), 10.19 (s, 1 H, 3-NH, exch), 10.65 (d, J = 0.97 Hz, 1 H, 
7-NH, exch). HPLC analysis: retention time, 5.4 min; peak area, 95.08%; eluent A, H2O; 
eluent B, ACN; gradient elution (95% H2O to 100% ACN) over 10 mins with flow rate of 
0.5 mL/min and detection at 254 nm; column temperature, rt. LRMS calculated for 
C21H24N6O6 = 456.18, found [M+H]+ 457.10. 
(4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propoxy)benzoyl)-L-glutamic acid (195).  
Compound 195 was prepared using the general method described for the preparation of 
194-197, from 350 (100 mg, 0.19 mmol) to give 195 (50 mg, 78%) as a light green powder. 
mp 150 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.89-2.11 (m, 4 H, β-CH2, CH2), 2.32-
2.35 (t, J=7.25, 7.25 Hz, 2 H, γ-CH2), 2.7-2.73 (m, 2 H, CH2), 4.0-4.03 (t, J = 6.27, 6.27 
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Hz, 2 H, CH2), 4.33-4.36 (m, 1 H, α-CH), 5.99 (s, 2 H, 2-NH2, exch), 6.36-6.37 (d, J = 1.43 
Hz, 1 H, C6-CH), 6.97-6.99 (d, J = 8.82 Hz, 2 H, Ar), 7.82-7.84 (d, J = 8.81 Hz, 2 H, Ar), 
8.38-8.40 (d, J = 7.56 Hz, 1 H, CONH, exch), 10.18 (s, 1 H, 3-NH, exch), 10.65 (d, J = 
0.99 Hz, 1 H, 7-NH, exch). Anal. Calcd for C21H23N5O7 ꞏ 1.25 H2O: C, 52.54; H, 5.35; N, 
14.58. Found C, 52.58; H, 5.2; N, 14.39.  
(4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)thio)benzoyl)-L-glutamic acid (196).  
Compound 196 was prepared using the general method described for the preparation of 
194-197, from 351 (120 mg, 0.22 mmol) to give 196 (40 mg, 45%) as a buff colored 
powder. mp 137 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.80-1.99 (m, 4 H, β-CH2, 
CH2), 2.33-2.37 (m, 2 H, γ-CH2), 2.99-3.03 (t, J=7.05, 7.05 Hz, 2 H, CH2), 4.36-4.38 (m, 
1 H, α-CH), 5.99 (s, 2 H, 2-NH2, exch), 6.37-6.38 (s, 1 H, C6-CH), 7.32-7.34 (d, J = 8.28 
Hz, 2 H, Ar), 7.79-7.81 (d, J = 8.39 Hz, 2 H, Ar), 8.62 (s, br, 1 H, CONH, exch), 10.18 (s, 
1 H, 3-NH, exch), 10.56 (d, J=0.97 Hz, 1 H, 7-NH, exch). Anal. Calcd for C21H23N5O7 ꞏ 
1.39 H2O: C, 50.58; H, 5.21; N, 14.04; S, 6.43. Found C, 50.65; H, 5.03, N, 13.85; S, 6.16.  
(4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)amino)benzoyl)-L-glutamate (197).  
Compound 197 was prepared using the general method described for the preparation of 
194-197, from 352 (50 mg, 0.09 mmol) to give 197 (30 mg, 67%) as a pink powder. mp 
129.7 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.54-1.59 (m, 2 H, CH2), 1.64-1.72 (m, 2 
H, CH2), 1.87-2.09 (m, 2 H, β-CH2), 2.31-2.35 (t, J=7.36, 7.36 Hz, 2 H, γ-CH2), 2.58-2.62 
(t, J=7.09, 7.09 Hz, 2 H, CH2), 3.04-3.09 (dd, J=6.14, 11.91 Hz, 2 H, CH2), 4.31-4.37 (m, 
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1 H, α-CH), 5.99 (s, 2 H, 2-NH2, exch), 6.19-6.22 (t, J = 5.33, 5.33 Hz, 1 H, Ar-NH, exch), 
6.36-6.362 (d, J = 1.20 Hz, 1 H, C6-CH), 6.53-6.56 (d, J = 8.80 Hz, 2 H, Ar), 7.64-7.66 
(t, J=8.63 Hz, 2 H, Ar), 8.08-8.10 (d, J = 7.16 Hz, 1 H, CONH, exch), 10.15 (s, br, 1 H, 3-
NH, exch), 10.63-10.64 (d, J=1.62 Hz, 1 H, 7-NH, exch). HPLC analysis: retention time, 
8.29 min; peak area, 96.17%; eluent A, H2O; eluent B, ACN; gradient elution (95% H2O 
to 100% ACN) over 10 mins with flow rate of 0.5 mL/min and detection at 254 nm; column 
temperature, rt. LRMS calculated for C22H26N6O6 = 470.19, found [M+H]+ 471.2 and [M-
H]- 469.2. 
Methyl 2-fluoro-4-(6-oxohexyl)benzoate (354).  
To a solution of methyl 4-bromo-2-fluorobenzoate (353) (2.33 g, 10 mmol, 1 eq) in 
anhydrous DMF (20 mL) was added hex-2-en-1-ol 299 (1.18 mL, 10 mmol, 1 eq), LiCl 
(424 mg, 10 mmol, 1 eq), LiOAc (1.65 g, 25 mmol, 2.5 eq), Bu4NCl (2.82 g, 10 mmol, 1 
eq), Pd(OAc)2 (135 mg, 0.6 mmol, 0.06 eq) and the mixture was stirred at 90 °C for 2.5 h. 
TLC showed the disappearance of the starting material and formation of one major non-
polar spot. After the reaction mixture was cooled to room temperature, ethyl acetate (3 X 
20 mL) was added and the resulting solution was extracted with H2O (2 X 20 mL) and 
dried over Na2SO4. After evaporation of solvent, the residue was loaded on a silica gel 
column and flash-chromatographed with hexane followed by gradual increase in polarity 
to 100% EtOAc and the desired fractions were pooled. After evaporation of solvent the 
residue was dried in vacuo using P2O5 to afford 354 (1.5 g, 59%), as a colorless syrup. TLC 
Rf = 0.8 (hexane/EtOAc, 1:1); 1H NMR (400 MHz, CDCl3): δ 1.38 (tt, J = 6.38, 6.38, 10.15, 
10.15 Hz, 2 H, CH2), 1.63-1.72 (m, 4 H, CH2CH2), 2.44-2.48 (dt, J = 1.62, 7.30, 7.30 Hz, 
2 H, CHO-CH2), 2.65-2.69 (m, 2 H, Ar-CH2), 3.94 (s, 3 H, COOCH3), 6.94-6.98 (dd, J = 
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1.34, 11.88 Hz, 1 H, Ar), 7.01-7.03 (dd, J = 1.44, 7.96 Hz, 1 H, Ar), 7.85-7.89 (t, J = 7.81, 
7.81 Hz, 1 H, Ar), 9.79 (t, J = 1.62, 1.62 Hz, 1 H, CHO). The intermediate 354 was used 
for the next reaction without further characterization. 
Methyl 4-(4-(2-amino-4-hydroxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)-2-
fluorobenzoate (356).  
To a solution of aldehyde 354 (500 mg, 1.88 mmol, 1 eq) in anhydrous Et2O was added 
5,5-dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 302 (283 mg, 0.94 mmol, 0.5 eq), 2 N 
HCl in Et2O solution (0.01 mL, 0.18 mmol, 0.1 eq) and the mixture was stirred at room 
temperature for 48 hours. TLC showed the disappearance of the starting material and 
formation of one major non-polar spot. The reaction solution was washed with 5% 
NaHCO3 solution and extracted with H2O and dried over Na2SO4. After evaporation of 
solvent, the orange colored syrupy residue, α-bromo aldehyde 355 was used for directly 
for next step without further characterization. To a solution of 2,6-diamino-4-
oxopyrimidine 22 (237 mg, 1.88 mmol, 1 eq) and sodium acetate (308 mg, 3.76 mmol, 2 
eq) in water (5 mL) and methanol (5 mL) was added α-bromo aldehyde 355 (649 mg, 1.88 
mmol, 1 eq). The reaction mixture was stirred at 45 °C for 4 hours. TLC showed the 
disappearance of starting materials and the formation of one new major spot 
(CHCl3/MeOH, 5:1). After evaporation of solvent, MeOH was added followed by silica 
gel. Evaporation of the solvent afforded a plug, which was loaded onto a silica gel column 
and eluted with 10% MeOH in CHCl3. Fractions with required Rf were pooled and 
evaporated to afford crude 356 (150 mg, 20%) as a pink sticky solid. TLC Rf = 0.5 
(CHCl3/MeOH 5:1); 1H NMR (500 MHz, DMSO-d6): δ 1.60-1.607 (m, 4 H, CH2CH2), 
2.57-2.60 (t, J=6.55, 6.55 Hz, 2 H, Ar-CH2), 2.65-2.67 (t, J=6.79, 6.79 Hz, 2 H, Ar-CH2), 
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3.83 (s, 1 H, COOCH3), 5.94 (s, 2 H, 2-NH2, exch), 6.332-6.335 (d, J = 1.85 Hz, 1 H, C6-
CH), 7.14-7.19 (dd, J = 7.52, 15.65 Hz, 2 H, Ar), 7.77-7.8 (t, J = 7.86, 7.86 Hz, 1 H, Ar), 
10.08 (s, 1 H, 3-NH, exch), 10.59 (s, 1 H, 7-NH, exch). The intermediate 356 was used for 
the next reaction without further characterization. 
4-(4-(2-amino-4-hydroxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)-2-fluorobenzoate 
(357).  
To 356 (150 mg, 0.4 mmol),  was added 1 N NaOH (3 mL) and the resulting mixture was 
stirred under N2 at room temperature for 12 h. TLC indicated the disappearance of starting 
material and the formation of one major spot at the origin. The resulting solution was 
cooled in an ice bath, and the pH was adjusted 3 to 4 using 1 N HCl. The resulting 
suspension was chilled in a dry ice/acetone bath and thawed to 4 °C overnight in a 
refrigerator. The precipitate was filtered, washed with cold water, and dried in a desiccator 
under reduced pressure using P2O5 to afford crude acid 357 (88 mg, 61%) as a buff colored 
powder. TLC Rf = 0.3 (CHCl3/MeOH 5:1); 1H NMR (400 MHz, DMSO-d6): δ 1.58-1.60 
(m, 4 H, CH2CH2), 2.45-2.68 (m, 4 H, Ar-CH2, Ar-CH2), 6.05-6.08 (s, 2 H, 2-NH2, exch), 
6.35-6.36 (d, J = 2.15 Hz, 1 H, C6-CH), 7.11-7.12 (m, 2 H, Ar), 7.77-7.8 (t, J = 8.09, 8.09 
Hz, 1 H, Ar), 10.19 (s, 1 H, 3-NH, exch), 10.65-10.66 (d, J=1.99 Hz, 1 H, 7-NH, exch). 
The intermediate 357 was used for the next reaction without further characterization. 
Diethyl (4-(4-(2-amino-4-hydroxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)-2-
fluorobenzoyl)-L-glutamate (358).  
To a solution of 357 (80 mg, 0.23 mmol, 1 eq) in anhydrous DMF (5 mL) was added 6-
chloro-2,4-dimethoxy-1,3,5-triazine (49 mg, 0.3 mmol, 1.2 eq) and N-methylmorpholine 
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(0.03 mL, 0.3 mmol, 1.2 eq). After the mixture was stirred at room temperature for 2 h, N-
methylmorpholine (0.03 mL, 0.3 mmol, 1.2 eq) and dimethyl L-glutamate hydrochloride 
(71 mg, 0.35 mmol, 1.5 eq) were added all at once. The mixture was stirred at room 
temperature for 12 h. TLC showed the formation of one major non-polar spot and 
disappearance of starting material (CHCl3/MeOH). The reaction mixture was evaporated 
to dryness under reduced pressure. To the residue, MeOH was added followed by silica gel 
and the mixture was evaporated to afford a plug. The plug was loaded onto a silica gel 
column and eluted initially with CHCl3 followed by gradual increase in polarity to 10% 
MeOH in CHCl3. Fractions with required Rf were pooled and evaporated to afford crude 
358 (100 mg, 81%) as a pink sticky solid. TLC Rf = 0.5 (CHCl3/MeOH 5:1); 1H NMR (500 
MHz, DMSO-d6): δ 1.15-1.21 (m, 6 H, COOCH2CH3), 1.50-1.54 (m, 2 H, CH2), 1.71-2.1 
(m, 4 H, β-CH2, CH2), 2.43-2.46 (m, 2 H, γ-CH2), 2.54-2.63 (m, 2 H, Ar-CH2), 4.02-4.14 
(m, 4 H, COOCH2CH3), 4.41-4.42 (m, 1 H, α-CH), 6.68 (s, br, 1 H, C6-CH), 7.08-7.13 (m, 
2 H, Ar), 7.46-7.5 (dt, J=3.11, 7.60, 7.61 Hz, 1 H, Ar), 8.56-8.57 (d, J=7.09 Hz, 1 H, 
CONH, exch), 10.51 (s, 1 H, 7-NH, exch). The intermediate 358 was used for the next 
reaction without further characterization. 
(4-(4-(2-amino-4-hydroxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)-2-fluorobenzoyl)-
L-glutamate (198).  
To 366 (70 mg, 0.13 mmol) was added 1 N NaOH (3 mL) and the resulting mixture was 
stirred at room temperature for 1 h. TLC indicated the disappearance of starting material 
and the formation of one major spot at the origin. The solution was cooled in an ice bath, 
and the pH was adjusted to 3-4 using 1 N HCl. The resulting suspension was chilled in a 
dry ice/acetone bath and thawed to 4 °C overnight in a refrigerator. The precipitate was 
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filtered, washed with cold water, and dried in a desiccator under reduced pressure using 
P2O5 to yield 198 (50 mg, 80%) as a yellow powder. mp 131.8 °C dec. 1H NMR (400 MHz, 
DMSO-d6): δ 1.60-1.66 (m, 4 H, CH2 CH2), 1.82-2.13 (m, 2 H, β-CH2,), 2. 3-2.38 (m, 2 H, 
γ-CH2), 2.57-2.69 (m, 2 H, Ar-CH2), 4.33-4.43 (m, 1 H, α-CH), 6.07 (s, br, 2 H, 2-NH2, 
exch) 6.32-6.41 (s, br, 1 H, C6-CH), 7.05-7.19 (m, 2 H, Ar), 7.46-7.56 (dt, J = 3.11, 7.60, 
7.61 Hz, 1 H, Ar), 8.39-8.46 (d, J = 7.09 Hz, 1 H, CONH exch), 10.15-10.17 (s, br, 1 H, 
3-NH, exch), 10.51 (s, 1 H, 7-NH, exch). Anal. Calcd for C22H24FN5O6 ꞏ 1.12 H2O: C, 
53.57; H, 5.35; N, 14.2; F, 3.85. Found: C, 53.57, H, 5.23, N, 14.01, F, 3.66  
2-Amino-6-hydrazinopyrimidin-4(3H)-one (360).  
To a stirred suspension of 359 (2 g, 13.74 mmol, 1 eq) in water (20 mL) was added 
anhydrous hydrazine (1.56 mL, 50 mmol, 3.65 eq), and the mixture was heated to reflux 
for 3 h. The resulting clear solution was cooled, and the precipitate that separated was 
collected by filtration, washed with water followed by ethanol and dried to give 360 (1.4 
g, 72%) as a buff colored powder. mp 274 °C dec. Compound 360 spots very faintly AND 
doesn’t run on TLC (CHCl3/MeOH). 1H NMR (400 MHz, DMSO-d6): δ 4.03 (s, 2 H, NH-
NH2, exch), 4.77 (s, 1 H, 6-NH, exch), 6.10 (s, 2 H, 2-NH2, exch), 7.25 (s, 1 H, C5-CH), 
9.65 (s, 1 H, 3-NH, exch). 1H NMR matches with the reported NMR.381  
Methyl 4-(4-oxopentyl)benzoate (363).  
To a solution of methyl 4-iodobenzoate (361) (1.4 g, 5 mmol, 1 eq) in DMF (20 mL) was 
added pent-4-en-2-ol 362 (0.52 ml, 5 mmol, 1 eq), LiCl (212 mg, 5 mmol, 1 eq), LiOAc 
(825 mg, 12.5 mmol, 2.5 eq), Bu4NCl (1.41 g, 5 mmol, 1 eq), Pd(OAc)2 (68 mg, 0.3 mmol, 
0.06 eq) and the mixture was stirred at 80 °C for 3 hours. TLC showed the disappearance 
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of the starting material and formation of one major polar spot (hexane/EtOAc). To the 
reaction mixture cooled to room temperature was added ethyl acetate. The resulting 
solution was extracted with H2O and dried over Na2SO4. After evaporation of solvent, the 
residue was loaded on a silica gel column and flash-chromatographed with hexane 
followed by gradual increase in polarity to 100% EtOAc. The desired fractions were 
pooled, evaporated and the residue was dried in vacuo using P2O5 to afford 363 (788 mg, 
72%) as colorless SYRUP. TLC Rf = 0.42 (hexane/EtOAc 3:1); 1H NMR (400 MHz, 
DMSO-d6): δ 1.73-1.81 (m, 2 H, CH2), 2.07 (s, 3 H, COCH3), 2.42-2.46 (t, J = 7.31, 7.31 
Hz, 2 H, Ar-CH2), 2.6-2.64 (m, 2 H, CH2), 3.84 (s, 3 H, COOCH3), 7.33-7.36 (d, J = 8.33 
Hz, 2 H, Ar), 7.87-7.89 (d, J = 8.30 Hz, 2 H). 1H NMR matches with the reported NMR.381 
Methyl-4-(4-(2-(2-amino-6-oxo-1,6-dihydropyrimidin-4-
yl)hydrazineylidene)pentyl)benzoate (364).  
A mixture of the ketone 363 (591 mg, 2.52 mmol, 1 eq) and 2-Amino-6-
hydrazinopyrimidin-4(3H)-one 360 (356 mg, 2.52 mmol, 1 eq) in 2-methoxyethanol (20 
mL) was refluxed for 14 h, then cooled to room temperature and filtered. The filtrate was 
concentrated to which 1:1 ether/hexanes were added, and the resulting brownish powder 
was collected by filtration to afford 364 (770 mg, 89%) as a light brown powder. TLC Rf 
= 0.2 (CHCl3/MeOH, 5:1); mp 240 °C.381 1H NMR (400 MHz, DMSO-d6): δ 1.78-86 (m, 
5 H, CNCH3, CH2), 2.2-2.24 (t, J=7.35, 7.35 Hz, 2 H, CH2), 2.66-2.7 (t, J=7.58, 7.58 Hz, 
2 H, CH2), 3.84 (s, 3 H, COOCH3), 5.09 (s, 1 H, C5-CH), 6.18 (s, 2 H, 2-NH2, exch), 7.36-
7.42 (m, 2 H, Ar), 7.88-7.89 (d, J = 8.22 Hz, 2 H, Ar), 8.75 (s, 1 H, 6-NH, exch), 9.95 (s, 
1 H, 3-NH, exch). 1H NMR matches with the reported NMR.381  
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Methyl 4-(2-(2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)benzoate (365).  
A mixture of 364 (350 mg, 1.02 mmol), in diphenyl ether (20 mL) was stirred and heated 
under reflux for 6 h. After cooling to room temperature, hexanes were added and the 
precipitated powder was collected by filtration and run through a quick silica column with 
5% MeOH in CHCl3 as the eluent to give cyclized 365 (255 mg, 77%) as a yellow powder. 
TLC Rf = 0.25 (CHCl3/MeOH, 5:1); mp 260 °C.381 1H NMR (400 MHz, DMSO-d6): δ 1.83 
(s, 3 H, Ar-CH3), 2.75-2.79 (t, J = 7.29, 7.29 Hz, 2 H, Ar-CH2), 2.89-2.93 (m, 2 H, Ar-
CH2), 3.83 (s, 3 H, COOCH3), 5.96 (s, 2 H, 2-NH2, exch), 7.26-7.28 (d, J = 8.20 Hz, 2 H, 
Ar), 7.83-7.85 (d, J = 8.16 Hz, 2 H, Ar), 10.1 (s, 1 H, 3-NH, exch), 10.5 (s, 1 H, 7-NH, 
exch). 1H NMR matches with the reported NMR.381  
4-(2-(2-amino-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)benzoate (366).  
To 365 (250 mg, 0.77 mmol)  was added 1 N NaOH (5 mL) and the resulting mixture was 
stirred under N2 at room temperature for 12 h. TLC indicated the disappearance of starting 
material and the formation of one major polar spot (CHCl3/MeOH). The resulting solution 
was cooled in an ice bath, and the pH was adjusted to 3-4 using 1 N HCl. The resulting 
suspension was chilled in a dry ice/acetone bath and thawed to 4 °C overnight in a 
refrigerator. The precipitate was filtered, washed with cold water, and dried in a desiccator 
under reduced pressure using P2O5 to afford acid 366 (150 mg, 63%) as a buff colored 
powder. TLC Rf = 0.1 (CHCl3/MeOH, 5:1); mp 194 °C.381 1H NMR (400 MHz, DMSO-
d6): δ 1.84 (s, 3 H, CH3), 2.75-2.79 (t, J=7.29, 7.29 Hz, 2 H, Ar-CH2), 2.87-2.91 (m, 2 H, 
Ar-CH2), 6.3 (s, 2 H, 2-NH2, exch), 7.23-7.25 (d, J = 8.16 Hz, 2 H, Ar), 7.81-7.83 (d, J = 
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8.13 Hz, 2 H, Ar), 10.4 (s, 1 H, 3-NH, exch), 10.7 (s, 1 H, 7-NH, exch). 1H NMR matches 
with the reported NMR.381  
 Ethyl (4-(2-(2-amino-4-hydroxy-6-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)benzoyl)-L-glutamate (367).  
To a solution of 366 (150 mg, 0.48 mmol, 1 eq) in anhydrous DMF was added 6-chloro-
2,4-dimethoxy-1,3,5-triazine (101 mg, 0.58 mmol, 1.2 eq) and N-methylmorpholine (0.06 
mL, 0.58 mmol, 1.2 eq). After the mixture was stirred at room temperature for 2 h, N-
methylmorpholine (0.06 mL, 0.58 mmol, 1.2 eq) and dimethyl L-glutamate hydrochloride 
(146 mg, 0.72 mmol, 1.5 eq) were added all at once. The mixture was stirred at room 
temperature for 12 h. TLC showed the formation of one major non-polar spot and 
disappearance of starting material (CHCl3/MeOH). The reaction mixture was evaporated 
to dryness under reduced pressure and the residue was dissolved in MeOH. To the solution, 
celite was added and the solvent was evaporated to afford a plug. The plug was loaded on 
a silica gel column and flash-chromatographed with CHCl3 followed by gradual increase 
in polarity to 5% MeOH in CHCl3. The fractions with desired Rf were pooled, evaporated 
and the residue was dried in vacuo using P2O5 to afford the glutamate ester 367 (100 mg, 
42%) as a light pink sticky solid. TLC Rf = 0.5 (CHCl3/MeOH, 5:1); 1H NMR (400 MHz, 
DMSO-d6): δ 1.15-1.2 (m, 6 H, COOCH2CH3), 1.85 (s, 3 H, Ar-CH3), 1.96-2.15 (m, 2 H, 
β-CH2), 2.42-2.46 (t, J = 7.86, 7.86 Hz, 2 H, γ-CH2) 2.75-2.79 (m, 2 H, Ar-CH2), 2.87-
2.91 (m, 2 H, Ar-CH2), 4.02-4.16 (m, 4 H, COOCH2CH3), 4.39-4.45 (m, 1 H, α-CH), 5.96 
(s, 2 H, 2-NH2, exch), 7.22-7.24 (d, J = 8.28 Hz, 2 H, Ar), 7.75-7.77 (d, J = 8.07 Hz, 2 H, 
Ar), 8.64-8.66 (d, J = 7.39 Hz, 1 H, CONH exch), 10.1 (s, 1 H, 3-NH, exch), 10.5 (s, 1 H, 
7-NH, exch). 1H NMR matches with the reported NMR.381   
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(4-(2-(2-amino-4-hydroxy-6-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoyl)-
L-glutamate (200).  
To 367 (60 mg, 0.12 mmol), was added 1 N NaOH (3 mL) and the resulting mixture was 
stirred at room temperature for 1 h. TLC indicated the disappearance of starting material 
and the formation of one major spot at the origin (CHCl3/MeOH). The solution was cooled 
in an ice bath, and the pH was adjusted to 3-4 using 1 N HCl. The resulting suspension was 
chilled in a dry ice/acetone bath and thawed to 4 °C overnight in a refrigerator. The 
precipitate was filtered, washed with cold water, and dried in a desiccator under reduced 
pressure using P2O5, to afford 200 (40 mg, 75%) as a buff colored powder. mp 164.6 °C. 
1H NMR (400 MHz, DMSO-d6): δ 1.85 (s, 3 H, Ar-CH3), 1.94-2.11 (m, 2 H, β-CH2), 2.33-
2.38 (t, J = 7.86, 7.86 Hz, 2 H, γ-CH2) 2.75-2.78 (m, 2 H, Ar-CH2), 2.86-2.9 (m, 2 H, Ar-
CH2), 4.35-4.42 (m, 1 H, α-CH), 5.97 (s, 2 H, 2-NH2, exch), 7.2-7.23 (d, J = 8.25 Hz, 2 H, 
Ar), 7.75-7.77 (d, J = 8.12 Hz, 2 H, Ar), 8.53-8.55 (d, J = 7.64 Hz, 1 H, CONH exch), 
10.11 (s, 1 H, 3-NH, exch), 10.5 (s, 1 H, 7-NH, exch). Anal. Calcd for C21H23N5O6 ꞏ 0.95 
H2O: C, 54.99; H, 5.47; N, 15.27. Found: C, 55.04; H, 5.42; N, 15.09. 1H NMR matches 
with the reported NMR.381  
Methyl 4-(6-oxoheptyl)benzoate (370).  
To a solution of methyl 4-bromobenzoate (361) (942 mg, 4.48 mmol, 1 eq) in DMF (20 
mL) was added hept-6-en-2-ol 377 (0.6 ml, 4.48 mmol, 1 eq), LiCl (186 mg, 4.48 mmol, 1 
eq), LiOAc (723 mg, 11 mmol, 2.5 eq), Bu4NI (1.64 g, 4.48 mmol, 1 eq), Pd(OAc)2 (59 
mg, 0.26 mmol, 0.06 eq) and the mixture was stirred at 80 °C for 3 hours. TLC 
(hexane/EtOAc) showed the disappearance of the starting material and formation of one 
major polar spot. To the reaction mixture cooled to room temperature was added ethyl 
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acetate. The resulting solution was extracted with H2O and dried over Na2SO4. After 
evaporation of solvent, the residue was dissolved in MeOH followed by the addition of 
celite. The solution was evaporated to dryness to afford a plug which was loaded on a silica 
gel column and flash-chromatographed with hexanes followed by gradual increase in 
polarity to 100% EtOAc. The desired fractions were pooled, evaporated and the residue 
was dried in vacuo using P2O5 to afford 370 (700 mg, 64%) as colorless liquid. TLC Rf = 
0.5 (hexane/EtOAc 3:1); 1H NMR (400 MHz, CDCl3): δ 1.3-1.38 (m, 2 H, CH2), 1.58-1.7 
(m, 4 H, CH2CH2), 2.15 (s, 3 H, COCH3), 2.4-2.46 (t, J=7.41, 7.41 Hz, 2 H, CH2), 2.66-
2.7 (t, J=7.69, 7.69 Hz, 2 H, CH2), 3.92 (s, 3 H, COOCH3), 7.24-7.26 (d, J = 8.04 Hz, 2 
H, Ar), 7.96-7.98 (d, J = 8.03 Hz, 2 H, Ar). The intermediate 370 was used for the next 
reaction without further characterization. 
Methyl 4-(6-(2-(2-amino-6-oxo-1,6-dihydropyrimidin-4-
yl)hydrazineylidene)heptyl)benzoate (371).  
A mixture of the ketone 370 (580 mg, 2.34 mmol, 1 eq) and 2-Amino-6-
hydrazinopyrimidin-4(3H)-one 360 (330 mg, 2.52 mmol, 1 eq) in 2-methoxyethanol (20 
mL) was refluxed for 14  h, then cooled to room temperature and filtered. The filtrate was 
concentrated to which 1:1 ether/hexanes were added, and the resulting brownish powder 
was collected by filtration to afford 371 (700 mg, 87%) as a light brown powder. TLC Rf 
= 0.3 (CHCl3/MeOH, 5:1);  1H NMR (400 MHz, DMSO-d6): δ 1.26-1.35 (m, 2 H, CH2), 
1.49-1.56 (m, 2 H, CH2), 1.58-1.66 (m, 2 H, CH2), 1.82 (s, 3 H, CNCH3), 2.17-2.21 (m, 2 
H, Ar-CH2), 2.63-2.68 (m, 2 H, Ar-CH2), 3.84 (s, 3 H, COOCH3), 5.07 (s, 1 H, C5-CH), 
6.16 (s, 2 H, 2-NH2, exch), 7.34-7.36 (d, J=8.18 Hz, 2 H, Ar), 7.86-7.88 (d, J=10.28 Hz, 
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2 H, Ar), 8.7 (s, 1 H, 6-NH, exch), 9.92 (s, 1 H, 3-NH, exch). The intermediate 371 was 
used for the next reaction without further characterization. 
Methyl 4-(1-hydroxybut-3-yn-1-yl)benzoate (376).  
To a solution of methyl 4-formylbenzoate 375 (12 g, 73 mmol, 1 eq) in THF (40 mL), sat. 
aqueous NH4Cl (160 mL) followed by propargyl bromide bromide (80% wt in toluene) 
312 (13.85 mL, 146 mmol, 2.0 equiv) were added. To this mixture, activated zinc dust 
(9.56 g, 146 mmol, 2.0 equiv) was slowly added portion wise at 0 °C and the resulting 
solution was stirred for 1 h at 0 °C. The reaction mixture was warmed to room temperature 
and stirred for additional 24 h until a new major polar spot was observed by TLC analysis 
(hexane/EtOAc). The reaction mixture was extracted by EtOAc (3 × 100 mL) and the 
combined organic layers were dried over anhydrous Na2SO4, filtered, and the organic phase 
was concentrated under reduced pressure to afford a colorless syrupy residue. Celite was 
added to the residue dissolved in MeOH and the solvent was evaporated to afford a celite 
plug. The plug was loaded onto a silica gel column and flash chromatographed with hexane 
followed by gradual increase in polarity to 100% EtOAc. The fractions with the required 
Rf were collected and evaporated to afford 376 (10.5 g, 70%) as a colorless syrup. TLC Rf  
= 0.2 (hexane/EtOAc 3:1); 1H NMR (400 MHz, DMSO-d6): δ 2.10-212 (t, J=2.64, 2.64 
Hz, 1 H, CH), 2.50-2.51 (d, J=2.42 Hz, 1 H, OH, exch),  2.61-2.74 (m, 2 H, CH2), 3.94 (s, 
3 H, COOCH3), 4.95-4.99 (m, 1 H, OH-CH), 7.48-7.51 (d, J = 8.67 Hz, 2 H, Ar), 8.05-
8.07 (d, J = 8.36 Hz, 2 H, Ar). 1H NMR matches with the reported NMR.397 The 
intermediate 376 was used for the next reaction without further characterization. 
 
 267 
Methyl 4-(1-(2,2,2-trifluoroacetoxy)but-3-yn-1-yl)benzoate (377).  
TFA (0.15 mL, 1.96 mmol, 2 eq) was added to a solution of 376 (200 mg, 0.98 mmol, 1 
eq) in CH2Cl2 (8 mL). The solution changed color immediately to bright pink. This solution 
was cooled in an ice bath to which triethylsilane (0.3 mL, 1.96 mmol, 2 eq) was added 
dropwise to form a light blue solution that gradually turned colorless. The reaction vessel 
was allowed to warm to room temperature and the mixture was kept stirring for 7 days. A 
new non-polar spot was observed under TLC and the reaction did not go to completion 
(hexane/EtOAc). The yellow solution formed was quenched with sat aq. NaHCO3 (10 mL), 
extracted with EtOAc (30 mL) and the organic layer was evaporated to afford a yellow 
residue. To the residue MeOH and celite were added and the resultant mixture was 
evaporated to dryness in vacuo to afford a plug. The plug was loaded onto a silica gel 
column and flash chromatographed with hexane followed by gradual increase in polarity 
to 100% EtOAc. The fractions with the required Rf were collected and evaporated to afford 
377 (88 mg, 48%) as a yellow syrup. TLC Rf  = 0.5 (hexane/EtOAc 3:1); 1H NMR (400 
MHz, DMSO-d6): δ 2.98-3.02 (m, 3 H, CH2, CH), 3.87 (s, 3 H, COOCH3), 6.17-6.2 (t, J = 
6.10, 6.10 Hz, 1 H, O-CH), 7.62-7.64 (d, J = 8.29 Hz, 2 H, Ar), 8.0-8.02 (d, J = 8.32 Hz, 
2 H, Ar). The intermediate 377 was not characterized further. 
2-Amino-6-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (378).  
To a suspension of 2,4-diamino-6-hydroxypyrimidine 22 (10g, 80 mmol, 1 eq) in water 
(200 mL), sodium acetate (6.5 g, 80 mmol, 1 eq) was added and refluxed. After  the  
addition  of chloroacetone (7.66 ml, 95 mmol, 1.2 eq)  in  portions  (1.5 h),  the  solution  
cleared  up  and was  stirred  at  reflux  for  3.5 h until the reaction went to completion a 
new non-polar spot was observed on TLC (CHCl3/MeOH).  The reaction mixture was 
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cooled at 4 °C overnight and the precipitate that formed was filtered, washed with cold 
water and dried in vacuo. The crude product 378 (9 g, 69%) was obtained as a pink powder. 
TLC Rf = 0.06 (CHCl3/MeOH, 5:1); mp 213 °C. 1H NMR (400 MHz, DMSO-d6): δ 2.15 
(a, 3 H, Ar-CH3), 5.84 (s, 1 H, C5-CH), 5.98 (s, 2 H, 2-NH2, exch), 10.14 (s, 1 H, 3-NH, 
exch), 10.8 (s, 1 H, 7-NH, exch). 1H NMR matches with the 1H NMR of reported 
compound.398  
N-(6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide (379).  
A solution of 378 (5 g, 30 mmol) in trimethylacetic anhydride (16 mL, 82 mmol, 2.7 eq) 
stirred at 120 °C for 12 h until the reaction went to completion and a new non-polar spot 
was observed under TLC (CHCl3/MeOH). The reaction mixture was brought to room 
temperature and then cooled in an ice bath. Freezer cold ether (100 ml) was added to give 
a precipitate which was filtered and dried on high vacuum to afford crude 379 (7 g, 6.83 
mmol, 93% yield) as a light brown powder. TLC Rf = 0.25 (CHCl3/MeOH, 5:1); mp 293 
°C dec.399 1H NMR (400 MHz, DMSO-d6) δ 1.24 (s, 9 H, (CH3)3), 2.26 (s, 3 H, Ar-CH3), 
6.08 (s, 1 H, C5-CH), 10.78 (s, 1 H, 2-NH, exch), 11.37 (s, 1 H, 3-NH, exch), 11.8 (s, 1 H, 
7-NH, exch). 1H NMR matches with the 1H NMR of reported compound.399  
N-(5-iodo-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide 
(373).  
To the suspension of 379 (6 g, 24 mmol, 1 eq) in CH2Cl2 (300 mL), NIS (3 mL, 29 mmol, 
1.2 eq) was added and the resulting solution was stirred at 40 °C for 0.5 h until the 
disappearance of starting material and formation of a non-polar spot (CHCl3/MeOH). The 
reaction was cooled to room temperature which was washed with aqueous Na2S2O3 
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followed by brine. The combined organic layers were filtered through a plug of silica, and 
rinsed with CH2Cl2/MeOH (95/5). The solvent was evaporated to obtain crude product 373 
(8.3 g, 93%) as a light brown powder. TLC Rf = 0.3 (CHCl3/MeOH, 5:1); mp 180.4 °C. 1H 
NMR (400 MHz, DMSO-d6): δ 1.22 (s, 9 H, (CH3)3), 2.22 (s, 3 H, CH3), 10.79 (s, 1 H, 2-
NH, exch), 11.82 (s, 1 H, 3-NH, exch), 11.88 (s, 1 H, 7-NH, exch). The intermediate 373 
was used for the next reaction without further characterization. 
N-(5-bromo-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-
yl)pivalamide (380).  
To the suspension of 379 (500 mg, 2 mmol, 1 eq) in CH2Cl2 (300 mL), NBS (430 mg, 2.42 
mmol, 1.2 eq) was added and the resulting solution was stirred at 40 °C for 0.5 h until the 
disappearance of starting material and formation of a non-polar spot (CHCl3/MeOH). The 
reaction was cooled to room temperature which was washed with aqueous Na2S2O3 
followed by brine. The combined organic layers were filtered through a plug of silica, and 
rinsed with CH2Cl2/MeOH (95/5). The solvent was evaporated to obtain crude product 380 
(611 mg, 93%) as a light brown powder. TLC Rf = 0.3 (CHCl3/MeOH, 5:1); mp >161 °C. 
1H NMR (400 MHz, DMSO-d6): δ 1.24 (s, 9 H, (CH3)3), 2.21 (s, 3 H, CH3), 10.85 (s, 1 H, 
2-NH, exch), 11.8 (s, 1 H, 3-NH, exch), 11.85 (s, 1 H, 7-NH, exch). The intermediate 380 
was used for the next reaction without further characterization. 
Methyl 4-(1-hydroxy-4-(6-methyl-4-oxo-2-pivalamido-4,7-dihydro-3H-pyrrolo[2,3-
d]pyrimidin-5-yl)but-3-yn-1-yl)benzoate (381).  
To a solution of 373 (50 mg, 0.13 mmol, 1 eq), dissolved in anhydrous  THF  (3  mL),  
copper(I) iodide (10 mg, 0.05 mmol, 0.4 eq), 376 (163 mg, 0.8 mmol, 6 eq), and 
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tetrakis(triphenylphosphine)palladium(0) (15 mg, 0.013 mmol, 0.1 eq) and  triethylamine 
(0.02 mL, 0.13 mmol, 1 eq) were added. The solution was stirred at room temperature for 
72 h under nitrogen until a new polar spot was observed on the TLC (CHCl3/MeOH). The 
solvent mixture was evaporated in vacuo and the residue was dissolved in MeOH. To the 
methanolic solution, celite was added and the solution was concentrated under reduced 
pressure to afford a celite plug. The plug was loaded onto a silica gel column and flash 
chromatographed with CHCl3 followed by gradual increase in polarity to 5% MeOH in 
CHCl3. The fractions with the required Rf were collected and evaporated to afford 381 (42 
mg, 70%) as a sticky pink solid. TLC Rf  = 0.3 (CHCl3/ MeOH 5:1); 1H NMR (400 MHz, 
DMSO-d6): δ 1.2 (s, 9 H, (CH3)3), 2.4 (s, 3H, Ar-CH3), 3.2-3.3 (m, 2 H, CH2), 3.84 (s, 3 
H, COOCH3), 4.61-4.66 (td, J = 4.87, 4.87, 9.37 Hz, 1 H, OH-CH), 5.36-5.37 (d, J = 4.60 
Hz, 1 H, OH), 7.45-7.47 (d, J = 8.29 Hz, 2 H, Ar), 7.89-7.91 (d, J = 8.25 Hz, 2 H, Ar), 
10.9 (s, 1 H, 2-NH, exch), 11.97 (s, 1 H, 3-NH, exch), 12.03 (s, 1 H, 7-NH, exch). The 
intermediate 381 was used for the next reaction without further characterization. 
(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-1-
yl)pyrimidine-2-carbonyl)glutamic acid (202).  
Compound 202 was prepared using the general method described for the preparation of 
179-180 from 297 (80 mg, 0.16 mmol) to give 202 (40 mg, 56%) as an orange powder. mp 
114.1 °C dec. 1H NMR (400 MHz, DMSO-d6): δ 1.97-2.17 (m, 2 H, β-CH2), 2.3-2.32 (m, 
2 H, γ-CH2), 4.44-4.49 (m, 1 H, α-CH), 6.0 (s, 2 H, 2-NH2, exch), 6.03-6.04 (d, J = 1.99 
Hz, 1 H, C5-CH), 8.97 (s, 2 H, Ar) 9.0-9.01 (d, J = 8.07 Hz, 1 H, CONH, exch), 10.16 (s, 
1H, 3-NH, exch) 10.91 (s, 7-NH, exch). Anal. Calcd for (C20H19N7O6 ꞏ 0.95 H2O) C, 51.04; 
H, 4.47; N, 20.83. Found C, 51.12; H, 4.60; N, 20.68.  
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Docking protocol for the molecular modeling of pyrrolo[2,3-d]pyrimidine classical 
antifolates inhibitors of GARFTase/AICARFTase/TS with selectivity for FRs and/or 
PCFT over RFC: 
The X-ray crystal structures of hFRα (PDB: 5IZQ, 3.6 Å), hFRβ (PDB: 4KN2, 2.6 Å), 
hGARFTase (PDB: 5J9F, 2.1 Å), hAICARFTase (1P4R, 2.55 Å) were obtained from 
protein database. Docking studies were performed using LeadIT 2.1.6. Default settings 
were used to calculate the protonation state of the proteins and the ligands, and the free 
rotation of water molecules in the active site (defined by amino acids 6.5 Å from the crystal 
structure ligand) were permitted. The ligands for docking were sketched in Maestro 11.2 
and prepared using the Ligprep (4) application. The docking was performed in LeadIT 
2.1.6 using the triangle matching placement method and scored using default settings. The 
docked poses were visualized in Maestro 11.2. To validate the docking process using 
LeadIT 2.1.6, the crystallized ligands were sketched in Maestro 11.2, prepared using 
Ligprep and docked as described. The RMSD of the docked crystal structures were <2, 
thus validating  LeadIT 2.1.6 for docking in FRα, FRβ, GARFTase and AICARFTase. 
Table 23. Docked scores of proposed compounds in crystal strucutures of FRα FRβ 
GARFTase AICARFTase and TS 
 FRα FRβ GARFTase AICARFTase TS 
179 -52.08 -62.52 -52.8 NA NA 
180 -56.6 -57.3 -53.2 NA NA 
181 -57.12 -57.8 -53.09 NA NA 
182 -58.25 -57.76 -49.74 NA NA 
183 -56.38 -60.3 -57.1 NA NA 
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184 -50.75 -54.48 -50.28 NA NA 
185 -53.07 -57.55 -55.07 NA NA 
186 -53.58 -60.6 -50.8 NA NA 
187 -55.5 -61.76 -53.1 NA NA 
188 -54.07 -59.58 -52.8 NA NA 
189 -55.6 -63.7 -56.3 NA NA 
191 -54.2 -60.26 -54.7 NA NA 
192 -51.95 -61.13 -54.34 NA NA 
193 -55.08 -63.96 -43.5 -42.11 NA 
194 -57.8 -70.52 -52.68 -39.32 NA 
195 -58.1 -63.3 -46.35 -34.99 NA 
196 -58.12 -66.15 -50.03 -32.24 NA 
197 -58 -68.18 -52.45 -41.12 NA 
198 -57.78 -65.99 -50.5 -39.17 NA 
200 -49.2 -63.88 -40.9 -30.49 -38.23 
202 54.97 62.36 -44.07 NA NA 
PMX -48.73 -58.25 -44.25 -37.69 -40.45 
2 -55 -60.4 -50.7 NA NA 
3 -54.74 -56.96 -56.4 NA NA 
4 -51 -62.2 -52.82 NA NA 
7 -50.65 -52.14 -52.8 NA NA 
9 -52.18 -59.14 -50.26 NA NA 
13 -56.13 -64.05 -48.06 -36.52 NA 
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IV. SUMMARY 
 
The dissertation describes the design and synthesis of  6- and/or 5-substituted, 2-amino-4-
oxo pyrrolo[2,3-d]pyrimidine- GARFTase/ AICARFTase inhibitors with selectivity for 
FRs and/or PCFT over RFC for targeted cancer chemotherapy. The novel compounds 
synthesized as part of this study are listed below: 
1. (4-(4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
fluorobenzoyl)-L-glutamic acid (179) 
2. (4-(4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3-
fluorobenzoyl)-L-glutamic acid (180) 
3. (4-(3-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-2-
fluorobenzoyl)-L-glutamic acid (181) 
4. (5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3-
fluoropicolinoyl)-L-glutamic acid (182) 
5. (5-(4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-3-
fluoropicolinoyl)-L-glutamic acid (183) 
6. (4-(3-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl)-3-
fluorothiophene-2-carbonyl)-L-glutamic acid (184) 
7. (5-(4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
fluorothiophene-3-carbonyl)-L-glutamic acid (185) 
8. (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2,6-
difluorobenzoyl)-L-glutamate (186) 
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9. (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2,5-
difluorobenzoyl)-L-glutamate (187) 
10. (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2,3-
difluorobenzoyl)-L-glutamate (188) 
11.  (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
methylbenzoyl)-L-glutamic acid (189) 
12. (4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl)-2-
(trifluoromethyl)benzoyl)-L-glutamate (191) 
13. (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-
yl)butyl)pyrimidine-2-carbonyl)-L-glutamic acid (192) 
14. (3-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)benzoyl)-L-glutamic acid (193) 
15. (4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)amino)benzoyl)-L-glutamate (194) 
16. (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propoxy)benzoyl)-L-glutamic acid (195) 
17. (4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)propyl)thio)benzoyl)-L-glutamic acid (196) 
18. (4-((3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-
yl)butyl)amino)benzoyl)-L-glutamate (197) 
19. (4-(4-(2-amino-4-hydroxy-7H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)-2-
fluorobenzoyl)-L-glutamate (198) 
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20. (5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)but-1-yn-1-
yl)pyrimidine-2-carbonyl)glutamic acid (202).  
 
Biological evaluation of proposed compounds were carried out in engineered CHO cell 
lines that overexpressing RFC, FRα, FRβ, and PCFT. The aim for this dissertation was to 
obtain compounds with potent tumor-targeted activity via uptake by FRs and PCFT over 
RFC and intracellular inhibition of one or more folate metabolizing enzymes. Majority of 
the proposed compounds showed improved selectivity compared to the lead compounds. 
Using traditional bioisosteric and regioisomeric substitutions,  we were able to successfully 
incorporate selectivity and improve potency. The major contributions of the currnt study 
are the (1) subsitution of sidechain aryl CH (sp) with CF (sp) which succesfully improved 
uptake by PCFT and incorporated intracellular inhibition of a new target (identification 
studies are underway),  and (2) subsitution of scaffold C6-CH (sp) with C6-C(CH3) (sp) 
for successful incorporation of selectivity in PMX analogs. 
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VII. APPENDIX 
Biological evaluation. The biological evaluation of all the analogs listed in the following 
tables were performed by Dr. Larry H. Matherly (Molecular Therapeutics Program, 
Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State 
University School of Medicine, Department of Pharmacology, Wayne State University 
School of Medicine). 
 
Reagents for biological studies. [3’, 5’, 7-3H]MTX (20 Ci/mmol), [3’, 5’, 7, 9-3H], folic 
acid (25 Ci/mmol), and [14C(U)]-glycine (87 mCi/mmol) were purchased from Moravek 
Biochemicals (Brea, CA). Unlabeled folic acid was purchased from Sigma-Aldrich (St. 
Louis, MO). LCV [(6R,S)5-formyl tetrahydrofolate] and MTX were provided by the Drug 
Development Branch, National Cancer Institute (Bethesda, MD). PMX [N-[4-[2-(2-amino-
3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid] 
(Alimta) was provided by Eli Lilly and Co. (Indianapolis, IN). PT523 [N(alpha)-(4-amino-
4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine] was a gift from A. Rosowsky 
(Boston, MA). Other chemicals were obtained from commercial sources in the highest 
available purities.  
 
Cell lines. The engineered CHO sublines including RFC-, PCFT- and FRα-null 
MTXRIIOuaR2-4 (R2), and RFC- (PC43-10), PCFT- (R2/PCFT4), FRα- (RT16) and FRβ- 
(D4) expressing CHO sublines were previously described.118, 400-403 The CHO cells were 
grown in α-minimal essential medium (MEM) supplemented with 10% bovine calf serum 
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(Invitrogen, Carlsbad, CA), L-glutamine (2 mM), penicillin (1000 U/ml), and streptomycin 
(1000 μg/ml) at 37 C with 5% CO2. R2 transfected cells (PC43-10, RT16, D4, R2/PCFT4) 
were cultured in complete α-MEM media plus G418 (1 mg/ml).  Prior to the cell 
proliferation assays (below), RT16 and D4 cells were cultured in complete folate-free 
RPMI 1640 (without added folate), plus 10% dialyzed fetal bovine serum (FBS) (Sigma-
Aldrich) and penicillin/streptomycin for 3 days.  
 
KB human nasopharyngeal carcinoma cells were obtained from the American Type Culture 
Collection (Manassas, VA). IGROV1 (NCI-IGROV1) (passage 5) epithelial ovarian 
cancer cells were obtained from the Division of Cancer Treatment and Diagnosis, National 
Cancer Institute (Frederich, MD). KB cells were cultured in folate-free RPMI 1640 
medium, supplemented with 10% FBS, penicillin-streptomycin solution, and 2 mM L-
glutamine at 37oC with 5% CO2.  
 
For growth inhibition studies, cells (CHO, KB, IGROV1) were plated in 96 well dishes 
(~2000 cells/well, total volume of 200 μl) and treated with a range of drug concentrations 
(0-1000 nM) in complete folate-free RPMI 1640 medium with 10% dialyzed FBS, 
supplemented with 2 nM (RT16, D4 CHO cells, KB and IGROV1) or 25 nM (all others) 
LCV, as described.118, 159, 400 To confirm FR-mediated drug uptake, 200 nM folic acid was 
added to parallel incubations for RT16 and D4 cells. After 96 h, viable cells were assayed 
with Cell-Titer BlueTM reagent (Promega, Madison, WI) and fluorescence measured with 
a fluorescence plate reader. Fluorescence measurements were used for calculations of 
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IC50s, corresponding to the drug concentrations at which cells showed 50% loss of 
proliferation.    
 
To confirm the targeted pathway/enzyme, in vitro growth inhibition of IGROV1 tumor 
cells was measured in the presence of thymidine (10 µM) or adenosine (60 µM).107, 116, 118, 
120, 158, 400, 404-406 For de novo purine biosynthesis inhibitors, additional protection 
experiments used AICA (320 µM) to distinguish inhibitory effects at GARFTase from 
those at AICARFTase.  
 
Folate receptor binding assays. To determine relative binding affinities of the 6-
substituted pyrrolo[2,3-d]pyrimidine analogues to FRα and FRβ, engineered CHO cells 
(RT16 and D4, respectively) were used.107, 116, 118, 120, 159, 400, 404-406  Cells were plated in 60 
mm dishes (7.5 x 105 cell/dish). Afer 2 days (~80% confluency), the cells were sequentially 
washed with PBS at 4 C (3x), followed by acidic buffer (10 mM sodium acetate, 150 mM 
NaCl, pH 3.5) (2x) to remove FR-bound folates, and finally HEPES-buffered saline (20 
mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 5 mM glucose, pH7.4) (HBS). 
Cells were treated with [3H]folic acid (50 nM, specific activity, 0.5 Ci/mmol) in HBS in 
the presence and absence of unlabeled folic acid, MTX (negative control), or the 6-
substituted pyrrolo[2,3-d]pyrimidine antifolates (10 to 1000 nM) for 15 min at 4 C. Dishes 
were washed with HBS  at 4 C (3x), after which the cells were solubilized with 0.5 N 
NaOH. Aliquots of the alkaline homogenates were measured for radioactivity and protein 
contents. Protein concentrations were measured using Folin-phenol reagent.407 FR-bound 
[3H]folic acid was calculated in units of pmol/mg protein, and binding affinities were 
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calculated as the inverse molar ratios of unlabeled ligands required to inhibit [3H]folic acid 
binding by 50%. The relative binding affinity of unlabeled folic acid was assigned a value 
of 1.  
PCFT and RFC transport assays. R2 and R2/PCFT4 CHO sublines and R1-11 and R1-
11-RFC2 HeLa sublines were grown in suspension as spinner cultures at densities of 2-5 x 
105 cells/mL.121, 408 Cells were isolated by centrifugation, washed with PBS (3x), and the 
cell pellets (~1 x 107 cells) were suspended in transport buffer (2 ml) for cellular uptake 
assays.  PCFT-dependent uptake of 0.5 µM [3H]MTX was assayed in cell suspension over 
2 min at 37° C (in a shaking water bath) in 4-morpholinopropane sulfonic (MES)-buffered 
saline  (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2, and 5 mM glucose) at pH 
5.5, or in HBS at pH 6.8 in the presence or 1 or 10 µM inhibitor, while RFC-dependent 
uptake was measured over 2 min at 37° C in pH 7.2 HBS. Transport was quenched with 
ice-cold PBS after 2 min and cells were washed three times with ice-cold PBS.  Cellular 
proteins were solubilized with 0.5 N NaOH (3 h, 37° C). Transport levels were expressed 
as pmol/mg protein, calculated from direct measurements of radioactivity and protein 
contents of the cell homogenates. Protein concentrations were measured using Folin-
phenol reagent.407 Transport levels were normalized to levels in untreated (R2/PCFT4 or 
R1-11-RFC2) controls.  To determine Ki values for the 6-pyrrolo[2,3-d]pyrimidine 
antifolates, transport was measured over 2 min with 0.5 µM [3H]MTX and 0.05-1 µM of 
unlabeled antifolate competitor.408 Dixon plots were used to analyze data. 
 
Protection experiments. IGROV1 cells were plated (2000 cells/well) in folate-free RPMI 
1640 medium with 10% dialyzed FBS, antibiotics, L-glutamine, and 25 nM LCV with a 
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range of drug concentrations in the presence of adenosine (60 μM), thymidine (10 μM), 
AICA (320 μM) or glycine (130 μM). Cell proliferation was assayed with Cell Titer Blue 
(Promega) using a fluorescence plate reader. Data are representative of at least triplicate 
experiments. Error bars represent the standard errors. 
 
In vivo efficacy study with IGROV1 human EOC xenografts. The methods for 
maintenance of the IGROV1 transplantable tumor xenografts, drug treatments, toxicity 
evaluations, and data analysis have been described previously.107, 405-406, 409-410 All animal 
studies were approved by the Institutional Animal Care and Use Committee of the Wayne 
State University.  Briefly IGROV1 human EOC cells were implanted subcutaneously (5 x 
106 cells/flank) to establish a tumor xenograft model in female NCR SCID mice (NCI 
Animal Production Program). Mice were 10 weeks old on day 0 (tumor implant) with an 
average body weight of 20 g. For the study, the mice were maintained on either a folate-
deficient diet from Harlan-Teklad (TD.00434) or a folate-replete diet from Lab Diet (5021; 
autoclavable mouse breeder diet) starting 14 days before subcutaneous tumor implant to 
ensure serum folate levels would approximate those of humans. Mice were supplied with 
food and water ad libitum.  Folate serum levels were determined prior to tumor implant 
and post study via Lactobacillus casei bioassay.411 The animals on both diets were 
respectively pooled and implanted bilaterally subcutaneously with 30-60 mg tumor 
fragments with a 12 gauge trocar. Mice were again respectively pooled before unselective 
distribution to the various treatment and control groups. Chemotherapy began 3 days post-
tumor implantation. Tumors were measured with a caliper two-to-three times weekly; mice 
were sacrificed when the cumulative tumor burden reached 1500 mg. Tumor weights were 
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estimated from two-dimensional measurements [i.e., tumor mass (in mg) = (a x b2)/2, 
where a and b are the tumor length and width in mm, respectively].  For calculation of end 
points, both tumors on each mouse were added together, and the total mass per mouse was 
used. Quantitative end points to assess antitumor activity include: (i) tumor growth delay 
[T-C, where T is the median time in days required for the treatment group tumors to reach 
a predetermined size (e.g., 1000 mg), and C is the median time in days for the control group 
tumors to reach the same size; tumor-free survivors are excluded from these calculations]; 
and (ii) T/C (in percent) for each treatment group when treatment (T) and control (C) 
groups for the control groups reached 700 mg in size (exponential growth phase). The 
median of each group was determined (including zeros).  
 
C.1.1. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-fluorophenyl classical 
antifolates 
The pyrrolo[2,3-d]pyrimidine compounds 179-181 were designed based on the 6-
substituted parents pyrrolo[2,3-d]pyrimidine analogs 1-3 (Table 24). The synthesized 
analogs showed a considerable improvement in FRs and PCFT assays. While the 3C linker 
analog 181 has the best PCFT uptake, it also has significant uptake by RFC. The 4C linker 
analogs show reduced uptake by RFC by a substantial amount while 
maintaining/improving potent activity against PCFT-expressing cells. Between the o- and 
m- fluorine substitution to the L-glutamate, o-substitution improved the overall activity, 
suggesting that in the 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine classical 
antifolates, a 4C linker with o- fluorine substitution is optimal for improved activity and 
selectivity. 
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Table 24. IC50 Values (nM) and protection studies of 6-substituted pyrrolo[2,3-
d]pyrimidine antifolates 179-180 
 
 CHO (IC50s) (nM) KB (IC50s) 
(nM) 
IGROV1 
(+Thd/Ade
/AICA)  RFC 
PC43-
10 
R2 FRα 
RT16 
FRβ 
D4 
PCFT 
R2/PCFT4
hRFC/hFRα/ 
FRβ/hPCFT 
2 304 
(89) 
>1000 4.1 
(1.6) 
5.6 
(1.2) 
23 (3.3) 1.7 (0.4) Ade/AICA 
3 >1000 >1000 6.3 
(1.6) 
10.0 
(2) 
213 (28) 1.9 (0.7) Ade/AICA 
179 >1000 >1000 0.58 
(0.12)
1.6 
(0.44)
23 (2) 0.59 Ade/AICA 
180 >1000 >1000 1.4 0.93 207 1.67 ND 
181 62 
(12) 
140 
(27) 
1.12 
(0.37)
3.87 
(0.14)
3.82 (0.27) 2.6  Ade/AICA 
 
C.1.2. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-fluoropyridyl 
classical antifolates 
The pyrrolo[2,3-d]pyrimidine compounds 182 and 183 were designed based on the 6-
substituted parent pyrrolo[2,3-d]pyrimidine analog 4 (Table 25). The 3C linker analog 182 
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showed improved PCFT uptake and comparable activity in FRs, PCFT and KB cell assays. 
The 4C linker analog 183 showed similar activity as the parent 4 in FRs, PCFT and KB 
cell assays. Notably, fluorination of the pyrdiyl sidechain resulted in improved uptake by 
RFC and the 3C linker was more potent against RFC-expressing CHO cells over the 4C 
linker. This minimal SAR study suggests that any loss of selectivity incurred upon fluorine 
substitution can potentially be overcome by increasing the linker chain length.  
Table 25. IC50 Values (nM) and protection studies of 6-substituted pyrrolo[2,3-
d]pyrimidine antifolates 182 and 183 
 
 CHO (IC50s) (nM) KB (IC50s) 
(nM) 
IGROV1 
(+Thd/Ade
/AICA)  RFC 
PC43-
10 
R2 FRα 
RT16 
FRβ 
D4 
PCFT 
R2/PCFT4
hRFC/hFRα/ 
FRβ/hPCFT 
4 >1000 >1000 1.3 
(0.1) 
0.51 
(0.09)
30.4 (10.7) 0.37 (0.08) Ade/AICA 
182 45 ND 3.11 1.16 9 0.75 ND 
183 468 
(142) 
>1000 0.69 
(0.39)
0.44 
(0.13)
67 (25) 0.27 Ade/AICA 
 
C.1.3. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-fluorothienyl 
classical antifolates 
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The pyrrolo[2,3-d]pyrimidine compounds 184 and 185 were designed based on the 6-
substituted parent pyrrolo[2,3-d]pyrimidine analogs 7 and 9 (Table 26). The 3C linker 
analog 184 showed improved RFC and PCFT uptake and comparable activity in FRs and 
KB cell assays. The 4C linker analog 185 showed improved activity compared to the parent 
9 in FRα and PCFT cell assays and comparable activity in FRβ. Notably, fluorination of 
the thienyl sidechain in the 3C linker analog 184 resulted in improved uptake by RFC as 
well as PCFT. However, the 4C linker analog 185 showed improved PCFT activity along 
with selectivity over RFC. This suggests that fluorintion in the 6-substituted, pyrrolo[2,3-
d]pyrimidine thienyl series improves RFC and PCFT activity and the loss of selectivity 
upon fluorine substitution can potentially be overcome by increasing the linker chain 
length.  
Table 26. IC50 Values (nM) and protection studies of 6-substituted pyrrolo[2,3-
d]pyrimidine antifolates 184 and 185 
 
 CHO (IC50s) (nM) KB (IC50s) 
(nM) 
IGROV1 
(+Thd/Ade
/AICA)  RFC 
PC43-
10 
R2 FRα 
RT16 
FRβ 
D4 
PCFT 
R2/PCFT4
hRFC/hFRα/ 
FRβ/hPCFT 
7 197 
(49)  
355 
(10) 
0.33 
(0.15)
0.34 
(0.03)
5.4 (1.3) 0.17 (0.05) Ade/AICA 
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9 >1000  >1000 2.5 
(0.5) 
0.43 
(0.14)
41.5 (3.1) 0.17 (0.02) Ade/AICA 
184 20.1 
(6.2) 
20.5 
(1.6) 
0.14 
(0.03)
0.19 
(0.02)
1.5 (0.4) 0.26 Ade/AICA 
185 >1000  >1000 0.36 
(0.13)
0.75 
(0.42)
6.00 (0.94) 0.33 Ade/AICA 
 
In vivo antitumor efficacy for compound 185 with IGROV1 EOC xenografts.  
Based on the in vitro efficacies of 185 (Table 26), we extended our studies to an in vivo 
drug efficacy trial. The in vivo trial was performed with female NCR severe combined 
immunodeficient (SCID) mice bilaterally (subcutaneous) implanted with IGROV1 human 
EOC xenografts. In vivo efficacy for 185 was compared to that for 5, the most active PCFT-
targeted pyrrolo[2,3-d]pyrimidine analogue previously identified.158-159, 166, 405 For the trial, 
the mice were fed a folate-deficient diet ad libitum to reduce serum folate concentrations 
to levels approximating those reported in humans.412 A control cohort included tumor-
bearing mice fed standard (folate-replete) chow. Mice were non-selectively randomized 
into control and treatment groups (5 mice/group). The pyrrolo[2,3-d]pyrimidine 
compounds were administered intravenously (IV) beginning on day 3 following tumor 
engraftment, using doses slightly below their respective maximum tolerated doses. Dosing 
was as follows: 185, Q4dX4 at 95 mg/kg/inj, for a total dose of 380 mg/kg; and 5, Q4dX3 
at 32 mg/kg/inj, for a total dose of 96 mg/kg. The tumors were measured twice each week; 
overall health and body weights of the mice were recorded daily. For mice on the folate-
deficient diet, both compounds 5 and 185 were efficacious. On day 60, the median tumor 
burdens were 700 mg (range, 259-1153 mg) for the control, 108 mg (range, 0-196 mg) for 
5, and 0 mg (range, 0-523 mg) for 185, giving T/C values (based on median tumor 
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measurements) of 15% for 5 and 0% for 185. Tumor growth delays (T-C to reach 1000 mg 
in days) of 28 days for 5 and 35 days for 185 were recorded (Figure 72). Treatments with 
5 and 185 were generally well tolerated with moderate weight losses (15.7% median nadir 
on day 14 and 12.1% median nadir on day 18) that were completely reversible upon 
conclusion of therapy. For mice on the standard (high folate) diet, antitumor activities for 
5 and 185 were ablated. No weight losses or other adverse symptoms were observed.  
 The results from the in vivo efficacy trial with FRα- and PCFT-expressing IGROV1 
human EOC xenografts substantiate our in vitro antitumor efficacy results and establish 
that at equitoxic dose levels, 185 is more efficacious in vivo than 5, as reflected in the T/C 
and T-C metrics, albeit with a higher dose requirement. For both 5 and 185, there were no 
acute or long term toxicities other than completely reversible loss of weight. 
 
Figure 72. In vivo efficacies of compounds 185 and 5 toward the IGROV1 EOC 
xenografts.  Female ICR SCID mice (10 weeks old; 20 g average body weight) were 
maintained on a folate-deficient diet ad libitum for 14 d prior to subcutaneous tumor 
 316 
implant to decrease serum folate to a concentration approximating that in human serum. 
Human IGROV1 tumors were implanted bilaterally and mice were non-selectively 
randomized into 5 mice/group. Dosing began on day 3 following engraftment and was as 
follows: 11, Q4dX4 at 95 mg/kg/inj, total dose of 380 mg/kg;  and 1, Q4dX3 at 32 
mg/kg/inj, total dose of 96mg/kg.  The drugs were dissolved in 5% ethanol (v/v), 1% 
Tween-80 (v/v), and 0.5% NaHCO3 and were administered intravenously (0.2 
ml/injection).  The tumors were measured twice each week.  
C.1.4. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-difluorophenyl 
classical antifolates 
The pyrrolo[2,3-d]pyrimidine compounds 186 and 187 were designed based on the 6-
substituted pyrrolo[2,3-d]pyrimidine 2'-fluorophenyl analogs 179-180 (Table 27). The 
most notable change in the activity brought about by difluorination is the loss of PCFT 
activity in all of the synthesized compounds. This implies that while mono fluorination 
improves PCFT activity as previously described, difluorination or fluorine scan with more 
than one fluorine atom substitution is detrimental towards uptake by PCFT.  
Table 27. IC50 Values (nM) and protection studies of 6-substituted pyrrolo[2,3-
d]pyrimidine antifolates 186 and 187. 
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 CHO (IC50s) (nM) KB (IC50s) 
(nM) 
IGROV1 
(+Thd/Ade
/AICA)  RFC 
PC43-
10 
R2 FRα 
RT16 
FRβ 
D4 
PCFT 
R2/PCFT4
hRFC/hFRα/ 
FRβ/hPCFT 
179 >1000 >1000 0.58 
(0.12)
1.6 
(0.44)
23 (2) 0.59 Ade/AICA 
180 >1000 >1000 1.4 0.93 207 1.67 ND 
181 62 
(12) 
140 
(27) 
1.12 
(0.37)
3.87 
(0.14)
3.82 (0.27) 2.6  Ade/AICA 
186 >1000  >1000 1.45 1.28 769.3 2.37 ND 
187 >1000   >1000 5.2 0.47 592 0.32 ND 
 
C.1.5. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-2'-substitutedphenyl 
classical antifolates 
The pyrrolo[2,3-d]pyrimidine compounds 189 and 191 were designed based on the 6-
substituted pyrrolo[2,3-d]pyrimidine 2'-fluorophenyl analog 179 (Table 28). The important 
structure activity relationship obtained from this study is the importance of sterics at the 
2'-position, as the activity is systematically reduced upon gradual increase in size. From 
the PCFT activity, it is also apparent that PCFT uptake is most sensitive to size of the side 
chain substitution, indicating a narrower pocket compared to the FRs.  
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Table 28. IC50 Values (nM) and protection studies of 6-substituted pyrrolo[2,3-
d]pyrimidine antifolates 189 and 191 
 
 CHO (IC50s) (nM) KB (IC50s) 
(nM) 
IGROV1 
(+Thd/Ade
/AICA)  RFC 
PC43-
10 
R2 FRα 
RT16 
FRβ 
D4 
PCFT 
R2/PCFT4
hRFC/hFRα/ 
FRβ/hPCFT 
3 >1000 >1000 6.3 
(1.6) 
10.0 
(2) 
213 (28) 1.9 (0.7) Ade/AICA 
179 >1000 >1000 0.58 
(0.12)
1.6 
(0.44)
23 (2) 0.59 Ade/AICA 
189 >1000  >1000 2.23 7.16 >1000 0.67 ND 
191 >1000  >1000 12 57.4 >1000 >1000 ND 
 
C.1.6. 6-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-pyrimidyl classical 
antifolates 
The pyrrolo[2,3-d]pyrimidine compounds 192 was designed based on the 6-substituted 
pyrrolo[2,3-d]pyrimidine-phenyl analog 3 (Table 29). The important structure activity 
relationship obtained from this varation is the influence of electronics of the sidechain. We 
already know from previous SAR studies (Tables 2 and 4) that varying the sidechain 
(het)aryl ring significantly varies the tumor cell potency as well as transporter selectivities. 
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Replacing the sidechain phenyl with a pyrimidyl ring did not influence the RT16 and KB 
cell activities but brought about a considerable activity difference in D4 and R2/PCFT4 
CHO cells. From the loss of R2/PCFT4 activity, it is apparent that along with sterics of the 
sidechain (Table 28), binding to/transport by PCFT is also influenced by the electronics of 
the side chain aryl ring.  
Table 29. IC50 Values (nM) of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate 192 
 
 CHO (IC50s) (nM) KB (IC50s) 
(nM) 
IGROV1 
(+Thd/Ade
/AICA)  RFC 
PC43-
10 
R2 FRα 
RT16 
FRβ 
D4 
PCFT 
R2/PCFT4
hRFC/hFRα/ 
FRβ/hPCFT 
3 >1000 >1000 6.3 
(1.6) 
10.0 
(2) 
213 (28) 1.9 (0.7) Ade/AICA 
192 >1000  >1000 6.33 1.96 >1000 0.56 ND 
202 >1000 >1000 5.8 0.52 >1000 44.5 ND 
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C.2.1. 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-3'-butylphenyl classical 
antifolates 
The 1',3'-substituted, pyrrolo[2,3-d]pyrimidine compounds 193 was designed based on the 
5-substituted pyrrolo[2,3-d]pyrimidine-phenyl analog 13 (Table 30). The anticipated loss 
of activity across all the cell lines, upon rearranging the relative substitution of the linker 
and the sidechain L-glutamate reestablished that the conformation of the scaffold and side-
chain, as a consequence of linker length and flexibility, plays an important role in overall 
activity. The important structure activity relationship obtained from this varation is that in 
the 5-substituted pyrrolo[2,3-d]pyrimidine-phenyl analogs 1',3'-relative substitution of the 
glutamate tail and scaffold is detrimental to activity.  
Table 30. IC50 Values (nM) of 5-substituted pyrrolo[2,3-d]pyrimidine antifolate 193 
 
 CHO (IC50s) (nM) KB (IC50s) 
(nM) 
IGROV1 
(+Thd/Ade
/AICA)  RFC 
PC43-
10 
R2 FRα 
RT16 
FRβ 
D4 
PCFT 
R2/PCFT4
hRFC/hFRα/ 
FRβ/hPCFT 
13 56.6 
(5.8) 
>1000 8.6 
(2.1) 
6.99 840 (90) 12.7 (5.4) Ade 
194 608  >1000 >1000 >1000 >1000 >1000 ND 
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C.2.2. 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-4'- 
propyloxy/propylthio/propylamino/butylaminophenyl classical antifolates 
The compounds 195 and 196 with a heteroatom substitution of benzylic CH2 was designed 
based on the 5-substituted pyrrolo[2,3-d]pyrimidine-phenyl analog 13 (Table 31) to 
evaluate the influence of varied bond angles of the benzylic position on selectivity and 
potency. Though heteroatom substitution resulted in reduced KB cell and RT16 potencies, 
there was a considerable improvement in activity against R2/PCFT4 cells. In 196 with a 
propyloxy linker, a significant improvement in FRβ activity was also observed. 
Additionally, the loss of overall activity upon increasing the linker length from 4C in 13 to 
5C in 14, despite improved selectivity, was slightly compensated in 196 with a restoration 
of activity against R2/PCFT4 cells along with improved selectivity. It would be worthwhile 
to explore the role of heteroatom substitutions further in the 5-substituted, pyrrolo[2,3-
d]pyrimidine analogs, especially for improved selectivity via increased uptake by FRβ and 
PCFT and decreased uptake by RFC.  
Table 31. IC50 Values (nM) of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates 195 and 
196 
 
 CHO (IC50s) (nM) KB (IC50s) 
(nM) 
IGROV1 
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 RFC 
PC43-
10 
R2 FRα 
RT16 
FRβ 
D4 
PCFT 
R2/PCFT
4 
hRFC/hFRα/ 
FRβ/hPCFT 
(+Thd/Ade
/AICA) 
13 56.6 
(5.8) 
>1000 8.6 
(2.1) 
6.99 840 (90) 12.7 (5.4) Ade 
14 196.4 
(55) >1000 
33.5 
(2.5) 
ND >1000 17.3 (8.9) Ade/AICA 
195 53.2  >1000 39.02 1.94 390 36.76 ND 
196 >1000   >1000 291.5 78.5 549 46.01 ND 
 
C.2.3. 5-substituted, 2-amino-4-oxo pyrrolo[2,3-d]pyrimidine-butyl-2'-fluorophenyl 
classical antifolates 
The compound 198 with a 2'-fluorine substitution on the sidechain phenyl was designed 
based on the 5-substituted pyrrolo[2,3-d]pyrimidine-phenyl analog 13 (Table 32) to 
evaluate the influence on PCFT uptake. As observed in the 6-substituted pyrrolo[2,3-
d]pyrimidines 2'-[ortho (o-) to the L-glutamate] fluorine substitution dramatically 
increased PCFT-mediated antiproliferative activity of R2/PCFT4 cells. The impact of 2'-
fluorine substitution on potencies against all the other cell lines remained similar. This 
preliminary data encourages the design, synthesis and evaluation of novel fluorinated, 5-
substituted pyrrolo[2,3-d]pyrimidine analogues. 
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Table 32. IC50 Values (nM) of 5-substituted pyrrolo[2,3-d]pyrimidine antifolate 198  
 
 CHO (IC50s) (nM) KB (IC50s) 
(nM) 
IGROV1 
(+Thd/Ade
/AICA)  RFC 
PC43-
10 
R2 FRα 
RT16 
FRβ 
D4 
PCFT 
R2/PCFT4
hRFC/hFRα/ 
FRβ/hPCFT 
13 56.6 
(5.8) 
>1000 8.6 
(2.1) 
6.99 840 (90) 12.7 (5.4) Ade 
198 40 >1000 5.23 2.11 52.7 7.99 Ade 
 
 
Figure 73. Growth inhibition assay of 198 in IGROV1 EOC cells and protection by 
nucleosides and AICA. 
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To investigate the intracellular targeted pathway/enzyme of 198, in vitro growth inhibition 
of IGROV1 tumor cells was measured in the presence of thymidine (10 µM) or adenosine 
(60 µM), or glycine (). For de novo purine biosynthesis inhibitors, additional protection 
experiments used AICA (320 µM) to distinguish inhibitory effects at GARFTase from 
those at AICARFTase. The results were normalized to those of untreated cells (no drug). 
The results shown are representative of triplicate expermients (Figure 73). The IGROV 
tumor cells were not protected by thymidine, suggesting that 199 is not a TS inhibitor. 
AICA only partially protected the cells, indicating a dual GARFTase and AICARFtase 
inhibition. However, partial protection by adenosine and complete protection by glycine at 
higher concentrations (data not shown) of 198, suggests additional intracellular targets 
(SHMT inhibition). Further studies are underway to investigate the possible targets. 
C.3.1. 5-substituted, 2-amino-4-oxo-6-methyl pyrrolo[2,3-d]pyrimidine classical 
antifolates 
Based on the general trend of reduced RFC binding by the 6-substituted pyrrolo[2,3-
d]pyrimidine series of analogs, compound 200 with a 6-methyl substitution was designed 
as a direct analog of 5-substituted pyrrolo[2,3-d]pyrimidine PMX (Table 33) to evaluate 
for selectivity over RFC. As expected, the activity against was PC43-10 was drastically 
reduced, implying a loss of uptake by RFC. Additionally, activities against KB tumor cells 
and D4 cells also improved. While the activity against RT16 remained roughly similar, the 
uptake by PCFT was reduced as reflected by the ~8 fold loss in R2/PCFT4 activity. 
Nevertheless, the drastic improvement in selectivities for FRs and PCFT over RFC (Table 
34) mainly due to the much needed loss of RFC uptake when compared with clinically 
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used PMX is a remarkable development and warrants future expolrations of 6-alkylated,  
5-substituted pyrrolo[2,3-d]pyrimidine classical antifolates. 
Table 33. IC50 Values (nM) and protection studies of 5-substituted, 6-methyl pyrrolo[2,3-
d]pyrimidine antifolate 200 
 
 CHO (IC50s) (nM) KB (IC50s) 
(nM) 
IGROV1 
(+Thd/Ade
/AICA)  RFC 
PC43-
10 
R2 FRα 
RT16
FRβ 
D4 
PCFT 
R2/PCFT4
hRFC/hFRα/ 
FRβ/hPCFT 
PMX 26.2 
(5.5) 
138 
(13) 
42 (9) 60 
(8) 
8.3 (2.7) 68 (12) Thd/Ade 
200 >1000   >1000 94.7 5.7 65 28.5 Ade/AICA 
 
To investigate the intracellular targeted pathway/enzyme of 200, in vitro growth inhibition 
of IGROV1 tumor cells was measured in the presence of thymidine (10 µM) or adenosine 
(60 µM), or glycine (130 μM) (Figure 74). For de novo purine biosynthesis inhibitors, 
additional protection experiments used were, AICA (320 µM) to distinguish inhibitory 
effects at GARFTase from those at AICARFTase. The results shown are representative of 
triplicate expermients. The IGROV tumor cells were not protected by thymidine, 
suggesting that 200 is not a TS inhibitor. Both adenosine and AICA completely protected 
the cells across the concentration range, indicating GARFTase inhibition. Unlike PMX, its 
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6-methylated analog 200 is not only a potential tumor-targeted inhibitor due to selectivity 
over RFC but primarily inhibits purine biosynthesis as a novel mechanism of action. As 
such, desirably, 200 is expected to not only circumvent the DLTs associated with PMX 
but also to overcome the PMX-assosiated drug-resistance due to its novel mechanism of 
action. 
 
Table 34. Selectivity ratios of PMX and 200 for FRα (RT16) FRβ (D4) and PCFT (PCFT4) 
over RFC (PC43-10) 
 PC43-
10/RT16 
PC43-
10/D4 
PC43-
10/PCFT4 
PMX 0.62 0.43 3.15 
200 10.5 175.4 >15 
 
 
Figure 74. Growth inhibition assays of 200 against IGROV1 EOC cells and protection by 
excess folic acid, folate free media, nucleosides, glycine, and AICA. 
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